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  Bryostatins is a novel family of marine natural products that were originally 
isolated by Pettit from the bryozoan Bugula neritina. Since its isolation, bryostatin 1 has 
gained extensive attention due to its unique biological activities. It has been shown to 
restore the apoptosis of cancer cells, reverse the multidrug resistance, stimulate the 
immune, synergize with other antineoplastic agents. Bryostatin 1 also demonstrates its 
capabilities of promotion of memory, recovery from the stroke and treatment of 
Alzheimer’s Disease. All those unique bioactivity are possibly related to the interaction 
with protein kinase C isozymes (PKC). Bryostatin 1 has been proved to be able to 
activate PKC through the binding with C1 domain of PKC, which initiates a variety of 
downregulation responses to the proliferation, division and apoptosis of cell. Bryostatin 1 
is not the only ligand binding with PKC C1 domain. In comparison with other PKC 
activator such as phorbol esters, bryostatin 1 is nontumor promoting, can even antagonize 
the tumor promoting effect of phorbol ester, which makes it in the front line for the 
development of new drug lead that target PKC. 
  The research on bryostatin has been hampered by its limited supply due to the low 
abundance in nature source. Our group has been involved in the synthesis of bryostatin 
and analogues to solve the problem of supply of bryostatin. Described herein is the 
exploration of convergent and efficient routes to prepare bryostatin analogues. Pyran 
annulation has been proven to be versatile and tolerant of functional groups in 
 iv 
 
construction of 2,6-syn pyran. Its application in our analogue synthesis successfully 
delivered the target molecules, which demonstrated high binding affinity with PKC, but 
the biological result of bryostatin analogue with C7 acetate indicated it behaved like 
phorbol ester instead of bryostatin 1.  
  In order to understand the role of northern hemisphere of bryostatin on its 
biological activities, analogue with functional group on different positions in the northern 
region is investigated systematically. The biological results from these analogues will 
help us to clarify the pharmacophoric groups that define the unique biological activities 
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INTRODUCTION OF CHEMISTRY AND BIOLOGY OF BRYOSTATINS 
Introduction 
The bryostatins are a novel family of marine natural products with exceptional 
bioactivities. During the 1960s, Pettit and coworkers found that extracts from the marine 
bryozoan Bugula neritina from the Gulf of Mexico demonstrated antitumor effects.1 The 
active components were not identified until 1982 when the Pettit group isolated and 
characterized bryostatin 1 with the help of crystallographic and spectroscopic 
techniques.2 The absolute stereochemistry of bryostatin 1 was confirmed by the same 
group in 1991 using X-ray crystallography of the heavy atom containing C7 para-
bromobenzoate derivative of bryostatin 2.3 Since then more bryostatins were added into 
the family which currently consists of a total of 20 members.4-13 The structures of 
bryostatins 1-20 are summarized in Figure 1.1. Each member of the bryostatin family is 
characterized by a 20-membered macrolactone in which there are three embedded highly 
substituted pyran rings linked by a C16-C17 (E)-disubstituted olefin and a methylene 
bridge; all family members also contain a pair of geminal dimethyls at C8 and C18, as 
well as an exocyclic methyl enoate in their B and C rings. Besides their structural 
differences of the substituents on C7 and C20, bryostatins 3 19, and 20 have a butenolide 
appended to the C-ring, bryostatins 15-17 have a simplified C ring of glycal, and 








o A 7 
Mel" OHO H 





Bryostatin 1: R1=Ac, R2= 02C~ 
Bryostatin 2: R1=H, R2= 02C~ 
Bryostatin 4: R1=CO-i-Bu, R2=OCO-n-Pr 
Bryostatin 5: R1=CO-i-Bu, R2=OAc 
Bryostatin 6: R1=CO-n-Pr, R2=OAc 
Bryostatin 7: R1=Ac, R2=OAc 
Bryostatin 8: R1=CO-n-Pr, R2=OCO-n-Pr 
Bryostatin 9: R1=CO-n-Pr, R2=OAc 
Bryostatin 10: R1=CO-t-Bu, R2=H 
Bryostatin 11: R1=Ac, R2=H 
Bryostatin 12: R1=CO-n-Pr, R2= 02C~ 
Bryostatin 13: R1=CO-n-Pr, R2=H 
Bryostatin 14: R1=CO-t-Bu, R2=OCO-n-Pr OH 
Bryostatin 15: R1=Ac, R2= 02C~ 
5 
Bryostatin 3: R1=Ac, R2= 02C~ 
Bryostatin 19: R1=CO-t-Bu, R2=OCO-n-Pr 
Bryostatin 20: R1=CO-t-Bu, R2=H 
Bryostatin 16 
5 
Bryostatin 17 Bryostatin 18 
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The bryozoans do not intend to produce bryostatins as an anti-cancer drug 
candidate, but as a chemical defender against predators. The Lopanik group found that 
bryostatins isolated from the larvae of bryozoan significantly reduced their palatability to 
the  pinfish,14 making it extremely likely that bryostatins play a role in the chemical 
defense of these young animals.  
Biosynthetic studies suggest that complex polyketides such as the bryostatins are 
synthesized by modular polyketide synthases (PKS).15 Modular PKS are typically only 
found in bacteria, which makes the bacterial symbiont of B. neritina a prime candidate 
for the true biosynthetic source of the bryostatins.   The bryozoan harbors an uncultivated 
gamma proteobacterium, “Candidatus Endobugula sertula,” which is passed to the larvae 
prior to their release from the adult. The confirmation of E. sertula as the true source of 
bryostatin has proved to be a difficult challenge due to the inability to cultivate these 
symbiotic bacteria. The Haygood group successfully cloned and sequenced the genes in 
the uncultivated E. sertula, among which there is a type I polyketide synthase (PKS-I).16 
The required β-ketoacyl synthase (KS) domain, for each elongation and modification step 
in the synthesis of the polyketide chain, was also found in the symbiont. Inhibition of E. 
sertula with the antibiotic gentamicin sulfate resulted in reduced detection of PKS-I and 
KS genes, as well as the reduction of bryostatin synthesis.16 Interestingly, this reduction, 
however, was not proportional to the loss of bacterial symbiont (46% loss in bryostatin 
activity compared to 95% estimated loss of “E. sertula”), which suggests the biosynthesis 
of bryostatins is more complicated than originally thought, and it may be under the 




The bryostatin gene clusters identified by the Haygood group consist of two 
groups: five genes (bryA-D and X) totaling 71 kb coding for modular PKSs and four 
genes (bryP-S) totaling 6 kb with accessory functions.17,18 Based on their discovery, the 
Haygood group proposed a biosynthetic pathway for bryostatins (Figure 1.2). The 
hypothetical biosynthesis starts with lactate, from which the four PKS genes bryA-D will 
elongate the carbon chain to C27. The common intermediate to all bryostatins is proposed 
as bryostatin 0 after manipulation from genes bryD, or bryo X, bryR and bryS. The 











Biological Activities of Bryostatins 
Since their discovery, bryostatins have received tremendous attention from the 
community of biologists and chemists due to their unique bioactivities. Initially, 
bryostatins were investigated due to their remarkable in vitro and in vivo anti-tumor 
effects against a range of cancer cells including HL-60 Human promyelocytic leukemia 
cells,19 P388 lymphocytic leukaemia,2 B16 melanoma,20 and M5076 reticulum cell 
sarcoma.21 These promising results led to the clinical trials of bryostatin 1 against a 
variety of cancers.22-25 Bryostatin 1 alone or in combination with other chemotherapeutic 
drugs has been involved in over 80 clinical trials.26 Although clinical results indicate that 
bryostatin 1 alone shows limited potential, its use in combination with existing 
chemotherapies has shown great promise. When bryostatin 1 is coadministrated with 
other anti-cancer drugs such as paclitaxel,27 vincristine,28 cisplatin,29 fludarabine,30 etc., a 
synergetic effect, the reversion of multidrug resistance,31 and protection of cells from 
ionizing radiation and restoration of apoptotic function are observed.32 
 The anti-tumor effects of bryostatin 1 are generally believed to be due to its 
ability to selectively modulate the function of various individual protein kinase C (PKC) 
isozymes within the cell.33  PKC is a class of serine/threonine isozymes catalyzing the O-
phosphorylation of a variety of protein targets and transducing a myriad of signals, which 
are essential for celluar functions such as cell division, proliferation, differentiation and 
apoptosis.34-36 
The PKC family comprises 10 isozymes grouped into 3 classes: conventional or 
classic (PKC α, βI, βII and γ), novel (PKC δ, ε, η and θ), and atypical (PKC ζ and ι).37 All 
family members share the same architecture: a carboxyl terminal kinase domain linked by 
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a flexible hinge segment to an amino-terminal region containing regulatory modules 
(Figure 1.3). This regulatory moiety contains two key functionalities: an autoinhibitory 
sequence and one or two membrane-targeting modules (C1 and C2 domains). The 
regulatory moiety of conventional PKC is composed of two tandem C1 domains, 
allowing them to respond to ligand binding such as second messenger diacylglycerol 
(DAG), and a C2 domain, which binds a Ca2+ ion. Novel PKC also contain two tandem 
C1 domains, conferring DAG sensitivity, but they contain a “novel” C2 domain that does 
not bind Ca2+ and does not serve as a membrane-binding module. Atypical PKC possess 
an “atypical” highly basic C1 domain which prevents ligand binding, so these isozymes 
respond to neither DAG nor Ca2+. The activation of different classes of PKCs requires 
different activators due to the structural difference.  The activity of conventional PKC 
isozymes is stimulated by DAG, Ca2+, and phosphatidylserine, that of novel isozymes by 
DAG and phosphatidylserine, and that of atypical PKC’s by phosphatidylserine only.  
PKC plays a key role in intracellular signal transduction. A wide range of external 
signals, including hormones, neurotransmitters, growth factors and cytokines, promote 
the stimulation of the isoforms of the phospholipase C (PLC1) family. PLCs catalyze the 
hydrolysis of phosphatidylinositol 4,5-bisphosphate to produce two secondary 
messengers: inositol-1,4,5 triphosphilate (IP3), which triggers the release of Ca2+ from 
internal stores; and DAG,  which  initiates  cellular  responses  through a  variety  of 
effectors. The most prominent intracellular targets of DAG are the PKC isozymes. 
When PKC is inactive, the pseudosubstrate lying N-terminal to the C1 domain 
occupies the substrate-binding cavity of PKC. In this closed, autoinhibited conformation, 
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membrance-bound alkaline phosphatases, which converts it into a catalytically inactive 
form. The inactive PKC is then degraded following ubiquitination downregulation in the 
process known as.38 
DAG is not the only ligand capable of binding with C1 domains and activating 
PKC, in fact there are a variety of structurally different compounds proven to bind with 
the same C1 domain in PKC (Figure 1.4). Phorbol esters are a group of 11 tetracyclic 
diterpene natural products isolated from the croton oil.39 They were found to be the 
potent tumor promoting substances. Among them, phorbol 12-myristate 13-acetate (PMA) 
is the most potent one.  
The phorbol esters initially became the object of intense research interest on the 
basis of their potent activity as mouse skin tumor promoters.40 The identification of PKC 
as the major target for the phorbol esters suggests that the phorbol esters can be very  
 
 





useful probes for identifying the physiological systems in which PKC is involved. Finally, 
the detailed understanding of the interaction of phorbol esters with the regulatory domain 
on PKC might permit the development of agents which interfere with protein kinase C 
activity, thereby functioning as anti-promoters or as inhibitors of physiological effectors. 
 The Zhang group was able to acquire the X-ray structure of the PKCδ C1 domain 
complex with PMA.41 The X-ray structure shows phorbol ester binding does not produce 
a significant conformational change within the activator-binding domain. Rather, it 
inserts into the groove and replaces the water molecules inside. PMA acts to cover the 
polar interior of the groove and completes a contiguous hydrophobic surface over a large 
portion of the C1 domain. The long-chain lipid tails of PMA are probably not directly 
involved in binding to PKC, but instead retain the activator within the membrane.  
  Bryostatin 1, like phorbol ester, has been shown to be a potent activator of PKC 
through the binding with the C1 domain. However, despite sharing the same binding sites, 
bryostatin 1 has antineoplastic properties that, in fact, can inhibit phorbol ester-mediated 
tumor promotion.42 This disparity is not completely understood but is attributed to 
differences in the down regulation of PKC.  Studies from the Blumberg group indicated 
bryostatin 1 and PMA showed different down-regulation of PKCδ in different cell lines. 
Bryostatin 1 can initiate a biphasic pattern of down-regulation of PKCδ, with reduced 
down-regulation at higher bryostatin 1 concentrations, whereas PMA causes monophasic 
down-regulation. This pattern of behavior has been seen in U937 cells,43  NIH3T3 cells,44 
primary mouse keratinocytes,45 B16/F10 melanocytes,46  and HOP-92 cells.47  Bryostatin 
1 at high concentrations (100–1000 nM) blocks the response induced by PMA through 
differentially modulating PKCδ translocation and preventing PKCδ-mediated release of 
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tumor necrosis factor-α (TNF-α). These results suggest byrostatin 1 anticancer activity in 
some cells to be attributable to protection and stabilization of PKCδ from PMA. 
  It is important to emphasize that the extracellular signal transduction is extremely 
complex. PKC isozymes are not the sole family of proteins with C1 domains that 
recognize DAG, phorbol esters and bryostatin 1. Other C1 domain-containing proteins, 
such as PKD, DGKs, RasGRPs, chimaerins, Munc13s, and MRCKs, might also be the 
targets of bryostatin 1. The actual mode of action of bryostatin 1 is still controversial and 
an important area of research. 
 Additionally, bryostatin 1 has been found to have immunostimulant effects,48-51 
as well as promoting the synthesis of protein necessary for long term memory,52,53 and 
aiding recovery from stroke.54 Even more interestingly, bryostatin 1 is indicated as a 
potential therapeutic candidate for the treatment of Alzheimer’s disease (AD).55,56 The 
FDA recently has approved a clinical trial of bryostatin 1 directed by the Alkon group for 
the treatment of AD.57 
Alzheimer's disease is the most common form of dementia, a general term for loss 
of memory and other intellectual abilities serious enough to interfere with daily life. In 
2006, the worldwide prevalence of Alzheimer’s disease was 26.6 million. By 2050, the 
prevalence is expected to quadruple, by which time 1 in 85 persons worldwide will be 
living with the disease.58 The underlying cause of AD is still not fully understood, 
however amyloid beta (Aβ) deposits are believed to be associated with the cause of this 
disease. The processing of amyloid protein precursor (APP) and its metabolic products 
plays a fundamental role in AD pathophysiology. APP is a large transmembrane protein 
that can be cleaved in three distinct sites by proteolytic enzymes collectively referred to 
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as ‘‘secretases’’, among which α-secretase cleaves within the Aβ sequence to generate a 
large extracellular soluble fragment (sAPP α). These fragments appear to have no 
pathological significance and sAPP α might even have neuroprotective properties. A 
deficiency of PKC activation could increase levels of amyloid β, resulting in amyloid 
plaques. The deficiency of PKC activation also could increase levels of phosphorylated 
tau (owing to reduced PKC-mediated inhibition of GSK-3b) and resulting neurofibrillary 
tangles. Bryostatin 1 markedly enhances the α-processing of APP by enhancing secretion 
of the α-secretase product sAPP α, resulting in reduced formation of amyloid plaques. 
Most recently, the Alkon group found that significant cognitive deficits occurred on mice 
five months before plaques were detected in their brains, providing evidence that plaques 
and tangles are not at the root of the disease.59 They also found the treatment of 
bryostatin could control the creation of synapsis and restore the space learning and 
memory of mice. Given its lack of tumor promotion activity, relatively low toxicity, and 
current use in clinical trials for cancer treatment, bryostatin 1 offers a plausible approach 
for developing AD therapeutics. 
While the remarkable biological activity of bryostatins has generated great 
attention for its potential uses as a therapeutic agent, the limited natural availability of 
those compounds has hindered the research on bryostatins. The isolation yield of 
bryostatins varies from 10-5% to 10-3% dependent on the location of bryozoan. The 
largest isolation of bryostatins provided 18 g of compounds from 13,000 kg of wet 
animals.60 An attempt by CalBioMarine Technologies to aquaculture Bugula neritina 
failed to produce a substantial supply. Currently, the only viable method to prepare 
bryostatins and their structurally simplified analogues is by chemical synthesis.  
12 
 
Total Syntheses of Bryostatins 
The unique and complicated structure of the bryostatins, in combination with their 
biological activities, has attracted extensive attention from the chemistry community to 
pursue their total synthesis of bryostatins. Bryostatin 7, the first member of the bryostatin 
family to be made by total synthesis, was reported by Masamune in 1990.61-63  Evans 
achieved an equally impressive total synthesis of bryostatin 2 in 1998;64,65 and two years 
later in 2000, Nishiyama and Yamamura reported their total synthesis of bryostatin 3.66-68  
Most recently, the Trost group finished the total synthesis of bryostatin 16 and C20-epi 
bryostatin 7, utilizing methodologies developed by their group to synthesize the B and C 
pyran rings of bryostatin.69-73  
The three total syntheses of bryostatin 2, 3 and 7 vary of the reactions to construct 
the similar moieties. Different strategies were chosen to construct the pyran ring and 
install the enoate on C13 and C20 positions with desired stereochemistry. Those 
syntheses also share some common strategies (Figure 1.5). In pursuit of a convergent 
route to the bryostatins, the pyran rings were prepared separately, then the moieties with 
pyring rings were coupled together to afford the seco acid intermediates. In orfer to 
overcome the steric hindrance from the gemi dimthyl group on C18 position, the Julia 
olefination was utilized to generate the trans C16-C17 double bond and connect northern 
and southern hemisphere moieties. This methodology was taken by all three groups and 
turned out to be an efficient route. Then a macrolactonization was used to form the 20-
membered macrolactone, and further modification on the pyran rings and deprotection 




Figure 1.5 Summary of total syntheses of bryostatin 2, 3 and 7 
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Interestingly, several groups have attempted to cyclize the macrolactone through a 
ring-closing metathesis between the C16 olefin and C17 olefin during their endeavor to 
synthesize byrostatin 1.72,74 Unfortunately, the metathesis reactions failed to provide the 
desired cyclized products under all the reaction conditions studied, and only a small 
amounts of the dimers were detected (Scheme 1.1). The failure of ring closing metathesis 











The Trost group took a conceptually novel approach to all of the above 
accomplishments in their synthesis of bryostatin 16 (Scheme 1.2). Intermediates alkene 
1.16 and alkyne 1.17, which were prepared with established routes, were coupled into a 
pyran 1.18 catalyzed by a cationic ruthenium complex. This impressive transformation, 
which is proposed to go through a tandem alkyne–enone coupling/Michael addition, 
generated a 2,6 syn-pyran ring with the desired stereochemistry on the  exocyclic double 
bond.70 The installation of the exocyclic enoate on the B ring was problematic in previous 
syntheses.65,68 Trost’s approach to the B ring provides a convergent and efficient route to 
quickly build up the complexity embedded within a natural product like bryostatin. 
Subsequent bromination of the exocyclic vinyl silane followed by a camphorsulfonic acid 
catalyzed transesterification/methyl ketalization/deprotection in one pot gave the desired 
intermediate containing both the A-ring and B-ring substructures. Palladium-catalysed 
carbonylation installed the methyl enoate to finish all the required modification on the A 
and B rings to afford alcohol 1.19. Dess–Martin oxidation of the primary alcohol 1.19 
followed by Ohira–Bestmann alkynylation and deprotection provided alkyne 1.20. 
Chemoselective hydrolysis of the β-hydroxy methyl ester on the C1 position in the 
presence of the α, β-unsaturated methyl ester was achieved by using trimethyltin 
hydroxide, and subsequent protection with TES group on C3 position afforded the 
carboxylic acid 1.21. Coupling of 1.21 with alcohol 1.22 using Yamaguchi conditions 
afford the advanced intermediate 1.23 with all the carbon atoms of bryostatin 16. After 
the deprotection of the PMB group on C23 postion, attention was focused on the 
cyclization to form the macrolactone (Scheme 1.3). The failure of ring-closing metathesis 

















approach to complete the task. An unprecedented alkyne–ynoate coupling reaction 
catalyzed by Pd(OAc)2 not only cyclized the macrolactone but also set up the desired 
stereochemistry on the enoate 1.24. The use of [Au(PPh3)]SbF6 was found to deliver a 
highly regioselective 6-endo pyran product 1.25. Finally, pivalation of the secondary 
hydroxy group on the A ring followed by global deprotection completed the synthesis of 
bryostatin 16. 
The Trost group also attempted to further convert bryostatin 16 to other 
bryostatins (Scheme 1.4). The oxidation of C ring glycal failed to afford the desired 
product under several standard reaction conditions. Finally, a Re-catalyzed epoxidation, 
using methyl rhenium trioxide (MTO) as the catalyst and urea-hydrogen peroxide (UHP) 
as the oxidant, regioselectively oxidized the C19-C20 double bond in intermediate 1.26 to 
give the epoxide 1.27, which underwent a methanolysis and acetylation to afford product 
1.28. Unfortunately, the stereochemistry on the C19 and C20 position of 1.28 is opposite 
to that of the natural bryostatins. Trost rationalized the unusual stereoselectivity due to 
the approach of the Re catalyst from the less hindered face of the C-ring at the 
epoxidation stage to minimize the steric effect from the gem-dimethyl group on the C19 
position. The following deprotection lead to C20-epi bryostatin 7 (1.29). In order to 
prepare natural bryostatin 7, the C20 alcohol was oxidized to a ketone and several 
reducing reagents were screened. The best selectivity is obtained with a CBS reduction, 
which gave a 1:2 mixture, favoring the undesired stereochemistry on C20 position. The 
diastereomer mixtures were separated, and bryostatin 7 was finally prepared after 




Scheme 1.4 The synthesis of C20-epi bryostatin 7 
 
 
Additionally, there are also several other groups working on the total synthesis of 
bryostatins, which include the formal synthesis of bryostatin 7 by the Hale group,75,76 and  
partial syntheses by Burke,75,77,78 Krische,79,80 Thomas,74,81 Vanderwalle,82-84 Kiyooka,85 
Roy,86 hoffmann,87 Janda,88 and our group.89-91 Each total synthesis of a bryostatin 
demonstrates an accomplishment of great challenge and is a masterpiece of synthetic 
organic chemistry. Due to the molecular size and its structural complexity, it will be more 
practical to pursue simplified structural analogues that retain or improve upon 
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bryostatin’s pharmaceutical profile. This approach could eventually provide a solution to 
fit the needs of biological research and future clinical trials.  
 
Wender’s Bryostatin Analogue Study 
The Wender group has been working on the design, synthesis and biological 
studies of bryostatin analogues since the 1980s. Based on the fact that the phorbol esters, 
diacyl glycerols, and bryostatins, which are structurally different, bind competitively to 
the same activator C1 domain of PKC, Wender envisioned that these compounds would 
be expected to possess a common pharmacophore, i.e., a similar three-dimensional array 
of homologous functional groups in their bound or active conformations.  
First, the Wender group used a computer comparison of x-ray and/or calculated 
structures of the ingenol, teleocidin, gnidimacrin, and DAG, classes of protein kinase C 
activators, to identify the isospatial functional groups and hydrophobic regions that 
constitute the putative PMA pharmacophore.92 This approach suggested a critical role 
for the C4, C9, and C20 oxygens of the phorbol esters. The structural comparison was 
further extended for bryostatin 1.93  Quantification of the structural relationships among 
bryostatin 1, phorbol ester, and (S)-1,2-diacyl-sn-glycerol was accomplished by a 
computer-assisted comparison of the respective pharmacophoric oxygens of those three 
protein kinase C activators. Since the relative coordinates of the rotationally mobile C25-
C26 hydroxyethyl atoms can vary, the relative energies of all conformations resulting 
from rotation about the C25-C26 bond were calculated (MMP2). 
The results indicated that the C26 oxygen of the bryostatins, together with the C1 











square deviation of 0.16 Å. The extension of the phorbol ester pharmacophore model to 
the bryostatins and its agreement with the structure-activity relations for the bryostatin 
class of compounds provide additional support for the validity of the model (Figure 
1.6).94 
In cooperation with the Pettit group and the Blumberg group, the Wender group 
also systematically studied the structure-activity relationship of bryostatins based on the 
binding affinity, which was determined by the measurement of competitive inhibition of 
[26-3H]bryostatin 4 binding with PKC (Table 1.1).94 Their observation showed that 
different substituted groups on C7 and C20 position of bryostatins have a limited effect 
on the binding affinity. The chemically modified C13-C30 epoxide bryostatin 4 
analogue10  has a little better  binding affinity with PKC. Analogues in which both the 
C13-C30 and side chain on C20 are hydrogenated showed modestly reduced affinities, 
while the analogue in which C13-C30, C21-C34 and side chain on C20 are hydrogenated 
showed markedly reduced affinities. Elimination of the C19 hydroxyl group or inversion 
of stereochemistry at C26 has a more pronounced effect on affinity. Finally, acetylation 
at C26 eliminates significant binding affinity. Viewed collectively, these observations 
suggest that the binding of the bryostatins is only modestly affected by changes in the 
northern hemisphere or side chain on C20, while the modifications in the southern 
hemisphere dramatically alter the binding affinity.  
All the above results lead to the hypothesis proposed by the Wender group that 
the C4-C16 moiety in bryostatin 1 acts as a spacer domain, while the C19-C26 domain 
acts as a recognition domain during the binding with C1 domain within PKC. This 
hypothesis has been applied in the design of simplified, fully synthetic bryostatin  
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Table 1.1 Comparison of binding affinities to PKC of bryostatins (Bryo) 


















Bryo4 13, 30 epoxide 
Bryo4 26 acetate 
Bryo1 epi-26 
Bryo2 13,30, 2’,3’,4’,5’-hexahydro 









































analogues (Figure 1.7). The first de novo synthesis of a bryostatin analogue was reported 
by the Wender group in 1998.95 Compared with bryostatin 1, the first analogue 1.30 
retained of all the functionality of bryostatin 1 on the southern hemisphere, while the 
northern hemisphere of the analogue had been simplified into a pyran ring and a six-
membered cyclic acetal. Functionality along the C7-C13 periphery of bryostatin 1 was 
completely eliminated, and C14 was replaced by an oxygen to facilitate synthesis. The 
unsaturated side chain on C20 of bryostatin 1 was replaced by a saturated side chain on 
the same position of bryostatin analogue.  
The retrosynthetic plan to the analogue 1.30 is outlined in Figure 1.8. The cyclic 
acetalization will both form the cyclic acetal and close the macrolactone. The precursor 
1.31 was expected to be prepared by an intermolecular esterification between carboxylic 
acid 1.32 and alcohol 1.33. This convergent plan did not only provide analogue in a 
highly efficient manner, but also provide an opportunity to approach analogue libraries  
 
 





through combinatorial synthesis involving the coupling of recognition domain moiety 
1.33 with various readily available acid-acetals. 
The synthesis of aldehyde 1.33 started with (D)-methyl lactate 1.34, which was 
protected with a benzyl group (Scheme 1.5). Exposure of lactate to DIBAL-H at -78 °C 
was able to deliver the partially reduced aldehyde product. A chelation-controlled 
allylation in the presence of SnCl4 as the Lewis acid was chosen to set the 
stereochemistry on C25 position to afford homoallylic alcohol 1.35, which was protected 
with a PMB group and oxidatively cleaved by ozonolysis to give aldehyde 1.36.  
 
   
Figure 1.8 The retrosynthesis of Wender’s first bryostatin analogue 
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Trifluoroacetic acid catalyzed aldol reaction between ketone 1.37 and 
paraformaldehyde, followed by hydrolysis delivered alcohol 1.38, which was protected as 
a TBS ether. A second aldol reaction with ethanal generated alcohol 1.39, which was 
oxidized to afford the 1,3-diketone 1.40. A third aldol between the enolate dianion of 
diketone 1.40 and aldehyde 1.36 lead to a β-hydroxy ketone, which was subjected to       
p-toluenesulfonic acid to promote a cyclization and dehydration to afford the pyranone 
product 1.41 with a 1:1 ratio at C23. The desired β-isomer was easily separated and 
reduced under Luche conditions and the resulting glycal was epoxidized with mCPBA in 
the presence of MeOH to afford a C19-methoxylated C20, C21-diol 1.42. Selective 
benzoylation of the C21 equatorial alcohol followed by oxidation of the remaining C20 
hydroxyl group with Dess-Martin periodinane provided benzoate 1.43. Treatment of 1.43 
with SmI2 selectively deoxygenated on C21 to give a ketone. which underwent  an aldol 
condensation with methyl glyoxylate to give product 1.44, and the following mesylation 
and elimination successfully installed the desired E-exocyclic unsaturated ester at C21, 
providing enone 1.45.  
The enone 1.45 was reduced under Luche reaction conditions to afford the C20 
axial alcohol exclusively, which was esterified with octanoic acid to afford compound 
1.46 (Scheme 1.6). Completion of the target fragment, requiring a demanding two carbon 
homologation at C17, which proceeded through removal of the TBS group with 
HF/pyridine and oxidation of the resulting alcohol with Dess-Martin periodinane to give 
aldehyde 1.47. This hindered aldehyde was found to react with allyldiethylborane 
followed by Ac2O to generate an inconsequential mixture of acetates 1.48 in high yield. 
Dihydroxylation of the terminal olefin with catalytic OsO4 (NMO co-oxidant) afforded 
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the diol 1.49 and Pb(OAc)4-mediated glycol cleavage transformed the diol 1.49 into enal 
1.50. Exposure of 1.50 to DDQ selectively liberated the C25 alcohol, then treatment with 
aqueous HF, gave the target hemiketal 1.33. 
The synthesis of carboxylic acid 1.32 started with a stereoselective resolution of  
TMS protected 1,3,5-pentantriol 1.51 with (-)-menthone and TMSOTf. The resulting 
mixtures were easily separated by flash column chromatography and the desired alcohol 
1.52 subjected to Dess-Martin periodinane to afford the aldehyde 1.53 (Scheme 1.7). A 
hetero-Diels-Alder reaction between aldehyde 1.53 and Danishefsky’s diene lead to the 
formation of a pyranone, which was regioselectively reduced by a Luche reaction to give 
pyran 1.54. A Claisen rearrangement was chosen to set the stereochemistry at C5 to give 
aldehyde 1.55, and the resulting double bond was reduced by a hydrogenation catalyzed 
by palladium. A Brown asymmetric allylation set up the C3 stereocenter, and the 
resulting homoallylic alcohol was protected with a TBS group to afford 1.56. The olefin 
was transformed into an acid by the combination of KMnO4 and NaIO4. The TBS group 
was swapped with a TES group in a two steps manner to give acid 1.32. 
The acid 1.32 and alcohol 1.33 were coupled together using Yamaguchi’s 
conditions to give 1.31, then the TES group on the C3 position was removed by HF/Py. 
Finally, treatment with Amberlyst-15 promoted the formation of the macrocycle and 
completion of bryostatin analogue 1.30 (Scheme 1.8). The C26 hydroxyl group was 





Scheme 1.5 Synthesis of recognition domain of first bryostatin analogue  
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The analogues 1.30 and 1.57 were evaluated for their ability to bind to a mixture 
of rat brain PKC isozymes. The results show that the analogue 1.30 has a similar binding 
affinity with PKC as does bryostatin 1.  (Analgoue 1.30, Ki = 3.4 ± 0.6 nM; bryostatin Ki 
= 1.37  ± 0.17 nM).95 The C26 acetate analogue 1.57 lost its binding affinity with PKC 
(Ki >> 100 nM), which confirmed the importance of the C26 hydroxyl group in binding 
with PKC. The growth inhibitory activities of the analogues 1.30 against several known 
cancer cell lines indicated that the analogue 1.30 could inhibit the growth of cancer cells 
in nanomolar concentration (Table 1.2).94 
 
 




Scheme 1.8 The completion of bryostatin analogue 1.30 
 
Table 1.2. In vitro cell growth inhibitory activity of analogue 1.30 
Human cancer cell line               GI50 (μg/ml) 
BXPC-3 (pancreas) 
NCI-H460 (lung-nonsmall cell) 
FADU (pharynx) 
DU-145 (prostate) 
           6.0 × 10-3 
2.3 × 10-1 
1.8 × 10-3 






The Wender group also studied the solution conformation of bryostatin analogue 
1.30.94 The high field one- and two-dimensional proton NMR spectra of analogue 1.30 
showed a close correlation between the 1H chemical shifts and multiplicities in CDCl3 
with those of bryostatin 10 throughout most of the putative pharmacophoric region (C16-
C23). Phase-sensitive nuclear Overhauser effect spectroscopy (NOESY), total correlation 
spectroscopy (TOCSY), and double quantum-filtered correlated spectroscopy (DQCOSY) 
spectra of analogue 1.30 in C6D6 were analyzed to determine the identity and categorical 
distances between protons throughout the structure. The results were applied to a 
constrained gas-phase molecular dynamics simulation, and followed by minimization. 
Among the conformers that were identified, six were within 2 kcal/mol of the global 
minimum. The lowest energy conformers satisfied all the nuclear Overhauser effect 
constraints and compared favorably with the published crystal structure of bryostatin 1 as 
well as the solution structure of bryostatin 10. Superpositioning of the lowest energy 
conformer and the crystal structure of bryostatin 1 (comparison of all atoms except 
hydrogen) gave a rms deviation of 0.506 Å, while the rms deviation calculated by 
superimposing the pharmacophoric atoms (C16-C23 region) of the lowest-energy 
conformer onto their counterparts in bryostatin 1 is 0.313 Å, indicating a remarkably 
good correlation between the two in their recognition region.  
All the results from the binding affinity, biological studies and computational 
analysis support Wender’s hypothesis of bryostatin analogue design, which also 
encouraged them to further improve their route by simplifying and diversifying these new 
leads to help elucidate the molecular basis for bryostatin’s activity. 
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In 2002, the Wender group published their second generation synthesis of 
bryostatin analogues.96 The synthesis of the C15-C26 recognition domain began with the 
monoprotection of diol 1.58 as a TBS ether and the resulting alcohol was oxidized by 
Parikh-Doering oxidation to generate aldehyde 1.59 (Scheme 1.9). Reaction of 1.59 with 
the Grignard reagent derived from 4-chloro-1-butanol followed by Swern oxidation 
afforded aldehyde 1.60. Keck asymmetric allylation of aldehyde 1.60 provided 
homoallylic alcohol 1.61. Dehydrative cyclization of 1.61 promoted by p-toluenesulfonic 
acid afforded the glycal 1.62, which underwent an epoxidation and in situ methanolysis 
to yield a mixture of diastereomers, the major of which was oxidized to ketone 1.63. 
Conversion of ketone 1.63 to enone 1.64 was accomplished in one step by treatment with 
K2CO3 and methyl glyoxylate in MeOH at room temperature as compared to the three 
step sequence in the first generation synthesis. A highly diastereoselective reduction of 
enone 1.64 followed by esterification afforded ester 1.65.  Deprotection of the TBS group 
on C17 followed by oxidation gave aldehyde 1.66.  
Because aldehyde 1.66 is both sterically hindered and susceptible to 
deprotonation at the C22 position, chain extension using this intermediate proved 
challenging. A reaction using a vinyl zincate derived from (Z)-1-bromo-2-ethoxyethene 
was found to be effective for the homologation of the carbon chain to afford the enal 1.67 
(Scheme 1.10).96 Sharpless asymmetric dihydroxylation conditions were used to convert 
1.67 to diol 1.68 with 2.5:1 diastereoselectivity. The diastereomers were separated 
following hydrolysis of the C19 ketal and selective protection of the primary alcohol on 







Scheme 1.9 The second generation synthesis of recognition domain   
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Scheme 1.10 The second generation synthesis of recognition domain 
 
The synthesis of the C1-C13 spacer domain began with ozonolysis and in situ 
reduction of 1.70, which produced pentane-1,3,5-triol in a manner superior to that of 
previous methods (Scheme 1.11). Desymmetrization of the resulting triol via acetal 
formation with (-)-menthone and subsequent oxidation yielded a mixture of aldehydes 
1.52, which were separated by flash column chromatography. A hetero Diels-Alder 
cycloaddition between aldehyde 1.52 and Danishefsky’s diene using Jacobsen’s tridentate 
Cr (III) catalyst provided a pyranone with exceptional selectivity (33:1). At this point, 





Scheme 1.11 The Second Generation Synthesis of Recognition Domain 
 
The carboxylic acid 1.32 and alcohol 1.69 were coupled together with the 
Yamaguchi protocol to give product 1.71 (Scheme 1.12). Treatment with HF/Py not only 
removed the silyl groups, but also promoted the transacetalization to close the 
macrocycle, and set the C15 stereocenter under thermodynamic control, leading to the 
final product 1.72. 
The bryostatin analogue 1.72, which does not have the C27 methyl group when 
compared with the first bryostatin analogue 1.30, shows a better binding affinity with 
37 
 
PKCs (Ki = 0.25 nM). When tested in vitro against various human cancer cell lines, both 
analogue 1.30 and 1.72 displayed greater potency than bryostatin 1. Analogue 1.72 
outperformed bryostatin 1 at inhibiting the growth of cancer cells, in some cases by up to 
three orders of magnitude.97 
The PKC translocation test indicated analogues were able to induce translocation 
of PKC as did bryostatin 1.98 The treatment with analogue 1.72 and 1.30 were able to 
cause the translation of PKC to the membrane, which could be visualized under 




Scheme 1.12 The Second Generation Synthesis of Bryostatin Analogue 1.72 
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RasGRP is a protein family with C1 domain that appears to play a critical role in 
T-cell receptor signaling. Activation of RasGRP appears to be responsible for some of the 
immune system effects previously attributed to PKC. Once RasGRP is activated and 
translocated to the plasma membrane, it activates Ras and initiates a series of 
downregulation relate to immune response. When analogues 1.72 and 1.30 were tested in 
HEK-293 cell assays measuring RasGRP1 activation, the compounds displayed the 
activities similar to bryostatin 1.99 
In summary, by utilizing their convergent methodology, the Wender group was 
able to systematically investigate the structure and activity relationship (SAR) through 
the synthesis of bryostatin analogues (Figure 1.9).96,100-105 All the bryostatin analogues 
show high potency of binding with PKCs. 
Wender concluded his bryostatin analogue work into a new term as function-
oriented synthesis (FOS) and illustrated its importance to drug discovery.97,106,107 He 
stated that natural products are not “designed” for human therapeutic use and as a 
consequence often have undesired side effects. By focusing on target-specific function, 
FOS can be used to minimize off-target activities and to enhance beneficial activities, 
such as optimize formulation, ADME, and pharmacokinetic performance, thereby 
voiding problems exhibited by many natural products. Most importantly, it can address 
the concern that some natural products are too complex to make practically by replacing 
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 CHAPTER 2 
STUDY OF THE EFFECT OF C7 ACETATE AND C13 ENOATE ON 
BIOACTIVITIES OF BRYOSTATIN 1 THROUGH THE  
SYNTHESIS OF BRYOSTATIN ANALOGUES 
Keck’s Bryostatin Analogue Study 
The Keck group has been involved in the synthesis of bryostatin 1 and analogues 
since the 1990s. The methodology termed as pyran annulation developed by Dr. Covel 
and Dr.Yu in the Keck group provides an efficient and flexible route to prepare 2,6-di-
substituted pyrans in a two step manner (Scheme 2.1).1 The first step involves a catalytic 
asymmetric allylation (CAA) between an aldehyde and 2-trimethylsilylmethallyl 
stannane 2.1 forming the corresponding β-hydroxyallylsilanes. The second step is a Prins 
type cyclization involving treatment of the hydroxyallylsilane with a second aldehyde 
and TMSOTf at -78 °C, which subsequently undergoes cyclization to afford the cis-2,6-






















Scheme 2.1 Asymmetric Pyran Annulation 
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Dr. Sanchez accomplished the total synthesis of dactylolide by using the pyran 
annulation to construct the 2,6-syn pyran ring (Scheme 2.2).2  The CAA reaction between 
stannane 2.1 and aldehyde 2.2 gave hydroxyallylsilane2.3, which underwent pyran 
annulation with aldehyde 2.4 to afford pyran 2.5 in excellent yield as a single 
diastereomer. The successs of the pyran annulation led to the completion of the synthesis 
of dactylolide in 7.1% overall yield. 
Bryostatins, which contain three highly functionized pyran rings incorporated 
onto a 20-membered macrolactone, are also excellent candidates to apply the pyran 
annulation technique. Dr. Covel demonstrated that the pyran annulation could work as a 
powerful tool in the approach to the core structure of the northerm hemisphere of 
bryostatin 1.1 The CAA reaction between aldehyde 2.6 and stannane 2.1 provided the 
hydroxyallylsilane 2.7, which underwent the first pyran annulation with aldehyde 2.2 to 
give the pyran product 2.8. The TBDPS group was removed by TBAF, and the resulting 
primary alcohol was oxidized into an aldehyde 2.9, which was subjected to a second 
pyran annulation with hydroxyallylic silane 2.3 to give the bis-pyran product 2.10, which 
contains the carbon skeleton of the C3-C16 moiety of bryostatin 1 (Scheme 2.3).  
This efficient and convergent route provided us a powerful approach to bryostatin 
analogues. Based on Wender’s hypothesis, the northern hemisphere of  bryostatin 1 acts 
as a spacer domain, presumably only assisting to help bryostatin to maintain certain 
conformations, and the removal of substituents on the A and B ring will  not have a 
dramatic change on its binding affinity or biological activity. We devised our first 
bryostatin analogue 2.11, which has the simplified pyran rings on the northern 














domain (Figure 2.1). The 2,6-cis pyran rings were to be constructed by the pyran 
annulation.  The exocyclic olefins on the A and B rings would allow us to install different 
groups there and study the structure activity relationship of the northern hemisphere. 
 Dr. Truong and Dr. Sanchez in our group accomplished the synthesis of the first 
bryostatin analogue 2.11.3,4 The retrosynthesis of this analogue is outlined in Figure 2.2. 
The target molecule was expected to be prepared from the advanced tricyclic 
intermediate 2.12, which was disconnected on the A ring into aldehyde 2.13 and 
hydroxyallylsilane 2.14. Those two fragments were to be coupled by a pyran annulation. 
The formation of the B ring was also expected to come from another pyran annulation 
between aldehyde 2.15 and allylsilane 2.3. Both allylsilane 2.14 and 2.3 would be 
prepared from reactions using the substituted stannane 2.1. The aldehyde 2.15 was to be  
planned to be prepared from the acyclic thioester, which would go through a cyclization 








Figure 2.2 Retrosynthesis of Keck’s bryostatin analogue 
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2.16 would be prepared from the simple aldehyde 2.17 through a series of carbon-chain 
elongation reactions, which include Horner-Emmons reaction, prenylation, and substrate 
controlled allylation.  
The synthesis of aldehyde 2.15 started with commercially available (R)-isobutyl 
lactate 2.18 (Scheme 2.4). BOM protection and half reduction by DIBAL-H afforded the 
aldehyde 2.17. Chelation-controlled allylation by reaction with allylstannane and 
MgBr2·Et2O provided the homoallylic alcohol 2.19 as a single diastereomer. After 
protection of the resulting alcohol as a PMB ether, oxidative cleavage of the olefin using 
ozonolysis led to aldehyde 2.20. The BOM and PMB ethers served both as protecting 
groups and also as directing groups to set the stereocenters on the C25 and C23 positions. 
Another chelation-controlled allylation was utilized to set a new stereocenter at C23. The 
resulting alcohol 2.21 was then protected as a TBS ether to give olefin 2.22. The 
Buchwald protocol of hydroformation with a bulky ligand 2.23 smoothly delivered the 
desired terminal aldehyde 2.24 in excellent yield. Treatment of aldehyde 2.24 with a 
prenyl indium reagent generated in situ in DMF afforded a mixture of alcohols, which 
were then oxidized with a combination of PCC and NaOAc to afford ketone 2.25. The 
olefin on 2.25 was oxidatively cleaved by ozonolysis. The resulting aldehyde is not stable, 
and was immediately subjected to a Horner-Emmons reaction to give the desired α, β-
unsaturated thiol ester 2.16. Deprotection of the TBS ether using HF/py buffer, and the 
ensuing cyclization and dehydration promoted by CSA in benzene gave the desired glycal 
2.26 in one pot. Half-reduction of the thiol ester with diisobutylaluminium hydride at -78 





Scheme 2.4 The synthesis of southern hemisphere of Keck’s first analogue 
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The pyran annulation between the aldehyde 2.15 and allylsilane 2.3 led to pyarn 
product 2.27 (Scheme 2.5). The removal of the TBDPS group and exposure to Dess-
Martin oxidation conditions afforded aldehyde 2.13.5 A second pyran annulation with 
allylsilane 2.14 furnished the tricyclic product 2.12. The glycal moiety on 2.12 was 
oxidized with mCPBA in MeOH, and the resulting epoxide was not stable, resulting in in 
situ methanolysis to afford the ketal. Removal of the TBDPS ether at C1 was achieved 
with TBAF, and the resulting diol 2.28 was oxidized to keto-aldehyde by TPAP and 
NMO. Pinnick oxidation transformed the aldehyde into an acid, and the deprotection of 
the PMB group afforded the seco-acid 2.29. Yamaguchi macrolactonizaiton was used to 
cyclize the macrocycle and global deprotection with LiBF4 finished the analogue 2.30 
with a tricyclic skeleton similar to bryostatin 1.6,7 
Analogue 2.30 was tested by our coworker, Dr. Blumberg at the NIH for its 
binding affinity with PKCα, the results shows the analogue has a Ki = 546 nM, which is 
about 2 orders of magnitude lower than bryostatin 1 (Ki = 1.37  ± 0.17 nM). The 
biological results suggest that functional groups on the C ring are important in binding.  
Dr. Sanchez synthesized analogue 2.11 with full functionality on the C ring from Dr. 
Troung’s work (Scheme 2.6). The synthesis started with advanced intermediate 2.31. The 
C3 hydroxyl group was protected as a TBS ether. The C20 ketone on 2.32 was subjected 
to an aldol reaction with methyl glyoxylate and an elimination reaction promoted by 
Burgess’s reagent was used to afford the enoate 2.33. The ketone on C20 was reduced 
with Luche conditions,8 and the resulting alcohol was immediately esterified with 
benzoic anhydride to generate the ester 2.34. The global deprotection with LiBF4 












































































































































































Ki = 1.4 ± 0.1 nM  






indicated 2.11 showed similar binding affinity with PKCα (Ki = 1.4 ± 0.1 nM) as does 
bryostatin 1 (Ki = 1.37 ± 0.17 nM). 
 
Synthetic and Biological Study of Bryostatin Analogue 
 With C7 Acetate 
After the completion of the first generation synthesis of bryostatin analogues, we 
sought to improve the synthetic route and explore to the bioactivities of diversified 
analogues. The second generation synthesis of bryostatin analogues concentrated on the 
follow aspects: (1) the first generation synthesis proceeded in a linear manner, through 
which the pyran rings were constructed sequentially. The linear route made it difficult to 
bring up enough material for biological testing. Only 0.6 mg of 2.11 was prepared. A 
more convergent route would make the synthesis more efficient and address the problem 
of supply; (2) the acid-sensitive glycal 2.15 decomposed during the pyran annulation 
resulting in a modest yield; (3) the structure and activity relationship study required us to 
install different functionality. Besides the analogue 2.11, we were also interesting in the 
preparation of analogues with different functional groups on C7 and C20 positions.  
The revised route to bryostatin analogues is outlined in Figure 2.3. The bryostatin 
analogues 2.35 was expected to be prepared from intermediate 2.36, which was 
disconnected into aldehyde 2.37 and allylsilane 2.38. The pryan annulation would act to 
connect two equally complicated moieties, with concommitment formation of the B ring, 
which represents a new route compared to the bryostatins. We envisioned that the 
allylsilane 2.38 would be prepared from the ester 2.39, which would be constructed using 
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expected to be synthesized from β-keto ester 2.41 by Noyori asymmetric hydrogenation.  
The synthesis of silane 2.14 began with monoprotection of 1,3 propandiol 2.42 
with a TBDPS group (Scheme 2.7) to give the alcohol 2.43, which was oxidized by  
Swern oxidation to afford aldehyde 2.2. Catalytic asymmetric allylation of aldehyde 2.2 
provided the homoallylic alcohol 2.44 with excellent yield and high enantioselectivity.9 
KHMDS was used at low temperature to install the PMB protecting group on 2.44 
smoothly without observation of silyl group transfer. The use of PMB imidate was also 
tested to install the PMB ether on C3 position; however, the difficulty of isolation after 
work-up makes the first method superior. The resulting olefin 2.45 was cleaved by 
ozonolysis to give aldehyde 2.46. A chelation-controlled allylation converted aldehyde 
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Scheme 2.7 Synthesis of intermediate allylsilane 2.14 
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The synthesis of aldehyde 2.40 started from benzyl alcohol 2.47 (Scheme 2.8). 
Michael addition between benzyl alcohol 2.47 and acrylonitrile in the presence of 40% 
NaOH aqueous solution gave nitrile 2.48 in quantitative yield without any purification 
after workup. Reformatsky reaction of α-bromo acetate with nitrile 2.48 and Zn/Cu 
couple gave a volatile enamine, and the following hydrolysis converted the enamine into 
β-keto ester 2.41.11 Slow adding α-bromo acetate into the reaction via syring pump 
proved to be the key for the Reformatsky reaction. The Noyori asymmetric 
hydrogenation was utilized to reduce 2.41 into alcohol 2.49 with high yield and high 
enantioselectivity.12 This procedure was utilized to prepare 50 grams of product 2.49 
without any problem in scale up. The hydroxyl group on alcohol 2.48 was protected with 
a TBS group to give silyl ether 2.50. Deprotection of the benzyl group by catalytic 
hydrogenation over Pd/C, and Parikh-Doering oxidation afforded the aldehyde 2.40. 
 
 
Scheme 2.8 Synthesis of aldehyde 2.40 
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With hydroxyallylsilane 2.14 and aldehyde 2.40 in hand, we were able to couple 
those two pieces using the pyran annulation (Scheme 2.9). In the presence of the Lewis 
acid TMSOTf, the pyran annulation gave the pyran 2.39 smoothly with a yield of 96% as 
a single diastereomer. The selective deprotection of the TBS group on 2.39 was not 
straightforward. A few reaction conditions with different acids and solvents were 
screened and the products after deprotection always included some amount of 2.51 with 
loss of both TBS and TBDPS groups. We also tested the route by replacing the TBS 
group with TES on aldehyde 2.40 in order to differentiate the deprotection of TES and 
TBDPS groups after pyran annulation; however the pyran annulation between the 
aldehyde with TES and hydroxyallylsilane 2.14 proceeded in low yield, and the TES 
group came off during the pyran annulation. The optimized reaction conditions for 
deprotection of the TBS group proved to be treatment of 2.39 with 2.0 equivalents of p-
toluenesulfonic acid in the media of benzene/MeOH (60/40) for 5 h at rt. After column 
chromatography, the product 2.51 was isolated in 35% yield and the desired product 2.52 
with 59% yield. Fortunately, the product 2.51 could be easily converted to 2.52 by 
treatment with TBDPSCl, NEt3 and 4-dimethylaminopyridine in a yield of 97%, which 
gave a total yield of 92% from 2.39 to 2.52. The hydroxyl group on 2.52 was protected 
with a TMS to give 2.53 in almost quantitative yield. Subjecting this ester to the Bunnelle 
reaction conditions afforded the hydroxylallylsilane 2.38 in 81% yield after acidic work-
up. Dehydration of CeCl3 •7H2O was critical to the Bunnelle reaction. Trace amounts of 
water would dramatically decrease the yield. In order to prepare anhydrous CeCl3 •7H2O, 





Scheme 2.9 Synthesis of hydroxyallylsilane 2.38 
 
In order to diversify the functionality at the C7 position, we investigated routes to 
modify the functionality on C7 (Scheme 2.10).  The olefin in pyran 2.53 was cleaved by 
ozonolysis and reduced by PPh3 to give ketone 2.54, which was reduced to alcohol 2.55 
by NaBH4.  The free hydroxyl group in 2.55 was protected with a TMS group to afford 
the precursor 2.56. The Bunnelle reaction was utilized again to convert 2.56 to 
hydroxyallylsilane 2.57. The free hydroxyl group on the C7 position of the 
hydroxyallylsilaneprovides us an opportunity to synthesize bryostatin analogues with 




Scheme 2.10 Synthesis of allylsilane 2.57 
 
 The stereochemistry at the C7 position was confirmed by observation of nOe of 
the C7 acetate product 2.58 from alcohol 2.55. The nOe results indicated that the proton 
on the C7 was axial (Scheme 2.11).  
While this work was in progress, Dr. Kraft in our group prepared aldehyde 2.37.13 
With both allylsilane and aldehyde in hand, we were able to test the pyran annulation. 
The coupling between hydroxyl aldehyde 2.37 and allylsilane 2.38 afforded the tricylic 
product 2.36 in good yield and as a single diastereomer. Dr. Kraft successfully carried 
this tricyclic product to the final bryostatin analogues, Merle 21-23, with different groups 




Scheme 2.11 Confirmation of stereochemistry of C7 hydroxyl group  
 
 The TBDPS group on C1 of the resulting pyran annulation product 2.36 was 
selectively removed by treatment with TBAF and AcOH without removing the TBS 
group on C25. The free alcohol was exposed to Parikh-Doering oxidation followed by 
Pinnick oxidation of the crude aldehyde to give the carboxylic acid 2.59 in excellent yield. 
The deprotection of the TBS group with HF/py afforded the seco acid, which was 
cyclized to give macrolactone 2.60 by utilizing Yamaguchi conditions. The remaining 
steps to the final products required functionalizing the C-ring and global deprotection. 
During the aldol reaction between ketone 2.59 and freshly prepared glyoxylate, the 
deprotonation of α-H of C20 ketone with KHMDS also induced elimination at the C3 
position due to the electron withdrawing effect from the C1 carbonyl. After optimiziation 
of the reaction conditions, the use of 3 equiv of freshly prepared LDA solution could 
avoid the undesired elimination reaction, affording the desired aldol product in 76% yield 
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turned into a real challenge. Conditions used in previous syntheses of bryostatins led to 
low yields or complete decomposition. Ultimately, a new procedure for this very 
demanding reaction was devised, which involved treatment with carbonyl diimidazole 
(CDI) in the presence of (i-Pr)2NEt to give the enoate 2.61. Luche reduction of the C20 
ketone in 2.61 gave the desired alcohol, which was immediately acylated to give 
protected versions of analogue precursors 2.62. Removal of the protecting groups 
commenced by deprotection of the PMB group with DDQ. Finally, global deprotection of 
the remaining groups could be accomplished using the LiBF4 conditions to afford 
analogues Merle 21-23.13 
The analogues were submitted to Dr. Blumberg at the National Cancer Institute 
for biological tests. All three of these compounds proved to have similar or higher 
binding affinity for PKCα than does bryostatin (bryostatin 1, Ki = 1.35 nM) since all the 
analogues have the same recognition domain as bryostatin 1.14 The different substituted 
groups on the C20 position have little effects on binding affinity with PKC, which 
provides a tunable position for future analogue design. Our attention was more focused 
on whether the analogues behaved like bryostatin 1 in living cells. Each of these 
analogues was screened for activity on the proliferation and attachment of U937 leukemia 
cells.15 In these assays, phorbol esters inhibit proliferation and induce attachment. 
Bryostatin 1 shows only a limited effect and correspondingly blocks the effect of the 
phorbol ester at high concentration. If the analogues were to act simply as PKC activators, 
they would inhibit proliferation and induce attachment both alone and in the presence of 
PMA. If they were to act as functional antagonists, they would show little reduction in 
proliferation or induction of attachment and would restore proliferation and block 
66 
 
attachment in the presence of 10 nM PMA. The biological test results indicated that all 
three analogues behaved like PMA instead of bryostatin.  Results with Merle 23 in the 
proliferation and attachment assay of U937 cell line are shown in Figure 2.4 and 2.5. It is 
clear that the fingerprint displayed here by Merle 23 is virtually identical to that of the 
tumor-promoting phorbol ester PMA and distinctly different from that of bryostatin 1. 
According to Wender’s hypothesis, the northern hemisphere acts only as the spacer 
domain, but the biological tests of Merle 21-23 suggest that this spacer domain also has a 
contribution to the unique bioactivities of bryostatin 1. This may have significant 
implications regarding the projected use of such compounds as therapeutic agents. 
Merle 23 can be seen to differ from bryostatin 1 at just four positions in the 
northern hemisphere. The identification, through synthesis, of the contribution of 
substituents in this region to the bryostatin-like behavior became essential to our study. 
We planned to investigate each functional group through chemical synthesis, and selected 
as our next target was analogue with the C7 acetate on the A ring.  
Wender’s docking study indicated that the C7 functionality of bryostatin is 
proximate to a conserved tryptophan residue in the novel class of PKC isozymes and a 
conserved tyrosine residue in the conventional class of PKC isoforms.16 The docking 
studies, using the crystal structures of PKC and bryostatin 1, are guided by their 
pharmacophore hypotheses rather than a global conformational search. In this approach, 
the conformation of bryostatin 1 obtained by X-ray crystallography was overlaid with the 
phorbol 13-acetate found in the PKCδ C1B domain crystal. The C1 carbonyl, the C19 


















C20 hydroxyls of phorbol 13-acetate. The phorbol molecule was then removed and the 
resulting bryostatin–PKCδ-C1B complex was minimized using the AMBER force field. 
We expected that the synthesis of C7 acetate analogue 2.63 would provide us the 
opportunity to investigate the effect of C7 acetate on the biological activity of the 
bryostatin analogue. The retrosynthetic strategy is outlined in Figure 2.6. In order to 
avoid the problematic elimination of the PMB ether on the C3 position, we decided to 
cyclize the macrolactone after installation of the enoate on the C ring. This analogue 
would be prepared from advanced intermediate 2.64, which we planned to synthesize 
from ketone 2.65. The pyran annulation between aldehyde 2.37 and hydroxyallylsilane 
2.57 was expected to allow construction of pyran product 2.65. 
Pyran annulation between C-ring enal 2.37 and allylsilane 2.57 under our standard 
conditions of TMSOTf in diethyl ether gave the desired tricyclic product 2.66, as a single 
diasteromer, in excellent yield (Scheme 2.13).  Protection of the C7 OH using TBSOTf 
and 2,6-lutidine gave 2.65 in almost quantitative yield. The aldol condensation with 3.0 
of equiv LDA solution and methyl glyoxalate smoothly gave a diastereomeric mixture of 
aldol products in 92% yield, which underwent elimination by treatment with Ac2O and 4-
dimethylaminopyridine  in pyridine at 60 °C to give 2.67 in 93% yield.  The changes of 
reaction order improved the yields during the aldol and elimination steps, and avoided the 
possible side reactions.  
The resulting enoate 2.67 was then subjected to Luche reduction followed by 
acylation with octanoic anhydride to give 2.64 (Table 2.1).8  When the same conditions 
were applied as with Merle 21-23, a mixture of diastereomers with selectivity of only 7:1 



























































































































































Scheme 2.13 Functionalization of C ring after pyran annulation 
 
and NaBH4 at -42 °C. Further optimization involved dissolution of CeCl3·7H2O at room 
temperature led to an improved diastereoselectivity of 22:1. The concentration also 
played some effect on the selectivity; the reaction in 0.005 M MeOH led to the single 
diastereomer of product.  
Selective removal of the TBDPS group at the C1 position of intermediate 2.64 
using TBAF and AcOH in DMF afforded the primary alcohol 2.68, which was 
transformed to acid 2.69 by sequential Parikh-Doering and Pinnick oxidations with a 
quantitative yield.  Removal of both TBS groups (at C7 and C25) using HF·Py then gave 
the corresponding dihydroxy acid 2.70. There are examples showing the successful 
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a: The yields were calculated based on the isolated ester 2.63 
b: CeCl3 • 7Η2Ο was added at -42 °C 
C: CeCl3 • 7H2O was added at rt. 
 
regioselective macrolactonization accomplished on the dihydroxy acid substrates in the 
syntheses of bryostatin and analogues.4,17 When we applied the Yamaguchi reaction to 
the dihydroxy acid 2.70, the only isolated product is the macrolactone 2.71 but with C7 
acylated by 2,4,6-trichlorobenzoyl chloride.18 Final global deprotection of the 
macrolactone 2.71 led to the unexpected analogue 2.72 (Scheme 2.14).  
In order to preclude the undesired acylation of C7, this hydroxyl needed to be 


































PH 7 buffer, 0°C
(2) LiBF4, MeCN/H2O
(25:1), 80°C,



































































Ki = 13 ± 3.8 nM
 
Scheme 2.14 Synthesis of unexpected analogue 2.70 
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used 4-dimethylaminopyridine  and TESCl at -15 °C to protect the C3 free hydroxyl 
group in the presence of a free C25 OH and the C1 carboxylic acid in their synthesis of 
bryostatin 3.19  The same reaction conditions were applied to substrate 2.70 to deliver the 
C7-protected seco-acid 2.71; the Yamaguchi reaction finally delivered the macrolactone 
2.72.  Removal of the TES group followed by acetylation gave the desired C7 acetate 
derivative 2.73.  Finally, protecting group removal by DDQ then LiBF4 in aqueous 
CH3CN gave analogue Merle 27 (Scheme 2.15).   
The C20 stereochemistry was determined by using a nOe experiment on 
intermediate 2.72.18 A nOe was observed between the equatorial C20 proton and the 
nearby C34 proton (Figure 2.7). Interestingly, the nOe between C20 proton and C34 
proton was not observed in the open-chain intermediate 2.63. 
Both analogues were also submitted to Dr. Blumberg of the NIH for the biological 
tests. Both compounds proved to have a similar affinity for PKCα to that of bryostatin 
and Merle 22.  The C7 acetate group did not change the binding affinity with PKC 
dramatically; but the bulky 2,4,6-trichloro benzoate group does lower the affinity about 
10 times  relative to that of Merle 22. The proliferation and attachment of the U937 
leukemia cells test indicated both analogues behaved like PMA instead of bryostatin 1 
(Figure 2.8 and 2.9).  In the test, both analogues inhibited the proliferation and initiated 
the attachment of the U937 cell line as did the phorbol ester, while bryostatin 1 showed 
limited effect on the proliferation and attachment of the U937 cell lines. From the 
biological test results, we concluded the C7 acetate is not the critical northern hemisphere 

































































pH 7 buffer, 0°C
(2) LiBF4, MeCN/H2O
(25:1), 80°C;



































Ki = 3.0 0.6 nM  




Figure 2.7 Confirmation of stereochemistry on C20 by nOe 
 
Interestingly, among the 12 C7-functionalized derivatives reported by the Wender 
group, the highest affinity for PKCs was shown by the C7-exomethylene derivative 
2.76.20 All other modifications at C7 gave materials with decreased affinity for PKCs. 
The ratio of Ki between C7 exomethylene analogue 2.76 and C7 acetate analogue 2.77 is 
2.45. The same is true of the C7 acetate Merle 27 and the C7 trichlorobenzoate analogue 
2.72, which are less potent than the exomethylene compounds Merle 22. The ratio of Ki 
between C7 exomethylene analogue Merle 23 and C7 acetate analogue Merle 27 is 2.86. 
Thus, on both platforms, the exomethylene compounds are approximately 2.5-3-fold 
more potent in terms of binding than the compounds incorporating the natural C7 acetate 
functionality (Figure 2.10). From the results of the binding affinity of analogues, we 
learned that there is a quantitative structure and activity relationship between the C7 
substituents and the binding affinity with PKC. We can tune the binding affinity with 
PKC by changing the substituents on C7 position, which is very helpful for the design of 





















Figure 2.10 Comparison of binding affinitites of bryostatin analogues 
 
 While this work was in progress, Dr. Poudel in our group successfully prepared 
the C30 decarbomethoxy bryostatin 1 analogue.21 The pyran annulation was used to 
couple aldehyde 2.78 and hydroxyallylsilane 2.79 to form the tricyclic intermediate 2.80. 
Similar steps were chosen to install the functional groups on the C ring to give product 
2.81. The steric hindrance from the bulky TBDPS group on the C3 position makes the 
hydrolysis of the thioester with hydroperoxide and lithium hydroxide very tedious, 
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causing the removal of the acetyl group on C7 as well. The deprotection of the TBDPS 
group at C2 position improved the ensuing hydrolysis of the thioester and afforded the 
desired carboxylic acid in just one hour without loss of the acetyl group. The free 
hydroxyl group on the C3 position was then reprotected as the TES ether 2.82, and the 
removal of the PMB group on C25 position afforded the seco acid. Yamaguchi reaction 
conditions were utilized to form the macrolactone 2.83 and global deprotection with 
LiBF4 gave the analogue Merle 28 (Scheme 2.16).  
 The biological tests from Dr. Blumberg showed Merle 28 has a high affinity with 
PKCα (Ki = 0.52 ± 0.06 nM). The deletion of C30 ester did not affect the binding affinity. 
The proliferation and attachment of U937 cell lines indicated that Merle 28 behaved like 
bryostatin 1 instead of phorbol ester (Figure 2.11 and 2.12). Merle 28 showed limited 
effect on the proliferation and attachment of U937 cells; furthermore, it antagonized the 
effect of PMA in high concentration. The finger-print of this response reveals that Merle 
28 behaves very much like bryostatin 1. Viewed collectively with the previous results for 
Merle 27, these results clearly show that: (1) the C7 acetate or C30 carbomethoxy group 
alone is not essential to obtain bryostatin-like biological responses with these analogues; 
the deletion of C30 carbomethoxy group or the installation of C7 acetate does not switch 
the bioactivity of bryostatin analogues between bryostaitn-like and phorbol-like, and (2) 
the C9 OH and/or the C8 gem-dimethyl group may be critical in conferring bryostatin- 
like biological responses as opposed to those characteristic of the tumor-promoting 
phorbol esters. The next target molecule in our study would be focus on the preparation 





















































(1) HF, Py, THF
(2) LiOH, H2O2



















































Ki = 0.52 0.06 nM  

















 Dr. Poudel also completed the synthesis of C9 deoxy bryostatin 1 analogue 
(Scheme 2.17).22  The common intermediate glycal 2.78 was sequentially oxidized by 
magnesium monoperoxyphthalate (MMPP) and TPAP/NMO to afford the α-ketone ketal 
2.84. The hemiketal on the C9 position was selectively reduced by Et3SiH in the presence 
of TMSOTf. Ozonolysis regioselectively cleaved the olefin on the C13 position to afford 
the ketone 2.85. The removal of the PMB group on the C25 position with DDQ and 
hydrolysis of the thiol ester using mCPBA in aqueous THF afforded the seco acid 2.86 in 
good yield. The hydrolysis of the thioester with mCPBA proved to be selective for the 
thiolester without any hydrolysis of the C19 methyl ketal or Baeyer-Villiger oxidation of 
the B or C ring ketones. Yamaguchi macrolactonization of the resulting seco acid 2.86 
then afforded the macrolactone, and an asymmetric Horner-Emmons reaction using a 
chiral phosphonate with ketone on the C13 position provided a 4:1 mixture of Z/E olefin 
isomers.23 The C20 ketone in 2.87 underwent an aldol reaction with methyl glyoxylate 
and K2CO3; C7 acetyl group was also removed during the reaction and was reinstalled 
during the elimination reaction with Ac2O and pyridine to give enone 2.88. Luche 
reduction and esterification finished the modifications on the C ring to deliver the 
precursor 2.89 with a 6:1 mixture of diastereomers. The final deprotection was achieved 
with the treatment of HF/Py, followed by LiBF4 in MeCN/H2O at 80 °C, affording the 
final product Merle 30.  
The biological test on U937 cell line showed Merle 30 has a high affinity with 
PKC (Ki = 0.38 ± 0.07 nM). The deletion of the C9 hydroxyl group does not affect the 




Scheme 2.17 Poudel’s synthesis of analogue Merle 30 
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behaved like bryostatin 1 instead of phorbol ester (Figure 2.13 and 2.14). Merle 30 
showed limited effect on the proliferation and attachment of U937 cells; furthermore, it 
antagonized the effect of PMA in high concentration. The profile of response suggests 
that Merle 30 behaves like bryostatin 1.  
The biological activity of Merle 30 was also examined in another system, the 
androgen-dependent human prostate cancer cell line LNCaP, for two different endpoints: 
proliferation and secretion of tumor necrosis factor α (TNFα), a key mediator of 
inflammation. In this system, PMA inhibited cell proliferation and induces apoptosis 
whereas bryostatin 1 does not. Merle 30 behaved almost identically to bryostatin 1; it did 
not inhibit LNCaP proliferation but antagonized the inhibition by PMA (Figure 2.15). For 
induction of TNFα secretion, the three agents behaved differently: PMA induced a potent 
response, bryostatin 1 induced no response, and Merle 30 induced a weak biphasic 
response (Figure 2.16). Once again, bryostatin 1 and Merle 30 blocked the response to 
PMA. Although there is clearly some effect due to the deletion of the C9 OH, we 
conclude that the C9 hydroxyl of bryostatin 1 makes only a minor specific contribution to 
the unique patterns of biological response to bryostatin 1. 
It has been suggested by the Itai group that the C9 OH might be a key structural 
feature based in their computational study. The docking study between simplified 
bryostatin 1 structure with X-ray structure of PKCδ C1 domain suggested that there are 
four hydrogen bonds existing during the binding of bryostatin with C1 domain. One of 
them occurs between the C9 OH and the carbonyl of Met239 in the PKCδ C1 domain. 
The biological results suggest that the proposed hydrogen bonding between the C9 OH 


































Synthetic and Biological Study of Bryostatin Analogue With  
C7 Acetate and C13 Enoate  
When all the bryostatin analogues prepared are viewed collectively, we find that 
the deletion of the the C30 carbomethoxyl or C9 OH substituent does not switch the 
bryostatin-like bioactivity into phorbol-like activity; moreover the installation of the C7 
acetate alone does not render the analogue with bryostatin-like activity. It is possible that 
no single functional group on the A and B pyran rings is responsible for the unique 
bioactivities of bryostatin 1, which may be based on the cooperation or well-balanced 
physico-chemical properties among those substituents. When we divide all the analogues 
examined into two groups as bryostatin-like and PMA-like, we can find (1) all the PMA-
like analogues have no polar group or only one polar group on the northern hemisphere; 
(2) all the bryostatin-like analogues and bryostatin 1 have 2 or more polar groups in the 
same region (Figure 2.17). 
Additionally, the membrane translocation of PKCs is considered as the hallmark 
of PKC activation. The Blumberg group reported that tumor-promoting PMA translocates 
PKC to the plasma membrane in CHO-K1 cells, while bryostatin 1 mainly translocates it 
to the nuclear membrane.24 They suggested the lipophilicity of PKC ligands to be a 
critical factor that controls the cellular localization of PKCH0 δ.25 Hydrophobic ligands, 
such as PMA, tended to translocate PKC to the plasma membrane, whereas more 
hydrophilic ligands, such as bryostatin 1, moved it to the nuclear membrane. It is not 
known how the localization of PKCδ is related to the anticancer activity associated with 
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 These results encouraged us to pursue the synthesis of the next bryostatin 
analogue with both C7 acetate and C13 enoate substituents. Based on the biological 
results from Merle 27 and Merle 28, the C7 acetate or C13 enoate alone does not 
determine the analogue behave biologically PMA-like or bryostatin-like. We expected 
that the synthesis of analogue 2.90 with both C7 acetate and C13 enoate would reveal the 
biological response of a simplified analogue with two polar groups. The retrosynthetic 
analysis of analogue 2.90 is outlined in Figure 2.18. We anticipated the analogue 2.90 
could be prepared from the advanced intermediate 2.91. 
The intermediate 2.91 is expected from the pyran annulation between the 
hydroxyallylsilane 2.57 and the aldehyde with fully functionalized C ring 2.92. The 
advantages of the fully functionalized C-ring moiety are expected in (1) making the 
whole synthesis of the bryostatin analogue more convergent and efficient by reducing the 
steps after coupling the two complex moieties; (2) avoiding the possible problems during 
the installation of substituted group on C ring in the late stage, which include the 
undesired side reaction during  the aldol reaction and elimination, and modest 
diastereoselectivities during the Luche reduction; (3) it can applied into synthesis of 
different bryostatin analogues and total synthesis natural bryostatins. 
The aldehyde with fully functionalized C ring 2.92 was envisioned to be 
synthesized from ketone 2.93.  The protected alcohol on C16 position instead of carbonyl 
was anticipated to avoid the undesired Michael addition to the α,β-unsaturated carbonyl 
based on our previous experience. The ketone 2.93 was expected to be available from the 





















































































The failed attempts to the aldehyde 2.92 are summarized in Scheme 2.18.  The 
Luche reduction on ketone 2.94 initiated Michael addition of the resulting C19 alcohol to 
the α,β-unsaturated thioester in situ to afford 2.95 before any acetylation could be applied 
on the alcohol. Another attempt of cross metathesis between olefin 2.96 and allylic 
alcohol TMS ether failed to afford the desired product 2.97, primarily due to the steric 
effect of gem-dimethyl group.26,27 Attempts to reduce thioester 2.26 with 
diisobutylaluminium hydride gave an inseparable mixture of 1,2-reduced product 2.98 



















































Scheme 2.18 Attempted routes to fully functionized C ring aldehyde 2.90 
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 In order to eliminate the undesired 1,4-reduction on α,β-unsaturated thioester 2.26, 
we expected of the oxo-ester would increase the regioselectivity during the reduction. In 
practice, we started with olefin 2.25 (Scheme 2.19), which was oxidatively cleaved by 
ozonolysis and was transformed into α,β-unsaturated oxo-ester 2.100 through a Horner-
Emmons reaction. Deprotection of the TBS ether using HF/py buffer, and subsequent 
cyclization and dehydration promoted by CSA in benzene gave the desired glycal 2.101. 
The ester in 2.101 was reduced to the allylic alcohol 2.102 without the formation of any 
fully reduced byproduct with diisobutylaluminium hydride, and the resulting alcohol was 
protected as a TBS ether 2.103. The sequential epoxidation with mCPBA and Ley 
oxidation with TPAP and NMO afforded the ketone 2.93 in 79% yield with a 
diastereoselectivity of 4:1 at the C19 hemi-ketal favoring the desired isomer. Fortunately, 
the mixture of diastereomers could be separated by flash chromatography. The aldol 
reaction and elimination could be performed in one pot with freshly prepared glyoxylate 
and K2CO3 to give the enoate 2.104 in good yield.28 The C20 ketone on 2.104 was 
reduced via Luche conditions and the resulting alcohol was immediately acylated to 
afford the product 2.105. Deprotection of the TBS group led to the primary alcohol 2.106. 
The alcohol 2.106 was oxidized using Dess-Martin periodinane, resulting in the 
formation of aldehyde 2.107. Due to the fact that there was a PMB group on the C3 
position of hydroxyallylsilane 2.57, the PMB group on the C25 position of 2.107 was 
swapped with a TBS group in order to avoid having two PMB protecting groups in the 
pyarn annulation product. The final steps included the deprotection of the PMB group at 




Scheme 2.19 Synthesis of Fully functionalized C ring aldehyde 2.90 
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Scheme 2.20 Synthesis of Fully functionalized C ring aldehyde 2.92 
 
The pyran annulation between aldehyde 2.92 and hydroxyallylsilane 2.57 
smoothly afforded the product 2.108 in good yield (Scheme 2.21). It was noticed that the 
reaction was slower than the previous pyran annulation reactions. The pyran annulation 
reaction between aldehyde 2.37 and hydroxyallylsilane 2.57 in the synthesis of Merle 27 
took only 1 h to complete at -78 ºC, while the pyran annulation with fully functionalized 
C ring was not complete after 6 h at -78 ºC.  Fortunately, we found that elevated 
temperature could increase the rate of the reaction. After 2 h at -78 ºC, the reaction was 
warmed to -15 ºC and kept for 1 h to push the reaction to completion.  
 The C7 free hydroxyl group was acetylated to give tricyclic product 2.91. The 
deprotection of TBDPS group at C1 position with TBAF and AcOH afforded the primary 
alcohol 2.109, which was exposed to sequential Parikh-Doering and Pinnick oxidation 
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conditions to afford the carboxylic acid 2.110. The removal of the TBS group with HF/Py 
gave the seco acid, which was subjected to Yamaguchi macrolactonization conditions to 
deliver macrolactone 2.75. The olefin at C13 was cleaved by careful addition of a 
solution of ozone in CH2Cl2 at -78 ºC, and the resulting ketone 2.111 was subjected to an 
asymmetric Hormer-Emmons reaction with Fuji’s chiral phosphonate 2.112 to afford a 
4:1 mixture of Z:E diastereomers 2.113.18,29 The global deprotection then afforded the 
bryostatin analogue Merle 33 (Scheme 2.22).  
The biological tests from Dr. Blumberg showed Merle 33 has a high affinity with 
PKCα (Ki = 0.68 ± 0.01 nM). The installation of the enoate at the C13 renders the 
bryostatin analogue a slightly better affinity binding with PKC. The proliferation and 
attachment of U937 cell lines supported our initial hypothesis that the analogue with two 
or more polar groups on the northern hemisphere behaviours likes bryostatin 1 (Figure 
2.19 and 2.20). The results indicated that Merle 33 demonstrated a similar response 
during the proliferation and attachemtn of U937 cell line as Merle 30 did. Merle 33 
showed limited effect on the proliferation and attachment of U937 cells; furthermore, it 
antagonized the effect of PMA in high concentration. The profile of response suggests 
that Merle 33 behaves like bryostatin 1. The results revealed Merle 33 behaved close to 
phorbol ester in low concentration, but behaved like bryostatin 1 in high concentration 
instead of the phorbol esters (Figure 2.11 and 2.12). The bryostatin-like response from 
Merle 33 excluded the possibility that the C8 gem dimethyl group is the critical 
substituent, which will be very helpful for the future work on the synthesis of bryostatin 
analogues. Currently our group is working on the synthesis of other bryostatin analogues 
































 The structurally simplified bryostatin analogues were prepared in a convergent 
manner by utilization of the pyran annulation methodology developed in our group. 
During the synthesis of analogue Merle 27, the functionalization on C ring before the 
formation of the macrolactone demonstrated better yields and diastereoselectivities in the 
steps of functionalization on the C ring. The biological studies of Merle 27 showed its 
high binding affinity with PKC similar to that of bryostatin 1, but the results from the 
proliferation and attachment assay of the U937 cell line suggested that Merle 27 behaved 
like the tumor promoter PMA instead of like bryostatin 1, which excludes the C7 acetate 
alone as playing a critical role in defining the unique biological activities of bryostatin as 
an antagonist to phorbol esters.  
In order to identify the pharmacophoric groups in the northern hemisphere of 
bryostatin 1 responsible for its unique biological activities, the bryostatin analogue Merle 
33 with C7 acetate and C13 was prepared through a pyran annulation involving the fully 
functionalized C ring aldehyde. The fullyl functionalized C ring aldehyde 2.92 not only 
made the whole synthesis more convergent and efficient, but also eliminated tedious 
protection and deprotection steps on C7 position. The biological results of analogue, 
Merle 33, revealed that the installation of C13 enotate on B ring switched the biological 
response from PMA-like to bryostatin-like. This change supports our hypothesis that the 
biological activities of bryostatin analogues are affected by the polarity of the northern 
hemisphere. The further study of how the polarity groups or polarity in the northern 
hemishpre of bryostatin analogues affect the biologic response of analogues will be the 




Solvents were purified according to the guidelines in Purification of Common 
Laboratory Chemicals (Perrin, Armarego, and Perrin, Pergamon: Oxford, 1966).30  
Diisopropylamine, diisopropylethylamine, pyridine, triethylamine, EtOAc, MeOH, and 
CH2Cl2 were distilled from CaH2.  The titer of n-BuLi was determined by the method of 
Eastham and Watson.31  All other reagents were used without further purification.  Yields 
were calculated for material judged homogenous by thin layer chromatography and 
nuclear magnetic resonance (NMR).  Thin layer chromatography was performed on 
Merck Kieselgel 60 Å F254 plates or Silicycle 60Å F254 eluting with the solvent 
indicated, visualized by a 254 nm UV lamp, and stained with an ethanolic solution of 12-
molybdophosphoric acid, or 4-anisaldehyde.  Flash chromatography was performed with 
Silicycle Flash Silica Gel 40 – 63 μm or Silicycle Flash Silica Gel 60 – 200 μm, slurry 
packed with 1% EtOAc/hexanes in glass columns.  Glassware for reactions was oven 
dried at 125 °C and cooled under a dry nitrogen atmosphere prior to use.   Liquid 
reagents and solvents were introduced by oven dried syringes through septum-sealed 
flasks under a nitrogen atmosphere.  Nuclear magnetic resonance spectra were acquired 
at 500 MHz for 1H and 125 MHz for 13C.  Chemical shifts for proton nuclear magnetic 
resonance (1H NMR) spectra are reported in parts per million relative to the signal of 
relative to the signal of residual CHCl3 at 7.27 ppm.  Chemicals shifts for carbon nuclear 
magnetic resonance (13C NMR and DEPT) spectra are reported in parts per million 
relative to the center line of the CDCl3 triplet at 77.23 ppm.  Chemical shifts of the 
unprotonated carbons (‘C’) for DEPT spectra were obtained by comparison with the 13C 
NMR spectrum.  The abbreviations s, d, apd, dd, ddd, dddd, ddddd, dddddd, t, td, tt, q, dq, 
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bs, and m stand for the resonance multiplicity singlet, doublet, apparent doublet, doublet 
of doublets, doublet of doublet of doublets, doublet of doublet of doublet of doublets, 
doublet of doublet of doublet of doublets of doublets, doublet of doublet of doublet of 
doublets of doublets of doublets, triplet, triplet of doublets, triplet of triplets, quartet, 
doublet of quartets, broad singlet, and multiplet, respectively.  Optical rotations (Na D 
line) were obtained using a microcell with 1 dm path length.  Specific rotations    ([α], 
Unit: °cm2/g) are based on the equation α = (100·α)/(l·c) and are reported as unit-less 
numbers where the concentration c is in g/l00 mL and the path length l is in decimeters.  
Mass spectrometry was performed at the mass spectrometry facility of the Department of 
Chemistry at The University of Utah on a double focusing high resolution mass 
spectrometer or at the mass spectrometry facility of the Department of Chemistry at the 
University of California, Riverside on an LCTOF mass spectrometer. The ratio of 
enantiomers (ee %) was determined by HPLC analysis using a Daicel Chiralcel OD-H 25 
cm column. Compounds were named using ChemDraw 12.0. 
 
  
Preparation of 3-(tert-Butyl-diphenyl-silanyloxy)-propan-1-ol (2.43). To a 
stirring solution of 1,3-propandiol (24.9 g, 327 mmol, 3.0 equiv), tert-butyldiphenylsilyl 
chloride (30.0 g, 109 mmol, 1.0 equiv), 4-dimethylaminopyridine (133 mg, 1.09 mmol, 
0.01 equiv) in CH2Cl2 (500 mL) in a 1000 mL rb flask under an atmosphere of N2 at rt, 
was added triethylamine (16.5 g, 164 mmol, 1.5 equiv) dropwise via syringe. After 24 h 
at rt, the reaction was quenched by the addition of water (200 mL), and the phases were 
separated. The aqueous phase was extracted with CH2Cl2 (3 × 100 ml). The combined 
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organic phases were washed with brine (2 × 100 ml), dried over Na2SO4, filtered and 
concentrated under reduced pressure to give the crude product. Purification was 
accomplished by flash chromatography on a 6.5 × 32 cm silica gel column, eluting with 
20% EtOAc/hexanes (4000 mL), collecting 25 mL fractions. The product containing 
fractions (75-152) were combined and concentrated under reduced pressure to give the 
product 2.43 as colorless crystals (32.6 g, 95% yield): MP = 41-42 °C; 500 MHz 1H 
NMR (CDCl3) δ 7.72-7.67 (m, 4H), 7.47-7.38 (m, 6H), 3.86 (t, J = 5.9, Hz, 2H), 3.85 
(ddd, J = 5.9, 5.4, 5.4 Hz, 2H), 2.35 (t, J = 5.4 Hz, 1H), 1.82 (dddd, J = 5.9, 5.9, 5.9, 5.4 
Hz, 2H), 1.07 (s, 9H); 125 MHZ 13C NMR (CDCl3) δ 135.8, 133.5, 130.0, 128.0, 63.5, 
62.1, 34.5, 27.0, 19.3. 125 MHz DEPT (CDCl3) CH3 δ 27.0; CH2 δ 63.5, 62.1, 34.5; CH δ 





Preparation of 3-(tert-Butyl-diphenyl-silanyloxy)-propion-aldehyde (2.2). To 
a stirring solution of oxalyl chloride (10.6 g, 83.4 mmol, 1.5 equiv) in CH2Cl2 (625 mL) 
in a 1000 mL rb flask at -78 °C was added dimethyl sulfoxide (13.0 g, 166.8 mmol, 3.0 
equiv) dropwise via syringe. After 1 h at -78°C, alcohol 2.43 (17.5 g, 55.6 mmol, 1.0 
equiv) in CH2Cl2 (50 mL) was added dropwise via cannula. An additional CH2Cl2 rinse 
(25 mL) was used to transfer the remaining alcohol residue into the reaction flask. After 1 
h at -78 °C, triethylamine (28.1 g, 278 mmol, 5.0 equiv) was added via syringe. After 2 h, 
the reaction was determined to be complete by TLC analysis and was then quenched by 
the addition of pH 7 buffer solution (100 mL). The phases were separated and the organic 
phase was washed with water (3 × 60 mL) and brine (3 × 60 mL), then dried over MgSO4, 
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filtered, and concentrated under reduced pressure to give the crude product. The 
purification was accomplished by flash chromatography on a 6.5 × 30 cm silica gel 
column, eluting with 10% EtOAc/hexanes (3000 mL), collecting 18 × 150 mm test tube 
fractions. The product containing fractions (44-97) were combined and concentrated 
under reduced pressure to give the aldehyde 2.2 (16.9 g, 97%) as white crystals: MP 40-
42 ºC; 500 MHz 1H NMR (CDCl3) δ 9.84 (t, J = 2.0 Hz, 1H), 7.69-7.65 (m, 4H), 7.47-
7.38 (m, 6H), 4.04 (t, J = 5.9 Hz, 2H), 2.62 (td, J = 5.9, 2.0 Hz, 2H), 1.06 (s, 9H); 125 
MHZ 13C NMR (CDCl3) δ 202.1, 135.8, 133.5, 130.0, 128.0, 58.5, 46.6, 27.0, 19.4. 125 
MHz DEPT (CDCl3) CH3 δ 27.0; CH2 δ 58.5, 46.6; CH δ 202.1, 135.8, 130.0, 128.0; CH0 





Preparation of (R)-1-(tert-butyldiphenylsilyloxy)hex-5-en-3-ol (2.44). A 250 
mL rb flask was charged with a magnetic stir bar, oven dried 4Å molecular sieves (8.64 g) 
and CH2Cl2 (60 mL). To the stirring suspension were added (R)-BINOL (1.212 g, 4.234 
mmol, 0.2 equiv) in one portion, a solution of Ti(Oi-Pr)4 (2.12 mL of 1.0 M, 2.117 mmol, 
0.1 equiv) in CH2Cl2 via syringe, and a freshly prepared solution of trifluoroacetic acid 
(1.48 mL of 0.1 M, 0.148 mmol, 0.007 equiv) in CH2Cl2. The mixture was heated at 
reflux (~38ºC) for 1 h, and then allowed to cool to rt. A solution of aldehyde 2.2 (6.615 g, 
21.16 mmol, 1.0 equiv) in CH2Cl2 (20 mL) was added via cannula. An additional CH2Cl2 
(5 mL) rinse was used to transfer the remaining aldehyde residue into the reaction flask 
via cannula. The reaction mixture was stirred for another 0.5 h at rt before it was cooled 
to -78ºC. Allyltributyltin (10.51 g, 31.74 mmol, 1.5 equiv) was added to the reaction 
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mixture down the inside wall of the reaction flask via syringe. The reaction mixture was 
stirred for an additional 10 min at -78 ºC then transferred to a –20 ºC freezer. After 5 days, 
the reaction mixture was quenched by the addition of saturated aqueous NaHCO3 solution 
(50 mL), then warmed to rt and stirred for 2 h. The molecular sieves were removed by 
filtration through a pad of celite®. The aqueous phase was separated and extracted with 
CH2Cl2 (3 × 100 mL). The combined organic phases were dried over Na2SO4, filtered, 
and concentrated under reduced pressure to give a red oil. Purification was accomplished 
by flash chromatography on a 6.5 × 27 cm silica gel column, eluting with 1500 mL 
hexanes and then 5% EtOAc/hexanes (3000 mL), collecting 18 × 150 mm test tube 
fractions. The product containing fractions (83-140) was combined and concentrated 
under reduced pressure to give the product 2.44 (6.83 g, 91%) as a colorless oil: 500 
MHz 1H NMR (CDCl3) δ 7.76-7.68 (m, 4H), 7.49-7.38 (m, 6H), 5.88 (dddd, J = 17.1, 
10.1, 7.1, 7.1 Hz, 1H), 5.17-5.11 (m, 2H), 4.00 (ddddd, J = 8.7, 6.1, 6.1, 3.0, 3.0 Hz, 1H), 
3.94-3.84 (m, 2H), 3.28 (bs, 1H), 2.35-2.25 (m, 2H), 1.81-1.69 (m, 2H), 1.09 (s, 9H); 125 
MHZ 13C NMR (CDCl3) δ 135.8, 135.8, 135.2, 133.3, 133.3, 130.0, 130.0, 128.0, 117.6, 
71.1, 63.5, 42.2, 38.1, 27.0 19.3. 125 MHz DEPT (CDCl3) CH3 δ 27.0; CH2 δ 117.6, 63.5, 
42.2, 38.1; CH δ 135.8, 135.8, 135.2, 130.0, 130.0, 128.0, 71.1; CH0 δ 133.3, 133.3, 19.3.  
Assay of enantiomeric excess: HPLC (5 % i-PrOH/hexanes, 0.45 mL/min); tr (major) = 





Preparation of (R)-tert-butyl(3-(4-methoxybenzyloxy)hex-5-enyloxy)diphenyl 
silane (2.45). To a solution of alcohol 2.44 (167 mg, 0.471 mmol, 1.0 equiv) in 3 mL 
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THF in a 25 mL rb flask under the atmosphere of N2 was added a solution of p-
methoxybenzyl bromide (473 mg, 2.35 mmol, 5.0 equiv) in 2 mL THF and triethylamine 
(713 mg, 7.05 mmol, 15 equiv) via syringe. The reaction mixture was cooled to -78ºC, 
and then a solution of 0.5 M potassium bis(trimethylsilyl)amide  (2.82 mL, 1.41 mmol, 
3.0 equiv) was added to the reaction dropwise via syringe. After 1 h at -78ºC, the reaction 
was warmed up to -15ºC and stirred for another 1.5 h. The reaction was quenched by 
addition of aqueous ammonium hydroxide (4.0 mL), and then the reaction was warmed 
up to rt and stirred overnight. The product was extract with Et2O (10 mL × 3). The 
organic phase was combined, dried over Na2SO4 and concentrated under reduced 
pressure. The purification was accomplished by flash chromatography column on a 
3.5 × 14 cm silica gel column, eluting with 3% EtOAc/hexanes (1000 mL), collecting 10 
mL fractions. The product containing fractions (35-68) was combined and concentrated 
under reduced pressure to give the product 2.45 as a colorless oil (164 mg, 74% yield). 
500 MHz 1H NMR (CDCl3) δ 7.72-7.67 (m, 4H), 7.47-7.38 (m, 6H), 7.23 (d, J = 8.8 Hz, 
2H),  6.88 (d, J = 8.3 Hz, 2H), 5.87 (dddd, J = 17.6, 10.3, 7.3, 7.3 HZ, 1H), 5.13-5.07 (m, 
2H), 4.47 (ABq, J = 11.2, Δν = 54.5 Hz, 2H), 3.88-3.83 (m, 1H), 3.82 (s, 3H), 3.81-3.72 
(m, 2H), 2.35 (t, J = 6.3 Hz, 2H), 1.83-1.77 (m, 2H), 1.08 (s, 9H); 125 MHZ 13C NMR 
(CDCl3) δ 159.3, 135.8, 135.1, 134.2, 134.2, 131.2, 129.8, 129.5, 127.8, 127.8, 117.1, 
113.9, 75.3, 71.0, 60.7, 55.5, 38.7, 37.2, 27.1, 19.4; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 
27.1; CH2 δ 117.1, 71.0, 60.7, 38.7, 37.2; CH δ 135.8, 135.1, 129.8, 129.5, 127.8, 127.8, 







Preparation of (S)-5-(tert-butyldiphenylsilyloxy)-3-(4-methoxybenzyloxy) pen 
tanal (2.46).To a stirring solution of alkene 2.45 (2.766 g, 5.827 mmol, 1.0 equiv) in a 
mixture of 20% MeOH/CH2Cl2 (100 mL) in a 250 mL rb flask was added sodium 
bicarbonate (2.766 g) in one portion. The reaction mixture was cooled to -78 ºC, and then 
a steady stream of ozone was bubbled into the solution for 1 min, during which time the 
color changed to light grey. The mixture was then purged with a steady stream of oxygen. 
Triphenylphosphine (2.637 g, 11.65 mmol, 2.0 equiv) was added in one portion to the 
solution, which was then allowed to warm to rt over a period of 1 h. Solid NaHCO3 was 
removed by filtration and the solution was concentrated under reduced pressure to give a 
yellow oil. Purification was accomplished by flash chromatography on a 5 × 18 cm silica 
gel column, eluting with 20% EtOAc/hexanes (1000 mL), collecting 18 × 150 mm test 
tube fractions. The product containing fractions (12-29) were combined and concentrated 
under reduced pressure to give the product 2.46 (2.494 g, 90%) as a colorless oil: 500 
MHz 1H NMR (CDCl3) δ 9.80 (t, J = 2.0 Hz, 1H), 7.73-7.69 (m, 4H), 7.51-7.41 (m, 6H), 
7.23 (d, J = 8.7 Hz, 2H),  6.89 (d, J = 8.7 Hz,, 2H), 4.50 (s, 2H),  4.24 (dddd, J = 6.7, 6.7, 
6.4, 5.7 Hz, 1H), 3.91-3.86 (m, 1H), 3.84 (s, 3H), 3.82-3.76 (m, 1H), 2.69 (ddd, J = 16.1, 
7.1, 2.4 Hz, 1H), 2.63 (ddd, J = 16.4, 6.7, 1.7 Hz, 1H), 2.00-1.93 (m, 1H), 1.87-1.80 (m, 
1H), 1.08(s, 9H). 125 MHZ 13C NMR (CDCl3) δ 201.8, 159.4, 135.7, 133.8, 133.7, 130.4, 
129.9, 129.9, 129.6, 127.9, 114.0, 71.4, 71.3, 60.3, 55.4, 48.7, 37.3, 27.1, 19.3; 125 MHz 
DEPT (CDCl3) CH3 δ 55.4, 27.1; CH2 δ 71.3, 60.3, 48.7, 37.3; CH δ 201.8, 135.8, 129.9, 




Preparation of (4S, 6S)-8-(tert-butyldiphenylsilyloxy)-6-(4-methoxybenzyloxy) 
-2-((trimethylsilyl)methyl)oct-1-en-4-ol (2.14). To a solution of aldehyde 2.46 (576 mg, 
1.209 mmol, 1.0 equiv) in CH2Cl2 (12 mL) in a 25 mL rb flask was added MgBr2·OEt2 
(623 mg, 2.418 mmol, 2.0 equiv) in one portion at rt. After 5 min at rt, the reaction 
mixture was cooled to -78 ºC and stirred for 30 min. Stannane 2.1 (1.009 g, 2.418 mmol. 
2.0 equiv) was added dropwise via syringe. After 5 h at -78 ºC, the reaction was 
quenched by the addition of saturated aqueous NaHCO3 solution (5 ml). The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (3 × 20 mL). The combined 
organic phases were washed with brine (10 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished by flash 
chromatography on a 3 × 25 cm silica gel column, eluting with 8% acetone/hexanes 
(1000 mL), collecting 13 × 100 mm test tube fractions. The product containing fractions 
(35-61) was combined and concentrated under reduced pressure to give the product 2.14 
(592 mg, 81%) as a colorless oil: 500 MHz 1H NMR (CDCl3) δ 7.71-7.67 (m, 4H), 7.47-
7.37 (m, 6H), 7.23 (d, J = 8.7Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 4.68 (dd, J = 1.0, 0.7 Hz, 
1H), 4.66 (s, 1H), 4.48 (s, 2H), 4.04-3.96 (m, 2H), 3.85-3.79 (m, 1H), 3.81 (s, 3H), 3.76 
(dt, J = 10.1, 6.0 Hz, 1H), 2.68 (d, J = 2.4 Hz, 1H), 2.12 (dd, J = 13.8, 8.4 Hz, 1H), 2.06 
(dd, J = 13.8, 5.0 Hz, 1H), 1.94 (dq, J = 12.8, 6.0 Hz, 1H), 1.79 (dq, J = 13.8, 6.7 Hz, 1H), 
1.72-1.60 (m, 2H), 1.55 (ABq, J = 13.4 Hz, Δν = 14.6 Hz, 2H), 1.08 (s, 9H), 0.04 (s, 9H); 
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125 MHZ 13C NMR (CDCl3) δ 159.4, 144.8, 135.8, 134.0, 134.0, 130.8, 129.8, 129.8,  
127.9, 127.8, 127.8, 114.0, 110.2, 74.0, 71.6, 66.2, 60.7, 55.5, 47.0, 40.8, 37.3, 27.1, 26.9, 
19.4, -1.1. 125 MHz DEPT (CDCl3) CH3 δ 55.4, 27.1, -1.1; CH2 δ 110.2, 71.6, 60.7, 47.0, 
40.8, 37.3, 27.1; CH δ 135.8, 129.8, 129.7, 127.9, 127.8, 114.0, 74.0, 66.2; CH0 δ 159.4, 





Preparation of 3-(benzyloxy)propanenitrile (2.48). To a stirring mixture of 
benzyl alcohol 2.47 (54.05 g, 500 mmol, 1.0 equiv) and 40% aqueous NaOH solution 
(5.0 mL) in a 250 mL rb flask at 0 ºC was added acrylonitrile (29.15 g, 550 mmol, 1.1 
equiv) dropwise via syringe. The mixture was warmed to rt and stirred overnight. The 
solution was neutralized by the addition of 1.0 N HCl (50 ml), and diluted with CH2Cl2 
(200 mL). The organic phase was separated, washed with 5% aqueous NaOH solution 
(25 mL) and brine (50 mL), then dried over Na2SO4, filtered, and concentrated under 
reduced pressure to give the product 2.48 (80.4 g, quantitative) as a light yellow oil: 500 
MHz 1H NMR (CDCl3) δ 7.40-7.30 (m, 5H), 4.60 (s, 2H), 3.69 (t, J = 6.4 Hz, 2H), 2.63 (t, 
J = 6.38 Hz, 2H); 125 MHZ 13C NMR (CDCl3) δ 137.4, 128.7, 128.2, 127.9, 118.0, 73.5, 
64.7, 19.1.  
 
 
Preparation of ethyl 5-(benzyloxy)-3-oxopentanoate (2.41).32 To a stirring 
solution of nitrile 2.48 (1.30 g, 8.06 mmol, 1.0 equiv) in THF (20 mL) in a three necked 
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50 mL rb flask equipped with a reflux condenser was added Zn/Cu couple (2.89 g, 44.3 
mmol, 5.5 equiv). The mixture was heated to reflux, and then ethyl 2-bromoacetate (4.17 
g, 25.0 mmol, 3.1 equiv) was added slowly by syringe pump over 2 h. The reaction 
mixture was then cooled to 0 ºC, and a solution of 3N HCl (20 mL) was added dropwise 
via syringe. The mixture was stirred at 0 ºC for 0.5 h, and then warmed to rt. The phases 
were separated and the aqueous phase was extracted with CHCl3 (3 × 20 mL). The 
combined organic phases were washed with water (3 × 20 mL), saturated aqueous 
NaHCO3 solution (20 mL), dried over Na2SO4, filtered, and concentrated under reduced 
pressure. Purification was accomplished by flash chromatography on a 4 × 19 cm silica 
gel column, eluting with 5% acetone/hexanes (1500 mL), collecting 18 × 150 mm test 
tube fractions. The product containing fractions (23-59) were combined and concentrated 
under reduced pressure to give the product 2.41 (1.56 g, 78%) as a colorless oil: 500 
MHz 1H NMR (CDCl3) δ 7.35-7.25 (m, 5H), 4.50 (s, 2H), 4.17 (q, J = 7.3 Hz, 2H), 3.74 
(t, J = 6.4 Hz, 2H), 3.47 (s, 2H), 2.82 (t, J = 6.3 Hz, 2H), 1.26 (t, J = 7.3 Hz, 3H); 125 
MHZ 13C NMR (CDCl3) δ 201.5, 167.2, 138.1, 128.6, 127.9, 127.9, 73.4, 65.2, 61.5, 49.9, 
43.3, 14.3. 125 MHz DEPT 13C NMR (CDCl3) CH3 δ 14.3; CH2 δ 73.4, 65.2, 61.5, 49.9, 




Preparation of (R)-ethyl 5-(benzyloxy)-3-hydroxypentanoate (2.49). A 250 
mL Parr bomb was charged with a magnetic stir bar, ester 2.41 (26.10 g, 104.3 mmol, 1.0 
equiv), degassed ethanol (91 mL) and [(R)-BINAP)]RuCl2 (91.0 mg, 0.114 mmol, 0.0011 
equiv) in the glove box. The gas inlet tube was attached to a hydrogen source and 
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hydrogen was introduced into the reaction vessel until the pressure gauge indicated 400 
psi. The pressure was carefully released to 1 atm by opening the stop valve. This 
procedure was repeated for three times, and finally hydrogen is pressurized to 400 psi. 
The reaction solution was stirred at rt for 5 days, during which time the hydrogen 
cylinder was kept connected. After the main valve of the hydrogen cylinder was closed, 
excess hydrogen in the reaction tube was carefully bled off, and the apparatus was 
disassembled. The reaction mixture was passed through a short silica pad and washed 
with 20% EtOAc/hexanes (500 mL). The resulting solution was concentrated under 
reduced pressure to give the alcohol product 2.49 (24.80 g, 95%) as a colorless oil: Rf = 
0.19 (20% EtOAc/hexanes); [ ] =20Dα -12.1 (c = 1.12, CHCl3); 500 MHz 1H NMR (CDCl3) 
δ 7.32-7.22 (m, 5H), 4.47 (s, 2H), 4.20 (dddd, J = 6.4, 6.4, 6.4, 5.9 Hz, 1H), 4.12 (q, J = 
6.8 Hz, 2H), 3.65 (ddd, J = 9.4, 6.4, 5.4 Hz, 1H), 3.60 (ddd, J = 9.4, 6.4, 5.4 Hz, 1H), 
3.34 (bs, 1H), 2.44 (d, J = 6.4 Hz,  2H), 1.79-1.73 (m, 2H), 1.22 (t, J = 7.3 Hz, 3H); 125 
MHZ 13C NMR (CDCl3) δ 172.6, 138.2, 128.6, 127.8, 127.8, 73.4, 68.0, 67.0, 60.7, 41.8, 
36.2, 14.3; 125 MHz DEPT 13C NMR (CDCl3) CH3 δ 14.3; CH2 δ 73.4, 68.0, 60.7, 41.8, 
36.2; CH δ 128.6, 127.8, 127.8, 67.0; CH0 δ 172.6, 138.2; Chiral HPLC (15 % i-






Preparation of (R)-ethyl 5-(benzyloxy)-3-(tert-butyldimethyl silyloxy) pent 
anoate (2.50). To a stirring solution of alcohol 2.49 (6.374 g, 25.26 mmol, 1.0 equiv) in 
DMF (135 mL, 0.19 M) in a 250 mL rb flask was added tert-butyldimethylsilyl chloride 
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(4.189 g, 27.70 mmol, 1.1 equiv) and imidazole (2.064 g, 30.32 mmol, 1.2 equiv) in one 
portion. After 12 h at rt, the reaction mixture was diluted with EtOAc (250 mL), then 
washed with water (100 mL), and brine (100 mL), and then dried over Na2SO4, filtered, 
and concentrated under reduced pressure to give the crude product. Purification was 
accomplished by flash chromatography on a 5.5 × 25 cm silica gel column, eluting with 
10% EtOAc/hexanes (1500 mL), collecting 18 × 150 mm test tube fractions. The product 
containing fractions (16-44) were combined and concentrated under reduced pressure to 
give the product 2.50 (8.781 g, 98%) as a colorless oil:  Rf = 0.33 (10% EtOAc/hexanes); 
[ ] =20Dα -5.5 (c = 1.28, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.32-7.20 (m, 5H), 4.42 (d, 
J = 6.4 Hz, 2H), 4.26 (dddd, J = 6.4, 5.9, 5.9, 5.9 Hz, 1H), 4.09-4.01 (m, 2H), 3.49 (t, J = 
6.4 Hz, 2H), 2.42 (d, J = 6.4 Hz, 2H), 1.80 (dd, J = 6.4, 1.7 Hz, 1H), 1.77 (dd, J = 6.4, 2.0 
Hz, 1H), 1.19 (t, J = 7.3 Hz, 3H), 0.80 (s, 9H), 0.01 (s, 3H), -0.01 (s, 3H). 125 MHZ 13C 
NMR (CDCl3) δ 171.7, 138.6, 128.5, 127.7, 127.7, 73.1, 67.1, 66.7, 60.5, 43.2, 37.6, 26.0, 
18.2, 14.4. -4.5, -4.6. 125 MHz DEPT 13C NMR (CDCl3) CH3 δ 26.0, 14.4, -4.5, -4.6; 




Preparation of (R)-ethyl 3-(tert-butyldimethylsilyloxy)-5-oxopentanoate (2.40) 
To a stirring solution of ether 2.50 (1.86 g, 5.12 mmol, 1.0 equiv) in EtOAc (51 mL, 0.1 
M) in a three-necked 100 mL rb flask was added 10 wt% Pd/C (0.5 g). The reaction flask 
was then equipped with a hydrogen balloon. After 2 days at rt, the reaction was 
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determined to be complete by TLC analysis. The reaction mixture was filtered over a pad 
of Celite®, and then concentrated under reduced pressure to give a colorless oil, which 
was used in the next step without purification.  
To a stirring solution of the aforementioned intermediate alcohol in CH2Cl2 (51 
mL, 0.1 M) in a 100 mL rb flask was added diisopropylethylamine (4.63 g, 35.81 mmol, 
7.0 equiv). The reaction mixture was cooled to -5 ºC, and then dimethyl sulfoxide (4.00 g, 
20.46 mmol, 4.0 equiv) was added via syringe.  After 5 min at -5 ºC, SO3·Py (3.26 g, 
20.46 mmol, 4.0 equiv) was added in one portion. After 1 h at -5 ºC, the reaction mixture 
was poured into a 250 mL Erlenmeyer flask containing 25 mL of saturated aqueous 
NaHCO3 solution. The reaction mixture was stirred at rt for 1 h, then the phases were 
separated, and the aqueous phase was extracted with CH2Cl2 (3 × 20 mL). The organic 
phases were combined and washed with brine (20 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished by flash 
chromatography on a 4 × 15 cm silica gel column, eluting with 10% EtOAc/hexanes 
(1000 mL), collecting 18 × 150 mm test tube fractions. The product containing fractions 
(12-20) were combined and concentrated under reduced pressure to provide the aldehyde 
2.40 (1.35 g, 96% over 2 steps) as a yellow oil: Rf = 0.52 (20% EtOAc/hexanes); [ ] =20Dα  
-9.9 (c = 1.15, CHCl3); 500 MHz 1H NMR (CDCl3) δ 9.80 (t, J = 2.0 Hz, 1H), 4.63 (dddd, 
J = 6.3, 6.3, 5.9, 5.9 Hz, 1H), 4.14 (m, 2H), 2.67 (ddd, J  = 16.6, 5.4, 1.7 Hz, 1H), 2.62 
(ddd, J = 16.6, 6.4, 2.4 Hz, 1H), 2.55 (dd, J = 15.1, 6.4 Hz, 1H), 2.55-2.50 (dd, J = 15.1, 
6.4 Hz, 1H), 1.25 (t, J = 7.3 Hz, 3H), 0.84 (s, 9H), 0.07 (s,  3H), 0.07 (s, 3H); 125 MHz 
13C NMR (CDCl3) δ 201.1, 170.9, 65.2, 60.8, 51.1, 42.8, 25.8, 18.1, 14.3, -4.6, -4.6; 125 
MHz DEPT 13C NMR (CDCl3) CH3 δ 25.8, 14.3, -4.6, -4.6; CH2 δ 60.8, 51.1, 42.8; CH δ 
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201.1, 65.2; CH0 δ  170.9, 18.1; IR (neat) 2931, 2858, 2728, 1734, 1473, 1377, 1317, 
1257, 1173, 1095, 1006, 940, 838, 813, 778, 681 cm-1; LRMS (EI) Calcd for C13H27O4Si 
(M+H): 275.2, Found: 275.2; HRMS (ESI/TOF) calcd for C13H26NaO4Si (M+Na) 
297.1493, found 297.1488. 
 
 
Preparation of (R)-ethyl 3-(tert-butyldimethyl silyloxy)-4-((2R,6S)-6-((S)-4-
(tert-butyldiphenylsilyloxy)-2-(4-methoxybenzyloxy) butyl)-4-methylenetetra hydro-
2H-pyran-2-yl)butanoate (2.39). To a stirring solution of aldehyde 2.40 (256 mg, 0.933 
mmol, 1.0 equiv) and hydroxyallylsilane 2.14 (621 mg, 1.03 mmol, 1.1 equiv) in Et2O 
(10 mL, 0.1M) in a 25 mL rb flask at -78 ºC was added trimethylsilyl triflate (249 mg, 
1.12 mmol, 1.2 equiv) dropwise via syringe. After 1 h at -78 ºC, the reaction mixture was 
quenched by the addition of diisopropylethylamine (0.2 mL) via syringe, followed by the 
addition of saturated aqueous NaHCO3 solution (2 mL). The mixture was warmed to rt, 
then the phases were separated, and the aqueous phase was extracted with Et2O (3 × 10 
mL). The organic phases were combined, dried over Na2SO4, filtered, and concentrated 
under reduced pressure. Purification was accomplished by flash chromatography on a 3 × 
21 cm silica gel column, eluting with 5% EtOAc/hexanes (2500 mL), collecting 18 × 150 
mm test tube fractions. The product containing fractions (24-50) were combined and 
concentrated under reduced pressure to provide the pyran 2.39 (750 mg, 96% ) as a 
colorless oil: Rf = 0.65 (20% EtOAc/hexanes); [ ] =20Dα  +2.2 (c = 1.11, CHCl3); 500 MHz 
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1H NMR (CDCl3) δ 7.74-7.71 (m, 4H), 7.47-7.39 (m, 6H), 7.20 (d, J = 8.8 Hz, 2H), 6.86 
(d, J = 8.8 Hz, 2H), 4.75 (s, 1H), 4.73 (s, 1H), 4.45 (ABq, J = 10.8, Δν = 24.1 Hz, 2H), 
4.43-4.38 (m, 1H), 4.12 (dq, J = 10.8, 7.3 Hz, 1H), 4.06 (dq, J = 10.7, 7.3 Hz, 1H), 3.92 
(dddd, J = 6.3, 6.3, 5.9, 5.9 Hz, 1H), 3.88-3.76 (m, 5H), 3.58-3.52 (m, 1H), 3.50-3.44 (m, 
1H), 2.58-2.50 (m, 2H), 2.26 (d, J = 13.2 Hz, 1H), 2.19 (d, J = 12.7 Hz, 1H), 1.98 (dd, J 
= 22.5, 11.7Hz, 2H), 1.92-1.83 (m, 3H), 1.72-1.66 (m, 3H), 1.21 (t, J = 7.3 Hz, 3H), 1.10 
(s, 9H), 0.90 (s, 9H), 0.12 (s, 3H), 0.08 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 171.8, 
159.2, 144.8, 135.8, 134.1 (×2), 131.3, 129.8, 129.5, 127.8 (×2), 113.9, 108.7, 75.1, 75.0, 
73.0, 71.8, 66.9, 60.8, 60.4, 55.4, 44.1, 42.8, 42.5, 41.3 (×2), 37.9, 27.1, 26.0, 19.4, 18.1, 
14.3, -4.2, -4.6; 125 MHz DEPT 13C NMR (CDCl3) CH3 δ 55.4, 27.1, 26.0, 14.3, -4.2, -
4.6; CH2 δ 108.7, 71.8, 60.8, 60.4, 44.1, 43.8, 42.8, 42.5, 41.3 (×2), 37.9; CH δ 135.8, 
129.8, 129.5, 127.8 (×2), 113.9, 75.1, 75.0, 73.0, 66.9; CH0 δ 171.8, 159.2, 144.8, 134.1 
(×2), 131.3, 19.4, 18.1;  IR (neat) 3072, 2933, 2857, 1737, 1652, 1613, 1588, 1514, 1472, 
1428, 1390, 1302, 1249, 1174, 1111, 1039, 940, 837, 777, 738, 702, 615, 505 cm-1; 
LRMS(EI) Calcd for C46H69O7Si2 (M+H): 789.5, Found: 789.2; HRMS (ESI/TOF) calcd 
for C46H68NaO7Si2 (M+Na) 811.4396, found 811.4389. 
 
 
Preparation of (R)-ethyl-4-((2R,6S)-6-((S)-4-(hydroxy)-2-(4-methoxy benzyl 




4-methylene tetrahydro-2H-pyran-2-yl)-3-hydroxy butanoate (2.51 and 2.52). To a 
stirring solution of silyl ether 2.39 (77.2 mg, 0.098 mmol, 1.0 equiv) in a mixture of 3:2 
benzene/MeOH (6.0 mL, 0.016 M) in a 25 mL rb flask was added p-toluenesulfonic acid 
(37.2 mg, 0.20 mmol, 2.0 equiv) in one portion. After 5 h at rt, the reaction mixture was 
quenched by the addition of triethylamine (0.2 mL), and then concentrated under reduced 
pressure. Purification was accomplished by flash chromatography on a 3 × 8 cm silica gel 
column, eluting with 20% EtOAc/hexanes (500 mL) and 35% EtOAc/hexanes (500 mL), 
collecting 18 × 150 mm test tube fractions. The product containing fractions (11-23) were 
combined and concentrated under reduced pressure to give the mono-deprotected product 
2.51 (39.0 mg, 59%) as a colorless oil: Rf = 0.31 (20% EtOAc/hexanes); [ ] =20Dα  +5.6 (c 
= 2.36, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.72-7.66 (m, 4H), 7.46-7.38 (m, 6H), 
7.21 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz,  2H), 4.72 (d, J = 1.7 Hz, 1H), 4.70 (d, J = 
1.7 Hz, 1H),  4.40 (ABq, J = 11.1 Hz, Δν = 40.4 Hz, 2H), 4.30-4.24 (m, 1H), 4.18-4.12 
(m, 2H), 3.83-3.75 (m, 7H), 3.57-3.50 (m, 2H), 2.55 (dd, J = 15.8, 7.7 Hz, 1H), 2.45 (dd, 
J =15.8, 5.4 Hz, 1H), 2.25 (d, J = 13.1 Hz, 1H), 2.17 (d, J = 13.1 Hz, 1H), 2.00 (t, J = 
12.1 Hz, 1H), 1.94 (t, J = 11.4 Hz, 1H), 1.86-1.64 (m, 6H), 1.25 (t, J = 7.4 Hz, 3H), 1.08 
(s, 9H); 125 MHz 13C NMR (CDCl3) δ 172.1, 159.3, 143.9, 135.8, 134.0 (×2), 131.0, 
129.8 (×2), 129.7, 127.8 (×2), 114.0, 109.2, 78.3, 75.4, 72.7, 71.5, 67.8, 60.7, 60.5, 55.4, 
42.5, 42.1, 41.9, 41.0 (×2), 37.5, 27.1, 19.3, 14.4;  125 MHz DEPT 13C NMR (CDCl3) 
CH3 δ 55.4, 27.1, 14.4; CH2 δ 109.2, 71.6, 60.7, 60.5, 42.5, 42.1, 41.9, 41.0 (×2), 37.5; 
CH δ 135.8, 129.8 (×2), 129.7, 127.9, 114.0, 78.4, 75.5, 72.8, 67.8; CH0 δ 172.1, 159.3, 
143.9, 134.0 (×2), 131.0, 19.3; IR (neat) 3496, 3072, 2937, 1734, 1653, 1613, 1588, 1514, 
1472, 1428, 1372, 1303, 1248, 1180, 1111, 1037, 891, 823, 738, 703, 615, 505 cm-1; 
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LRMS (EI) calcd for C40H55O7Si (M+H) 675.4, found 675.2; HRMS (ESI/TOF) calcd for 
C40H54NaO7Si (M+Na) 697.3531, found 697.3533. 
  The product containing fractions (56-70) were combined and concentrated under 
reduced pressure to provide the di-deprotected product 2.52 (15 mg, 34%) as a colorless 
oil: Rf = 0.38 (EtOAc); [ ] =20Dα  +3.0 (c = 0.570, CHCl3); 500 MHz 1H NMR (CDCl3) δ 
7.27 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 4.75 (s, 2H), 4.49 (ABq, J = 11.2, Δν = 
36.4 Hz, 2H), 4.27-4.21 (m, 1H), 4.16 (q, J = 7.3 Hz, 2H), 3.83-3.75 (m, 2H), 3.82 (s, 
3H), 3.74-3.67 (m, 1H), 3.55-3.47 (m, 2H), 3.38 (bs, 1H), 2.52 (dd, J = 15.6, 7.8 Hz, 1H), 
2.44 (dd, J = 15.6, 5.4 Hz, 1H), 2.27 (bs, 1H), 2.25-2.16 (m, 2H), 2.00 (d, J = 12.2 Hz, 
1H),1.95 (q, J = 11.7 Hz, 1H), 1.92-1.85 (m, 1H), 1.79-1.64 (m, 5H), 1.26 (t, J = 7.3 Hz, 
3H); 125 MHz 13C NMR (CDCl3) δ 172.1, 159.4, 143.7, 130.6, 129.9, 114.1, 109.4, 78.4, 
75.8, 74.5, 71.6, 67.8, 60.8, 60.1, 55.5, 42.5, 42.1, 41.4, 41.1, 41.0, 36.6, 14.4; 125 MHz 
DEPT 13C NMR (CDCl3) CH3 δ 55.5 14.4; CH2 δ 109.5, 71.6, 60.8, 60.1, 42.5, 42.1, 41.4, 
41.1, 41.0, 36.6; CH δ 129.9, 114.1, 78.5, 75.8, 74.5, 67.8; CH0 δ 172.1, 159.4, 143.7, 
130.6;  IR (neat) 3450, 2940, 1733, 1653, 1613, 1514, 1372, 1302, 1248, 1175, 1035, 893, 
822, 705, 542 cm-1; LRMS (EI) calcd for C24H37O7 (M+H) 437.3, Found 437.2; HRMS 
(ESI/TOF) calcd for C24H36NaO7 (M+Na) 459.2353, found 459.2349. 
To a stirring solution of diol 2.51 (140 mg, 0.32 mmol, 1.0 equiv) in CH2Cl2 (5.0 
mL, 0.064 M) in a 15 mL rb flask were added 4-dimethylaminopyridine (catalytic 
amount), tert-butyldiphenylsilyl chloride (132 mg, 0.481 mmol, 1.5 equiv) and 
triethylamine (48.7 mg, 0.481 mmol, 1.5 equiv) via syringe.  After 12 h at rt, the reaction 
mixture was quenched by the addition of water (5.0 mL). The phases were separated and 
the aqueous phase was extracted with Et2O (3 × 10 mL). The organic phases were 
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combined, dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash chromatography on a 3 × 15 cm silica gel column, 
eluting with 20% EtOAc/hexanes (500 mL), collecting 18 × 150 mm test tube fractions. 
The product containing fractions (9-12) were combined and concentrated under reduced 
pressure to provide the alcohol 2.52 (210 mg, 97%) as a colorless oil. The overall yield 
from 2.39 to 2.52 is 92%.  
 
 
Preparation of (R)-ethyl 4-((2R,6S)-6-((S)-4-(tert-butyldiphenyl silyloxy)-2-(4-
methoxybenzyloxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)-3-(trimethyl silylo 
xy) butanoate (2.53). To a stirring solution of alcohol 2.52 (751 mg, 1.11 mmol, 1.0 
equiv) in CH2Cl2 (40 mL, 0.03 M) in a 100 mL rb flask were added trimethylsilyl 
chloride (363 mg, 3.34 mmol, 3.0 equiv), and triethylamine (676 mg, 6.68 mmol, 6.0 
equiv) dropwise via syringe. After 12 h at rt, the reaction mixture was quenched by the 
addition of water (10 mL). The phases were separated and the aqueous phase was 
extracted with Et2O (3 × 20 mL). The organic phases were combined, dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification was accomplished by flash 
chromatography on a 4.5 × 17 cm silica gel column, eluting with 10% EtOAc/hexanes 
(1000 mL), collecting 18 × 150 mm test tube fractions. The product containing fractions 
(15-21) were combined and concentrated under reduced pressure to provide  the silyl 
ether 2.53 (823 mg, 99%) as a colorless oil: Rf  = 0.60 (20% EtOAc/hexanes); [ ] =20Dα  
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+5.9 (c =1.07, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.75-7.70 (m, 4H), 7.50-7.40 (m, 
6H), 7.24-7.20 (m, 2H), 6.90-6.86 (m, 2H), 4.76 (d, J =1.0 Hz, 1H), 4.74 (s, 1H), 4.47 
(ABq, J = 10.7 Hz, Δν = 27.2 Hz, 2H), 4.43-4.39 (m, 1H), 4.18-4.06 (m, 2H), 3.94 (m, 
1H), 3.88-3.79 (m, 5H), 3.60-3.52 (m, 1H), 3.48-3.40 (m, 1H), 2.54 (d, J = 1.0 Hz, 1H), 
2.53 (s, 1H), 2.30 (d, J = 12.7 Hz, 1H), 2.22 (d, J = 13.2 Hz, 1H), 2.01 (d, J = 13.2 Hz, 
1H), 1.95 (d, J = 12.2 Hz, 1H), 1.94-1.84 (m, 3H), 1.72-1.66 (m, 3H), 1.22 (t, J = 7.3 Hz, 
3H), 1.10 (s, 9H), 0.16 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 171.7, 159.2, 144.7, 135.8 
(×2), 134.1, 134.0, 131.2, 129.7, 129.5, 127.8, 113.9, 108.7, 75.1 (×2), 72.8, 71.7, 66.8, 
60.7, 60.4, 55.4, 44.2, 43.0, 42.4, 41.3, 41.1, 37.8, 27.1, 19.3, 14.4, 0.5; 125 MHZ DEPT 
13C NMR (CDCl3) CH3 δ 55.4, 27.1, 14.4, 0.5; CH2: 108.7, 71.7, 60.7, 60.4, 44.2, 43.0, 
42.4, 41.3, 41.1, 37.8; CH: 135.8 (×2), 129.7, 129.5, 127.8, 113.9, 75.1 (×2), 72.8, 66.8; 
CH0: 171.7, 159.2, 144.7, 134.1, 134.0, 131.2, 19.3; IR (neat) 3072, 2940, 1737, 1653, 
1613, 1588, 1514, 1473, 1428, 1376, 1302, 1250, 1177, 1111, 1038, 842, 742, 703, 615 
cm-1; LRMS (EI) Calcd for C43H63O7Si2 (M+H) 747.4, Found 747.2; HRMS (ESI/TOF) 
calcd for C43H62NaO7Si2 (M+Na) 769.3926, found 769.3931. 
 
 
Preparation of (S)-1-((2R,6S)-6-((S)-4-(tert-butyldiphenyl silyloxy)-2-(4-meth 
oxybenzyloxy) butyl)-4-methylenetetrahydro-2H-pyran-2-yl)-4-((trimethylsilyl)meth 
yl) pent-4-en-2-ol (2.38). A 10 mL rb flask was charged with powdered CeCl3·7H2O 
(773 mg, 2.07 mmol, 10.0 equiv) and heated to 170 ºC under 1 mmg Hg vacuum. After 
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16 h at 170 ºC , the dry CeCl3 was cooled to rt, and the flask was flushed with N2. THF 
(2.0 mL) was added via syringe, and the mixture was stirred at rt for 2 h.  
Meanwhile, to a 25 mL three-necked rb flask equipped with a condenser and a 
magnetic stir bar, were added magnesium turnings (124 mg, 5.0 mmol), and a crystal of 
iodine. The flask was heated with a heat gun for 5 min while stirring. THF (5.0 mL) was 
added into the reaction flask via syringe, and the reaction mixture was heated with a heat 
gun to reflux. Chloromethyl trimethylsilane (0.613 g, 5.0 mmol) was then added 
dropwise via syringe. The mixture was stirred at rt for 1.5 h to afford a 1.0 M solution of 
TMSCH2MgCl.  
The reaction flask containing CeCl3 was cooled to -78 ºC, then a solution of 
TMSCH2MgCl (2.07 mL, 2.07 mmol, 10.0 equiv) was added dropwise via syringe. After 
1 h at -78 ºC, a solution of ester 2.53 (155 mg, 0.207 mmol, 1.0 equiv) in THF (1.8 mL) 
was added via cannula. Additional THF (0.2 mL) was used to transfer the remaining ester 
residue into the reaction mixture. The resulting mixture was allowed to warm to rt and 
stirred overnight. The reaction was recooled to -78 ºC, and then a 1N HCl solution (4.0 
mL) was added dropwise via syringe. The mixture was warmed to rt and the phases were 
separated. The aqueous phase was extracted with Et2O (3 × 10 mL). The organic phases 
were combined, and washed with saturated aqueous NaHCO3 solution (10 mL), and then 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash chromatography on a 3 × 14 cm silica gel column, eluting with 10% 
EtOAc/hexanes (1000 mL), collecting 13 × 100 mm test tube fractions. The product 
containing fractions (48-100) were combined and concentrated under reduced pressure to 
provide the hydroxyallylsilane 2.38 (120 mg, 81%) as a colorless oil: Rf = 0.55 (20% 
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EtOAc/hexanes); [ ] =20Dα  +2.5 (c = 0.51, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.70-
7.66 (m, 4H), 7.46-7.36 (m, 6H), 7.20 (d, J = 8.7 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 4.72 
(d, J = 1.7 Hz, 1H), 4.70 (d, J = 1.7 Hz, 1H), 4.67-4.63 (m,  2H), 4.41 (ABq, J = 10.7 Hz, 
Δν = 30.4 Hz, 2H), 3.97 (m, 1H), 3.82-3.73 (m, 6H), 3.59-3.48 (m, 3H), 2.26-2.16 (m, 
3H), 2.09-2.04 (dd, J =13.8, 6.4 Hz, 1H), 2.00 (t, J = 12.1 Hz, 1H), 1.94 (t, J = 12.1 Hz, 
1H), 1.80 (q, J = 6.4 Hz, 2H), 1.73-1.60 (m, 4H), 1.56 (s, 2H), 1.07 (s, 9H), 0.03 (s, 9H); 
125 MHz 13C NMR (CDCl3) δ 159.3, 144.7, 144.2, 135.8, 134.1 (×2), 131.1, 129.8 (×2), 
129.7, 127.9, 114.0, 110.0, 109.1, 79.3, 75.6, 72.9, 71.6, 69.7, 60.6, 55.5, 46.6, 42.6, 42.0, 
41.2, 41.1, 37.6,  27.2, 27.1, 19.4, -1.1; 125 MHz DEPT 13C NMR (CDCl3) CH3 δ 55.5, 
27.1, -1.1; CH2 δ 110.0, 109.1, 71.6, 60.6, 46.6, 42.6, 42.0, 41.2, 41.1, 37.6, 27.2; CH δ 
135.8, 129.8 (×2), 129.7, 127.9, 114.0, 79.3, 75.6, 72.9, 69.7; CH0 δ 159.3, 144.7, 144.2, 
134.1 (×2), 131.1, 19.4; IR (neat) 3504, 3072, 2940, 1653, 1613, 1588, 1514, 1472, 1428, 
1361, 1303, 1248, 1116, 1038, 849, 738, 702, 615, 505   cm-1; LRMS (EI) Calcd for 
C43H63O5Si2 (M+H) 715.4, Found 715.2; HRMS (ESI/TOF) calcd for C43H62NaO5Si2 
(M+Na) 737.4028, found 737.4032. 
 
 
Preparation of (R)-ethyl 4-((2S,6R)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-
methoxy benzyloxy)butyl)-4-oxotetrahydro-2H-pyran-2-yl)-3-(trimethylsilyloxy) but 
anoate (2.54). To a stirring solution of alkene 2.53 (109.0 mg, 0.146 mmol, 1.0 equiv) in 
CH2Cl2 (25 mL, 0.0058 M) in a 50 ml rb flask was added NaHCO3 (109.0 mg). The 
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mixture was cooled to -78 ºC, and then a steady stream of ozone was bubbled through the 
solution for 1 min, during which time the solution developed a light grey color. The 
solution was then purged with a steady stream of oxygen until the grey color disappeared. 
Triphenylphosphine (115 mg, 0.438 mmol, 3.0 equiv) was added in one portion, and the 
reaction mixture was allowed to warm to rt and stir overnight. The solid NaHCO3 was 
removed by filtration and the filtrate was concentrated under reduced pressure to give a 
yellow oil. Purification was accomplished by flash chromatography on a 2 × 17 cm silica 
gel column, eluting with 20% EtOAc/hexanes (500 mL), collecting 13 × 100 mm test 
tube fractions. The product containing fractions (6-10) were combined and concentrated 
under reduced pressure to give the product 2.54 (98.8 mg, 91% yield) as a colorless oil: 
Rf = 0.27 (20% EtOAc/hexanes); [ ] =20Dα  +13.7 (c = 1.65, CHCl3); 500 MHz 1H NMR 
(CDCl3) 7.69 (dd, J = 3.0, 1.4 Hz, 2H), 7.67 (dd, J = 3.0, 1.4 Hz, 2H), 7.45-7.36 (m, 6H), 
7.16 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 4.47 (d, J = 11.1 Hz, 1H), 4.38-4.32 (m, 
1H), 4.36 (d, J = 10.7 Hz, 1H), 4.11 (dddd, J = 10.7, 7.1, 7.1, 7.1 Hz, 1H), 4.05 (dddd, J 
= 10.7, 7.1, 7.1, 7.1 Hz, 1H), 3.91 (dddd, J = 9.1, 5.7, 5.7, 3.0 Hz, 1H), 3.83 (dddd, J = 
9.1, 9.1, 2.7, 2.7 Hz, 1H), 3.84-3.78 (m, 5H), 3.76-3.70 (m, 2H), 2.53 (dd, J = 14.8, 7.7 
Hz, 1H), 2.48 (dd, J = 14.8, 7.7 Hz, 1H), 2.40 (ddd, J = 14.4, 2.0, 2.0 Hz, 1H), 2.33 (ddd, 
J = 14.4, 2.0, 2.0 Hz, 1H), 2.25 (dd, J = 14.1, 11.8 Hz, 1H), 2.20 (dd, J = 14.1, 11.8 Hz, 
1H), 1.96-1.86 (m, 2H), 1.84-1.73 (m, 2H), 1.72-1.62 (m, 2H), 1.20 (t, J = 7.4 Hz, 3H), 
1.06 (s, 9H), 0.10 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 207.1, 171.5, 159.3, 135.8, 
135.8, 134.0, 134.0, 131.0, 129.8, 129.5, 127.9, 127.9, 114.0, 73.8, 73.6, 72.7, 71.6, 66.4, 
60.6, 60.5, 55.5, 48.3, 48.1, 44.0, 42.8, 42.6, 37.4, 27.1, 19.4, 14.4, 0.5; 125 MHz DEPT 
13C NMR (CDCl3)  CH3 δ 55.5, 27.1, 14.4, 0.5; CH2 δ 71.6, 60.6, 60.6, 48.3, 48.1, 44.0, 
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42.8, 42.6, 37.4; CH δ 135.8, 129.8, 129.5, 129.5, 127.9, 73.8, 73.6, 72.7, 66.4; CH0 δ 
207.1, 171.5, 159.3, 19.3; IR (neat) 2956, 1732, 1612, 1513, 1428, 1377, 1302, 1249, 
1173, 1111, 1037, 842, 742, 703, 614, 542 cm-1; HRMS (ESI/TOF) calcd for 
C42H60O8NaSi2 (M+Na) 771.3719, found 771.3715. 
 
 
Preparation of (R)-ethyl 4-((2R,4S,6S)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-
(4-methoxy benzyloxy)butyl)-4-hydroxytetrahydro-2H-pyran-2-yl)-3-(trimethylsilyl 
oxy) butanoate (2.55). To a solution of ketone 2.54 (59.0 mg, 0.0788 mmol, 1.0 equiv) 
in MeOH (5.0 mL, 0.015M) in a 15 mL rb flask at 0 ºC was added NaBH4 (6.0 mg, 0.158 
mmol, 2.0 equiv) in one portion. After 30 min at 0 ºC, the mixture was quenched by the 
addition of acetone (0.1 mL), and then concentrated under reduced pressure.  Purification 
was accomplished by flash chromatography column on a 3 × 12 cm silica gel column, 
eluting with 40% EtOAc/hexanes (500 mL), collecting 18 × 150 mm test tube fractions. 
The product containing fractions (6-10) were combined and concentrated under reduced 
pressure to give the alcohol product 2.55 (55.6 mg, 94%) as a colorless oil: Rf = 0.40 (50% 
EtOAc/hexanes); [ ] =20Dα  +16 (c = 0.29, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.70-7.66 
(m, 4H), 7.46-7.37 (m, 6H), 7.17 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 4.45 (d, J 
= 10.8 Hz, 1H), 4.38 (d, J = 11.1 Hz, 1H), 4.40-4.32 (m, 1H), 4.10 (dddd, J = 10.7, 7.1, 
7.1, 7.1 Hz, 1H), 4.05 (dddd, J = 10.7, 7.1, 7.1, 7.1 Hz, 1H), 3.91-3.86 (m, 1H), 3.82-3.74 
(m, 7H), 3.56-3.50 (m, 1H), 3.46-3.39 (m, 1H), 2.50 (d, J = 5.5 Hz, 1H), 2.49 (d, J = 3.0 
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Hz, 1H),  1.97 (ddd, J = 12.4, 4.4, 2.4 Hz, 1H), 1.90-1.76 (m, 4H), 1.68-1.45 (m, 5H), 
1.20 (t, J = 7.1 Hz, 3H), 1.06 (s, 9H), 0.12 (s, 9H); 125 MHz 13C NMR (CDCl3) δ 171.8, 
159.3, 135.8, 135.8, 134.1, 134.1, 131.2, 129.8, 129.5, 127.9, 127.9, 114.0, 72.9, 72.1, 
72.1, 71.7, 68.3, 66.8, 60.7, 60.5, 55.5, 43.9, 42.9, 42.3, 41.8, 41.5, 37.8, 27.1, 19.4, 14.4, 
0.5; 125 MHz DEPT 13C NMR (CDCl3)  CH3 δ 55.5, 27.1, 14.4, 0.5; CH2 δ 71.7, 60.7, 
60.5, 43.9, 42.9, 42.3, 41.8, 41.5, 37.8; CH δ 135.8, 135.8, 129.8, 129.5, 127.9, 127.9, 
114.0, 72.9, 72.1, 68.4, 66.8; CH0 δ 171.8, 159.3, 134.1, 134.1, 131.2, 19.4;  IR (neat) 
3440, 2940, 1735, 1612, 1513, 1428, 1376, 1250, 1175, 1109, 1037, 741, 704, 613, 536 
cm-1; HRMS (ESI/TOF) calcd for C42H62O8Na (M+Na) 773.3881, found 773.3886. 
 
 
Preparation of (R)-ethyl 4-((2R,4S,6R)-4-acetoxy-6-((S)-4-(tert-butyldiphenyl 
silyloxy) -2-(4-methoxy benzyloxy) butyl) tetrahydro-2H-pyran-2-yl)-3-(trimethyl 
silyloxy) butanoate (2.58). To a stirring solution of alcohol 2.55 (25.0 mg, 0.0333 mmol, 
1.0 equiv) in CH2Cl2 (3.3 mL, 0.01 M) in a 15 mL rb flask at rt were added 4-
dimethylaminopyridine (4.1 mg, 0.0333 mmol, 1.0 equiv), pyridine (105.4 mg, 1.332 
mmol, 40.0 equiv), and acetic anhydride (68.0 mg, 0.666 mmol, 20.0 equiv) via syringe.  
The solution was stirred at rt overnight, and then quenched by the addition of saturated 
aqueous NaHCO3 solution (5 mL). The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3 × 10 mL). The organic phases were combined, dried over 
Na2SO4, and concentrated under reduced pressure. Purification was accomplished by 
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flash chromatography on a 2 × 12 cm silica gel column, eluting with 50% EtOAc/hexane 
(250 mL), collecting 13 × 100 mm test tube fractions. The product containing fractions 
(2-4) were combined and concentrated under reduced pressure to give the product 2.58 
(12.1 mg, 46% yield) as colorless oil: Rf = 0.34 (20% EtOAc/hexanes); [ ] =20Dα  + 9 (c = 
0.27, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.70-7.66 (m, 4H), 7.45-7.36 (m, 6H), 7.17 
(d, J = 8.3 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 4.88 (dddd, J = 11.2, 11.2, 4.9, 4.9 Hz, 1H), 
4.45 (d, J = 10.7 Hz, 1H), 4.36 (d, J = 11.2 Hz, 1H), 4.33 (dddd, J = 6.3, 6.3, 6.3, 6.3 Hz, 
1H), 4.10 (dddd, J = 10.7, 7.3, 7.3, 7.3 Hz, 1H), 4.05 (dddd, J = 10.7, 7.3, 7.3, 7.3 Hz, 
1H), 3.86 (m, 1H), 3.82-3.74 (m, 5H), 3.62-3.56 (m, 1H), 3.52-3.46 (m, 1H), 2.48 (d, J = 
2.9 Hz, 1H), 2.47 (s, 1H), 2.05 (s, 3H), 2.03-2.00 (m, 1H), 1.92-1.76 (m, 5H), 1.70-1.56 
(m, 4H), 1.20 (t, J = 7.3 Hz, 3H), 1.07 (s, 9H), 0.12 (s, 9H); 125 MHz 13C NMR (CDCl3) 
δ 171.7, 170.6, 159.3, 135.8, 134.0, 134.0, 131.1, 129.8, 129.5, 127.8, 114.0, 72.8, 72.1, 
72.0, 71.8, 70.6, 66.7, 60.7, 60.5, 55.5, 43.9, 42.9, 42.2, 37.8, 37.7, 37.6, 27.1, 21.5, 19.4, 
14.4, 0.5; 125 MHz DEPT 13C NMR (CDCl3)  CH3 δ 55.5, 27.1, 21.5, 14.4, 0.5; CH2 δ 
71.8, 60.7, 60.5, 43.9, 42.9, 42.2, 37.8, 37.7, 37.6; CH δ 135.8, 129.8, 129.5, 127.8, 114.0, 
72.8, 72.1, 72.0, 70.6, 66.7; CH0 δ 171.7, 170.6, 159.3, 134.0, 134.0, 131.1, 19.4; IR 
(neat) 2953, 2859, 1738, 1612, 1513, 1428, 1365, 1247, 1175, 1109, 1033, 842, 741, 704, 





Preparation of (R)-ethyl 4-((2R,4S,6R)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-
(4-methoxy benzyloxy)butyl)-4-(trimethylsilyloxy) tetrahydro-2H-pyran-2-yl)-3-
(trimethylsilyloxy) butanoate (2.56). To a solution of alcohol 2.55 (83.1 mg, 0.111 
mmol, 1.0 equiv) in CH2Cl2 (11 mL, 0.01 M) in a 25 mL rb flask were added 
chlorotrimethylsilane (60.3 mg, 0.555 mmol, 5.0 equiv) and triethylamine (112.3 mg, 
1.11 mmol, 10.0 equiv) dropwise via syringe. After 12 h at rt, the reaction mixture was 
quenched by the addition of water (5.0 mL). The phases were separated and the aqueous 
phase was extracted with Et2O (3 × 10 mL). The organic phases were combined, dried 
over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash chromatography on a 3.5 × 13 cm silica gel column, eluting with 
10% EtOAc/hexanes (500 mL), collecting 18 mm × 150 mm test tube fractions. The 
product containing fractions (5-9) were combined and concentrated under reduced 
pressure to give the product 2.56 (87.6 mg, 96% yield) as a colorless oil: Rf = 0.52 (20% 
EtOAc/hexanes); [ ] =20Dα  +12.5 (c = 2.71, CHCl3);  500 MHz 1H NMR (CDCl3) δ 7.69 
(ddd, J = 4.4, 1.4, 1.4 Hz, 2H), 7.67 (dd, J = 4.0, 1.7 Hz, 2H), 7.45-7.35 (m, 6H), 7.18 (d, 
J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 4.45 (d, J = 11.1 Hz, 1H), 4.37 (d, J = 11.1 Hz, 
1H), 4.37-4.30 (m, 1H), 4.10 (dddd, J = 10.7, 7.1, 7.1, 7.1 Hz, 1H), 4.05 (dddd, J = 10.7, 
7.1, 7.1, 7.1 Hz, 1H), 3.90-3.84 (m, 1H), 3.80 (s, 3H), 3.80-3.71 (m, 3H), 3.56-3.50 (m, 
1H), 3.45-3.38 (m, 1H), 2.50 (d, J = 4.7 Hz, 1H), 2.48 (d, J = 2.7 Hz, 1H), 1.86-1.72 (m, 
5H), 1.66-1.54 (m, 3H), 1.20 (t, J = 7.1 Hz, 3H), 1.05 (s, 9H), 0.13 (s, 9H), 0.11 (s, 9H); 
125 MHz 13C NMR (CDCl3) δ 171.8, 159.3, 135.8, 135.8, 134.1, 134.1, 129.8, 129.6, 
127.9, 114.0, 72.9, 72.2, 72.1, 71.8, 68.8, 66.8, 60.7, 60.5, 55.5, 44.0, 43.1, 42.3, 42.3, 
41.9, 37.7, 27.1, 19.4, 14.4, 0.5, 0.5; 125 MHz DEPT 13C NMR (CDCl3) CH3 δ 55.5, 27.1, 
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14.4, 0.5, 0.5; CH2 δ  71.8, 60.7, 60.5, 44.0, 43.1, 42.3, 42.3, 41.9, 37.7; CH δ  135.8, 
129.8, 129.6, 127.9, 114.0, 72.9, 72.2, 72.1, 68.8, 66.8; CH0 δ  171.8, 159.3, 135.8, 134.1, 
134.1, 19.4; IR (neat) 3071, 2952, 2859, 1613, 1588, 1467, 1428, 1377, 1302, 1250, 1175, 




Preparation of (2S,4R,6S)-2-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-methoxy 
benzyloxy) butyl)-6-((S)-2-hydroxy-4-((trimethylsilyl) methyl)pent-4-enyl)tetrahydr 
o-2H-pyran-4-ol (2.57). Powdered CeCl3 ·7H2O (757.0 mg, 2.03 mmol, 10.0 equiv) was 
placed in a 10 mL rb flask and heated to 170 ºC under 1 mm Hg vacuum. After 16 h at 
170 ºC, the dried CeCl3 was cooled to rt, and the flask was purged with N2. THF (2.5 mL) 
was added via syringe, and the mixture was stirred at rt for 2 h.  
Meanwhile, a 25 mL three-necked rb flask equipped with a condenser and a 
magnetic stir bar was charged with magnesium turnings (124.0 mg, 5 mmol, 1.0 equiv), 
and a crystal of iodine. The flask was heated with a heat gun for 5 min while stirring. 
THF (5.0 mL) was added via syringe, and the reaction mixture was heated with a heat 
gun to reflux. Chloromethyl trimethylsilane (0.613 g, 5.0 mmol, 1.0 equiv) was then 
added dropwise via syringe. The mixture was then stirred at rt for 1.5 h to give an 
assumed 1.0 M solution of TMSCH2MgCl.  
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The CeCl3/THF mixture was cooled to -78 ºC, then a solution of TMSCH2MgCl 
(2.03 mL of 1.0 M, 2.03 mmol, 10.0 equiv) was added dropwise via syringe. After 1 h at 
-78 ºC, a solution of ester 2.56 (167.2 mg, 0.203 mmol, 1.0 equiv) in THF (1.0 mL) was 
then added via cannula. An additional THF (0.6 mL) rinse was used to transfer the 
remaining ester residue into the reaction mixture. The solution was allowed to warm to rt 
and stirred overnight. The mixture was then recooled to -78 ºC, and then a 1N HCl 
solution (4.0 mL) was added dropwise via syringe. The reaction mixture was then 
warmed to rt and the phases were separated. The aqueous phase was extracted with Et2O 
(3 × 10 mL). The organic phases were combined, washed with saturated aqueous 
NaHCO3 solution (10 mL), then dried over Na2SO4, filtered, and concentrated under 
reduced pressure. Purification was accomplished by flash chromatography on a 3 × 12 cm 
silica gel column, eluting with 50% EtOAc/hexanes (1000 mL), collecting 18 × 150 mm 
test tube fractions. The product containing fractions (19-22) were combined and 
concentrated under reduced pressure to give the product 2.57 (103.4 mg, 71%) as a 
colorless oil: Rf = 0.31 (50% EtOAc/hexanes); [ ] =20Dα  +15.8 (c = 1.04, CHCl3); 500 
MHz 1H NMR (CDCl3)  δ 7.69 (dd, J = 11.4, 1.7 Hz, 2H), 7.68 (dd, J = 4.4, 1.3 Hz, 2H), 
7.46-7.38 (m, 6H), 7.21 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 4.67 (dd, J = 14.1, 
2.0 Hz, 2H), 4.46 (d, J = 11.1 Hz, 1H), 4.37 (d, J = 11.1 Hz, 1H), 4.00-3.94 (m, 1H), 
3.81-3.74 (m, 6H), 3.60-3.50 (m, 2H), 3.44 (bs, 1H), 2.22 (dd, J = 13.8, 7.1 Hz, 1H), 2.07 
(dd, J  = 13.8, 6.0 Hz, 1H), 1.96 (ddd, J  = 12.1, 2.4, 2.0 Hz, 1H), 1.87 (ddd, J  = 12.4, 2.4, 
2.4 Hz, 1H), 1.84-1.78 (m, 3H), 1.72-1.60 (m, 5H), 1.57 (s, 2H), 1.07 (s, 9H), 0.05 (s, 
9H); 125 MHZ 13C NMR (CDCl3) δ 159.3, 144.6, 135.8, 134.0, 134.0, 131.1, 129.8, 
129.7, 127.8, 127.8 114.0, 110.1, 76.3, 72.8, 72.5, 71.6, 69.5, 67.8, 60.5, 55.4, 46.6, 42.4, 
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41.8, 41.6, 41.5, 37.5, 27.1, 27.1, 19.3, -1.2; 125 MHz DEPT 13C NMR (CDCl3) CH3 δ 
55.4, 27.1, -1.2; CH2 δ  101.1, 71.6, 60.5, 46.6, 42.4, 41.8, 41.6, 41.5, 37.5, 27.1; CH δ  
135.8, 129.8, 129.7, 127.8, 127.8, 114.0, 76.3, 72.8, 72.5, 69.5, 67.8  CH0 δ  159.3, 144.6, 
134.0, 134.0, 131.1, 19.3; IR (neat) 3441, 2941, 1612, 1513, 1427, 1248, 1111, 1037, 848, 
738, 702, 614, 541, 505 cm-1; HRMS (ESI/TOF) calcd for C42H62O6NaSi2 (M+Na) 
741.3977, found 741.3979. 
 
 
Preparation of (2S,6S)-6-((2R,3R)-3-(benzyloxy methoxy)-2-(tert-butyldimeth 
yl silyloxy)butyl)-2-((E)-4-(6-(((4S)-6-((S)-4-(tert-butyl diphenylsilyloxy)-2-(4-methox 
y benzy loxy) butyl)-4-hydroxytetrahydro-2H-pyran-2-yl)methyl)-4-methylene tetra 
hydro-2H-pyran-2-yl)-2-methylbut-3-en-2-yl)-2-methoxydihydro-2H-pyran-3(4H)-
one (2.66). To a solution of hydroxyallylsilane 2.56 (31.6 mg, 0.0439 mmol, 1.1 equiv) 
and aldehyde 2.37 (21.9 mg, 0.0399 mmol, 1.0 equiv) in Et2O (4.0 mL, 0.01M) in a 10 
mL rb flask at -78 ºC was added a solution of TMSOTf in Et2O (47.9 μL of 1.0 M, 
0.0479 mmol, 1.2 equiv) dropwise via syringe. After 1 h at -78 ºC, the reaction mixture 
was quenched by the addition of diisopropylethylamine (0.2 mL), followed by the 
addition of saturated aqueous NaHCO3 solution (2 mL). The mixture was warmed to rt, 
then the phases were separated and the aqueous phase was extracted with Et2O (3 × 10 
mL). The organic phases were combined, dried over Na2SO4, filtered, and concentrated 
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under reduced pressure. Purification was accomplished by flash chromatography column 
on a 3 × 12 cm silica gel column, eluting with 40% EtOAc/hexanes, collecting 13 × 100 
mm test tube fractions. The product containing fractions (7-15) were combined and 
concentrated under reduced pressure to give the product 2.66 (43.0 mg, 92%) as a 
colorless oil: Rf = 0.38 (50% EtOAc/hexanes); [ ] =20Dα  +14 (c = 0.08, CHCl3);  500 MHz 
1H NMR (CDCl3) δ 7.70-7.66 (m, 4H), 7.45-7.34 (m, 11H), 7.18 (d, J = 8.7 Hz, 2H), 6.84 
(d, J = 8.4 Hz, 2H), 6.06 (dd, J = 16.1, 1.0 Hz, 1H), 5.45 (dd, J = 16.1, 6.0 Hz, 1H), 4.79 
(d, J = 1.3 Hz, 2H), 4.66-4.58 (m, 2H), 4.63 (s, 2H), 4.46 (d, J = 11.1 Hz, 1H), 4.37 (d, J 
= 10.8 Hz, 1H), 4.13-4.04 (m, 2H), 3.95-3.89 (m, 1H), 3.84-3.76 (m, 9H), 3.60-3.46 (m, 
3H), 3.29 (s, 3H), 2.45 (d, J = 6.4 Hz, 1H), 2.43 (d, J = 5.7 Hz, 1H), 2.24 (d, J = 13.1 Hz, 
1H), 2.18 (d, J = 13.4 Hz, 1H), 2.02-1.91 (m, 6H), 1.91-1.84 (m, 2H), 1.83-1.71 (m, 2H), 
1.68-1.48 (m, 6H), 1.15 (d, J = 6.4 Hz, 3H), 1.12 (s, 3H), 1.09 (s, 3H), 1.05 (s, 9H), 0.88 
(s, 9H), 0.09 (s, 3H), 0.08 (s, 3H);  125 MHz 13C NMR (CDCl3) δ 207.7, 159.3, 144.3, 
138.0, 137.2, 135.8 (×2), 134.1, 134.0, 131.2, 129.8, 129.6, 129.1, 128.6 (×2), 128.0 (×2), 
127.9 (×2), 114.0, 109.1, 104.1, 93.4, 79.1, 75.2, 75.0, 72.7, 72.1, 72.0 (×2),  70.7, 69.9, 
69.6, 68.4,  60.6, 55.5, 55.5, 52.8, 44.4, 42.5, 42.3, 41.8, 41.4, 41.2, 40.5, 38.2, 37.9, 37.7, 
30.6,  27.1,  26.1, 23.2, 22.1, 19.4, 18.3, 13.9, -3.8, -4.5; 125 MHz DEPT NMR (CDCl3) 
CH3 δ 55.5, 52.8, 27.1, 26.1, 23.2, 22.1, 13.9, -3.9, -4.5; CH2 δ  109.1, 93.4, 72.0, 69.6, 
60.6, 42.5, 42.3, 41.8, 41.4, 41.2, 40.5, 38.2, 37.9, 37.7, 30.6; CH δ  137.2, 135.8 (×2), 
129.8, 129.6, 129.1, 128.6 (×2), 128.0 (×2), 127.9 (×2), 114.0, 79.1, 75.2, 75.0, 72.7, 72.1, 
72.0, 70.7, 69.9, 68.4,  CH0 δ  207.7, 159.3, 144.3, 138.0, 134.1, 134.0, 131.2, 104.1, 
44.4, 19.4, 18.3; IR (neat) 3445, 2931, 2857, 1724, 1612, 1513, 1465, 1383, 1251, 1110, 
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1042, 835, 776, 739, 702, 612, 536 cm-1; HRMS (ESI/TOF) calcd for C69H100O12NaSi2 
(M+Na) 1199.6646, found 1199.6636. 
 
 




hoxy dihydro-2H-pyran-3(4H)-one (1.145). To a solution of alcohol 1.144 (83.8 mg, 
0.0712 mmol, 1.0 equiv) in CH2Cl2 (7.1 mL, 0.01M) in a 25 mL rb flask at 0 ºC were 
added diisopropylethylamine (45.8 mg, 0.427 mmol, 6.0 equiv) and TBSOTf (47.0 mg, 
0.178 mmol, 2.5 equiv) via syringe. The solution was stirred at 0 ºC for 40 min, then 
quenched by the addition of 1.0 mL of methanol.  Stirring was continued for another 10 
min, and then saturated aqueous NaHCO3 solution (5 mL) was added. The aqueous phase 
was separated and extracted with CH2Cl2 (3 × 10 mL). The organic phases were 
combined, dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification was accomplished by flash chromatography on a 4 × 10 cm silica gel column, 
eluting with 10% EtOAc/hexanes, collecting 18 × 150 mm test tube fractions. The 
product containing fractions (6-13) were combined and concentrated under reduced 
pressure to give the product 2.64 (89.3 mg, 98% yield) as a colorless oil: Rf = 0.73 ( 20% 
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EtOAc/hexanes); [ ] =20Dα  +8.1 (c = 0.40, CHCl3);  500 MHz 1H NMR (CDCl3)  δ 7.70-
7.66 (m, 4H), 7.44-7.35 (m, 11H), 7.20 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 8.3 Hz, 2H), 6.02 
(d, J = 5.6 Hz, 1H), 5.47 (dd, J = 16.1, 6.3 Hz, 1H), 4.78 (ABq, J = 7.3, Δν = 6.9 Hz, 2H), 
4.65 (s, 1H), 4.63 (s, 2H), 4.56 (s, 1H), 4.46 (d, J = 10.7 Hz, 1H), 4.38 (d, J = 10.7 Hz, 
1H), 4.14-4.04 (m, 2H), 3.95-3.88 (m, 1H), 3.85-3.71 (m, 8H), 3.60-3.50 (m, 2H), 3.50-
3.44 (m, 1H), 3.29 (s, 3H), 2.43 (dd, J = 8.3, 5.9 Hz, 2H), 2.29 (d, J = 13.2 Hz, 1H), 2.17 
(d, J = 13.2 Hz, 1H), 2.04-1.90 (m, 6H), 1.86-1.72 (m, 5H), 1.68-1.48 (m, 5H), 1.16 (d, J 
= 6.3 Hz, 3H), 1.12 (s, 3H), 1.09 (s, 3H), 1.06 (s, 9H), 0.89 (s, 9H), 0.88 (s, 9H), 0.09 (s, 
3H), 0.08 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 207.4, 159.3, 
144.4, 138.1, 137.1, 135.8 (×2), 134.1, 134.0, 131.3, 129.8 (×2), 129.6, 129.4, 128.6, 
128.0, 127.9 (×2), 114.0, 109.0, 104.1, 93.4, 79.2, 75.3, 75.1, 72.9, 72.2, 72.0, 72.0, 70.8, 
69.9, 69.6, 69.1, 60.6, 55.5, 52.8, 44.4, 42.8, 42.5, 42.5, 42.1, 41.2, 40.4, 38.2, 38.0, 37.7, 
30.7, 27.2, 26.1 (×2), 23.3, 21.9, 19.4, 18.3, 18.3, 14.0, -3.9, -4.2, -4.3, -4.4; 125 MHz 
DEPT  NMR (CDCl3) CH3 δ 55.5, 52.8, 27.2, 26.1 (×2), 23.3, 21.9, 14.0, -3.9, -4.2, -4.3, 
-4.4; CH2 δ  109.0, 93.4, 72.2, 69.6, 60.6, 42.8, 42.5, 42.5, 42.1, 41.2, 40.4, 38.2, 38.0, 
37.7, 30.7; CH δ  137.1, 135.8 (×2), 129.8 (×2), 129.6, 129.4, 128.6, 128.0, 127.9 (×2), 
114.0, 79.2, 75.3, 75.1, 72.9, 72.0, 72.0, 70.8, 69.9, 69.1,  CH0 δ  207.4, 159.3, 144.4, 
138.1, 134.1, 134.0, 131.3, 104.1, 44.4, 19.4, 18.3, 18.3; IR (neat) 2930, 2856, 1728, 
1513, 1465, 1382, 1250, 1110, 835, 775, 738, 703, 536cm-1; HRMS (ESI/TOF) calcd for 








-en-2-yl)-2-methoxy-3-oxo-2H-pyran-4(3H,5H,6H)-ylidene) acetate (2.67). To a 
stirring solution of ketone 2.65 (63.2 mg, 0.0489 mmol, 1.0 equiv) in THF (0.98 mL, 
0.05M)  in a 10 mL rb flask at -78 °C was added a freshly prepared solution of LDA in 
THF (0.587 mL of 0.25 M, 0.147 mmol, 3.0 equiv). The mixture was stirred at -78 °C for 
30 min, then a solution of methyl glyoxylate in THF (0.489 mL of 3.0 M, 1.47 mmol, 30 
equiv) was added via syringe. The reaction mixture stirred at -78 ºC for 30 min and was 
then quenched by the addition of saturated aqueous NH4Cl solution (1.0 mL). The 
mixture was warmed to rt and was then partitioned between 5 mL of EtOAc and 5 mL of 
brine. The phases were separated and the aqueous phase was extracted with EtOAc 
(3 × 10 mL). The combined organic phases were dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification was accomplished by flash 
chromatography on a 4 × 11 cm silica gel column, eluting with 15% EtOAc/hexanes, 
collecting 18 × 150 mm test tube fractions. The product containing fractions (9-23) were 
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combined and concentrated under reduced pressure to give a diastereomeric mixture of 
products (62.1 mg, 92% yield), which were carried into the next step. 
To a stirring solution of the aforementioned product (62.1mg, 0.0450 mmol, 1.0 
equiv) in pyridine (4.5 mL, 0.01 M) in a 25 mL rb flask with a condenser were added 4-
dimethylaminopyridine  (5.5 mg, 0.040 mmol, 1.0 equiv) and a solution of Ac2O in 
CH2Cl2 (1.80 mL of 0.5 M, 0.890 mmol, 20 equiv) via syringe. The reaction mixture was 
heated to 60 °C and stirred overnight.  The solution was cooled to rt, and then was then 
partitioned between 10 mL of CH2Cl2 and 5 mL of saturated aqueous NaHCO3 solution. 
The aqueous phase was separated and extracted with CH2Cl2 (3 × 10 mL). The organic 
phases were combined, dried over Na2SO4, filtered, and concentrated under reduced 
pressure.  Purification was accomplished by flash chromatography on a 3 × 12 cm silica 
gel column, eluting with 10% EtOAc/hexanes, collecting 18 × 150 mm test tube fractions. 
The product containing fractions (4-9) were combined and concentrated under reduced 
pressure to give the product 2.67 (57.2 mg, 93% yield) as a yellow oil: Rf = 0.71 (20% 
EtOAc/hexanes); [ ] =20Dα  -16.1 (c = 0.90, CHCl3);  500 MHz 1H NMR (CDCl3)  δ 7.72-
7.67 (m, 4H), 7.45-7.28 (m, 11H), 7.19 (d, J = 8.1Hz, 2H), 6.86 (d, J = 7.7 Hz, 2H), 6.55 
(t, J = 1.7 Hz, 1H), 5.82 (d, J = 15.8 Hz, 1H), 5.38 (dd, J = 16.1, 6.4Hz, 1H), 4.79 (ABq, 
J = 7.1 Hz, Δν = 8.5 Hz, 2H), 4.65-4.60 (m, 3H), 4.55 (s, 1H), 4.47 (d, J = 10.4 Hz, 1H), 
4.37 (d, J = 10.4 Hz, 1H), 4.11-.4.05 (m, 2H), 3.95-3.89 (m, 1H), 3.86-3.77 (m, 6H), 
3.77-3.71 (m, 4H), 3.71-3.65 (m, 1H), 3.59-3.50 (m, 2H), 3.50-3.43 (m, 1H), 3.32 (s, 3H), 
2.86 (ddd, J = 15.8, 12.4, 3.0 Hz, 1H), 2.28 (d, J = 12.8 Hz, 1H), 2.09 (ddd, J = 10.1, 7.7, 
2.4Hz, 1H), 2.04 (d, J = 13.8 Hz, 1H), 1.98 (ddd, J = 13.8, 8.1, 5.7 Hz, 1H), 1.90 (t, J = 
11.1 Hz, 2H), 1.85-1.72 (m, 4H), 1.69-1.60 (m, 2H), 1.60-1.50 (m, 2H), 1.29-1.20 (m, 
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3H), 1.17 (d, J = 6.0 Hz, 3H), 1.11 (s, 3H), 1.07 (s, 9H), 1.04 (s, 3H), 0.90 (s, 9H), 0.86 (s, 
9H), 0.08 (s, 3H), 0.07 (s, 3H), 0.07 (s, 3H), 0.03 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 
197.5, 166.3, 159.3, 148.3, 144.2, 138.0, 136.1, 135.8, 134.1, 134.0, 131.2, 130.1, 129.8, 
129.6, 128.6, 128.0 (×2), 127.9, 123.2, 114.0, 109.0, 104.6, 93.5, 79.2, 75.3, 75.1, 72.9, 
72.3, 72.0, 71.9, 71.0, 69.9, 69.6, 69.0, 60.5, 55.5, 52.4, 52.0, 44.8, 42.7, 42.5, 42.4, 42.0, 
40.6, 40.3, 38.4, 37.9, 36.6, 27.2, 26.1, 26.0, 22.8, 21.4, 19.4, 18.3, 18.2, 13.9, -3.8, -4.3, -
4.3, -4.5; 125 MHz DEPT  NMR (CDCl3) CH3 δ 55.5, 52.4, 52.0, 27.2, 26.1, 26.0, 22.8, 
21.4, 13.9, -3.8, -4.3, -4.3, -4.5 ; CH2 δ  109.0, 93.5, 72.3, 69.6, 60.5, 42.7, 42.5, 42.4, 
42.0, 40.6, 40.3, 38.4, 37.9, 36.6; CH δ  136.1, 135.8, 130.1, 129.8, 129.6, 128.6, 128.0 
(×2), 127.9, 123.2, 114.0, 79.2, 75.3, 75.1, 72.9, 72.0, 71.9, 71.0, 69.9, 69.0; CH0 δ  197.5, 
166.3, 159.3, 148.3, 144.2, 138.0, 134.1, 134.0, 131.2, 104.6, 44.8, 19.4, 18.3, 18.2; IR 
(neat) 2934, 2857, 1724, 1513, 1466, 1381, 1250, 1111, 835, 775, 738, 703, 536 cm-1; 
HRMS (ESI/TOF) calcd for C78H116O14NaSi3 (M+Na) 1383.7565, found 1383.7555. 
 
 






2-ethoxy-4-(2-methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl octanoate (2.64). 
To a stirring solution of ketone 2.67 (14.1 mg, 0.0104 mmol, 1.0 equiv) in methanol (2.1 
mL, 0.005M) in a 10 mL rb flask at rt was added CeCl3·7H2O (77.5 mg, 0.208 mmol, 20 
equiv). The reaction mixture was stirred at rt until all the CeCl3·7H2O crystals had 
dissolved. The reaction mixture was then cooled to -40 °C and kept for 15 min. NaBH4 
(3.9 mg, 0.104 mmol, 10 equiv) was then added in one portion. The mixture was stirred 
at -40 °C for 3 h, then diluted with 40% EtOAC/hexanes (10 mL), and quenched by the 
addition of saturated aqueous NH4Cl solution (5 mL). The mixture was poured into a 
separatory funnel with the aid of 50 mL of 40% EtOAc/hexanes. The organic phase was 
separated, then washed with 10 mL of H2O and 10 mL of brine, then dried over Na2SO4, 
filtered, and concentrated under reduced pressure. The resulting crude product was used 
in the next step without further purification. 
To a stirring solution of the aforementioned crude alcohol in CH2Cl2 (1.1 mL, 
0.01M) in a 10 mL rb flask at rt, were added pyridine (8.2 mg, 0.104 mmol, 10 equiv), 4-
dimethylaminopyridine (2.5 mg, 0.0208 mmol, 2.0 equiv), and octanoic anhydride (14.1 
mg, 0.052 mmol, 5.0 equiv). The reaction mixture stirred at rt overnight, then diluted 
with 10 mL of CH2Cl2. The mixture was poured into a separatory funnel containing 5 mL 
of saturated aqueous NaHCO3 solution.  The aqueous phase was separated and extracted 
with CH2Cl2 (3 × 15 mL). The organic phases were combined, dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification was accomplished by flash 
chromatography on a 2 × 16 cm silica gel column, eluting with 8% EtOAc/hexanes, 
collecting 13 × 100 mm test tube fractions. The product containing fractions (9-15) were 
combined and concentrated under reduced pressure to give the product 2.64 (12.6 mg, 82% 
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yield) as a colorless oil. Rf = 0.60 (20% EtOAc/hexanes); [ ] =20Dα  +3.2 (c = 1.45, CHCl3);  
500 MHz 1H NMR (CDCl3)  δ 7.69-7.65 (m, 4H), 7.44-7.34 (m, 11H), 7.17 (d, J = 8.8 Hz, 
2H), 6.86 (d, J = 8.3 Hz, 2H), 5.93 (d, J = 16.1 Hz), 5.88 (s, 1H), 5.57 (s, 1H), 5.43 (dd, J 
= 16.1, 5.9 Hz, 1H), 4.80 (s, 2H), 4.64 (s, 3H), 4.55 (s, 1H), 4.44 (d, J = 10.8 Hz, 1H), 
4.36 (d, J = 10.3 Hz, 1H), 4.12-4.06 (m, 2H), 3.92-3.86 (m, 1H), 3.84 (dd, J = 6.4, 4.4 Hz, 
1H), 3.81 (s, 3H), 3.80-3.70 (m, 4H), 3.79 (s, 3H), 3.57-3.44 (m, 4H), 3.30 (s, 3H), 2.35 
(ddd, J = 7.3, 7.3, 1.5 Hz, 2H), 2.29 (d, J = 13.2 Hz, 1H), 2.17 (d, J = 12.7 Hz, 1H), 2.03-
1.95 (m, 3H), 1.90 (t, J = 12.2 Hz, 1H), 1.85-1.72 (m, 4H), 1.65-1.52 (m, 6H), 1.33-1.28 
(m, 10H), 1.17 (d, J = 6.4 Hz, 3H), 1.11 (s, 3H), 1.11 (s, 3H), 1.04 (s, 9H), 0.92-0.85 (m, 
21H), 0.08 (s, 3H), 0.06 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 
172.3, 166.6, 159.4, 153.1, 144.4, 138.2, 138.0, 135.8 (×2), 134.1 (×2), 131.3, 129.8 (×2), 
129.5, 128.6, 128.0, 127.9, 127.8, 127.5, 117.0, 114.1, 109.0, 102.7, 93.3, 79.1, 75.2, 75.1, 
73.0, 72.2 (×2), 72.0, 71.6, 70.4, 69.5, 69.1, 68.5, 60.6, 55.5, 51.6, 51.3, 46.1, 42.8, 42.5, 
42.5, 42.1, 40.8, 40.4, 38.8, 38.0, 34.6, 33.6, 31.9, 29.3, 29.2, 27.2, 26.1, 25.0, 24.2, 24.2, 
22.8, 19.4, 18.3 (×2), 14.3, 14.0, -3.8, -4.2, -4.3,  -4.4; 125 MHz DEPT NMR (CDCl3) 
CH3 δ 55.5, 51.6, 51.3, 27.2, 26.1, 26.1, 24.2, 24.2, 14.3, 14.0, -3.8, -4.2, -4.3,  -4.4; CH2 
δ  109.0, 93.3, 72.2, 69.5, 60.6, 42.8, 42.5, 42.5, 42.1, 40.8, 40.4, 38.8, 38.0, 34.6, 33.6, 
31.9, 29.3, 29.2, 25.0, 22.8; CH δ  138.0, 135.8 (×2), 129.8 (×2), 129.5, 128.6, 128.0, 
127.9, 127.5, 117.0, 114.0, 79.1, 75.2, 75.1, 73.0, 72.0 (×2), 71.6, 70.4, 69.1, 68.5; CH0 δ  
172.3, 166.6, 159.4, 153.1, 144.4, 138.2, 134.1 (×2), 131.3, 127.8, 102.7, 46.1, 19.4, 18.3 
(×2); IR (neat) 2931, 2857, 1722, 1513, 1465, 1381, 1251, 1154, 1111, 836, 775, 739, 





Preparation of (2S,3S,6S,E)-6-((2R,3R)-3-(benzyloxy methoxy)-2-(tert-butyl 
dimethyl silyloxy)butyl)-2-((E)-4-((2R,6S)-6-(((2S,4S,6R)-4-(tert-butyl dimethylsilyl 
oxy)-6-((S)-4-hydroxy-2-(4-methoxy benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)met 
hyl)-4-methylene tetrahydro-2H-pyran-2-yl)-2-methylbut-3-en-2-yl)-2-methoxy-4-
(2-methoxy-2-oxoethy lidene) tetrahydro-2H-pyran-3-yl octanoate (2.68). To a 
stirring solution of silyl ether 2.64 (11.0 mg, 0.00738 mmol, 1.0 equiv) in DMF (0.738 
mL, 0.01 M) in a 4 mL reaction vial, were added a solution of TBAF solution in THF 
(7.4 μL of 1.0 M, 0.00738 mmol, 1.0 equiv) and a solution of acetic acid solution in DMF 
(7.4 μL of 1.0 M, 0.00738 mmol, 1.0 equiv). The solution was stirred at rt for 1 d, then 
diluted with 40% EtOAc/hexanes (5 mL) and quenched with water (5 mL). The phases 
were separated and the aqueous phase was extracted with 40% EtOAc/hexanes (3 × 5 
mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated 
under reduced pressure. Purification was accomplished using flash chromatography on a 
2 × 13 cm silica gel column, eluting with 20% EtOAc/hexanes, collecting 13 × 100 mm 
test tube fractions. The product containing fractions (10-20) were combined and 
concentrated under reduced pressure to provide the product alcohol 2.68 (8.2 mg, 89%) 
as a colorless oil. Rf = 0.44 (20% EtOAc/hexanes); [ ] =20Dα  +7.4 (c = 0.575, CHCl3);  500 
MHz 1H NMR (CDCl3)  δ 7.36-7.34 (m, 5H), 7.27 (d, J = 8.3 Hz), 6.89 (d, J = 8.3 Hz, 
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2H), 5.94 (d, J = 16.1 Hz, 1H), 5.89 (s, 1H), 5.57 (s, 1H), 5.42 (dd, J = 16.1, 5.9 Hz, 1H), 
4.80 (s, 2H), 4.66 (s, 1H), 4.65 (s, 2H), 4.57 (s, 1H), 4.50 (d, J = 10.7 Hz, 1H), 4.45 (d, J 
= 10.7 Hz, 1H), 4.12-4.06 (m, 2H), 3.92-3.82 (m, 2H), 3.82-3.75 (m, 5H), 3.75-3.65 (m, 
5H), 3.55-3.40 (m, 4H), 3.30 (s, 3H), 2.39-2.32 (m, 3H), 2.28 (d, J = 13.2 Hz, 1H), 2.18 
(d, J = 13.2 Hz, 1H), 2.00 (q, J = 12.2 Hz, 2H), 1.95-1.86 (m, 3H), 1.84-1.66 (m, 4H), 
1.66-1.50 (m, 6H), 1.38-1.20 (m, 10H),  1.16 (d, J = 6.3 Hz, 3H), 1.12 (s, 6H), 0.90-0.84 
(m, 21H), 0.08 (s, 3H), 0.06 (s, 3H). 0.06 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 172.4, 
166.7, 159.6, 153.1, 144.5, 138.4, 138.1, 130.7, 129.7, 128.6, 128.0, 127.9, 127.3, 117.0, 
114.2, 109.0, 102.6, 93.3, 79.4, 75.5, 75.2, 75.1, 72.5, 72.2 (×2), 71.6, 70.3, 69.5, 68.9, 
68.4, 60.4, 55.5, 51.6, 51.3, 46.1, 42.8, 42.5, 42.0, 41.7, 40.9, 40.4, 38.7, 36.9, 36.8, 34.6, 
31.9, 29.3, 29.2, 26.1, 26.1, 25.0, 24.2, 24.1, 22.8, 18.3, 18.3, 14.3, 14.0, -3.8, -4.3, -4.4; 
125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 51.6, 51.3, 26.1, 26.1, 24.2, 24.1, 14.3, 14.0, 
-3.8, -4.3, -4.4 ; CH2 δ  109.0, 93.3, 72.2, 69.5, 60.4, 42.8, 42.5, 42.0, 41.7, 40.9, 40.4, 
38.7, 36.9, 36.8, 34.6, 31.9, 29.3, 29.2, 25.0, 22.8; CH δ  138.4, 129.7, 128.6, 128.0, 
127.9, 127.3, 117.0, 114.2, 79.4, 75.5, 75.2, 75.1, 72.5, 72.2, 71.6, 70.3, 68.9, 68.4; CH0 δ  
172.4, 166.7, 159.6, 153.1, 144.5, 138.1, 130.7, 102.6, 46.1, 18.3, 18.3; IR (neat) 2930, 
2857, 1722, 1514, 1463, 1380, 1250, 1155, 1044, 836, 775 cm-1; HRMS (ESI/TOF) calcd 




Preparation of (R)-4-((2R,4S,6S)-6-(((2S,6R)-6-((E)-3-((2S,3S,6S,E)-6-((2R, 
3R)-3-(benzyloxy methoxy)-2-(tert-butyldimethylsilyloxy) butyl)-2-methoxy-4-(2-me 
thoxy-2-oxoethylidene)-3-(octanoyloxy)tetrahydro-2H-pyran-2-yl)-3-methylbut-1-en 
yl)-4-methylene tetrahydro-2H-pyran-2-yl)methyl)-4-(tert-butyldimethyl silyloxy) te 
trahydro-2H-pyran-2-yl)-3-(4-methoxy benzyloxy) butanoic acid (2.69). To a stirring 
solution of alcohol 2.68 (7.1 mg, 0.0057 mmol, 1.0 equiv) in CH2Cl2 (0.57 mL), in a 4 
mL reaction vial at 0 °C, were added diisopropylethylamine (21 μL, 0.119 mmol, 21.0 
equiv) and DMSO (12 μL, 0.171 mmol, 30.0 equiv). The solution was stirred at 0 °C for 
5 min and SO3·py (5.4 mg, 0.0340 mmol, 6.0 equiv) was added in one portion.  Stirring 
continued at 0 °C for 1.25 h, after which the reaction mixture was diluted with CH2Cl2 (1 
mL) and quenched by the addition of saturated aqueous NaHCO3 solution (1 mL). The 
mixture was stirred at rt for 10 min until effervescence was complete.  The reaction 
mixture was then partitioned between CH2Cl2 (5 mL) and saturated aqueous NaHCO3 
solution (5 mL). The phases were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 5 mL). The combined organic phases were dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  The resulting residue was washed through a small 
plug of silica gel with 20 % EtOAc/hexanes (30 mL), and the solvent was removed under 
reduced pressure to provide the aldehyde, which was used in the next step without further 
purification.  
To a stirring solution of the aforementioned aldehyde (7.1 mg, 0.0057 mmol, 1.0 
equiv) in 2-methyl-2-butene (570 μL) and tert-butyl alcohol (570 μL), in a 4 mL reaction 
vial at rt, was added a aqueous KH2PO4 solution (109 μL of 1.25 M).  The mixture was 
cooled to -10 °C, and NaClO2 (80% Aldrich, 13 mg, 0.114 mmol, 20.0 equiv) was added 
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in one portion.  The reaction mixture stirred vigorously at -10 °C for 4 h, and was then 
quenched with the addition of aqueous pH 4 buffer solution (1 mL).  The reaction 
mixture was partitioned between CH2Cl2 (5 mL) and aqueous pH 4 buffer solution (5 
mL).  The phases were separated, and the aqueous phase was extracted with CH2Cl2 
(4 × 5 mL).  The combined organic phases were dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification was accomplished using flash 
chromatography on a 0.8 × 6.5 cm silica gel column, eluting with 20 % EtOAc/hexanes 
then 1 % methanol / 30 % EtOAc/hexanes, collecting 6 × 50 mm test tube fractions.  The 
product containing fractions (10-21) were combined and concentrated under reduced 
pressure to provide pure carboxylic acid 2.69 (8.0 mg, quant. yield over 2 steps) as a 
colorless oil: Rf = 0.38 (50% EtOAc/hexanes); [ ] =20Dα  +12 (c = 0.27, CHCl3); 500 MHz 
1H NMR (CDCl3) δ 7.38-7.28 (m, 5H), 7.36 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.4 Hz, 2H), 
5.96 (d, J = 5.8 Hz, 1H), 5.88 (s, 1H), 5.59 (s, 1H), 5.44 (dd, J = 15.8, 6.1 Hz, 1H), 4.82 
(ABq, J = 7.1 Hz, Δν = 7.2 Hz, 2H), 4.66 (s, 2H), 4.60 (s, 1H), 4.57 (d, J = 10.7 Hz, 1H), 
4.45 (d, J = 10.8 Hz, 1H), 4.14-4.05 (m, 3H), 3.87 (ddd, J = 12.4, 6.4, 6.4 Hz, 1H), 3.81 
(s, 3H), 3.77 (t, J = 5.0 Hz, 1H), 3.75-3.68 (m, 4H), 3.57-3.40 (m, 4H), 3.31 (s, 3H), 2.61 
(dddd, J = 15.4, 15.4, 15.4, 5.4 Hz, 2H), 2.40-2.31 (m, 3H), 2.28 (d, J = 13.1 Hz, 1H), 
2.17 (d, J = 12.4 Hz, 1H), 2.08-1.88 (m, 5H), 1.84-1.72 (m, 3H), 1.70-1.52 (m, 5H), 1.35-
1.25 (m, 10H), 1.17 (d, J = 6.4 Hz, 3H), 1.12 (s, 6H), 0.90-0.86 (m, 21H), 0.09 (s, 3H), 
0.08 (s, 3H), 0.06 (s, 6H); 125 MHz 13C NMR (CDCl3) δ 173.2, 172.5, 166.8, 159.6, 
153.2, 144.3, 138.8, 137.9, 130.3, 129.7, 128.6, 128.1, 127.9, 127.2, 116.9, 114.2, 109.1, 
102.6, 93.1, 79.6, 75.3, 75.1, 73.3, 72.5, 72.2, 72.1, 71.6, 70.1, 69.5, 68.8, 68.4, 55.5, 51.6, 
51.4, 46.1, 42.8, 42.2, 42.0, 42.0, 40.8, 40.4, 40.0, 38.7, 34.6, 33.6, 31.9, 29.3, 29.2, 26.1 
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(×2), 25.0, 24.4, 24.0, 22.8, 18.3 (×2), 14.3, 14.0, -3.8, -4.3, -4.5; 125 MHz DEPT  NMR 
(CDCl3) CH3 δ 55.5, 51.6, 51.4, 26.1 (×2), 24.4, 24.0, 14.3, 14.0, -3.8, -4.3, -4.5 ; CH2 δ  
109.1, 93.1, 72.5, 69.5, 42.8, 42.2, 42.0, 42.0, 40.8, 40.4, 40.0, 38.7, 34.6, 33.6, 31.9, 29.3, 
29.2, 25.0, 22.8; CH δ  138.8, 129.7, 128.6, 128.1, 127.9, 127.2, 116.9, 114.1, 79.6, 75.3, 
75.1, 73.3, 72.2, 72.1, 71.6, 70.1, 68.8, 68.4; CH0 δ  173.2, 172.5, 166.8, 159.6, 153.2, 
144.3, 137.9, 130.3, 102.6, 46.1, 18.3 (×2); IR (neat) 2930, 2857, 1722, 1514, 1463, 1380, 
1250, 1156, 1111, 836, 775, 542 cm-1  ; HRMS (ESI/TOF) calcd for C70H112O16NaSi2 
(M+Na) 1287.7381, found 1287.7361. 
 
 
  Preparation of (R)-4-((2S,4S,6R)-6-(((2S,6R)-6-((E)-3-((2S,3S,6S,E)-6-((2R, 
3R)-3-(benzyloxy methoxy)-2-hydroxybutyl)-2-methoxy-4-(2-methoxy-2-oxoethyli de 
ne)-3-(octanoyloxy) tetra hydro-2H-pyran-2-yl)-3-methylbut-1-enyl)-4-methylenete 
trahydro-2H-pyran-2-yl) methyl)-4-hydroxy tetrahydro-2H-pyran-2-yl)-3-(4-meth 
oxy benzyloxy) butanoic acid (2.70). To a stirring solution of TBS ether 2.69 (7.6 mg, 
0.0060 mmol, 1.0 equiv) in 9:1 THF/ pyridine (600 μL, 0.01 M) in a 4 mL plastic vial 
was added HF·Py (20 %, 240 μL). The solution was stirred at rt for 48 h, then diluted 
with 50 % EtOAc/hexanes (50 mL), and washed with brine (2 × 10 mL). The solution 
was dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification 
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was accomplished using flash chromatography with a 2 × 14 cm silica gel column, 
eluting with 10% methanol/40% EtOAc/hexanes, collecting 10 × 130 mm test tube 
fractions.  The product containing fractions (6-8) were combined and concentrated under 
reduced pressure to provide the product 2.70 (5.4 mg, 87%) as a colorless oil: Rf = 0.48 
(10% methanol/40 %EtOAc/hexanes); [ ] =20Dα  +6 (c = 0.20, CHCl3);  500 MHz 1H NMR 
(CDCl3)  δ 7.37-7.29 (m, 5H), 7.25 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 6.00 (d, 
J = 16.1 Hz, 1H), 5.87 (s, 1H), 5.54 (s, 1H), 5.40 (dd, J = 16.1, 6.4 Hz, 1H), 4.86 (ABq, J 
= 6.8 Hz, Δν = 20.5 Hz 2H), 4.70 (s, 2H), 4.66 (d, J = 2.9 Hz, 2H), 4.57 (d, J = 10.7 Hz, 
1H), 4.46 (d, J = 10.7 Hz, 1H), 4.22-4.16 (m, 1H), 4.14-4.06 (m, 2H), 3.89-3.84 (m, 1H), 
3.80 (s, 3H), 3.78-3.72 (m, 2H), 3.70-3.62 (m, 5H), 3.52-3.40 (m, 4H), 3.33 (s, 3H), 2.65 
(dd, J = 15.6,  5.9 Hz, 1H), 2.57 (dd, J = 15.6, 5.9 Hz, 1H), 2.40-2.32 (m, 3H), 2.26-2.18 
(m, 3H), 2.05-1.85 (m, 5H), 1.80-1.55 (m, 7H), 1.34-1.24 (m, 10H), 1.18-1.08 (m, 9H), 
0.88 (t, J = 6.8 Hz, 3H); 125 MHz 13C NMR (CDCl3) δ 173.5, 172.3, 166.9, 159.6, 153.2, 
144.4, 139.7, 137.7, 130.2, 129.7, 128.7, 128.1 (×2), 127.0, 116.8, 114.2, 109.1, 102.9, 
93.9, 80.0, 77.9, 75.1, 72.9, 72.5, 72.2 (×2), 71.3, 70.1, 68.2, 68.2, 60.6, 55.5, 51.5, 51.4, 
46.2, 42.2, 41.8, 41.5, 41.1, 40.8 (×2), 39.9, 34.7, 31.9, 29.9, 29.3, 29.1, 25.0, 24.9 (×2), 
23.0, 22.8, 17.0, 14.3; 125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 51.5, 51.4, 25.0, 23.0, 
17.0, 14.3; CH2 δ  109.1, 93.9, 72.2, 70.1, 42.2, 41.8, 41.5, 41.1, 40.8 (×2), 39.9, 34.7, 
31.9, 29.9, 29.3, 29.1, 24.9 (×2), 22.8; CH δ  139.7, 129.7, 128.7, 128.1 (×2), 127.0, 
116.8, 114.2, 80.0, 77.9, 75.1, 72.9, 72.5, 72.2 (×2), 71.3, 68.2, 68.2; CH0 δ  173.5, 172.3, 
166.9, 159.6, 153.3, 144.4, 137.7, 130.2, 102.9, 46.2; IR (neat) 3426, 2930, 1719, 1514, 
1458, 1379, 1247, 1156, 1105, 1038, 745 cm-1; HRMS (ESI/TOF) calcd C58H84O16Na for 





Preparation of (R)-4-((2R,4S,6S)-6-(((2S,6R)-6-((E)-3-((2S,3S,6S,E)-6-((2R, 
3R)-3-(benzyloxy methoxy)-2-hydroxybutyl)-2-methoxy-4-(2-methoxy-2-oxoethylid 
ene)-3-(octanoyloxy) tetra hydro-2H-pyran-2-yl)-3-methylbut-1-enyl)-4-methylene 
tetrahydro-2H-pyran-2-yl)methyl)-4-(triethyl silyloxy)tetrahydro-2H-pyran-2-yl)-3-
(4-methoxybenzyl oxy)butanoic acid (2.73). To a stirring solution of alcohol 2.70 (3.0 
mg, 0.0029 mmol, 1.0 equiv) in CH2Cl2 (116 μL, 0.025 M) in a 4 mL reaction vial at rt 
was added 4-dimethylaminopyridine (1.6 mg, 0.013 mmol, 4.5 equiv). The solution was 
cooled to -15 °C, then a solution of TESCl in CH2Cl2 (6.1 μL of 1.0 M, 0.0061 mmol, 2.1 
equiv) was added via syringe. The mixture was stirred at -15 °C for 90 min. The reaction 
mixture was then quenched by the addition of saturated aqueous NaHCO3 solution (1 
mL), and the mixture was partitioned between 10 mL of EtOAc and 5 mL of saturated 
aqueous NaHCO3 solution. The aqueous phase was separated and extracted with EtOAc 
(3 × 10 mL). The combined organic phases were dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished using flash 
chromatography on a 0.6 × 4 cm silica gel column, eluting with 5% methanol/35% 
EtOAc/hexanes, collecting 6 × 50 mm test tube fractions.  The product containing 
fractions (11-25) were combined and concentrated under reduced pressure to provide 
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pure product 2.73 (2.5 mg, 76%) as a colorless oil: Rf = 0.63 (5% methanol/35% 
EtOAc/hexanes); [ ] =20Dα  +5 (c = 0.085, CHCl3);  500 MHz 1H NMR (CDCl3)  δ 7.37-
7.30 (m, 5H), 7.26 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 5.98 (d, J = 15.6 Hz, 1H), 
5.88 (s, 1H), 5.56 (s, 1H), 5.42 (dd, J = 16.1, 6.3 Hz, 1H), 4.88 (ABq, J = 6.8 Hz, Δν = 
19.5 Hz 2H), 4.70-4.60 (m, 4H), 4.57 (d, J = 10.7 Hz, 1H), 4.47 (d, J = 10.7 Hz, 1H), 
4.26-4.18 (m, 1H), 4.15-4.05 (m, 1H), 3.90-3.85 (m, 1H), 3.81 (s, 3H), 3.74-3.62 (m, 7H), 
3.56-3.40 (m, 4H), 3.34 (s, 3H), 2.65 (dd, J = 15.6, 5.4 Hz, 1H), 2.57 (dd, J = 15.1, 5.4 
Hz, 1H), 2.43-2.37 (m, 1H), 2.35 (ddd, J = 7.3, 7.3, 2.9 Hz, 2H), 2.28 (d, J = 13.2 Hz, 
1H), 2.20 (d, J = 12.2 Hz, 1H), 2.10-2.00 (m, 2H), 2.00-1.88 (m, 3H), 1.86-1.80 (m, 1H), 
1.80-1.55 (m, 7H), 1.34-1.22 (m, 10H), 1.12 (s, 6H), 0.95 (t, J = 7.8 Hz, 9H), 0.88 (m, 
6H), 0.60 (q, J = 7.8 Hz, 6H); 125 MHz 13C NMR (CDCl3) δ 174.0, 172.3, 166.8, 159.5, 
153.2, 144.3, 139.2, 139.2, 137.7, 129.6, 128.7, 128.1, 128.1, 126.9, 116.8, 114.1, 109.1, 
102.8, 93.9, 79.7, 78.0, 77.4, 75.7, 73.6, 72.4, 72.2, 72.1, 71.1, 70.1, 68.6, 68.2, 55.5, 51.4, 
51.4, 46.2, 42.9, 42.3, 42.1, 40.8, 40.7, 39.8, 34.6, 31.9, 31.8, 29.9, 29.3, 29.2, 25.0, 24.6, 
23.6, 22.9, 22.8, 17.0, 14.4, 7.1, 5.2; 125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 51.4, 
51.4, 24.6, 23.6, 17.0, 14.4, 7.1; CH2 δ  109.1, 93.9, 72.4, 70.1, 42.9, 42.3, 42.1, 40.8, 
40.7, 39.8, 34.6, 31.9, 29.9, 29.3, 29.2, 25.0, 23.6, 22.9, 22.8, 5.2; CH δ  139.2, 139.2, 
129.6, 128.7, 128.1, 128.1, 126.9, 114.1, 79.7, 78.0, 75.7, 73.6, 72.4, 72.2, 72.1, 71.1, 
68.6, 68.2; CH0 δ  174.0, 172.3, 166.8, 159.5, 153.2, 144.3, 137.7, 116.8, 102.8, 46.2; IR 
(neat) 2930, 1719, 1513, 1459, 1380, 1247, 1154, 1040, 822, 742 cm-1; HRMS (ESI/TOF) 








29-tetra oxatetra cyclo [21.3.1.13,7.111,15]nonacos-8-en-12-yl octanoate) (2.74). To a 
stirring solution of seco acid 2.73 (2.0 mg, 0.0017 mmol, 1.0 equiv) in THF (58 μL, 0.03 
M) at 0 °C in a 4 mL reaction vial were added triethylamine (1.1 mg, 0.010 mmol, 6.0 
equiv) and 2,4,6-trichlorobenzoyl chloride (1.3 mg, 0.0052 mmol, 3.0 equiv) by syringe. 
The solution was stirred at 0 °C for 5 min, then warmed to rt and stirred for 2 h. The 
reaction mixture was diluted with 1:3 THF/toluene (696 μL, 0.0025 M), and taken up into 
a 1.0 mL gas-tight syringe. The resulting solution was added into a stirring solution of 4-
dimethylaminopyridine  (4.3 mg, 0.035 mmol, 20 equiv) in toluene (1.2 mL, 0.0015 M) 
in a 15 mL rb flask at 40 °C over 12 h by means of a syringe pump. The vial was rinsed 
with toluene (0.2 mL) and the rinsing solution was added into the reaction mixture by 
syringe pump over 2 h. The solution was cooled to rt and diluted with 50 mL of 40% 
EtOAc/hexanes. The solution was washed with saturated aqueous NaHCO3 solution (5 
mL) and brine (5 mL). The organic phases were dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished using flash 
chromatography on a 1.6 × 10 cm silica gel column, eluting with 20% EtOAc/hexanes, 
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collecting 12 × 75 mm test tube fractions.  The product containing fractions (7-10) were 
combined and concentrated under reduced pressure to give the product macrolactone 2.74 
(1.8 mg, 91%) as a colorless oil: Rf = 0.45 (20% EtOAc/hexanes); [ ] =20Dα  +21 (c = 0.075, 
CHCl3);  500 MHz 1H NMR (CDCl3)  7.40-7.28 (m, 5H), 7.22 (d, J = 8.3 Hz, 2H), 6.82 
(d, J = 8.8 Hz, 2H), 6.22 (d, J = 6.1 Hz, 1H), 5.95 (s, 1H), 5.57 (ddd, J = 12.2, 4.0, 2.4 Hz, 
1H), 5.34 (dd, J = 15.6, 8.3 Hz, 1H), 5.15 (s, 1H), 4.82 (ABq, J = 5.8 Hz, Δν = 10.1 Hz 
2H), 4.75 (d, J = 3.9 Hz, 2H), 4.64 (ABq, J = 11.7 Hz, Δν = 16.8 Hz, 2H), 4.51 (s, 2H), 
4.17 (m, 1H), 3.95 (m, 2H), 3.75 (s, 3H), 3.73-3.66 (m, 5H), 3.50 (m, 1H), 3.35 (t, J = 
11.7 Hz, 1H), 3.15-3.05 (m, 4H), 3.08 (s, 3H), 2.54 (d, J = 15.6 Hz, 1H), 2.46 (dd, J = 
15.6, 9.8 Hz, 1H), 2.32-2.26 (m, 3H), 2.20 (d, J = 12.7 Hz, 1H), 2.15-2.03 (m, 4H), 1.99 
(d, J = 12.2 Hz, 1H), 1.94 (d, J = 12.7 Hz, 1H), 1.85 (t, J = 13.2 Hz, 1H), 1.83-1.67 (m, 
3H), 1.64-1.55 (m, 2H), 1.52 (dd, J = 13.7, 7.3 Hz, 1H), 1.46-1.38 (m, 1H), 1.30-1.22 (m, 
10H), 1.09 (s, 3H), 1.08 (s, 3H), 1.06 (d, J = 6.4 Hz, 3H), 0.95 (t, J = 7.8 Hz, 9H), 0.88 (t, 
J = 7.4 Hz, 3H), 0.58 (q, J = 7.8 Hz, 6H); 125 MHz 13C NMR (CDCl3) δ 172.3, 172.2, 
167.0, 159.3, 151.5, 144.7, 141.8, 138.1, 131.1, 129.6, 128.6, 128.1, 127.8, 125.7, 119.4, 
113.9, 108.9, 103.4, 93.7, 81.5, 76.5, 75.3, 73.8, 73.7, 73.4, 73.2, 72.2, 70.7, 69.8, 68.6, 
67.3, 55.5, 52.8, 51.4, 45.3, 44.2, 43.0, 42.2, 42.1 (×2), 41.5, 41.0, 34.8, 31.9, 31.1, 30.0, 
29.2, 29.1, 26.4, 24.9, 22.8, 20.2, 15.3, 14.3, 7.1, 5.1; 125 MHz DEPT NMR (CDCl3) 
CH3 δ 55.5, 52.8, 51.4, 26.4, 20.2, 15.3, 14.3, 7.1; CH2 δ  108.9, 93.7, 72.2, 69.8, 44.2, 
43.0, 42.2, 42.1 (×2), 41.5, 41.0, 34.8, 31.9, 31.1, 30.0, 29.2, 29.1, 24.9, 22.8, 5.1; CH δ  
141.8, 129.6, 128.6, 128.1, 127.8, 125.7, 119.4, 113.9, 81.5, 76.5, 75.3, 73.8, 73.7, 73.4, 
73.2, 70.7, 68.6, 67.3 ; CH0 δ  172.3, 172.2, 167.0, 159.3, 151.5, 144.7, 138.1, 131.1, 
103.4, 45.3; IR (neat) 2930, 1725, 1513, 1459, 1377, 1246, 1156, 1088, 1044, 824, 742, 
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Preparation of Protected (1S,3S,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-
25-acetoxy-17-((R)-1-((benzyloxy)methoxy)ethyl)-11-methoxy-13-(2-methoxy-2-oxoe 
thylidene)-21-((4-methoxybenzyl)oxy)-10,10-dimethyl-5-methylene-19-oxo-18,27,28, 
29-tetraoxatetra cyclo [21.3.1.13,7.111,15]nonacos-8-en-12-yl octanoate (2.75): To a 
stirring solution of TES ether 2.74 (2.0 mg, 0.0018 mmol, 1.0 equiv) in 9:1 THF/pyridine 
(272 μL, 0.0067 M) in a 4 mL plastic vial was added HF·py (20 %, 108 μL).  The 
solution was stirred at rt for 48 h, then diluted with 50 % EtOAc/hexanes (50 mL), and 
washed with brine (3 × 5 mL). The solution was dried over Na2SO4, filtered, and 
concentrated under reduced pressure. The resulting crude product was carried into the 
next step without further purification. 
To a stirring solution of the aforementioned alcohol in CH2Cl2 (352 μL, 0.005 M) 
in a 4 mL reaction vial at rt were added pyridine (7.0 mg, 0.088 mmol, 50 equiv), 4-
dimethylaminopyridine (2.2 mg, 0.018 mmol) and Ac2O (5.4 mg, 0.053 mmol, 30 equiv). 
The mixture was stirred at rt overnight, and then diluted with CH2Cl2 (1 mL) and 
quenched by the addition of saturated aqueous NaHCO3 solution (1 mL). The mixture 
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was then partitioned between 10 mL of CH2Cl2 and 5 mL of saturated aqueous NaHCO3 
solution. The aqueous phase was separated and extracted with CH2Cl2 (3 × 10 mL). The 
combined organic phases were dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  Purification was accomplished using flash chromatography with a 
1 × 9 cm silica gel column, eluting with 50% EtOAc/hexanes, collecting 12 × 75 mm test 
tube fractions.  The product containing fractions (4-7) were combined and concentrated 
under reduced pressure to provide pure product 2.75 (1.8 mg, 95% over 2 steps) as a 
colorless oil: Rf = 0.45 (50% EtOAc/hexanes); [ ] =20Dα  +13 (c = 0.080, CHCl3);  500 
MHz 1H NMR (CDCl3)  δ 7.39-7.28 (m, 5H), 7.21 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.8 
Hz, 2H), 6.22 (d, J = 15.6 Hz, 1H), 5.95 (d, J = 1.5 Hz, 1H), 5.58 (ddd, J = 11.7, 4.4, 2.4 
Hz, 1H), 5.34 (dd, J = 15.6, 8.8 Hz, 1H), 5.18 (s, 1H), 4.86-4.80 (m, 3H), 4.77 (d, J = 7.3 
Hz, 2H), 4.66 (ABq, J = 11.7 Hz, Δν = 18.0 Hz, 2H), 4.48 (ABq, J = 10.7 Hz, Δν = 18.0 
Hz, 2H), 4.47 (d, J = 10.7 Hz, 1H), 4.22-4.16 (m, 1H), 3.99-3.92 (m, 2H), 3.76 (s, 3H), 
3.73-3.66 (m, 5H), 3.52-3.40 (m, 2H), 3.18 (t, J = 10.7 Hz, 1H), 3.08 (s, 3H), 2.52 (dd, J 
= 11.6, 3.4 Hz, 1H), 2.47 (dd, J = 15.6, 9.3 Hz, 1H), 2.32-2.26 (m, 3H), 2.20 (d, J = 13.2 
Hz, 1H), 2.13-2.07 (m, 2H), 2.05 (s, 3H), 1.99 (d, J = 14.7 Hz, 1H), 1.94 (d, J = 11.7 Hz, 
1H), 1.64-1.50 (m, 3H), 1.46-1.38 (m, 1H), 1.34-1.22 (m, 10H), 1.09 (s, 6H), 1.07 (s, 3H), 
0.88 (t, J = 6.8 Hz, 3H); 125 MHz 13C NMR (CDCl3) δ 172.2, 171.3, 170.7, 167.0, 159.3, 
151.5, 144.4, 141.7, 138.1, 130.9, 129.6, 128.6, 128.1, 127.9, 125.7, 119.4, 113.9, 109.1, 
103.4, 93.7, 81.5, 76.3, 74.8, 73.7, 73.5, 73.3, 73.2, 72.3, 70.8, 70.4, 69.8, 67.3, 55.5, 52.8, 
51.4, 45.2, 44.0, 42.9, 41.9, 41.4, 41.0, 37.6, 34.8, 34.8, 31.9, 31.0, 29.9, 29.2, 29.1, 26.5, 
24.9, 22.8, 21.5, 20.2, 15.3, 14.3; 125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 52.8, 51.4, 
26.5, 21.5, 20.2, 15.3, 14.3; CH2 δ  109.1, 93.7, 72.3, 69.8, 44.0, 42.9, 41.9, 41.4, 41.0, 
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37.6, 34.8, 34.8, 31.9, 31.0, 29.9, 29.2, 29.1, 24.9, 22.8; CH δ  141.7, 129.6, 128.6, 128.1, 
127.9, 125.7, 119.4, 113.9, 81.5, 76.3, 74.8, 73.7, 73.5, 73.3, 73.2, 70.8, 70.4, 67.3; CH0 δ  
172.2, 171.3, 170.7, 167.0, 159.3, 151.5, 144.4, 138.1, 130.9, 103.4, 45.2; IR (neat) 2929, 
2856, 1665, 1613, 1514, 1436, 1377, 1309, 1243, 1158, 1091, 1040, 892, 815, 753, 699, 







8-en-12-yl octanoate (Merle 27). To a stirring solution of 1.154 (1.4 mg, 0.0013mmol, 
1.0 equiv) in CH2Cl2 (0.26 mL, 0.005 M) in a 4 mL reaction vial at 0 ºC were added 
aqueous pH 7 buffer (0.15 mL) and DDQ (1.5 mg, 0.0068 mmol, 5.0 equiv). The reaction 
mixture was stirred at 0 ºC for 2 h and additional DDQ (1.5 mg, 0.0068 mmol, 5.0 equiv) 
was then added. Stirring continued for 1.5 h and the reaction mixture was diluted with 
CH2Cl2 (1 mL) and quenched by addition of saturated aqueous NaHCO3 solution (1 mL). 
After stirring vigorously for 10 min at rt the mixture was partitioned between CH2Cl2 (5 
mL) and saturated aqueous NaHCO3 solution (5 mL). The aqueous phase was separated 
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and extracted with CH2Cl2 (3 × 5 mL). The combined organic phases were dried over 
Na2SO4, filtered and then concentrated under reduced pressure. The crude material was 
taken on to the next step without purification.  
To a 4 mL reaction vial containing the aforementioned analogue precursor was 
added a LiBF4 in 25:1 CH3CN/H2O (238 μL of 0.25 M, 0.059 mmol, 45.0 equiv). The 
reaction vial was sealed and the mixture was stirred at 80 ºC for 10 h. After cooling to rt, 
the reaction mixture was diluted with EtOAc (1 mL) and was quenched by the addition of 
saturated aqueous NaHCO3 solution (0.5 mL). The mixture was partitioned between 
EtOAc (10 mL) and saturated NaHCO3 aqueous solution (5 mL). The phases were 
separated and the aqueous phase was extracted with EtOAc (3 × 10 mL). The combined 
organic phases were dried over Na2SO4, filtered and then concentrated under reduced 
pressure. Purification was accomplished using flash chromatography with a 0.6 × 4 cm 
silica gel column, eluting with 40% EtOAc/hexanes, collecting 6 × 50 mm test tube 
fractions. The product containing fractions (4-13) were combined and concentrated under 
reduced pressure to provide analogue Merle 27 (0.93 mg, 87% over 2 steps) as a 
colorless oil:  Rf = 0.11 (50% EtOAc/hexanes); [ ] =20Dα  +20 (c = 0.047, CHCl3);  500 
MHz 1H NMR (CDCl3)  δ 5.99 (d, J = 2.0 Hz, 1H), 5.79 (d, J = 16.1 Hz, 1H), 5.33 (dd, J 
= 15.6, 8.3 Hz, 1H), 5.23 (ddd, J = 11.7, 5.9, 2.9 Hz, 1H), 5.13 (s, 1H), 4.90-4.80 (m, 1H), 
4.72 (d, J = 4.4 Hz, 2H), 4.41 (d, J = 12.2 Hz, 1H), 4.23 (t, J = 11.7 Hz, 1H), 4.08-4.00 
(m, 2H), 3.83 (q, J = 6.3 Hz, 1H), 3.73-3.71 (m, 1H), 3.68 (s, 3H), 3.65-3.50 (m, 3H), 
2.51 (dd, J = 12.2, 2.0 Hz, 1H), 2.45 (t, J = 11.7 Hz, 1H), 2.31 (ddd, J = 7.8, 3.9, 3.9 Hz, 
2H), 2.13-2.06 (m, 2H), 2.06-2.00 (m, 5H), 2.00-1.96 (m, 2H), 1.96-1.92 (m, 6H), 1.78-
1.68 (m, 1H), 1.66-1.60 (m, 2H), 1.56-1.48 (m, 2H), 1.36-1.22 (m, 13H), 1.14 (s, 3H), 
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1.01 (s, 3H), 0.88 (t, J = 7.3 Hz,3H); 125 MHz 13C NMR (CDCl3) δ 172.3, 172.2, 170.7, 
167.2, 152.1, 143.9, 139.0, 130.0, 119.9, 108.9, 99.1, 80.2, 77.8, 76.9, 74.4, 73.9, 73.6, 
70.5, 69.6, 68.7, 64.7, 51.3, 45.1, 43.1, 42.8, 41.5, 40.0, 37.5, 36.1, 34.9, 31.9, 31.8, 31.5, 
29.2, 29.1, 25.0, 24.9, 22.9, 22.8, 21.4, 20.0, 20.0, 4.3; 125 MHz DEPT NMR (CDCl3) 
CH3 δ 51.3, 25.0, 21.4, 20.0, 20.0, 14.3; CH2 δ  108.9, 43.1, 42.8, 41.5, 40.0, 37.5, 36.1, 
34.9, 31.9, 31.8, 31.5, 29.2, 29.1, 24.9, 22.9, 22.8; CH δ  139.0, 130.0, 119.9, 80.2, 77.8, 
76.9, 74.4, 73.9, 73.6, 70.5, 69.6, 68.7, 64.7; CH0 δ  172.3, 172.2, 170.7, 167.2, 152.1, 
143.9, 99.1, 45.1; IR (neat) 3583, 3458, 3070, 2955, 2932, 2857, 1734, 1612, 1513, 1472, 
1463, 1377, 1250, 1172, 1105, 843, 823, 742, 703, 688 cm-1; HRMS (ESI/TOF) calcd for 







(2.71). Prepared from 2.70 (2.8 mg) in the same manner as 2.73 to provide product 2.71 
(2.6 mg, 79 %) as a white film: Rf = 0.20 (20% EtOAc/hexanes); [ ] =20Dα  +5 (c = 0.10, 
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CHCl3);  500 MHz 1H NMR (CDCl3)  δ 7.40-7.28 (m, 7H), 7.22 (d, J = 8.8 Hz, 2H), 6.85 
(d, J = 8.8 Hz, 2H), 6.22 (d, J = 15.6 Hz, 1H), 5.93 (d, J = 1.0 Hz, 1H), 5.58 (ddd, J = 
11.7, 4.4, 2.4 Hz, 1H), 5.34 (dd, J = 15.6, 8.3 Hz, 1H), 5.20-5.11 (m, 2H), 4.83 (s, 1H), 
4.78 (d, J = 8.8 Hz, 2H), 4.65 (ABq, J = 11.7 Hz, Δν = 19.7 Hz, 2H), 4.50 (d, J = 10.7 Hz, 
Δν = 21.4 Hz, 2H), 4.24-4.15 (m, 1H), 4.00-3.90 (m, 2H), 3.77 (s, 3H), 3.72-3.66 (m, 4H), 
3.62 (dd, J = 14.2, 7.3 Hz, 1H), 3.54-3.46 (m, 2H), 3.24 (t, J = 11.3 Hz, 1H), 3.06 (s, 3H), 
2.50 (d, J = 6.9 Hz, 2H), 2.33-2.23 (m, 3H), 2.20 (d, J = 12.7 Hz, 1H), 2.13-1.95 (m, 6H), 
1.90-1.81 (m, 2H), 1.80-1.75 (m, 1H), 1.65-1.50 (m, 6H), 1.34-1.20 (m, 10H), 1.10 (s, 
6H), 1.08 (s, 3H), 0.88 (t, J = 6.8 Hz, 3H); 125 MHz NMR (CDCl3) δ 172.2, 172.1, 167.0, 
164.9, 159.3, 151.5, 144.4, 141.7, 138.1, 134.7, 133.2, 132.3, 130.9, 129.9, 129.8, 129.6, 
128.6, 128.1, 127.9, 127.8, 125.8, 119.5, 113.9, 109.1, 103.4, 93.7, 81.5, 76.3, 74.6, 73.7, 
73.5, 73.3, 73.2, 72.3, 71.5, 70.9, 69.8, 67.3, 55.5, 52.8, 51.4, 45.3, 44.0, 42.9, 42.0, 41.5, 
41.0, 37.3, 34.8, 31.9, 31.1, 29.9, 29.2, 26.5, 24.9, 22.8, 20.3, 15.4, 14.3; 125 MHz DEPT 
13C NMR (CDCl3) CH3 δ 55.5, 52.8, 51.4, 26.5, 15.3, 14.3; CH2 δ  109.1, 93.7, 72.3, 69.8, 
44.0, 42.9, 42.0, 41.5, 41.0, 37.3, 34.8, 31.9, 31.1, 29.9, 29.2, 29.1, 24.9, 22.8, 20.3; CH δ 
141.7, 129.6, 128.6, 128.1, 127.9, 127.9, 125.8, 119.5, 113.9, 81.5, 76.3, 74.6, 73.7, 73.5, 
73.3, 73.2, 71.5, 70.9, 67.3; CH0 δ  172.2, 172.1, 167.0, 164.9, 159.3, 151.5, 144.4, 138.1, 
134.7, 133.2, 132.3, 130.9, 129.9, 129.8, 103.4, 45.3; IR (neat) 2926, 2853, 1738, 1651, 
1580, 1548, 1514, 1435, 1382, 1249, 1160, 1103, 1042, 819, 668, 541 cm-1; LRMS (EI) 





Preparation of (1S,3S,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-11,21-dihy 
droxy-17-((R)-1-hydroxyethyl)-13-(2-methoxy-2-oxoethylidene)-10,10-dimethyl-5-m 
ethylene-12-(octanoyloxy)-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15] 
nonacos-8-en-25-yl 2,4,6-trichlorobenzoate (2.72). Prepared from 2.71 (2.6 mg) in the 
same manner as Merle 27 to provide the analogue 2.72 (1.3 mg, 63 %) as a white film: Rf 
= 0.45 (50% EtOAc/hexanes); [ ] =20Dα  +3 (c = 0.065, CHCl3);  500 MHz 1H NMR 
(CDCl3)  δ 7.35-7.40 (m, 2H), 5.99 (s, 1H), 5.79 (d, J = 15.6 Hz, 1H), 5.33 (dd, J = 16.1, 
8.8 Hz, 1H), 5.22 (m, 1H), 5.14 (s, 1H), 4.76-4.70 (m, 3H), 4.40 (d, J = 12.2 Hz, 1H), 
4.27-4.20 (m, 1H), 4.07-4.00 (m, 2H), 3.85-3.80 (m, 1H), 3.73-3.70 (m, 1H), 3.68 (s, 3H), 
3.62-3.55 (m, 3H), 2.54 (d, J = 12.2 Hz,1H), 2.47 (d, J = 11.7 Hz, 1H), 2.31 (ddd, J = 3.4, 
7.3, 7.3 Hz, 2H), 2.18-1.80 (m, 12H), 1.66-1.40 (m, 5H), 1.32-1.22 (m, 13H), 1.14 (s, 3H), 
1.04 (s, 3H), 0.88(t, J = 6.8 Hz, 3H); 125 MHz 13C NMR (CDCl3) δ 172.4, 172.2, 167.2, 
163.6, 159.7, 152.1, 143.8, 139.0, 132.7, 129.9, 128.3, 119.9, 108.9, 99.1, 95.0, 80.2, 77.8, 
77.4, 74.4, 73.9, 73.6, 72.0, 70.5, 68.7, 64.7, 51.3, 45.1, 43.1, 42.8, 42.3, 41.6, 40.0, 37.1, 
36.7, 36.1, 34.9, 31.9, 31.5, 29.3, 29.1, 25.0, 24.9, 22.8, 20.1, 20.0, 14.3; IR (neat) 3458, 
2933, 2859, 1732, 1611, 1513, 1466, 1428, 1376, 1250, 1172, 1106, 843, 742, 704, 613 





Preparation of (9S,11R,12R,E)-methyl-12-(benzyloxymethoxy)-9-(tert-butyl 
dimethylsilyloxy)-11-(4-methoxybenzyloxy)-4,4-dimethyl-5-oxotridec-2-enoate 
(2.100). To a stirring solution of alkene 2.25 (761.1 mg, 1.242 mmol, 1.0 equiv) in 5% 
methanol/EtOAc (50 mL) in a 100 mL rb flask at -78 °C was added NaHCO3 (1.043 g, 
12.42 mmol, 10.0 equiv).  A steady stream of O3 was bubbled through the reaction 
mixture until a light blue color developed.  The excess O3 was removed by bubbling O2 
through the mixture for 15 min until the light blue color faded.  PPh3 (325.8 mg, 1.863 
mmol, 1.5 equiv) was added in one portion, and the reaction mixture was slowly warmed 
to rt, and stirred for 12 h.  The solids were removed via filtration, and the filtrate was 
concentrated under reduced pressure. The resulting yellow oil was taken up in 10% Et2O/ 
pentane (200 mL) in a 500 mL rb flask, and placed in a -20 °C freezer for 6 h.  The 
triphenylphosphine oxide precipitate was removed via filtration, and rinsed with 100 mL 
of ice cold 1% Et2O/pentane. The solvent was removed under reduced pressure to yield 
the crude aldehyde as a light yellow oil, which was taken on to the next step without 
further purification.   
 To a stirring solution of methyl diethyl phosphonoacetate (574.3 mg, 2.732 mmol, 
2.2 equiv) in THF (15 mL) in a 100 mL rb flask at 0 °C, was added NaH (65.6 mg, 2.732 
mmol, 2.2 equiv) portionwise over 10 min.  The reaction mixture was stirred at 0 °C for 
30 min, and then a solution of the aforementioned crude aldehyde in THF (5 mL) was 
added to the mixture slowly via cannula.  The transfer was completed with two 2.5 mL 
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rinses using THF.  The reaction mixture was stirred at 0 °C for an additional 2 h, then 
quenched by the addition of saturated aqueous NH4Cl solution (25 mL).  The phases were 
separated and the aqueous phase was extracted with EtOAc (3 × 50 mL).  The combined 
organic phases were dried with Na2SO4, filtered and then concentrated under reduced 
pressure.  Purification was accomplished using flash chromatography on a 3 × 20 cm 
silica gel column, eluting with 15% EtOAc/hexanes (1000 mL), collecting 18 × 150 mm 
test tube fractions.  The product containing fractions (9-20) were combined and 
concentrated under reduced pressure to give the product 2.100 (781.5mg, 94% over 2 
steps) as a colorless oil: Rf = 0.40 (20% EtOAc/hexanes); [ ] =20Dα  +27.9 (c = 0.405, 
CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.38-7.33 (m, 4H), 7.33-7.28 (m, 1H),  7.25 (d, J 
= 8.8 Hz, 2H), 7.06 (d, J = 15.6 Hz, 1H), 6.87 (d, J = 8.8 Hz, 2H), 5.89 (d, J = 15.6 Hz, 
1H), 4.81 (ddd, J = 7.3, 6.8, 6.4 Hz, 2H), 4.63 (q, J = 11.7 Hz, 2H), 4.59 (d, J = 11.2 Hz, 
1H), 4.45 (d, J = 10.7 Hz, 1H), 4.02 (dd, J = 16.4, 14.9 Hz, 1H), 3.89 (dddd, J = 8.8, 8.8, 
5.4 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 3.64 (ddd, J = 9.4, 4.4, 2.4 Hz, 1H), 2.42 (ddd, J = 
7.3, 7.3, 2.0 Hz, 2H), 1.69 (ddd, J = 14.2, 8.8, 2.4 Hz, 1H), 1.62-1.54 (m, 3H), 1.47-1.40 
(m, 2H), 1.27 (s, 6H), 1.18 (d, J = 6.4 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 6H);  125 MHz 13C 
NMR (CDCl3) 210.8, 166.9, 159.2, 152.0, 138.1, 131.1, 129.3, 128.6, 128.0, 127.8, 
120.5, 113.9, 93.4, 78.2, 73.0, 72.1, 69.6, 69.5, 55.4, 51.9, 50.7, 38.5, 37.8, 37.4, 26.1, 
23.7, 19.2, 18.3, 15.2, -3.5, -4.2; 125 MHz DEPT (CDCl3) CH3 δ 55.4, 51.9, 26.1, 23.7, 
15.2, -3.6, -4.2; CH2 δ 93.4, 72.1, 69.5, 38.5, 37.8, 37.4, 19.2; CH δ 152.0, 129.3, 128.6, 
128.0, 127.8, 120.5, 113.9, 78.2, 73.0, 69.6; CH0 δ 210.8, 166.9, 159.2, 138.1, 131.1, 
50.7, 18.3; IR (neat) 2953, 1725, 1648, 1613, 1513, 1463, 1382, 1300, 1249, 1174, 1040, 
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834, 774, 737, 698, 590, 536 cm-1;  HRMS (ESI/TOF) calcd for C38H58NaO8Si (M+Na) 












Preparation of (E)-methyl 4-((S)-2-((2R,3R)-3-(benzyloxymethoxy)-2-(4-me 
thoxybenzyloxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-4-methylpent-2-enoate (2.101). 
To a stirring solution of silyl ether 2.100 (769.2 mg, 1.146 mmol, 1.0 equiv) in 20:1 
CH3CN/ H2O (23 mL) in a 50 mL high density polyethylene bottle at 0 °C were added 
pyridine (3.8 mL) and a 48% aqueous HF solution (0.5 mL).  The solution was stirred at 
0 °C for 30 min, and then warmed to rt.  After 30 min of stirring at rt, an additional 0.5 
mL of aqueous HF solution (48%) was added every hour until TLC analysis indicated 
complete consumption of the starting material.  The reaction mixture was quenched by 
slowly pipetting the solution into a mixture of saturated aqueous NaHCO3 solution (50 
mL) and EtOAc (50 mL).  Then solid NaHCO3 was added until effervescence was 
complete.  The phases were separated and the aqueous phase was extracted with EtOAc 
(3 × 20 mL).  The combined organic phases were washed with saturated aqueous CuSO4 
solution (2 × 20 mL), and brine (2 × 20 mL).  The solution was dried over Na2SO4, 
filtered, and concentrated under reduced pressure to give the crude intermediate alcohol 




 To a stirring solution of the aforementioned crude alcohol in benzene (23 mL) in a 
50 mL rb flask equipped with a condenser and a Dean-Stark trap was added CSA (26.6 
mg, 0.115 mmol, 0.1 equiv).  The solution was heated at reflux for 1 h, and then cool to 
rt.  The reaction mixture was quenched with by the addition of pyridine (0.1 mL), and the 
solvent was removed under reduced pressure.  Purification was accomplished using flash 
chromatography on a 3.0 × 17 cm silica gel column, eluting with 10% EtOAc/hexanes 
(1000 mL), collecting 18 × 150 mm test tube fractions.  The product containing fractions 
(10-22) were combined and concentrated under reduced pressure to give the product 
dihydropyran 2.101  (553.7 mg, 90% over 2 steps) as a colorless oil: Rf = 0.42 (20% 
EtOAc/hexanes);  [ ] =20Dα +54.6 (c = 0.455, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.37-
7.34 (m, 4H), 7.33-7.29 (m, 1H), 7.26 (d, J = 8.8 Hz, 2H), 7.07 (d, J = 15.6 Hz, 1H), 6.87 
(d, J = 8.8 Hz, 2H), 5.84 (d, J = 16.1 Hz, 1H), 4.83 (d, J = 2.9 Hz, 2H), 4.65 (d, J = 2.9 
Hz, 2H), 4.62 (d, J = 10.7 Hz, 1H), 4.63-4.61 (m, 1H), 4.50 (d, J = 10.7 Hz, 1H), 4.05-
3.99 (m, 1H), 3.97 (dd, J = 6.5, 5.4 Hz, 1H), 3.82 (dd, J = 5.4, 2.0 Hz, 1H), 3.80 (s, 3H), 
3.64 (s, 3H), 2.14-2.06 (m, 1H), 2.04-1.96 (m, 1H), 1.84-1.74 (m, 2H), 1.62 (ddd, J = 
14.2,10.7, 2.4 Hz, 1H), 1.52 (dddd, J = 13.2, 9.8, 9.8, 5.9 Hz, 1H), 1.24 (s, 3H), 1.22 (s, 
3H), 1.21 (d, J = 6.4 Hz, 3H); 125 MHz 13C NMR (CDCl3) 167.6, 159.4, 157.2, 156.4, 
138.2, 131.1, 129.6, 128.6, 128.0, 127.8, 118.0, 114.0, 94.5, 93.6, 77.7, 73.9, 73.6, 72.0, 
69.5, 55.4, 51.5, 41.4, 36.2, 28.2, 25.3, 25.2, 20.5, 15.6; 125 MHz DEPT (CDCl3) CH3 δ 
55.4, 51.5, 25.3, 25.2, 15.6; CH2 δ 93.6, 73.6, 69.5, 36.2, 28.2, 20.5; CH δ 156.4, 129.6, 
128.6, 128.0, 127.8, 118.0, 114.0, 94.5, 77.7, 73.9, 72.0; CH0 δ 167.6, 159.4, 157.2, 
138.2, 131.1, 41.4; IR (neat) 2949, 1723, 1659, 1613, 1586, 1513, 1456, 1381, 1294, 
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1248, 1175, 1095, 1039, 821, 737, 699, 588 cm-1; HRMS (ESI/TOF) calcd for 
C32H42NaO7 (M+Na) 561.2828, found 561.2845. 
 
 
Preparation of (E)-4-((S)-2-((2R,3R)-3-(benzyloxymethoxy)-2-(4-methoxy 
benzyloxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-4-methylpent-2-en-1-ol (2.102). To a 
stirring solution of ester 2.101 (200.6 mg, 0.3724 mmol, 1.0 equiv) in CH2Cl2 (7.5 mL, 
0.05 M) at -78 °C was added a solution of diisobutylaluminium hydride (782 μL of 1.0 
M, 0.7820 mmol, 2.1 equiv) in CH2Cl2 slowly via syringe. The solution was stirred at -78 
°C for 2 h, then warmed to 0 °C and stirred for 0.5 h. The reaction was quenched by the 
addition of EtOAc (0.5 mL) and the mixture was stirred at 0 °C for 10 min. A saturated 
Rochelle salt solution (10 mL) was added. Then the aqueous phase was separated and 
extracted with CH2Cl2 (3 × 25 mL). The combined organic phases were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished using flash chromatography on a 3 × 14 cm silica gel column, eluting with 
30% EtOAc/hexanes (500mL), collecting 18 × 150 mm test tube fractions. The product 
containing fractions (6-12) were combined and concentrated under reduced pressure to 
give the product alcohol 2.102 (171.6 mg, 90%) as a clear colorless oil: Rf = 0.27 (30% 
EtOAc/hexanes);  [ ] =20Dα +40.7 (c = 0.945, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.38-
7.34 (m, 4H), 7.32-7.28 (m, 1H), 7.26 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 5.77 
(d, J = 16.1 Hz, 1H), 5.62 (ddd, J = 15.6, 5.9, 5.9 Hz, 1H), 4.84 (s, 2H), 4.65 (s, 2H), 4.62 
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(d, J = 10.7 Hz,1H), 4.57 (d, J = 3.7 Hz, 1H), 4.53 (d, J = 10.7 Hz, 1H), 4.06 (d, J = 5.4 
Hz, 2H), 4.03-3.94 (m, 2H), 3.85 (ddd, J = 10.3, 4.9, 2.4 Hz, 1H), 3.80 (s, 3H), 2.09 
(dddd, J = 16.6, 9.8, 6.8, 2.9 Hz, 1H), 2.03-1.96 (m, 1H), 1.83 (ddd, J = 14.2, 10.7, 2.0 
Hz, 1H), 1.77 (ddd, J = 13.7, 6.4, 3.4Hz, 1H), 1.60 (ddd, J = 14.2, 10.3, 2.4 Hz, 1H), 
1.55-1.46 (m, 1H), 1.20 (d, J =6.4 Hz, 3H), 1.18 (s, 6H); 125 MHz 13C NMR (CDCl3) 
159.4, 158.9, 140.5, 138.1, 131.2, 129.6, 128.6, 128.1, 127.9, 125.8, 114.1, 93.6, 93.3, 
78.0, 74.2, 73.4, 71.8, 69.7, 64.1, 55.5, 40.7, 36.1, 28.3, 26.1, 26.0, 20.5, 15.7; 125 MHz 
DEPT (CDCl3) CH3 δ 55.4, 26.1, 26.0, 15.7; CH2 δ 93.3, 73.4, 69.7, 64.1, 36.1, 28.3, 
20.5; CH δ 140.5, 129.6, 128.6, 128.1, 127.9, 125.8, 114.1, 93.3, 78.0, 74.2, 71.8; CH0 δ 
159.4, 158.9, 138.1, 131.2, 40.7; IR (neat) 3452 (b), 3031, 2933, 1661, 1612, 1586, 1513, 
1457, 1381, 1296, 1248, 1174, 1151, 1039, 977, 821, 740, 698 cm-1; HRMS (ESI/TOF) 
calcd for C31H42NaO6 (M+Na) 533.2879, found 533.2874. 
 
 
Preparation of ((E)-4-((S)-2-((2R,3R)-3-(benzyloxymethoxy)-2-(4-methoxy 
benzyloxy) butyl)-3,4-dihydro-2H-pyran-6-yl)-4-methylpent-2-enyloxy)(tert-butyl) 
dimethylsilane (2.103). To a stirring solution of alcohol 2.102 (141.5 mg, 0.2771 mmol, 
1.0 equiv) in CH2Cl2 (5.5 mL, 0.05M) in a 25 mL rb flask at 0 °C were added 2,6-lutidine 
(178.2 mg, 1.663 mmol, 6.0 equiv) and tert-butyldimethylsilyl triflate (183.1 mg, 0.6927 
mmol, 2.5 equiv) via syringe. The solution was stirred at 0 °C for 1h, then quenched by 
the addition of methanol (0.1 mL). After 5 min at 0°C, the mixture was transferred to a 
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separatory funnel containing saturated NaHCO3 aqueous solution (10 mL). The aqueous 
phase was separated and extracted with CH2Cl2 (3 × 20 mL). The combined organic 
phases were dried over Na2SO4, filtered, and concentrated under reduced pressure.  
Purification was accomplished using flash chromatography on a 3 × 15 cm silica gel 
column, eluting with 10% EtOAc/hexanes (500 mL), collecting 18 × 150 mm test tube 
fractions.  The product containing fractions (5-7) were combined and concentrated under 
reduced pressure to give the product 2.103  (173.0 mg, quant. yield) as a colorless oil: Rf 
= 0.25 (10% EtOAc/hexanes); [ ] =20Dα  +38.4  (c = 0.475, CHCl3); 500 MHz 1H NMR 
(CDCl3) δ 7.40-7.35 (m, 4H), 7.34-7.29 (m, 1H), 7.27 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.8 
Hz, 2H), 5.77 (ddd, J = 15.6, 1.5,1.5 Hz, 1H), 5.54 (ddd, J = 15.6, 5.4, 5.4 Hz, 1H), 4.85 
(d, J = 2.4 Hz, 2H), 4.66 (d, J = 3.9 Hz, 2H), 4.64 (d, J = 10.8 Hz, 1H), 4.57 (dd, J = 4.4, 
2.9 Hz, 1H), 4.53 (d, J = 10.7 Hz, 1H), 4.15 (dd, J = 5.4, 1.5 Hz, 2H), 4.03 (dddd, J = 9.8, 
9.8, 2.4, 2.4 Hz, 1H), 3.97 (ddd, J = 11.2, 6.4, 6.4, Hz, 1H), 3.85 (ddd, J = 10.3, 2.0, 2.0 
Hz, 1H), 3.80 (s, 3H), 2.09 (dddd, J = 17.1, 9.8, 6.8, 2.9 Hz, 1H), 2.02-1.95 (m, 1H), 1.82 
(ddd, J = 14.1, 10.7, 2.4 Hz, 1H), 1.77 (ddd, J = 13.2, 7.4, 2.9 Hz, 1H), 1.63 (ddd, J = 
14.2, 10.8, 2.4 Hz, 1H), 1.51 (dddd, J = 13.2, 9.8, 9.8 5.9 Hz, 1H), 1.22 (d, J = 6.3 Hz, 
3H), 1.19 (s, 3H), 1.18 (s, 3H), 0.92 (s, 9H), 0.07 (s, 6H); 125 MHz 13C NMR (CDCl3) 
159.3, 159.1, 138.7, 138.1, 131.1, 129.6, 128.6, 128.0, 127.8, 125.9, 114.0, 93.6, 93.2, 
78.0, 74.1, 73.6, 71.7, 69.6, 64.6, 55.5, 40.5, 36.4, 28.3, 26.2, 26.1, 25.9, 20.6, 18.6, 15.8, 
-4.8; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 26.2, 26.1, 25.9, 15.8, -4.8; CH2 δ 93.6, 73.6, 
69.6, 64.6, 36.4, 28.3, 20.6; CH δ 138.7, 129.6, 128.6, 128.0, 127.8, 125.9, 114.0, 93.2, 
78.0, 74.1, 71.7; CH0 δ 159.3, 159.1, 138.1, 131.1, 40.5, 18.6; IR (neat) 2930, 2856, 
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1661, 1581, 1462, 1381, 1249, 1098, 1042, 837, 776 cm-1; HRMS (ESI/TOF) calcd for 
C37H56NaO6Si (M+Na) 647.3744, found 647.3754. 
 
 
Preparation of (2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(4-methoxy ben 
zyloxy)butyl)-2-((E)-5-(tert-butyldimethylsilyloxy)-2-methylpent-3-en-2-yl)-2-metho 
xydihydro-2H-pyran-3(4H)-one (2.93). To a stirring solution of dihydropyran 2.103 
(92.7 mg, 0.148 mmol, 1.0 equiv) in CH2Cl2 (2.9 mL) in a 15 mL rb flask at -15 °C was 
added methanol (0.4 mL).  The solution was stirred at -15 °C for 5 min, then a solution of 
purified mCPBA (48.6 mg, 0.282 mmol, 1.9 equiv) in methanol (240 μL) was added 
dropwise via syringe.  The syringe was rinsed with an additional 200 μL of methanol and 
and the resulting solution was added into the reaction mixture. The solution was stirred at 
-15 °C for 1.5 h, and then warmed to 0 °C and stirred for an additional 30 min. The 
reaction mixture was quenched by the addition of saturated aqueous NaHCO3 solution 
(10 mL) followed by saturated aqueous NaHSO3 solution (2 mL).  The mixture was 
stirred at rt for 10 min until effervescence was complete. The phases were separated and 
the aqueous phase was extracted with CH2Cl2 (3 × 20 mL). The combined organic phases 
were dried with Na2SO4, filtered, and then concentrated under reduced pressure to 
provide the crude intermediate alcohol as a colorless oil which was carried on to the next 
step without further purification. 
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 To a stirring solution of the aforementioned crude alcohol in CH2Cl2 (3.0 mL) in a 
25 mL rb flask at rt were added 4 Å molecular sieves (100 mg), tetrapropylammonium 
perruthenate (5.2 mg, 0.0148 mmol, 0.1 equiv) and 4-methylmorpholine-N-oxide (52.1 
mg, 0.445 mmol, 3.0 equiv).  The mixture was stirred at rt for 1 h. The purification was 
accomplished by flash chromatography on a 3 × 12 cm flash chromatography, eluting 
with 15% EtOAc/hexanes (500 mL), collecting 18 × 150 mm test tube fractions.  The 
product containing fractions (5-7) were combined and concentrated under reduced 
pressure to give the product ketone 2.93  (78.4 mg, 79% over 2 steps) as a colorless oil: 
Rf = 0.47 (30% EtOAc/hexanes); [ ] =20Dα  +25  (c = 0.24, CHCl3); 500 MHz 1H NMR 
(CDCl3) δ; 7.38-7.30 (m, 5H), 7.22 (d, J = 8.3 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 5.97 (dt, 
J = 15.6, 1.5 Hz, 1H), 5.50 (dt, J = 16.1, 4.9 Hz,1H), 4.85 (ABq, J = 7.3 Hz, Δν = 7.8 Hz, 
2H), 4.67 (s, 2H), 4.63 (d, J = 10.8 Hz, 1H), 4.45 (d, J = 10.8 Hz, 1H), 4.15 (dd, J = 4.9, 
1.5 Hz, 2H), 3.89 (ddd, J = 12.2, 4.9, 2.0 Hz, 1H), 3.81-3.79 (m, 1H), 3.79 (s, 3H), 3.24 
(s, 3H), 2.45 (dd, J = 5.4, 1.0 Hz, 1H), 2.42 (d, J = 5.4 Hz, 1H), 2.00-1.86 (m, 3H), 1.66 
(ddd, J = 13.2, 10.3, 2.4 Hz, 1H), 1.22 (d, J = 6.4 Hz, 3H), 1.44 (s, 3H), 1.10 (s, 3H), 0.07 
(s, 3H), 0.06 (s, 3H); 125 MHz 13C NMR (CDCl3); 207.7, 159.4, 138.0, 136.2, 130.8, 
129.4, 128.7, 128.0, 127.9, 127.8, 114.0, 104.3, 93.6, 77.3, 72.6, 72.2, 70.2, 69.7, 64.2, 
55.5, 52.3, 44.1, 37.7, 36.4, 30.2, 26.2, 23.0, 22.2, 18.6 14.9, -5.0; 125 MHz DEPT 
(CDCl3) CH3 δ 55.5, 52.3, 26.2, 23.0, 22.2, 14.9, -5.0; CH2 δ 93.6, 72.2, 69.7, 64.2, 37.7, 
36.4, 30.2; CH δ 136.2, 129.4, 128.7, 128.0, 127.9, 127.8, 114.0, 77.3, 72.6, 70.2; CH0 δ 
207.7, 159.4, 138.0, 130.8, 104.3, 44.1, 18.6; IR (neat);  2952, 2931, 2885, 2856, 1724, 
1612, 1585, 1513, 1489, 1471, 1382, 1361, 1249, 1174, 1112, 1042, 836, 776, 735, 698, 




Preparation of (E)-methyl 2-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(4-
methoxy benzyloxy)butyl)-2-((E)-5-(tert-butyldimethylsilyloxy)-2-methylpent-3-en-
2-yl)-2-methoxy-3-oxo-2H-pyran-4(3H,5H,6H)-ylidene)acetate (2.104). To a stirring 
solution of ketone 2.93(56.3 mg, 0.0839 mmol, 1.0 equiv) in methanol (0.84 mL, 0.1 M) 
at rt was added K2CO3 (63.8 mg, 0.462 mmol, 5.5 equiv) in one portion.  A solution of 
freshly prepared methyl glyoxylate solution in THF (0.987 mL of 1.7 M, 1.678 mmol, 
20.0 equiv) wad added via syringe. The mixture was stirred at rt for 1 h, and then diluted 
with Et2O (10 mL) and quenched by the addition of saturated aqueous NH4Cl solution 
(10 mL). The aqueous phase was separated and extracted with Et2O (3 × 25 mL ). The 
combined organic phases were dried over Na2SO4, filtered, and concentrated under 
reduced pressure.  Purification was accomplished using flash chromatography on a 3 × 14 
cm column, eluting with 15% EtOAc/hexanes (500 mL), collecting 18 × 150 mm test 
tube fractions.  The product containing fractions (8-10) were combined and concentrated 
under reduced pressure to give the product 2.104  (45.2 mg, 73%) as a yellow oil:  Rf = 
0.48 (30% EtOAc/hexanes);  [ ] =20Dα  -49 (c = 0.195, CHCl3); 500 MHz 1H NMR 
(CDCl3) δ; 7.37-7.35 (m, 4H), 7.34-7.30 (m, 1H), 7.17 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 
8.8 Hz, 2H), 6.54 (dd, J = 3.4, 2.0 Hz, 1H), 5.81 (ddd, J = 15.6, 1.5, 1.5 Hz, 1H), 5.41 
(ddd, J = 16.1, 5.4, 5.4 Hz, 1H), 4.85 (dd, J = 12.2, 6.8 Hz, 2H), 4.67 (s, 2H), 4.61 (d, J = 
10. 7 Hz, 1H), 4.41 (d, J = 10.7 Hz, 1h), 4.17-4.08 (m, 2H), 4.06 (dd, J = 9.3, 2.0 Hz, 
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1H), 3.90 (ddd, J = 10.3, 4.4, 2.0 Hz, 1H), 3.78 (s, 3H), 3.75 (s, 3H), 3.31 (ddd, J = 18.6, 
2.0, 2.0 Hz, 1H), 3.20 (s, 3H),  2.86 (ddd, J = 18.6, 12.2, 3.4 Hz, 1H), 1.97 (ddd, J = 14.7, 
9.3, 2.0 Hz, 1H), 1.75 (ddd, J = 14.7, 9.8, 2.4 Hz, 1H), 1.21 (d, J = 6.4 Hz, 3H), 1.10 (s, 
3H), 1.04 (s, 3H), 0.90 (s, 9H), 0.04 (s, 6H); 125 MHz 13C NMR (CDCl3); 197.7, 166.2, 
159.3, 148.2, 138.0, 134.8, 130.6, 129.3, 128.7, 128.6,  128.0, 127.9, 122.7, 114.0, 93.6, 
76.9, 72.3, 71.7, 69.7, 69.5, 64.1, 55.4, 52.2, 51.9, 44.6, 36.1, 36.1, 26.1, 22.5, 22.0, 14.7,  
-5.0 ; 125 MHz DEPT (CDCl3) CH3 δ 55.4, 52.2, 26.1, 22.5, 22.0,  14.7, -5.0; CH2 δ 93.6, 
71.7, 69.7, 64.1, 36.1, 36.1; CH δ 134.8, 129.3, 128.7, 128.6, 128.0, 127.9, 122.7, 114.0, 
76.9, 72.3, 69.5; CH0 δ 197.7, 166.2, 159.3, 148.2, 138.0, 130.6, 44.6; IR (neat); 2933, 
2857, 1724, 1706, 1613, 1513, 1462, 1382, 1250, 1205, 1177, 1108, 1043, 938, 835, 777, 




Preparation of (2S,3S,6S,E)-6-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-methox 
ybenzyl)oxy)butyl)-2-((E)-5-((tert-butyldimethylsilyl)oxy)-2-methylpent-3-en-2-yl)-2 
-methoxy-4-(2-methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yloctanoate (2.105). 
To a stirring solution of ketone 2.104 (41.2 mg, 0.0556 mmol, 1.0 equiv) in methanol (1.9 
mL, 0.03M) in a 10 mL rb flask at rt was added CeCl3·7H2O (10.4 mg, 0.0278 mmol, 0.5 
equiv). The reaction mixture was stirred at rt until all the CeCl3·7H2O crystals had 
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dissolved, then cooled to -40 °C and stirred for 15 min. NaBH4 (4.2 mg, 0.111 mmol, 2.0 
equiv) was then added in one portion. The mixture was stirred at -40 °C for 3 h, and then 
diluted with 40% EtOAc/hexanes (10 mL), and quenched by the addition of saturated 
aqueous NH4Cl solution (5.0 mL). The mixture was poured into a separatory funnel with 
the aid of 40% EtOAc/hexanes (50 mL). The organic phase was separated, washed with 
H2O (10 mL) and brine (10 mL), then dried over Na2SO4, filtered, and concentrated 
under reduced pressure. The resulting crude product was used in the next step without 
further purification. 
To a stirring solution of the aforementioned crude alcohol in CH2Cl2 (2.8 mL, 
0.02M) in a 10 mL rb flask at rt, were added pyridine (44.0 mg, 0.556 mmol, 10 equiv), 
4-dimethylaminopyridine (13.6 mg, 0.111 mmol, 2.0 equiv), and octanoic anhydride 
(75.2 mg, 0.278 mmol, 5.0 equiv). The reaction mixture was stirred at rt overnight, then 
quenched by the addition of methanol (1.0 mL). The mixture was stirred for another 10 
min and 10 mL of CH2Cl2 was added. The mixture was poured into a separatory funnel 
containing 10 mL of saturated aqueous NaHCO3 solution.  The aqueous phase was 
separated and extracted with CH2Cl2 (3 × 25 mL). The organic phases were combined, 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash chromatography on a 3 × 15 cm silica gel column, eluting with 
20% EtOAc/hexanes (1000 mL), collecting 18 × 150 mm test tube fractions. The product 
containing fractions (11-23) were combined and concentrated under reduced pressure to 
give the product 2.105 (48.1 mg, quant. yield) as a colorless oil. Rf = 0.34 (20% 
EtOAc/hexanes); [ ] =20Dα  -3.7 (c = 0.84, CHCl3);  500 MHz 1H NMR (CDCl3)  δ 7.38-
7.30 (m, 5H), 7.21 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 5.98 (d, J = 15.6 Hz, 
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1H), 5.88 (s, 1H), 5.42 (s, 1H), 5.40 (ddd, J = 16.1, 5.3, 5.3 Hz, 1H), 4.86 (ABq, J = 6.8  
Hz, Δν = 7.0 Hz, 2H), 4.67 (ABq, J = 12.2 Hz, Δν = 7.2 Hz, 2H), 4.62 (d, J = 10.7 Hz, 
1H0, 4.43 (d, J = 10.8 Hz, 1H), 4.15-4.03 (m, 3H), 3.90 (ddd, J = 10.3, 4.4, 2.0 Hz, 1H), 
3.79 (s, 3H), 3.69 (s, 3H), 3.51 (dd, J = 15.6, 2.4 Hz, 1H), 3.23 (s, 3H), 2.36 (t , J = 7.3 
Hz, 2H), 2.29 (ddd, J = 7.3, 2.9, 2.9 Hz, 2H), 1.91 (ddd, J = 14.2, 9.8, 2.0 Hz, 1H), 1.73 
(ddd, J = 13.7, 10.3, 2.4 Hz, 1H), 1.64 (d, J = 7.3 Hz, 2H), 1.62-1.57 (m, 1H), 1.37-1.26 
(m, 10H), 1.23 (d, J = 6.3 Hz, 3H), 1.11 (s, 6H), 0.91 (s, 9H), 0.89 (t, J = 7.3 Hz, 3H), 
0.06 (s, 3H), 0.05 (s, 3H); 125 MHz 13C NMR (CDCl3) δ 179.8, 172.3, 166.7, 159.4, 
152.7, 138.2, 130.7, 129.5, 128.7, 128.0, 127.9, 124.9, 117.5, 114.0, 102.8, 93.5, 77.0, 
72.6, 72.1, 72.0, 69.6, 68.4, 64.7, 55.5, 51.7, 51.3, 45.9, 36.5, 34.5, 34.2, 32.8, 31.9, 29.2, 
26.2, 24.9, 24.6, 23.7, 22.8, 18.6, 15.0, 14.3, -4.9;  125 MHz DEPT 13C NMR (CDCl3) 
CH3 δ 55.5, 51.7, 51.3, 26.2, 24.6, 23.7, 15.0, 14.3; CH2 δ  93.5, 72.1, 69.6, 64.7, 36.5, 
34.5, 34.2, 32.8, 31.9, 29.2, 24.9, 22.8; CH δ  138.2, 129.5, 128.7, 127.9, 117.5, 114.0, 
77.0, 72.6, 72.0, 68.4; CH0 δ  179.8, 172.3, 166.7, 159.4, 152.7, 130.7, 102.8, 45.9, 18.6; 
IR (neat) 2953, 2929, 2856, 1743, 1721, 1665, 1612, 1514 1462, 1435, 1382, 1301, 1249, 
1156, 1108, 1044, 836, 776, 737, 687, 576 cm-1; HRMS (ESI/TOF) calcd for 






Preparation of (2S,3S,6S,E)-6-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-metho 
xybenzyl)oxy) butyl)-2-((E)-5-hydroxy-2-methylpent-3-en-2-yl)-2-methoxy-4-(2-met 
hoxy-2-oxoethylidene) tetrahydro-2H-pyran-3-yl octanoate (2.106). To a stirring 
solution of the TBS ether 2.105 (201.2 mg, 0.241 mmol, 1.0 equiv) in a 9:1 THF/ 
pyridine solution (4.0 mL, 0.06M) at 0 °C in a 25 mL plastic bottle were added methanol 
(0.4 mL) and 20% HF/Py (1.0 mL). The solution was stirred at 0 °C for 5 min and then 
warmed to rt. Stirring was continued for 3 h and the reaction mixture was then quenched 
by pipetting it into a mixture of saturated aqueous NaHCO3 solution (40 mL) and 50% 
EtOAc/hexanes (40 mL) in a separatory funnel. The aqueous phase was separated and 
extracted with 50% EtOAc/hexanes (3 × 50 mL). The combined organic phase was dried 
over Na2SO4, filtered, and then concentrated under reduced pressure. Purification was 
accomplished by flash chromatography on a 3 × 15 cm silica gel column, eluting with 
20% EtOAc/hexanes (1000 mL), collecting 18 × 150 mm test tube fractions. The product 
containing fractions (10-22) were combined and concentrated under reduced pressure to 
give the product 2.106 (164.4 mg, 94% yield) as a colorless oil: Rf = 0.28 (30% 
EtOAc/hexanes); [ ] =20Dα  -6 (c = 0.23, CHCl3);  500 MHz 1H NMR (CDCl3)  δ 7.38-7.30 
(m, 5H), 7.21 (d, J = 8.3 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 5.97 (d, J = 15.6 Hz, 1H), 
5.88 (s, 1H), 5.50 (ddd, J = 15.6, 5.9, 5.9 Hz, 1H), 5.48 (s, 1H), 4.86 (ABq, J = 6.8 Hz, 
Δν = 6.3 Hz, 2H), 4.68 (s, 2H), 4.67-4.61 (m, 1H), 4.62 (d, J = 11.2 Hz, 1H), 4.42 (d, J = 
10.7 Hz, 1H), 4.14 (dd, J = 6.4, 4.4, Hz, 1H), 4.10-4.00 (m, 3H), 3.90 (ddd, J = 10.3, 4.4, 
2.0 Hz, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 3.45 (dd, J = 16.1, 2.0 Hz, 1H), 3.23 (s, 3H), 2.38-
2.32 (m, 1H), 2.30 (ddd, J = 7.3, 7.3, 3.4 Hz, 2H), 1.92 (ddd, J = 14.2, 9.8, 2.0 Hz, 1H), 
1.73 (ddd, J = 14.2, 10.3, 2.4 Hz, 1H), 1.65-1.58 (m, 1H), 1.35 -1.26 (m, 10H), 1.22 (d, J 
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= 6.3 Hz, 3H), 1.13 (s, 3H), 1.10 (s, 3H), 0.89 (t, J = 6.8 Hz, 3H); 125 MHz 13C NMR 
(CDCl3) δ 172.5, 166.8, 159.4, 152.7, 139.8, 138.1, 130.7, 129.5, 128.7, 128.0, 127.9, 
125.3, 117.2, 114.0, 102.7, 93.5, 76.8, 72.4, 72.0, 71.9, 69.7, 68.5, 64.4, 55.5, 51.4 (×2), 
46.3, 36.4, 34.7, 33.1, 31.9, 29.2, 29.1, 24.8, 24.3, 24.1, 22.8, 14.8, 14.3; 125 MHz DEPT 
NMR (CDCl3) CH3 δ 55.5, 51.4 (×2), 24.3, 24.1, 14.8, 14.3; CH2 δ  93.5, 72.0, 69.7, 36.4, 
34.7, 33.1, 31.9, 29.2, 29.1, 24.8, 22.8; CH δ  139.8, 129.5, 128.7, 128.0, 127.9, 125.3, 
117.2, 114.0, 76.8, 72.4, 71.9, 68.5; CH0 δ  172.5, 166.8, 159.4, 152.7, 138.1, 130.7, 
102.7, 46.3; IR (neat) 2952, 2931, 2857, 1741, 1719, 1663, 1612, 1586, 1462, 1435, 
1381, 1301, 1248, 1229, 1155, 1106, 1039, 979, 903, 883, 821, 737, 698 cm-1; HRMS 
(ESI/TOF) calcd for C43H62O11Na (M+Na) 777.4190, found 777.4191. 
 
 
Preparation of (2S,3S,6S,E)-6-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-metho 
xybenzyl)oxy)butyl)-2-methoxy-4-(2-methoxy-2-oxoethylidene)-2-((E)-2-methyl-5-ox 
opent-3-en-2-yl)tetrahydro-2H-pyran-3-yl octanoate (2.107). To a stirring solution of 
alcohol 2.106 (32.8 mg, 0.0434 mmol, 1.0 equiv) in CH2Cl2 (4.3 mL, 0.01M) at 0 °C in a 
25 mL rb flask were added pyridine (68.7 mg, 0.868 mmol, 20 equiv) and Dess-Martin 
periodinane (55.3 mg, 0.130 mmol, 3.0 equiv) in one portion. The mixture was stirred at 
0 °C for 1 h, and then quenched by the addition of saturated aqueous Na2S2O3 solution 
(1.0 mL). The mixture was stirred until the solution turned clear, then transferred into a 
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mixture of saturated aqueous NaHCO3 solution (5 mL) and CH2Cl2 (20 mL) in a 
separatory funnel. The aqueous phase was separated and extracted with CH2Cl2 (3 × 25 
mL). The combined organic phases were dried over Na2SO4, filtered, and then 
concentrated under reduced pressure. Purification was accomplished by flash 
chromatography on a 3 × 12 cm silica gel column, eluting with 20% EtOAc/hexanes (500 
mL), collecting 18 × 150 mm test tube fractions. The product containing fractions (4-8) 
were combined and concentrated under reduced pressure to give the product 2.107 (30.1 
mg, 92% yield) as a colorless oil. Rf = 0.27 (20% EtOAc/hexanes); [ ] =20Dα  -6.2 (c = 
0.37, CHCl3); 500 MHz 1H NMR (CDCl3)  δ 7.29-7.20 (m, 5H), 7.12 (d, J = 8.8 Hz, 2H), 
6.76 (d, J = 8.8 Hz, 2H), 5.84 (dd, J = 16.1, 7.8, 1H), 5.79 (s, 1H), 5.38 (s, 1H), 4.78 
(ABq, J = 6.8 Hz, Δν = 11.4 Hz, 2H), 4.58 (s, 2H), 4.54 (d, J = 11.2 Hz, 1H), 4.31 (d, J = 
11.2 Hz, 1H), 4.09 (dd, J = 6.4, 5.4 Hz, 1H), 4.03 (ddd, J = 9.3, 9.3, 2.4 Hz, 1H), 3.81 
(ddd, J = 10.3, 4.4, 2.0 Hz, 1H), 3.71 (s, 3H), 3.61 (s, 3H), 3.45 (dd, J = 16.1, 2.0 Hz, 
1H), 3.17 (s, 3H), 2.29 (dd, J = 13.2, 12.8 Hz, 1H), 2.08 (ddd, J = 16.1, 7.8, 7.8 Hz, 1H), 
2.01 (ddd, J = 16.1, 7.3, 7.3 Hz, 1H), 1.88 (ddd, J = 14.7, 9.8, 2.0 Hz, 1H), 1.70 (ddd, J = 
14.2, 10.3, 2.9 Hz, 1H), 1.49-1.42 (m, 1H), 1.23-1.12 (m, 10H), 1.14 (d, J = 6.4 Hz, 3H), 
1.07 (s, 3H), 1.05 (s, 3H), 0.80 (t, J = 6.8 Hz, 3H); 125 MHz 13C NMR (CDCl3) δ 194.7, 
171.9, 167.1, 166.4, 159.4, 151.6, 137.9, 130.5, 129.5, 128.7, 128.0, 127.9, 127.1, 117.9, 
114.0, 102.6, 93.5, 76.6, 72.2, 71.7, 71.2, 69.7, 69.1, 55.5, 51.5, 51.4,47.6, 36.2, 34.6, 
32.9, 31.8, 29.1 (×2), 24.7, 23.9, 22.7, 22.0, 14.6, 14.3; 125 MHz DEPT NMR (CDCl3) 
CH3 δ 55.5, 51.5, 51.4, 23.9, 22.0, 14.6, 14.3; CH2 δ  93.5, 71.7, 69.7, 36.2, 34.6, 32.9, 
31.8, 29.1 (×2), 24.7, 22.7; CH δ  194.7, 167.1, 129.5, 128.7, 128.0, 127.9, 127.1, 117.9, 
114.0, 76.6, 72.2, 71.2, 69.1; CH0 δ  171.9, 166.4, 159.4, 151.6, 137.9, 130.5, 102.6, 47.6; 
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IR (neat) 3064, 3030, 2952, 2930, 2857, 2724, 1745, 1720, 1687, 1612, 1514, 1455, 
1436, 1380, 1301, 1248, 1229, 1155, 1107, 1042, 819, 736, 698 cm-1; HRMS (ESI/TOF) 
calcd for C43H60O11Na (M+Na) 775.4033, found 775.4047. 
 
 
Preparation of (2S,3S,6S,E)-6-((2R,3R)-3-((benzyloxy)methoxy)-2-((tert-butyl 
dimethylsilyl) oxy)butyl)-2-methoxy-4-(2-methoxy-2-oxoethylidene)-2-((E)-2-methyl-
5-oxopent-3-en-2-yl)tetrahydro-2H-pyran-3-yl octanoate (2.92). To a stirring solution 
of PMB ether 2.107 (77.9 mg, 0.103 mmol, 1.0 equiv) in CH2Cl2 (4.0 mL) and tert-butyl 
alcohol (0.2 mL), in a 25 mL rb flask at rt was added aqueous pH 7 buffer solution (0.2 
mL). The mixture was cooled to 0 °C and DDQ (47.0 mg, 0.206 mmol, 2.5 equiv) was 
added in one portion. Stirring was continued at 0 °C for 5 h. The reaction mixture was 
then quenched by the addition of saturated aqueous NaHCO3 solution (5 mL). The phases 
were separated and the aqueous phase was extracted with CH2Cl2 (3 × 15 mL). The 
combined organic phases were dried over Na2SO4, filtered, and concentrated under 
reduced pressure to give the crude intermediate alcohol as a light orange oil. This 
material was taken on to the next step without further purification.  
To a stirring solution of the aforementioned crude alcohol in CH2Cl2 (5.1 mL, 
0.02M) in a 25 mL rb flask at 0 °C were added 2,6-lutidine (66.2 mg, 0.618 mmol, 6.0 
equiv) and tert-butyldimethylsilyl triflate (68.1 mg, 0.258 mmol, 2.5 equiv) dropwise via 
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syringe. The reaction mixture was stirred at 0 °C for 30 min, and then quenched by the 
addition of methanol (0.1 mL). Stirring was continued for 10 min at 0 °C and then 
saturated aqueous NaHCO3 solution (5 mL) was added. The phases were separated and 
the aqueous phase was extracted with CH2Cl2 (3 × 5 mL). The combined organic phases 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification 
was accomplished using flash chromatography on a 3 × 10 cm silica gel column, eluting 
with 15 % EtOAc/hexanes (500 mL), collecting 18 × 150 mm test tube fractions. The 
product containing fractions (4-10) were combined and concentrated under reduced 
pressure to provide the product TBS ether 2.92 (63.5 mg, 82% over 2 steps) as a  
colorless oil: Rf =  0.57 (20% EtOAc/hexanes); [ ] =20Dα  -2.9 (c = 0.31, CHCl3); 500 MHz 
1H NMR (CDCl3)  δ 9.45 (d, J = 7.8 Hz, 1H), 7.30-7.20 (m, 5H), 5.87 (dd, J = 16.1, 7.8 
Hz, 1H), 5.84 (s, 1H), 5.48 (s, 1H), 4.74 (ABq, J = 6.8 Hz, Δν = 6.3 Hz, 2H), 4.57 (s, 
2H), 4.15-4.08 (m, 2H), 3.87 (dd, J = 6.4, 4.4 Hz, 1H), 3.64 (s, 3H), 3.49 (dd, J = 16.1, 
2.0 Hz, 1H), 3.30 (s, 3H), 2.30 (dd, J = 14.2, 13.7 Hz, 1H), 2.13 (ddd, J = 16.1, 7.3, 7.3 
Hz, 1H), 2.04 (ddd, J = 16.1, 7.3, 7.3 Hz, 1H), 1.98 (ddd, J = 14.2, 8.8, 2.4 Hz, 1H), 1.59 
(ddd, J = 14.2, 8.8, 2.9 Hz, 1H), 1.51-1.44 (m, 1H), 1.25-1.15 (m, 10H), 1.12 (d, J = 6.4 
Hz, 3H), 1.11 (s, 3H), 1.08 (s, 3H), 0.82 (s, 9H), 0.80 (t, J = 6.8 Hz, 3H), 0.03 (s, 3H), 0.0 
(s, 3H); 125 MHz 13C NMR (CDCl3) δ 194.8, 172.1, 167.1, 166.4, 151.8, 137.9, 128.7, 
128.0 (×2), 127.3, 117.9, 102.6, 93.3, 75.1, 70.8, 70.3, 69.6, 69.2, 51.9, 51.5, 47.6, 38.7, 
34.6, 33.2, 31.8, 29.1 (×2), 26.1, 24.8, 23.7, 22.8, 22.1, 18.3, 14.3, 13.9, -3.8, -4.5; 125 
MHz DEPT NMR (CDCl3) CH3 δ 51.9, 51.5, 26.1, 23.7, 22.2, 14.3, 13.9, -3.8, -4.5; CH2 
δ  93.3, 69.6, 38.7, 34.6, 33.2, 31.8, 29.1 (×2), 24.8, 22.8; CH δ  194.8, 167.1, 128.7, 
128.0 (×2), 127.3, 117.9, 75.1, 70.8, 70.3, 69.2; CH0 δ  172.1, 166.4, 151.8, 137.9, 102.6, 
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47.6, 18.3; IR (neat) 2953, 2930, 2857, 1746, 1722, 1689, 1627, 1512, 1463, 1435, 1380, 
1301, 1255, 1228, 1156, 1110, 1071, 1043, 836, 776, 736, 698 cm-1; HRMS (ESI/TOF) 
calcd for C41H66O10Na (M+Na) 769.4323, found 769.4335. 
 
 




(2-methoxy-2-oxoethylidene) tetrahydro-2H-pyran-3-yl octanoate (2.108). To a 
stirring solution of hydroxyallylsilane 2.57 (24.2 mg, 0.0336 mmol, 1.3 equiv) and 
aldehyde 2.92 (19.3 mg, 0.0258 mmol, 1.0 equiv) in Et2O (4.3 mL) in a 15 mL rb flask at 
-78 ºC was added a solution of TMSOTf in Et2O (33.6 μL of 1.0 M, 0.0336 mmol, 1.3 
equiv) dropwise via syringe. After 2 h at -78 ºC, the mixture was slowly warmed to -15 
ºC and stirred for 1 h, and then quenched by the addition of saturated aqueous NaHCO3 
solution (2 mL). The mixture was warmed to rt, and then the phases were separated, and 
the aqueous phase was extracted with Et2O (3 × 10 mL). The organic phases were 
combined, dried over Na2SO4, filtered, and concentrated under reduced pressure.  
Purification was accomplished by flash chromatography on a 3 × 11 cm silica gel 
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column, eluting with 40% EtOAc/hexanes, collecting 18 × 150 mm test tube fractions. 
The product containing fractions (4-7) were combined and concentrated under reduced 
pressure to give the product 2.108 (25.5 mg, 72% yield) as a colorless oil. Rf = 0.49 (50% 
EtOAc/hexanes); [ ] =20Dα  +10.1 (c = 0.47, CHCl3); 500 MHz 1H NMR (CDCl3) 125 MHz 
(CDCl3) 7.70-7.65 (m, 4H), 7.44-7.30 (m, 11H), 7.18 (d, J = 8.3 Hz, 2H), 6.85 (d, J = 8.3 
Hz, 2H), 5.93 (d, J = 16.1 Hz, 1H), 5.89 (s, 1H), 5.61 (s, 1H), 5.42 (dd, J = 16.1, 5.9 Hz, 
1H), 4.79 (s, 2H), 4.66-4.59 (m, 2H), 4.64 (s, 2H), 4.40 (ABq, J = 10.7 Hz, Δν = 37.6 Hz, 
2H),4.12-4.06 (m, 2H), 3.93-3.89 (m, 1H), 3.88 -3.72 (m, 5H), 3.80 (s, 3H), 3.68 (s, 3H), 
3.60-3.47 (m, 4H), 3.31 (s, 3H), 2.40-2.28 (m, 3H), 2.24 (d, J = 13.2 Hz, 1H), 2.16 (d, J = 
13.7 Hz, 1H), 2.02-1.85 (m, 6H), 1.84 -1.73 (m, 3H), 1.67-1.50 (m, 6H), 1.32-1.22 (m, 
10H), 1.16 (d, J = 6.4 Hz, 3H), 1.12 (s, 3H), 1.11 (s, 3H), 1.04 (s, 9H), 0.90-0.85 (m, 3H), 
0.87 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (CDCl3) δ 172.3, 166.6, 159.3, 153,3, 
144.4, 138.0, 137.9, 135.8, 134.1, 134.0, 131.2, 129.8, 129.5 (×2), 128.6, 128.0, 127.8, 
127.6, 116.6, 114.0, 109.0, 102.6, 93.2, 79.2, 75.0 (×2), 72.7, 72.0 (x3), 71.5, 70.2, 69.5, 
68.4 (×2), 60.6, 55.5, 51.5, 51.3, 46.2, 42.5, 42.4, 41.8, 41.3, 41.0, 40.5, 38.7, 37.9, 34.6, 
33.8, 31.9, 29.3, 29.2, 27.2, 26.1, 25.0, 24.4, 24.0, 22.8, 19.4, 18.3, 14.3, 14.0, -3.8, -4.4; 
125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 51.5, 51.3, 27.2, 26.1, 24.4, 24.0, 14.3, 14.0, 
-3.8, -4.4; CH2 δ  109.0, 93.2, 72.0, 69.5, 60.6, 42.5, 42.4, 41.8, 41,3, 41.0, 40.5, 38.7, 
37.9, 34.6, 33.8, 31.9, 29.3, 29.2, 25.0, 22.8; CH δ  137.9, 135.8, 129.8, 129.5 (×2), 
128.6, 128.0, 127.8, 127.6, 116.6, 114.0, 79.2, 75.0, 72.7, 72.0 (×2), 71.5, 70.2, 68.4 (×2); 
CH0 δ  172.3, 166.6, 159.3, 153.3, 144.3, 138.0, 134.1, 134.0, 131.2, 102.6, 46.2, 19.4, 
18.3; IR (neat) 3473, 3069, 2932, 2856, 1743, 1720, 1653, 1611, 1512, 1464, 1430, 1380, 
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1360, 1248, 1155, 1107, 1041, 890, 834, 737, 613 cm-1; HRMS (ESI/TOF) calcd for 




















methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl octanoate (2.91). To a stirring 
solution of the alcohol 2.108 in CH2Cl2 (14 mL, 0.003 M) in a 25 mL rb flask at rt were 
added pyridine (168 mg, 2.13 mmol, 50 equiv), 4-dimethylaminopyridine  (51.9 mg, 
0.425 mmol, 10 equiv) and Ac2O (130 mg, 1.28 mmol, 30 equiv). The mixture was 
stirred at rt overnight, and then quenched by the addition of saturated aqueous NaHCO3 
solution (5 mL). The aqueous phase was separated and extracted with CH2Cl2 (3 × 20 
mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated 
under reduced pressure.  Purification was accomplished using flash chromatography with 
a 3 × 18 cm silica gel column, eluting with 40% EtOAc/hexanes, collecting 18 × 150 mm 
test tube fractions.  The product containing fractions (4-6) were combined and 
concentrated under reduced pressure to provide the product 2.91 (60.8 mg, quant. yield) 
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as a colorless oil: Rf = 0.40 (30% EtOAc/hexanes); [ ] =20Dα  +15 (c = 0.17, CHCl3); 500 
MHz 1H NMR (CDCl3)  125 MHz (CDCl3) 7.70-7.65 (m, 4H), 7.45-7.32 (m, 11H), 7.17 
(d, J = 8.3 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 5.93 (d, J = 16.1 Hz, 1H), 5.89 (s, 1H), 5.58 
(s, 1H), 5.42 (dd, J = 16.1, 5.4 Hz, 1H), 4.80 (s, 2H), 4.65-4.59 (m, 3H), 4.53 (bs, 1H), 
4.44 (d, J = 10.7 Hz, 1H), 4.34 (d, J = 10.7 Hz, 1H), 4.11-4.05 (m, 2H), 3.91-3.82 9m, 
2H), 3.80 (s, 3H), 3.79-3.72 (m, 2h), 3.68 (s, 3H), 3.67-3.60 (m, 2H), 3.58-3.45 (m, 3H), 
3.30 (s, 3H), 2.38-2.30 (m, 3H), 2.26 (d, J = 12.7 Hz, 1H), 2.17 (d, J = 14.7 Hz, 1H), 2.04 
(s, 3H), 2.06-1.95 (m, 3H), 1.92-1.85 (m, 2H), 1.81-1.73 (m, 3H), 1.66-1.54 (m, 6H), 
1.33-1.23 (m, 10H), 1.16 (d, J = 6.4 Hz, 3H), 1.11 (s, 6H), 1.05 (s, 9H), 0.90-0.85 (m, 
3H), 0.88 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (CDCl3) δ 172.4, 170.6, 166.7, 
159.4, 153,1, 144.2, 138.1, 138.1, 135.8, 134.1, 134.0, 131.2, 129.8, 129.5, 128.6, 128.0, 
127.9, 127.3, 117.0, 114.1, 109.1, 102.6, 93.3, 79.0, 75.0, 74.9, 72.8, 72.0, 71.8, 71., 70.7, 
70.3, 69.5, 68.4, 60.6, 55.5, 51.6, 51.3, 46.1, 42.8, 42.3, 40.8, 40.4, 38.7, 37.9 (×2), 37.8, 
34.6, 33.5, 31.9, 29.3, 29.2, 27.1, 26.1, 24.9, 24.2, 24.1, 22.8, 21.5, 19.4, 18.3, 14.0, -3.9, 
-4.4; 125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 51.6, 51.3, 27.1, 26.1, 24.4, 24.1, 21.5, 
14.3, 14.0, -3.9, -4.4; CH2 δ  109.1, 93.3, 72.2, 69.5, 60.6, 42.8, 42.3, 40.8, 40,4, 38.7, 
37.9 (×2), 37.8, 34.6, 33.5, 31.9, 29.3, 29.2, 24.9, 22.8; CH δ  138.1, 135.8, 131.1, 129.8, 
129.5, 128.6, 128.0, 127.9, 127.3, 117.0, 114.1, 79.0, 75.0, 74.9, 72.8, 72.0, 71.8, 71.5, 
70.7, 70.3, 68.4; CH0 δ  172.4, 170.6, 166.7, 159.4, 153.1, 144.2, 128.1, 134.1, 134.0, 
102.6, 46.1, 19.4, 18.3; IR (neat) 2952, 2856, 2811, 1741, 1722, 1652, 1611, 1513, 1462, 
1428, 1379, 1361, 1246, 1160, 1110, 1083, 1041, 972, 835, 775, 737, 701 cm-1; HRMS 









dene)tetrahydro-2H-pyran-3-yl octanoate (2.109). To a stirring solution of TBDPS 
silyl ether 2.91 (30.0 mg, 0.0212 mmol, 1.0 equiv) in DMF (2.1 mL, 0.01 M) in a 15 mL 
rb flask, were added a solution of TBAF solution in THF (42.3 μL of 1.0 M, 0.0423 
mmol, 2.0 equiv) and a solution of AcOH solution in DMF (42.3 μL of 1.0 M, 0.0423 
mmol, 2.0 equiv). The solution was stirred at rt for 2 days, and then diluted with 40% 
EtOAc/hexanes (100 mL) and water (5 mL). The phases were separated and the organic 
phase was washed with water (3 × 10 mL). The organic phases were dried over Na2SO4, 
filtered, and then concentrated under reduced pressure. Purification was accomplished 
using flash chromatography on a 2 × 15 cm silica gel column, eluting with 30% 
EtOAc/hexanes (500 mL), collecting 13 × 100 mm test tube fractions. The product 
containing fractions (26-41) were combined and concentrated under reduced pressure to 
provide the alcohol 2.109 (21.4 mg, 86%) as a colorless oil. Rf = 0.33(30% 
EtOAc/hexanes); [ ] =20Dα  +19 (c = 0.20, CHCl3); 500 MHz 1H NMR (CDCl3)  125 MHz 
(CDCl3) 7.36-7.28 (m, 5H), 7.25 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 5.94 (dd, J 
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= 16.1, 1.0 Hz, 1H), 5.89 (s, 1H), 5.57 (s, 1H), 5.43 (dd, J = 16.1, 5.9 Hz, 1H), 4.95-4.88 
(m, 1H), 4.80 (s, 2H), 4.68-4.57 (m, 2H), 4.64 (s, 2H), 4.47 (ABq, J = 10.7 Hz, , Δν = 
33.5 Hz, 2H), 4.12-4.05 (m, 3H), 3.90-3.83 (m, 3H), 3.81 (s, 3H), 3.76-3.70 (m, 2H), 3.69 
(s, 3H), 3.62-3.45 (m, 4H), 3.30 (s, 3H), 2.39-2.30 (m, 1H), 2.34 (td, J = 7.3, 2.4 Hz, 2H), 
2.25 (d, J = 13.2 Hz, 1H), 2.18 (d, J = 12.7 Hz, 1H), 2.04 (s, 3H), 2.04-1.88 (, 7H), 1.80-
1.70 (m, 2H), 1.70-1.52 (m, 6H), 1.33-1.23 (m, 10H), 1.16 (d, J = 6.4 Hz, 3H), 1.10 (s, 
6H), 0.90-0.85 (m, 3H), 0.88 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 13C NMR (CDCl3) δ 
172.4, 170.7, 166.7, 159.6, 153.1, 144.2, 138.4, 138.1, 130.5, 129.7, 128.6, 128.0, 127.9, 
127.2, 117.0, 114.2, 109.1, 102.6, 93.2, 79.3, 75.2, 75.0 (×2), 72.4, 72.2, 72.0, 71.5, 70.5, 
70.2, 69.5, 68.4, 60.3, 55.5, 51.6, 51.3, 46.1, 42.7, 41.6, 40.8, 40.3, 38.6, 38.0, 37.6, 36.8, 
34.6, 33.5, 31.9, 29.3, 29.2, 26.1, 24.9, 24.2, 24.1, 22.8, 21.5, 18.3, 14.3, 14.0, -3.8, -4.5; 
125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 51.6, 51.3, 26.1, 24.2, 24.1, 21.5, 14.3, 14.0, 
-3.8, -4.5; CH2 δ  109.1, 93.2, 72.2, 69.5, 60.3, 42.7, 41.6, 40.8, 40.3, 38.6, 38.0, 37.6, 
36.8, 34.6, 33.5, 31.9, 29.3, 29.2, 24.9, 22.8; CH δ  138.4, 129.7, 128.6, 128.0, 127.9, 
127.2, 117.0, 114.2, 79.3, 75.2, 75.0 (×2), 72.4, 72.0, 71.5, 70.5, 70.2, 68.4; CH0 δ  172.4, 
170.7, 166.7, 159.6, 153.1, 144.2, 138.1, 130.5, 102.6, 46.1, 18.3; IR (neat) 3493, 2951, 
2930, 2891, 2856, 1740, 1723, 1612, 1513, 1462, 1434, 1378, 1361, 1301, 1245, 1160, 
1108, 1040, 895, 775, 737, 697, 667 cm-1; HRMS (ESI/TOF) calcd for C66H102O16SiNa 








an-2-yl)-3-((4-methoxybenzyl)oxy)butanoic acid (2.110). To a stirring solution of 
alcohol 2.109 (37.2 mg, 0.0315 mmol, 1.0 equiv) in CH2Cl2 (3.2 mL, 0.01M) in a 25 mL 
rb flask at 0 °C were added diisopropylethylamine (85.6 mg, 0.662 mmol, 21.0 equiv) 
and then dimethyl sulfoxide (73.8 mg, 0.947 mmol, 30.0 equiv).  The solution was stirred 
at 0 °C for 5 min and SO3·Py (30.1 mg, 0.189 mmol, 6.0 equiv) was added in one portion.  
Stirring was continued at 0 °C for 1.25 h, after which the reaction mixture was diluted 
with CH2Cl2 (1 mL) and quenched by the addition of saturated aqueous NaHCO3 solution 
(1 mL). The mixture was stirred at rt for 10 min until effervescence was complete.  The 
reaction mixture was partitioned between CH2Cl2 (20 mL) and saturated aqueous 
NaHCO3 solution (20 mL) and the phases were separated.  The aqueous phase was 
extracted with CH2Cl2 (3 × 25 mL), and the combined organic phases were dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  The resulting residue was 
washed through a small plug of silica gel with 20 % EtOAc/hexanes (100 mL), and the 
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solvent was removed under reduced pressure to provide the aldehyde, which was used in 
the next step without further purification.  
To a stirring solution of the aforementioned aldehyde in 2-methyl-2-butene (3.5 
mL) and tert-butyl alcohol (3.5 mL) in a 25 rb flask at rt was added aqueous solution of 
KH2PO4 (670 μL of 1.25 M).  The mixture was cooled to 0 °C, and NaClO2 (80%, 71.2 
mg, 0.630 mmol, 20.0 equiv) was added in one portion.  The reaction mixture was stirred 
vigorously at 0 °C for 4 h, and then quenched by the addition of aqueous pH 4 buffer 
solution (5 mL).  The resulting mixture was partitioned between CH2Cl2 (25 mL) and 
aqueous pH 4 buffer solution (5 mL).  The phases were separated, and the aqueous phase 
was extracted with CH2Cl2 (2 × 25 mL).  The combined organic phases were dried over 
Na2SO4, and concentrated under reduced pressure.  Purification was accomplished using 
flash chromatography with a 3 × 13 cm silica gel column, eluting with 5 % methanol/30 % 
EtOAc/hexanes, collecting 18 × 150 mm test tube fractions.  The product containing 
fractions (6-10) were combined and concentrated under reduced pressure to provide the 
product carboxylic acid 2.110 (37.5 mg, quant. yield over 2 steps) as a colorless oil: Rf =  
0.12 (5% methanol/30% EtOAc/hexanes); [ ] =20Dα  +20 (c = 0.19, CHCl3); 500 MHz 1H 
NMR (CDCl3)  7.37-7.28 (m, 5H), 7.25 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 5.95 
(d, J = 16.1 Hz, 1H), 5.90 (s, 1H), 5.58 (s, 1H), 5.42 (dd, J = 15.6, 6.3 Hz, 1H), 4.94-4.87 
(m, 1H), 4.81 (ABq, J = 6.8 Hz, Δν = 4.5 Hz, 2H), 4.65 (ABq, J = 11.7 Hz, Δν = 5.2 Hz, 
2H), 4.64-4.58 (m, 2H), 4.57 (d, J = 10.7 Hz, 1H), 4.43 (d, J = 10.7 Hz, 1H), 4.14-4.05 
(m, 3H), 3.88-3.83 (m, 1H), 3.80 (s, 3H), 3.80-3.70 (m, 2H), 3.69 (s, 3H), 3.63-3.44 (m, 
4H), 3.31 (s, 3H), 2.61 (d, J = 5.9 Hz, 2H), 2.40-2.30 (m, 2H), 2.25 (d, J = 12.7 Hz, 1H), 
2.17 (d, J = 13.2 Hz, 1H), 2.07-1.90 (m, 7H), 2.03 (s, 3H), 1.77-1.55 (m, 7H), 1.34-1.24 
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(m, 10H), 1.16 (d, J = 6.4 Hz, 3H), 1.11 (s, 6H), 0.90-0.85 (m, 3H), 0.88 (s, 9H), 0.08 (s, 
3H), 0.06 (s, 3H); 13C NMR (CDCl3) δ 174.5, 172.5, 170.7, 166.7, 159.6, 153.2, 144.1, 
138.7, 138.0, 130.3, 129.7, 128.6, 128.1, 127.9, 127.2, 116.9, 114.1, 109.2, 102.6, 93.1, 
79.4, 75.2, 75.1, 75.0, 73.0, 72.4, 72.0, 71.6, 70.4, 70.1, 69.5, 68.4, 55.5, 51.6, 51.4, 46.1, 
42.7, 41.9, 40.8, 40.4, 40.1, 38.6, 37.8, 37., 34.6, 33.5, 31.9, 29.2 (×2), 26.1, 24.9, 24.3, 
24.0, 22.8, 21.5, 18.3, 14.3, 14.0, -3.8, -4.5; 125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 
51.6, 51.4, 26.1, 24.3, 24.0, 21.5, 14.3, 14.0, -3.8, -4.5; CH2 δ  109.2, 93.1, 72.4, 69.5, 
42.7, 41.9, 40.8, 40.4, 40.1, 38.6, 37.8, 37.6, 34.6, 33.5, 31.9, 29.2 (×2), 24.9, 22.8; CH δ  
138.7, 129.7, 128.6, 128.1, 127.9, 127.2, 116.9, 114.1, 79.4, 75.2, 75.1, 75.0, 73.0, 72.0, 
71.6, 70.4, 70.1, 68.4; CH0 δ  174.5, 172.5, 170.7, 166.7, 159.6, 153.2, 144.1, 138.0, 
130.3, 102.6, 46.1, 18.3; IR (neat) 2951, 2931, 2885, 2857, 1738, 1724, 1681, 1651, 
1613, 1548, 1463, 1434, 1380, 1245, 1161, 1108, 1073, 1040, 97-, 913, 835, 776, 746, 









,29-tetraoxatetra cyclo [21.3.1.13,7 .111,15]nonacos-8-en-12-yl octanoate (2.75). To a 
stirring solution of TBS ether 2.110 (12.0 mg, 0.0101 mmol, 1.0 equiv) in 9:1 
THF/pyridine (1.0 mL, 0.01 M) in a 4 mL plastic vial were added methanol (0.1 mL) and 
HF·Py (20 %, 0.41 mL). The solution was stirred at rt for 48 h, and then diluted with 50 
% EtOAc/hexanes (100 mL), and washed with brine (2 × 10 mL). The solution was dried 
over Na2SO4 and concentrated under reduced pressure. The crude seco acid was taken on 
to the next step without purification.  
To a stirring solution of aforementioned seco acid in THF (0.34 mL) in a 4 mL 
reaction vial at 0 °C were added triethylamine (6.1 mg, 0.0606 mmol, 6.0 equiv) and 
2,4,6-trichlorobenzoyl chloride (7.4 mg, 0.303 mmol, 3.0 equiv). After 5 min the mixture 
was warmed to rt and stirring was continued for an additional 3 h. The reaction mixture 
was diluted with 3:1 toluene/THF (4.0 mL, 0.0025 M) and placed into a 25 mL gas-tight 
syringe. This solution was added by syringe pump to a stirring solution of 4-
dimethylaminopyridine (24.7 mg, 0.202 mmol, 20.0 equiv) in toluene (6.7 mL, 0.0015 
M) that was maintained at 40 °C over 12 h. The residual contents of the syringe were 
rinsed into the flask with toluene (2 × 1.0 mL) and stirring was continued for an 
additional 2 h. The reaction mixture was then cooled to rt, diluted with 40% 
EtOAc/hexanes (100 mL), and washed with water (3 × 10 mL) and with brine (10 mL). 
The organic phase was dried over Na2SO4, filtered, and concentrated under reduced 
pressure. Purification was accomplished using flash chromatography with a 2 × 12 cm 
silica gel column, eluting with 30% EtOAc/hexanes, collecting 13 × 100 mm test tube 
fractions. The product containing fractions (4-7) were combined and concentrated under 
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Preparation of ketone (1S,3R,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-
acetoxy-17-((R)-1-((benzyloxy)methoxy)ethyl)-11-methoxy-13-(2-methoxy-2-oxoethy 
lidene)-21-((4-methoxybenzyl)oxy)-10,10-dimethyl-5,19-dioxo-18,27,28,29-tetraoxate 
tracyclo [21.3.1.13, 7.111,15] nonacos-8-en-12-yl octanoate (2.111). A 100 ml flask 
containing 50 mL of CH2Cl2 was cooled to -78 °C, and a stream of O3 was passed in for 3 
min. The color of the solution changed to light blue. The flask was sealed and kept at -
78 °C for immediate use. This O3 solution was added in 50 μL portion via a plastic 
syringe to a stirring solution of olefin 2.75 (1.8 mg, 0.0017 mmol, 1.0 equiv) at -78 °C. 
The reaction was monitored by TLC and the addition of the O3 solution was continued 
every 10 min until the starting material was fully consumed. Dimethyl sulfide (0.1 mL) 
was then added and the mixture was warmed to rt. The solution was stirred at rt for 12 h 
after which the solvent was removed under reduced pressure. Purification was 
accomplished using flash chromatography on a 1 × 8 cm silica gel column, eluting with 
40% EtOAc/hexanes (250 mL), collecting 13 × 100 mm test tube fractions. The product 
containing fractions (11-16) were combined and concentrated under reduced pressure to 
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provide ketone 2.111 (1.4 mg, 78%) as a colorless oil. Rf = 0.49 (40% EtOAc/hexanes); 
[ ] =20Dα  +32 (c = 0.05, CHCl3); 500 MHz 1H NMR (CDCl3)  δ 7.38-7.28 (m,5H), 7.20 (d, 
J = 8.8 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 6.27 (d, J = 15.6 Hz, 1H), 5.94 (d, J = 1.5 Hz, 
1H), 5.59-5.53 (m, 1H), 5.33 (dd, J = 15.6, 8.8 Hz, 1H), 5.18 (s, 1H), 4.80 (s, 2H), 4.62 
(ABq, J = 11.7, , Δν = 14.4 Hz, 2H), 4.42 (ABq, J = 11.2 Hz, , Δν = 7.0 Hz, 2H), 42.9-
4.22 (m, 1H), 4.16-4.10 (m, 1H), 3.90 (dd, J = 6.4, 4.4 Hz, 1H), 3.77-3.74 (m, 1H), 3.76 
(s, 3H), 3.70-3.65 (m, 3H), 3.67 (s, 3H), 3.48-3.40 (m, 1H), 3.14-3.08 (m, 1H), 3.06 (s, 
3H), 2.50-2.40 (m, 2H), 2.35-2.18 (m, 4H), 2.16-2.06 (m, 2H), 2.02 (s, 3H), 1.96-1.76 
(m, 5H), 1.64-1.50 (m, 6H), 1.34-1.22 (m, 10H), 1.10-1.06 (m, 9H), 0.86 (t, J = 6.3 Hz, 
3H); 125 MHz 13C NMR (CDCl3) δ 206.8, 172.3, 172.2, 170.7, 167.0, 159.5, 151.3, 
142.7, 138.1, 130.6, 129.8, 128.7, 128.0, 127.9, 124.3, 119.6, 114.0, 103.3, 93.7, 79.8, 
77.4, 74.5, 74.4, 73.6, 73.4, 72.7, 71.8, 70.9, 70.2, 69.9, 67.3, 55.5, 52.7, 51.4, 48.9, 48.2, 
45.3, 43.9, 42.9, 41.4, 37.6, 35.0, 34.8, 31.8, 31.0, 29.2 (×2), 29.1, 26.4, 24.9, 22.8, 21.5, 
20.1, 15.4, 14.3; 125 MHz DEPT NMR (CDCl3) CH3 δ 55.5, 52.7, 51.4, 26.4, 21.5, 20.1, 
15.4, 14.3; CH2 δ  93.7, 71.8, 69.9, 48.9, 48.2, 43.9, 42.9, 41.4, 37.6, 35.0, 34.8, 31.8, 
31.0, 29.2 (×2), 29.1, 24.9, 22.8; CH δ  142.7, 129.8, 128.7, 128.0, 127.9, 124.3, 119.6, 
114.0, 79.8, 77.4, 74.5, 74.4, 73.6, 73.4, 72.7, 70.9, 70.2, 67.3; CH0 δ  206.8, 172.3, 
172.2, 170.7, 167.0, 159.5, 151.3, 138.1, 130.6, 103.3, 45.3; IR (neat) 2934, 2857, 2347, 
1732, 1652, 1540, 1457, 1363, 1150, 1119, 1038, 747, 703  cm-1; HRMS (ESI/TOF) 




Preparation of (2Z,2'E)-dimethyl 2,2'-((1S,3S,7R,11S,12S,15S,17R,21R, 23R, 
25S,E)-25-acetoxy-17-((R)-1-((benzyloxy)vmethoxy)ethyl)-11-methoxy-21-((4-metho 
xybenzyl)oxy)-10,10-dimethyl-12-(octanoyloxy)-19-oxo-18,27,28,29-tetraoxatetracycl 
o[21.3.1.13,7.111,15]nonacos-8-ene-5,13-diylidene)diacetate (2.113). A stirring 
solution of chiral R-BINOL phosphonoacetate 2.112 (26.3 mg, 0.65 mmol, 50 equiv) in 
THF (0.65 mL, 0.002 M) was cooled in an ice water bath under N2. A solution of 
KHMDS in THF (0.039 mL of 1.0 M, 0.039 mmol, 30 equiv) was then added dropwise. 
After 15 min, the resulting cloudy white mixture was added to neat ketone 2.111 (1.4 mg, 
0.0013 mmol, 1.0 equiv) in a reaction vial, previously cooled in an ice water bath. The 
resulting mixture was stirred overnight at 0 °C. The reaction mixture was quenched by 
the addition of saturated aqueous NH4Cl (1.0 mL). The biphasic mixture was diluted with 
water (5 mL) and Et2O (10 mL). The aqueous phase was separated and extracted with 
Et2O (3 × 25 mL). The combined organic phases were dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished using flash 
chromatography on a 1 × 8 cm silica gel column, eluting with 35% EtOAc/hexanes (100 
mL), collecting 12 × 75 mm test tube fractions. The product containing fractions (4-8) 
were combined and concentrated under reduced pressure to provide a mixture of Z:E 
(4:1) enoate 2.113 (1.2 mg, 82% yield) as a colorless oil. The The E and Z diastereomers 
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were further separated using preparative thin layer chromatography eluting with 10% 
acetone/benzene providing 0.8 mg of the desired Z isomer as a colorless oil. Rf = 0.45 
(30% EtOAc/hexanes); [ ] =20Dα  +48 (c = 0.07, CHCl3); 500 MHz 1H NMR (CDCl3)  δ 
7.40-7.30 (m, 5H), 7.20 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 6.23 (d, J = 15.6 
Hz, 1H), 5.95 (d, J = 2.0 Hz, 1H), 5.74 (s, 1H), 5.55 (ddd, J = 11.9, 4.3, 2.4 Hz, 1H), 5.35 
(dd, J = 15.6, 8.3 Hz, 1H), 5.18 (s, 1H), 4.85-4.80 (m, 4H), 4.64 (s, 2H), 4.46 (ABq, J = 
10.7Hz, , Δν = 8.5 Hz, 2H), 4.17-4.13 (m, 1H), 4.00-3.90 (m, 2H), 3.76-3.74 (m, 1H), 
3.75 (s, 3H), 3.71 (s, 3H), 3.69 (s, 3H), 3.59-3.54 (m, 1H), 3.50-3.44 (m, 1H), 3.20-3.14 
(m, 1H), 3.07 (s, 3H), 2.54-2.44 (m, 2H), 2.31-2.25 (m, 3H), 2.12-1.98 (m, 2H), 2.03 (s, 
3H), 1.94-1.84 (m, 4H), 1.84-1.72 (m, 3H), 1.65-1.50 (m, 5H), 1.32-1.22 (m, 10H), 1.11-
1.05 (m, 9H), 0.87 (t, J = 6.7 Hz, 3H); 125 MHz 13C NMR (CDCl3) δ 172.3 (×2), 170.8, 
167.1, 167.0, 159.4, 157.3, 151.5, 142.3, 138.1, 130.8, 129.6, 128.6, 128.1, 127.9, 125.4, 
119.5, 114.9, 113.9, 103.4, 93.8, 80.5, 77.4, 75.6, 75.0, 73.7, 73.4 (×2), 72.0, 70.9, 70.3, 
69.8, 67.3, 55.5, 52.8, 51.4, 51.2, 45.3, 44.0, 43.6, 42.9, 41.3, 37.6, 36.1, 34.9, 34.8, 31.9, 
31.0, 29.9, 29.2, 29.1, 26.4, 24.9, 22.8, 21.5, 20.2, 15.4, 14.3; 125 MHz DEPT NMR 
(CDCl3) CH3 δ 55.5, 52.8, 51.4, 51.2, 26.4, 21.5, 20.2, 15.4, 14.3; CH2 δ  93.8, 72.0, 69.8, 
44.0, 43.6, 42.9, 41.3, 37.6, 36.1, 34.9, 34.8, 31.9, 31.0, 29.9, 29.2, 29.1, 24.9, 22.8; CH δ  
142.3, 129.6, 128.6, 128.1, 127.9, 125.4, 119.5, 114.9, 113.9, 80.5, 77.4, 75.6, 75.0, 73.7, 
73.4 (×2), 70.9, 70.3, 67.3; CH0 δ  172.3 (×2), 170.8, 167.1, 167.0, 159.4, 157.3, 151.5, 
138.1, 130.8, 103.4, 45.3; IR (neat) 2993, 1738, 1681, 1513, 1452, 1383, 1364, 1237, 
1111, 1079, 1040, 821, 737, 701, 665 cm-1; HRMS (ESI/TOF) calcd for C62H86O18Na 




Preparation of (2Z,2'E)-dimethyl 2,2'-((1S,3S,7R,11S,12S,15S,17R, 21R,23R, 
25S,E)-25-acetoxy-11,21-dihydroxy-17-((R)-1-hydroxyethyl)-10,10-dimethyl-12-(oct 
anoyloxy)-19-oxo-18,27,28,29-tetraoxatetracyclo [21.3.1.13,7.111,15] nonacos-8-ene-
5,13-diylidene) diacetate (Merle 33). To a stirring solution of 2.113 (2.0 mg, 0.0018 
mmol, 1.0 equiv) in CH2Cl2 (1.0 mL, 0.0018 M) in a 4 mL reaction vial at 0 ºC were 
added aqueous tert-butyl alcohol (0.05 mL), pH 7 buffer (0.5 mL) and DDQ (1.6 mg, 
0.0072 mmol, 4.0 equiv). The reaction mixture was stirred at 0 ºC for 5 h, then diluted 
with CH2Cl2 (1 mL) and quenched by the addition of saturated aqueous NaHCO3 solution 
(1 mL). After stirring vigorously for 10 min at rt the mixture was partitioned between 
CH2Cl2 (5 mL) and saturated aqueous NaHCO3 solution (5 mL). The aqueous phase was 
separated and extracted with CH2Cl2 (3 × 5 mL). The combined organic phases were 
dried over Na2SO4, and concentrated under reduced pressure. The crude material was 
taken on to the next step without purification.  
To a 4 mL reaction vial containing the aforementioned analogue precursor was 
added a 0.25 M solution of LiBF4 in 25:1 CH3CN/H2O (324 μL, 0.081 mmol, 45.0 
equiv). The reaction vial was sealed and the mixture was stirred at 80 ºC for 10 h. After 
cooling to rt, the mixture was diluted with EtOAc (1 mL) and was quenched by addition 
of saturated aqueous NaHCO3 solution (0.5 mL). The mixture was partitioned between 
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EtOAc (10 mL) and saturated aqueous NaHCO3 solution (5 mL). The phases were 
separated and the aqueous phase was extracted with EtOAc (3 × 10 mL). The combined 
organic phases were dried over Na2SO4 and concentrated under reduced pressure. 
Purification was accomplished using flash chromatography with a 0.6 × 6 cm silica gel 
column, eluting with 40% EtOAc/hexanes, collecting 6 × 50 mm test tube fractions. The 
product containing fractions (17-31) were combined and concentrated under reduced 
pressure to provide analogue Merle 33 (1.1 mg, 71% over 2 steps) as a colorless oil: Rf = 
0.32  (50 % EtOAc/hexanes); [ ] =20Dα  + 15 (c = 0.04, CHCl3); 500 MHz 1H NMR 
(CDCl3)  δ 5.99 (d, J = 1.5 hz, 1H), 5.81 (d, J = 15.6 Hz, 1H), 5.68 (s, 1H), 5.34 (dd, J = 
15.6 , 8.8 Hz, 1H), 5.20 (s, 1H), 5.14 (s, 1H), 4.88-4.80 (m, 1H), 4.37 (d, J = 11.7 Hz, 
1H), 4.24-4.16 (m, 1H), 4.10-4.00 (m, 2H), 3.84-3.79 (m, 1H), 3.71 (s, 3H), 3.68 (s, 3H), 
3.67-3.63 (m, 1H), 3.63-3.57 (m, 1H), 3.52 (t, J = 10.7 Hz, 1H), 2.51 (dd, J = 10.2, 2.0 
Hz, 1H), 2.42 (dd, J = 12.2, 11.7 Hz, 1H), 2.32 (td, J = 7.3, 2.4 Hz, 1H), 2.24-2.15 (m, 
1H), 2.13-2.08 (m, 2H), 2.04 (s, 3H), 2.04-2.00 (m, 1H), 1.96-1.82 (m, 7H), 1.66-1.50 
(m, 6H), 1.36-1.20 (m, 10H), 1.24 (d, J = 6.4 Hz, 3H), 1.15 (s, 3H), 1.11 (s, 3H), 0.88 (t, 
J = 6.8 Hz, 3H); 125 MHz 13C NMR (CDCl3) δ 172.1 ( ×2 ), 170.7, 170.6, 167.2, 156.7, 
152.1, 139.6, 129.4, 119.8, 114.6, 99.1, 79.3, 77.2, 76.7, 74.4, 73.9, 73.6, 70.5, 69.5, 68.7, 
64.7, 51.2 (×2), 45.2, 43.9, 43.1, 42.7, 39.9, 37.4, 36.7, 36.1, 34.9, 31.9, 31.5, 29.9, 29.3, 
29.1, 24.9, 22.9, 22.8, 21.5,20.1, 20.0, 14.3;v125 MHz DEPT  NMR (CDCl3) CH3 δ 51.2 
(×2), 29.1, 21,5 20.1, 20.0, 14.3; CH2 δ  43.9, 43.1, 42.7, 39.9, 37.4, 36.7, 36.1, 34.9, 
31.9, 31.5, 29.9, 29.3, 24.9, 22.9, 22.8; CH δ  139.6, 129.4, 119.8, 114.6, 79.3, 77.2, 76.7, 
74.4, 73.9, 73.6, 70.5, 69.5, 68.7, 64.7; CH0 δ 172.1 (×2), 170.7, 170.6, 167.2, 156.7, 
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152.1, 99.1, 45.2; IR (neat) 2930, 2360, 2342, 1733, 1470, 1426, 1263, 1245, 1166, 1110, 
1037 cm-1; HRMS (ESI/TOF) calcd for C45H68O16Na (M+Na) 887.4405, found 887.4423. 
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CHAPTER 3  
SYNTHETIC STUDY OF A BRYOSTATIN ANALOGUE WITH A  
C9 HEMIKETAL 
Introduction  
 Our group has been interested in addressing the supply of bryostatin through the 
synthesis of bryostatin analogues. All the results from the biological tests on our 
bryostatin analogues suggest the northern hemisphere of bryostatin 1 plays a critical role 
responsible for its unique biological activities as antagonist to phorbol ester. Our focus of 
bryostatin analogue study has evolved from just the preparation of bryostatin analogues 
with similar or higher binding affinity with PKC in comparison with bryostatin 1 to 
identifying the pharmacophoric groups responsible for the unique bioactivities of 
bryostatin 1.  
 Our next interesting site is the C9 hydroxyl group. In cooperation with Dr. Peach 
in NIH, we were able to perform the molecular docking studying of analogues on the C1 
domain of PKCδ (Figure 3.1).1  The docking results indicated (1) the conformational 
search of Merle 28 itself in water and octanol solvents has a single well-defined low-
energy conformer, due to the intramolecular hydrogen bonding between the hydroxyl 
groups at C3 and C19; (2) the docking of Merle 28 into the C1 domain binding site is 
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crystal, solvent and bound states, which is also supported by the results from the X-ray 
structure of PKCδ C1-PMA complex; (3) In this binding mode, the A and B rings lie 
above the binding site in the plane of the bilayer. The only direct interaction they make 
with the C1 domain is via a hydrogen bond between the hydroxyl at C9 and the backbone 
carbonyl oxygen of Met 259 in the C1 domain. This results is very similar to previous 
results reported by the Itai group with a different docking program.2 
The biological results from Merle 30 indicate that the removal of C9 OH did not 
switch biological activities of analogue from bryostatin-like to PMA-like. We also notice 
that Merle 30 does show certain shift of biological activities towards PMA in both U937 
and LNCaP cell lines. The importance of investigating the effect of C9 OH on the 
biological activities of bryostatin 1 encourages us to pursue the synthesis of bryostatin 
analogue with the C9 hemi-ketal functionality. The aims were (1) discovery of a 
convergent and efficient route to access bryostatin analogues containing the C9 hemi-
ketal; (2) study of biological activities of those analogues to evaluate the effect of C9 
hydroxyl group alone and with other substituents present on their biological activities. 
There is limited precedent that we can utilize to access the C9 hydroxyl analogue 
from known bryostatin analogues. The only example of the synthesis of the bryostatin 
analogue with a C9 hemi-ketal through a direct C-H activation was reported by the 
Wender group (Scheme 3.1).3 The DMDO oxidation converted analogue 3.1 into 
analogue 3.2 in good yield. The oxidation turned into highly regioselective given the fact 
there are five potential oxidation sites on compound 3.1. Wender attributed the 
regioselectivtiy of DMDO oxidation to the conformation of analogue 3.1 and 
extraordinary selectivity of DMDO as a single oxygen transfer reagent. However, the 
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regioselectivity only applied to the special substrate 3.1.  The specialty of DMDO 
oxidation on analogue 3.1 prevents application to a wider variety of substituents. 
 
Results And Discussion 
In order to fit our need to diversify our bryostatin analogues, we decided to 
approach the bryostatin analogue with C9 hemi-ketal through a different route, which 
will allow us to install other functional groups in other sites. The first analogue target has 
C9 hemi-ketal and C13 olefin. The inclusion of the C13 olefin would allow us to 
construct the B ring via pyran annulation as in our previous syntheses of bryostatin 
analogues.  The original retrosynthetic strategy to analogue 3.3 is outlined on Figure 3.2. 
Analogue 3.3 was to be prepared from intermediate seco acid 3.4. The pyran annulation 
disconnection on the B ring leads to two intermediates, aldehyde 3.5 and 
hydroxyallylsilane 3.6. The hydroxyallylsilane was to be prepared from ester 3.7 through 
the Bunnelle reaction. The construction of the ester was to be achieved by a cross 
metathesis between vinyl ketone 3.8 and terminal olefin 3.9. Vinyl ketone 3.8 would be  
 
 







































































































prepared from the known aldehyde 2.40. Both aldehyde 2.40 and olefin 3.9 have been 
prepared in our previous syntheses of bryostatin analogues, which allows us to utilize the 
well-established routes to start the preparation of analogue 3.3. 
The synthesis of ester 3.7 started with aldehyde 2.40 (Scheme 3.2). The addition 
of vinyl magnesium bromide to aldehyde 2.40 at -78 °C afford the desired allylic alcohol 
3.10 in good yield, which was oxidized by Dess-Martin periodinane to the vinyl ketone 
3.8. There was also starting material recovered from the Grignard reaction. Any attempt 
to push the reaction to completion by elevating the reaction temperature only resulted in 
the formation of six membered lactone via transesterification. In order to prevent the 
formation of the undesired lactone product, the Grignard reaction was kept at -78 °C, and 
the resulting alcohol was oxidized immediately after purification. 
In the seminal report of Grubbs’ study on the selectivity of cross metathesis 
reaction,4 Grubbs classified olefin into four types: Type I olefins are categorized as those 
able to undergo a rapid homodimerization and the resulting homodimers can participate 
in cross metathesis as well as their terminal olefin counterpart, typical examples are 
terminal olefins and olefins with electron rich groups. Type II olefins homodimerize 
slowly, and unlike Type I olefins, their homodimers can only be sparingly consumed in 
subsequent metathesis reactions, α,β−unsaturated carbonyl compounds and sterically 
hindered allylic alcohol belong to this group; Type III olefins are essentially unable to be 
homodimerized by the catalyst but are still able to undergo cross metathesis with Type I 
and Type II olefins, this group include tri-substituted or all-substituted olefins, for which 
steric effects inhibit homodimerization. Type IV olefins are not able to participate in CM 
with a particular catalyst but do not inhibit catalyst activity toward other olefins. 
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 The cross metathesis of type I with type II Olefins usually affords the trans 
product in high yield and stereoselectivity. Terminal olefin 3.9 as Type I and vinyl ketone 
3.8 as Type II are perfect match for the cross metathesis reaction. The Grubbs reaction 
conditions, with a ratio of 1:2 for a Type I and Type II olefins, was able to deliver 
product 3.7 as exclusively the E diastereomer in quantitative yield. In order to limit the 
usage of terminal olefin 3.9, the ratio was changed from 1:2 to 1:1.1, the cross metathesis 
still gave product 3.7 in 92% yield. 
 The chemoselective reduction of the C7-C8 double bond was achieved with 
NaBH4 in the presence of NiCl2•6H2O in methanol. NaBH4 reacted with NiCl2 to 
generate nickel boride in situ,5 which chemoselectively reduced the C7-C8 double bond 
to give ketone 3.11 with good yield. Attempts to effect this transformation via catalytic 
hydrogenation with Pd/C afforded a mixture of different reduced products. During the 
catalytic hydrogenation, both the PMB ether on C5 and thioester on C1 position were 
partially reduced as well.  
 With the ketone 3.11 in hand, our focus was transferred to forming the cyclic 
hemi-ketal and swapping the protecting group on the C11 position with TMS. The PMB 
group was removed with DDQ, and the resulting alcohol was subjected to reaction with 
CSA in methanol to afford the cyclic ketal. The TBS group on C11 position was also 
removed and the resulting free hydroxyl group was protected as the TMS ether to give 
product 3.12. The application of Bunnelle reaction conditions to the ester 3.12 did not 
afford the desired hydroxyallylsilane; instead, a spiro ether product 3.13 was isolated 




Scheme 3.2 Failed route to hydroxyl allylsilane 3.6 
 
 
Figure 3.2 Confirmation of stereochemistry on C9 position of 3.13 by nOe 
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Peterson olefination/intramolecular Prins reaction. The stereochemistry at C9 in the 
product 3.13 was confirmed by the results from the nOe experiments (Figure 3.2).  
This failure in preparation of the hydroxyallylsilane made us revise the route 
(Scheme 3.3). The ketone on the C9 position was reduced to give alcohol 3.14, which 
will avoid the formation of an oxocarbenium ion during the acidic work up in the 
Bunnelle reaction. The TBS group on the C11 position was then swapped with TMS by 
deprotection with CSA and reprotection with TMSCl and NEt3 in excellent yield. The 
ester 3.15 was then subjected to Bunnelle reaction conditions to deliver the desired 














































 After the completion of the synthesis of hydroxyl allylsilane 3.16, we turned our 
attention into the aldehyde moiety 3.5. Similar steps to those used previous were utilized 
to provide the fully functionalized C ring aldehyde 3.5 (Scheme 3.4). Ketone 3.17 was 
subjected to Luche reduction conditions to afford the alcohol, which was acylated to 
afford ester 3.18. The natural unsaturated side chain of bryostatin 1 was installed on the 
C20 position. The TBS group in 3.18 was removed by CSA in methanol to afford the 
alcohol 3.19.  Dess-Martin periodinane converted the alcohol into aldehyde 3.5. Finally, 
the pyran annulation between aldehyde 3.5 and hydroxyallylsilane 3.16 delivered the 
desired product 3.20 The oxidation of the C9 hydroxyl group in 3.20 with normal 
oxidation conditions such as TPAP/NMO, Dess-Martin periodinane, SO3·Py/DMSO and 
(COCl)2/DMSO did not provide any ketone product, only starting material was recovered 
from these reactions. The reluctance of the alcohol towards oxidation is most likely due 
to the complexity of the molecule and possible steric hindrance from nearby groups. 
Fortunately, the Goldman-Albright protocol successfully oxidized the secondary alcohol 
to give ketone 3.21 in excellent yield.6 This solvent-free reaction has proved to be an 
efficient methodology to oxidize hindered secondary alcohol into ketone. We also found 
the TEMPO/DIAB condition could oxidize the alcohol 3.20 to the ketone in excellent 
yield.7 This reaction was utilized due to ease of workup. Removal of the PMB group at 
C5 position with DDQ and treatment with CSA in methanol afforded the C9 ketal in 
good yield. Unfortunately, the product 2.22 was not stable, and underwent a hydrolysis 
on of the C9 ketal to release methanol. This unexpected problem prevented us from 
moving towards the final product given five more steps needed to complete the synthesis 
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Scheme 3.4  Synthesis of unstable C9 ketal 3.22 
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During Wender’s synthesis of bryostatin analogue 3.27. an intramolecular pyran 
annulation was chosen to cyclize the ring and form the macrolactone (Scheme 3.5). 
Yamaguchi reaction conditions were used to couple the carboxylic acid 3.23 and alchol 
3.24 The TES group was removed regioselectively with PPTS to afford product 3.25 
ready for pyran annulation. The intramolecular pyran annulation constructed the B ring 
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(2) PPTS , H2O:THF, rt,
















































 We envisioned that an intramolecular pyran annulation pathway would allow us 
to avoid the formation of the unstable C9 ketal before formation of the macrolactone. A 
revised route of intramolecular pyran annulation is outlined in Scheme 3.6. The PMB 
group on aldehyde 3.5 was removed with DDQ to afford the alcohol 3.28. The thioester 
2.16 was hydrolyzed by LiOH and H2O2, then the free hydroxyl groups on C9 and C11 
were protected as TES ethers. The alcohol 3.27 and carboxylic acid 3.30 were coupled 
together by Yamaguchi reaction conditions, and the resulting ester 2.31 was exposed to 
CSA in methanol for the removal of the TES groups. The resulting substrate was 
subjected to TMSOTf for the pyran annulation. Unfortunately, the only product isolated 
after reaction is the acetal 3.32 rather than the desired B ring pyran. Attempts were made 
to force reaction from the acetal, but increasing temperature and increase in the amount 
of TMSOTf used did not promote the intramolecular Prins reaction to form the B ring 
pryan. It appears that the acetal embedded on this macrocylic framework is unusually 
stable. The failure of the desired intramolecular pyran annulation made us revisit the first 
route. Although the ketal 3.22 was not very stable at rt, it might survive if it was 
subjected to the Yamaguchi macrolactonization immediately after the preparation of ketal. 
In order to avoid the tedious steps of hydrolyzing thioester into carboxylic acid, we 
decided to hydrolyze the thioester before the pyran annulation (Scheme 3.7). This 
unprecedent pyran annulation between aldehyde 3.5 and hydroxyallylsilane 3.29 turned 
out to be a smooth reaction with excellent yield. The existence of carboxylic acid 
functional group in the hydroxyallylsilane unexpectedly improve the yield compared with 
the hydroxyallylsilane with thiolester moiety. The resulting product 3.33 was protected as 










































































































































































C9 hydroxyl group into ketone 3.34. After the removal of the PMB group, treatment with 
CSA in methanol not only promoted the formation of the cyclic ketal, but also removed 
the TIPS group from C1, affording the seco acid ready for the cyclization. The crude seco 
acid was subjected to Yamaguchi reaction conditions immediately after work up, the 
desired product 3.35 was isolated after reaction with yield of 18% over three steps. The 
macrolactone product 3.35 was found to be stable. 
 The low yield of macrolactonization makes it really difficult to bring up enough 
material at this stage. Attempts to optimize this reaction conditions did not provide 
improved yield. The fact that the C9 ketal is not stable in open chain environment but 
stable in macrolactone suggests us that we should investigate formation of the ketal after 
macrolactonization. Based on this strategy, a new route has been designed and will be 
tested in future work. Firstly, in order to differentiate the protecting groups on the C25 
position of the aldehyde with the C5 position of the hydroxyallylsilane, the PMB ether 
group at C25 was swapped for a TBS group, which will allow us to approach the seco 
acid without the problem of dealing with the C9 ketal. After the pyran annulation 
between aldehyde 3.36 and hydroxyallylsilane 3.16, the free hydroxyl group on C9 of 
product 2.37 will be oxidized by TEMPO/DIAB. Both silyl groups will be removed with 
HF/Py to give diol 3.38. The removal of the TBDPS group at C3 will ensure the 
regioselective hydrolysis of the thiolester under LiOH/H2O2 conditions.9 The C3 free 
hydroxyl group will be reprotected with TESCl and DMAP, then the resulting seco acid 
will be subjected to Yamaguchi macrolactonization to afford the marcolactone 3.39. The 
global deprotection will remove the remaining protecting groups and form the C9 hemi-




Scheme 3.8 The future route to bryostatin analogue 3.3 
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 During our approach to the bryostatin analogue with C9 hemi-ketal, several routes 
were tested. The unstable C9 ketal in an open chain environment proved very frustrating 
and prevented us from preparing the final analogue product through our initial route. An 
intramolecuar pyran annulation strategy was designed to overcome the problem from the 
unstable C9 ketal. Unfortunately, the intramolcular pyran annulation failed to provide the 
desired product, instead only cyclized acetal product was isolated after reaction. The 
resistance of this acetal to react further was also surprising. Another attempt to cyclize 
the seco acid with the Yamaguchi protocol right after the formation of C9 ketal 
successfully delivered the desired macrolactone, but the low yield prevented us from 
acquiring enough material to the final product.  
A revised route has been designed based on information gleaned from these 
studies and will be examined in the future. Moreover, in the course of this work, we 
explored the scope of pyran annulation with many different substrates. The results 
demonstrated that the pyran annulation reaction is versatile and flexible. It is also tolerant 
of functional groups such as hydroxyl and carboxylic acid. This methodology will be 










Solvents were purified according to the guidelines in Purification of Common 
Laboratory Chemicals (Perrin, Armarego, and Perrin, Pergamon: Oxford, 1966).10 
Diisopropylamine, diisopropylethylamine, pyridine, triethylamine, EtOAc, MeOH, and 
CH2Cl2 were distilled from CaH2. The titer of n-BuLi was determined by the method of 
Eastham and Watson.11 All other reagents were used without further purification. Yields 
were calculated for material judged homogenous by thin layer chromatography and 
nuclear magnetic resonance (NMR). Thin layer chromatography was performed on 
Merck Kieselgel 60 Å F254 plates or Silicycle 60 Å F254 eluting with the solvent 
indicated, visualized by a 254 nm UV lamp, and stained with an ethanolic solution of 12-
molybdophosphoric acid, or 4-anisaldehyde. Flash column chromatography was 
performed with Silicycle Flash Silica Gel 40 – 63 μm or Silicycle Flash Silica Gel 60 – 
200 μm, slurry packed with 1% EtOAc/hexanes in glass columns. Glassware for reactions 
was oven dried at 125 °C and cooled under a dry nitrogen atmosphere prior to use. Liquid 
reagents and solvents were introduced by oven dried syringes through septum-sealed 
flasks under a nitrogen atmosphere. Nuclear magnetic resonance spectra were acquired at 
500 MHz for 1H and 125 MHz for 13C. Chemical shifts for proton nuclear magnetic 
resonance (1H NMR) spectra are reported in parts per million relative to the signal of 
residual CHCl3 at 7.27 ppm. Chemicals shifts for carbon nuclear magnetic resonance (13C 
NMR and DEPT) spectra are reported in parts per million relative to the center line of the 
CDCl3 triplet at 77.23 ppm. Chemical shifts of the unprotonated carbons (‘CH0’) for 
DEPT spectra were obtained by comparison with the 13C NMR spectrum. The 
abbreviations s, d, apd, dd, ddd, dddd, ddddd, dddddd, t, td, tt, q, dq, and m stand for the 
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resonance multiplicity singlet, doublet, apparent doublet, doublet of doublets, doublet of 
doublet of doublets, doublet of doublet of doublet of doublets, doublet of doublet of 
doublet of doublets of doublets, doublet of doublet of doublet of doublets of doublets of 
doublets, triplet, triplet of doublets, triplet of triplets, quartet, doublet of quartets, and 
multiplet, respectively. Optical rotations (Na D line) were obtained using a microcell with 
1 dm path length. Specific rotations ([α], Unit: °cm2/g) are based on the equation α = 
(100·α)/(l·c) and are reported as unit-less numbers where the concentration c is in g/l00 
mL and the path length l is in decimeters. Mass spectrometry was performed at the mass 
spectrometry facility of the Department of Chemistry at The University of Utah on a 




Preparation of (R)-ethyl 3-(tert-butyldimethylsilyloxy)-5-hydroxyhept-6-
enoate (3.10). To a stirring solution of aldehyde 2.40 (255.8 mg, 0.9321 mmol, 1.0 equiv) 
in CH2Cl2 (18.6 mL, 0.05 M) in a 50 mL rb flask at rt was added MgBr2·OEt2 (481.4 mg, 
1.864 mmol, 2.0 equiv) in one portion. The mixture was stirred at rt for 5 min, then 
cooled to -78 °C. The mixture was stirred at -78 °C for 5 min, and then a solution of vinyl 
magnesium bromide (1.40 mL of 1.0M, 1.40 mmol, 1.5 equiv) was added via syringe. 
The mixture was stirred at -78 °C for 2 h before being quenched by the addition of 
saturated aqueous NH4Cl solution (20 mL). The mixture was warmed to rt, and the 
aqueous phase was separated and extracted with CH2Cl2 (3 × 40 mL). The organic phases 
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were combined, dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash chromatography on a 3 × 19 cm column, eluting 
with 10% EtOAc/hexanes (1000 mL), collecting 18 × 150 mm test tube fractions. The 
product containing fractions (17-23) were combined and concentrated under reduced 
pressure to give the product 3.10 (206.0 mg, 73%) as a colorless oil: Rf = 0.41 (20% 
EtOAc/hexanes); [ ] =20Dα  +5 (c = 0.08, CHCl3); 500 MHz 1H NMR (CDCl3) δ 5.87 (ddd, 
J = 17.1, 10.3, 5.9 Hz, 1H), 5.29 (t, J = 1.5 Hz, 1H), 5.25 (t, J = 1.5 Hz, 1H), 4.36-4.27 
(m, 2H), 4.16-4.09 (m, 2H), 2.60 (d, J = 2.9 Hz, 1H), 2.56 (t, J = 5.9 Hz, 2H), 1.82-1.70 
(m, 2H), 1.26 (t, J = 7.3 Hz, 3H), 0.89 (s, 9H), 0.12 (s, 3H), 0.09 (s, 3H); 125 MHz 13C 
NMR (CDCl3) δ 171.6, 140.9, 114.6, 71.0, 68.7, 60.7, 44.1, 43.2, 25.9, 18.1, 14.4, -4.3, -
4.5; 125 MHz DEPT (CDCl3) CH3 δ 25.9, 14.4, -4.3, -4.5; CH2 δ 114.6, 60.7, 44.1, 43.2; 
CH δ 140.9, 71.0, 68.7; CH0 δ 171.6, 18.1; IR (neat) 3509, 2978, 2955, 2930, 2897, 2856, 
1736, 1464, 1410, 1376, 1309, 1254, 1209, 1175, 1085, 1032, 960, 923, 836, 808, 776, 




  Preparation of (R)-ethyl 3-(tert-butyldimethylsilyloxy)-5-oxohept-6-enoate 
(3.8). To a solution of alcohol 3.10 (206.0 mg, 0.6810 mmol, 1.0 equiv) in CH2Cl2 (6.8 
mL, 0.1 M) in a 25 mL rb flash at rt was added Dess-Martin periodinane (433.3 mg, 
1.022 mmol, 1.5 equiv) in one portion. The reaction mixture was stirred at rt overnight, 
and then quenched by the addition of saturated aqueous Na2S2O3 solution (10 mL). The 
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mixture was stirred at rt until the whole solution turned clear, the aqueous phase was 
separated and extracted with CH2Cl2 for (3 × 20 mL). The organic phases were combined, 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash chromatography on a 3 × 14 cm column, eluting with 10% 
EtOAc/hexanes (500 mL), collecting 18 × 150 mm test tube fractions. The product 
containing fractions (6-8) were combined and concentrated under reduced pressure to 
give the product 3.8 (168.1 mg, 82%) as a colorless oil: Rf = 0.60 (20% EtOAc/hexanes); 
[ ] =20Dα  +7.4 (c = 1.72, CHCl3); 500 MHz 1H NMR (CDCl3) δ 6.36 (dd, J = 17.6, 10.3 Hz, 
1H), 6.24 (d, J = 17.6 Hz, 1H), 5.87 (d, J = 11.7 Hz, 1H), 4.63 (dddd, J = 11.7, 5.9, 5.9, 
5.9 Hz, 1H), 4.18-4.08 (m, 2H), 2.90 (dd, J = 15.6, 6.8 Hz, 1H), 2.81 (dd, J = 15.6, 6.4 
Hz, 1H), 2.55 (dd, J = 15.1, 5.9 Hz, 1H), 2.49 (dd, J = 14.6, 5.9 Hz, 1H), 1.26 (t, J = 7.3 
Hz, 3H), 0.84 (s, 9H), 0.07 (s, 3H), 0.03 (s, 3H);  125 MHz 13C NMR (CDCl3) δ 199.0, 
171.2, 137.4, 128.9, 66.2, 60.6, 47.0, 42.9, 25.9, 18.1, 14.4, -4.6, -4.7; 125 MHz DEPT 
(CDCl3) CH3 δ 25.9, 14.4, -4.6, -4.7; CH2 δ 128.9, 60.6, 47.0, 42.9; CH δ 137.4, 66.2; 
CH0 δ 199.0, 171.2, 18.1; IR (neat) 2933, 2858, 1737, 1685, 1615, 1468, 1375, 1255, 
1195, 1092, 965, 778, 665 cm-1; HRMS (ESI/TOF) calcd for C15H28NaO4Si (M+Na) 
323.1655, found 323.1655. 
 
 
Preparation of (3R,9S,11R,E)-ethyl 3-(tert-butyldimethylsilyloxy)-11-(tert-
butyldi phenyl silyloxy)-13-(tert-butylthio)-9-(4-methoxybenzyloxy)-5,13-dioxotridec 
-6-enoate (3.7). To a solution of vinyl ketone 3.8 (168.1 mg, 0.5595 mmol, 1.1 equiv) 
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and olefin 3.9 (307.7 mg, 0.5086 mmol, 1.0 equiv) in CH2Cl2 (28 mL, 0.019 M) in a 50 
mL rb flask at rt was added Grubbs’ 2nd generation catalyst (21.6 mg, 0.0254 mmol, 0.05 
equiv) in one portion. Then the flask was equipped with a condenser, and the reaction 
mixture was heated to reflux and kept overnight. The mixture was cooled to rt and the 
solvent was removed under reduced pressure. Purification was accomplished by flash 
chromatography on a 3 × 19 cm column, eluting with 10% EtOAc/hexanes (1000 mL), 
collecting 18 × 150 mm test tube fractions. The product containing fractions (13-26) were 
combined and concentrated under reduced pressure to give the product 3.7 (412.1 mg, 
92%) as a brown oil: Rf = 0.54 (20% EtOAc/hexanes); [ ] =20Dα  -12 (c = 0.23, CHCl3); 
500 MHz 1H NMR (CDCl3) 1H NMR (CDCl3) δ 7.72-7.66 (m, 4H), 7.45-7.35 (m, 6H), 
7.08 ( d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 6.65 (ddd, J = 15.6, 7.4, 7.3 Hz, 1H), 
6.00 (d, J =16.1 Hz, 1H), 4.63 (dddd, J = 12.2, 6.4, 6.4, 6.4 Hz, 1H), 4.36 (dddd, J = 12.2, 
6.4, 6.4, 6.4 Hz, 1H), 4.22 (d, J = 11.2 Hz, 1H), 4.18-4.10 (m, 2H), 4.05 ( d, J = 10.7 Hz, 
1H), 3.40 (dddd, J = 9.8, 5.4, 5.4, 5.4 Hz, 1H), 2.78 (dd, J = 15.6, 6.3 Hz, 1H), 2.71 (dd, J 
= 10.3, 5.9 Hz, 1H), 2.68 (dd, J = 10.3, 5.9 Hz, 1H), 2.68 (dd, J = 10.3, 5.9 Hz, 1H), 2.61 
(dd, J = 14.7, 6.3 Hz, 1H), 2.46 (dd, J = 14.6, 6.3 Hz, 1H), 1.80 (ddd, J = 14.2, 7.8, 5.4 
Hz, 1H), 1.58 (ddd, J = 14.2, 6.5, 4.4 Hz, 1H), 1.42 (s, 9H), 1.26 (t, J = 7.3Hz, 3H), 1.03 
(s, 9H), 0.84 (s, 9H), 0.08 (s, 3H), 0.03 (s, 3H);  125 MHz 13C NMR (CDCl3) δ 198.0, 
197.7, 171.2, 159.2, 143.9, 136.1, 136.1, 134.0, 133.7, 133.2, 130.5, 130.0, 129.9, 129.4, 
127.8, 113.9, 74.9, 70.6, 68.8, 66.2, 60.6, 55.4, 52.9, 48.2, 47.3, 42.9, 42.8, 37.5, 29.9, 
27.1, 25.9, 19.6, 18.1, 14.4, -4.5, -4.8; 125 MHz DEPT (CDCl3) CH3 δ 55.4, 29.9, 27.1, 
25.9, 14.4, -4.5, -4.8; CH2 δ 70.6, 60.6, 52.9, 47.3, 42.9, 42.8, 37.5; CH δ 143.9, 136.1, 
136.1, 133.2, 130.0, 129.9, 129.4, 127.8, 113.9, 74.9, 68.8, 66.2; CH0 δ 198.0, 197.7, 
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171.2, 159.2, 134.0, 133.7, 130.5, 48.2, 19.6, 18.1; IR (neat) 2931, 2858, 1736, 1679, 
1615, 1464, 1427, 1365, 1302, 1250, 1174, 1107, 830, 778, 740, 704, 590, 536 cm-1; 
HRMS (ESI/TOF) calcd for C49H72NaO8Si2S (M+Na) 899.4384, found 899.4379. 
 
 
Preparation of (3R,9R,11R)-ethyl 3-(tert-butyldimethylsilyloxy)-11-(tert-butyl 
di phenyl silyloxy)-13-(butylthio)-9-(4-methoxybenzyloxy)-5,13-dioxotridecanoate 
(3.11). To a stirring solution of unsaturated ketone 3.7 (207.9 mg, 0.2370 mmol, 1.0 
equiv) in THF/MeOH (1:4) (1.8 mL, 7.9 mL, 0.03 M) in a 50 mL rb flask at 0 °C was 
added NiCl2·6H2O (28.2 mg, 0.119 mmol, 0.5 equiv). Once the crystals had dissolved, 
NaBH4 (17.9 mg, 0.4740 mmol, 2.0 equiv) was added portionwise. The color of the 
solution changed from light green to dark brown quickly. After the addition of NaBH4, 
the reaction mixture was stirred at 0 °C for 1 h, and then quenched by the addition of 1N 
HCl (0.6 mL). After 5 min at 0 °C, the mixture was transferred into a separatory funnel 
with 50% EtOAc/hexanes (20 mL). The aqueous phase was separated and extracted with 
50% EtOAc/hexanes (3 × 20 mL). The combined organic phases were dried with Na2SO4, 
filtered and concentrated under reduced pressure.  Purification was accomplished by flash 
chromatography on a 3 × 14 cm column, eluting with 10% EtOAc/hexanes (1000 mL), 
collecting 18 × 150 mm test tube fractions.  The product containing fractions (10-22) 
were combined and concentrated under reduced pressure to give the product 3.12 (158.4 
mg, 76%) as a colorless oil: Rf = 0.54 (20% EtOAc/hexanes); [ ] =20Dα    -15.2 (c = 0.57, 
CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.73-7.67 (m, 4H), 7.44-7.35 (m, 6H), 7.12 (d, J = 
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8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 4.57 (dddd, J = 6.4, 5.9, 5.9, 5.9 Hz, 1H), 4.35 
(dddd, J = 6.4, 6.4, 5.9, 5.9 Hz, 1H), 4.22 (d, J = 10.7 Hz,1H), 4.15-4.10 (m, 2H), 4.06 (d, 
J = 10.7 Hz, 1H), 3.80 (s, 3H), 3.30-3.22 (m, 1H), 2.70 (dd, J = 14.7, 6.3 Hz, 1H), 2.64 
(dd, J = 16.1, 6.8 Hz, 1H), 2.62 (dd, J = 13.7, 6.8 Hz, 1H), 2.57 (dd, J = 15.6, 5.4 Hz, 1H), 
2.47 (dddd, J = 14.7, 14.7, 14.7, 5.9 Hz, 2H), 2.27 (dd, J =7.8, 6.8 Hz, 2H), 1.79 (ddd, J = 
13.7, 7.3, 5.9 Hz, 1H), 1.56 (ddd, J = 10.8, 5.9, 4.4 Hz, 1H), 1.41 (s, 9H), 1.28 (t, J = 6.8 
Hz, 3H), 1.02 (s, 9H), 0.85 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H); 125 MHz 13C NMR 
(CDCl3) δ 208.7, 197.9, 171.2, 159.1, 136.1, 136.1, 134.1, 133.9, 131.0, 129.8, 129.8, 
129.4, 127.8, 113.8, 75.6, 70.1, 69.0, 65.9, 60.6, 55.4, 52.8, 49.9, 48.1, 44.3, 42.7, 42.4, 
33.5, 29.9, 27.1, 25.9, 19.6, 19.0, 18.1, 14.4, -4.6, -4.8; 125 MHz DEPT (CDCl3) CH3 δ 
55.4, 29.9, 27.1, 25.9, 14.4, -4.6, -4.8; CH2 δ 70.1, 60.6, 52.8, 49.9, 44.3, 42.7, 42.4, 33.5, 
19.0; CH δ 136.1, 136.1, 129.8, 129.8, 129.4, 127.8, 113.8, 75.6, 69.0, 65.9; CH0 δ 208.7, 
197.9, 171.2, 159.1, 134.1, 133.9, 131.0, 48.1, 19.6, 18.1; IR (neat) 3070, 2955, 2858, 
1735, 1682, 1613, 1588, 1513, 1463, 1427, 1366, 1301, 1250, 1175, 1108, 1037, 832, 778, 
740, 705, 611, 536, 509 cm-1; HRMS (ESI/TOF) calcd for C49H74NaO8Si2S (M+Na) 
901.4541, found 901.4537. 
 
 
Preparation of (R)-ethyl 4-((2R,6S)-6-((R)-2-((tert-butyldiphenylsilyl)oxy)-4-
(tert-butylthio)-4-oxobutyl)-2-methoxytetrahydro-2H-pyran-2-yl)-3-((trimethylsilyl) 
oxy) butanoate (3.12). To a stirring solution of PMB ether 3.11 (238.0 mg, 0.2707mmol, 
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1.0 equiv) in CH2Cl2 (50 mL, 0.005 M) in a 100 mL rb flask at 0 ºC were added tert-butyl 
alcohol (4.3 mL), aqueous pH 7 buffer (4.3 mL), and DDQ (185 mg, 0.8121 mmol, 3.0 
equiv). The reaction mixture was stirred at 0 ºC for 2 h and additional DDQ (185 mg, 
0.8121 mmol, 3.0 equiv) was then added. Stirring was continued for 1.5 h and the 
reaction mixture was quenched by the addition of saturated aqueous NaHCO3 solution (5 
mL). After stirring vigorously for 10 min at rt, the aqueous phase was separated and 
extracted with CH2Cl2 (3 × 50 mL). The combined organic phases were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. The crude material was taken 
on to the next step without purification.  
To a 25 mL rb flask containing the aforementioned alcohol in methanol (9.0 mL, 
0.03 M) at 0 ºC was added CSA (113.2 mg, 0.4873 mmol, 1.8 equiv) in one portion. The 
reaction mixture was stirred at 0 ºC for 5 h, and then quenched by the addition of 
saturated aqueous NaHCO3 solution (5 mL). The aqueous phase was separated and 
extracted with 50% EtOAc/hexanes (3 × 30 mL). The combined organic phases were 
dried over Na2SO4, filtered and concentrated under reduced pressure.  The crude material 
was taken on to the next step without purification.  
To a 25 mL rb flask containing the aforementioned alcohol in CH2Cl2 (9.0 mL, 
0.03 M) at 0 ºC was added NEt3 (274.1 mg, 2.708 mmol, 10 equiv) and TMSCl (147.0 
mg, 1.354 mmol, 5 equiv) via syringe. After 12 h at rt, the mixture was quenched by the 
addition of water (10 mL). The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3 × 20 mL). The organic phases were combined, dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash chromatography on a 3 × 18 cm silica gel column, eluting with 5% 
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EtOAc/hexanes (1000 mL), collecting 25 mL fractions. The product containing fractions 
(11-18) were combined and concentrated under reduced pressure to provide  silyl ether 
3.12 (96.9 mg, 57% over three steps) as a colorless oil: Rf = 0.68 (20% EtOAc/hexanes); 
[ ] =20Dα  + 2.2 (c = 1.47, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.72-7.66 (m, 4H), 7.45-
7.35 (m, 6H), 4.34-4.27 (m, 1H), 4.27-4.21 (m, 1H), 4.16 (dddd, J = 10.8, 7.3, 7.3, 7.3 Hz, 
1H), 4.10 (dddd, J = 11.2, 7.3, 7.3, 7.3 Hz, 1H), 3.27-3.21 (m, 1H), 3.00 (s, 3H), 2.76 (dd, 
J = 14.7, 4.4 Hz, 1H), 2.70 (dd, J = 14.7, 7.3 Hz, 1H), 2.59 (dd, J = 15.1, 7.3 Hz, 1H), 
2.36 (dd, J = 15.1, 7.3 Hz, 1H), 1.76 (dd, J = 14.2, 6.4 Hz, 1H), 1.70 (dd, J = 14.7, 5.9 Hz, 
1H), 1.64-1.54 (m, 3H), 1.45 (s, 9H), 1.45-1.38 (m, 4H), 1.27 (t, J = 6.8 Hz, 3H), 1.10 (d, 
J = 11.3 Hz, 1H), 1.04 (s, 9H), 0.10 (s, 9H);  125 MHz 13C NMR (CDCl3) δ 198.2, 171.9, 
136.2, 136.1, 134.6, 134.0, 129.9, 129.8, 127.8, 127.7, 98.5; 125 MHz DEPT (CDCl3) 
CH3 δ 47.7, 30.0, 27.2, 14.5, 0.5; CH2 δ 60.4, 53.2, 44.3, 44.0 ( × 2), 32., 30.9, 18.8; CH δ 
136.2, 136.1, 129.9, 129.8, 127.8, 127.7, 69.7, 68.1, 66.5; CH0 δ 198.2, 171.9, 134.6, 
134.0, 98.5, 48.1, 19.6; IR (neat) 3072, 2955, 2853, 1735, 1682, 1613, 1588, 1515, 1463, 
1427, 1366, 1321, 1250, 1175, 1108, 1037, 832, 778, 740, 705, 611, 536, 509 cm-1;  
HRMS (ESI/TOF) calcd for C39H62NaO7Si2 (M+Na) 753.3653, found 753.3657. 
 
 
Preparation of (3R)-S-tert-butyl 3-((tert-butyldiphenylsilyl)oxy)-4-((2S,8S)-8-
hydroxy-10-methylene-1-oxaspiro[5.5]undecan-2-yl)butanethioate (3.13). Powdered 
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CeCl3·7H2O (917.3 mg, 2.462 mmol, 10.0 equiv) was placed in a 25 mL rb flask and 
heated to 170 ºC under 1 mm Hg vacuum. After 16 h at 170 ºC, the dried CeCl3 was 
cooled to rt, and the flask was purged with N2. THF (2.5 mL) was added, and the mixture 
was stirred at rt for 2 h.  
Meanwhile, a 25 mL three-necked rb flask equipped with condenser and magnetic 
stir bar was charged with magnesium turnings (124.0 mg, 5 mmol, 1.0 equiv), and a 
crystal of iodine. The flask was heated with a heat gun for 5 min while stirring. THF (5.0 
mL) was added via syringe, and the reaction mixture was heated with the heat gun to 
reflux. Chloromethyl trimethylsilane (0.613 g, 5.0 mmol, 1.0 equiv) was then added 
dropwise via syringe. The mixture was stirred at rt for 1.5 h to give an assumed 1.0 M 
solution of TMSCH2MgCl.  
The CeCl3/THF mixture was cooled to -78 ºC, and then a solution of 
TMSCH2MgCl (2.46 mL, 2.46 mmol, 10.0 equiv) was added dropwise via syringe. After 
1 h at -78 ºC, ester 3.12 (180.0 mg, 0.2462 mmol, 1.8 equiv) in THF (1.0 mL) was added 
via cannula. An additional THF (0.6 mL) rinse was used to transfer the remaining ester 
residue into the reaction mixture. The solution was allowed to warm to rt and stirred 
overnight. The mixture was then cooled to -78 ºC, and then was quenched by the addition 
of saturated aqueous NaHCO3 solution (5 mL). The reaction mixture was then allowed to 
warm to rt and the phases were separated. The aqueous phase was extracted with Et2O (3 
× 30 mL). The organic phases were combined, dried over Na2SO4, filtered, and 
concentrated under reduced pressure. The residue was dissolved in THF (10 mL), and the 
resulting solution was cooled to 0 ºC. Two drops of 1N HCl solution was added into flask 
with pipette. After 5 min at 0 ºC, the reaction mixture was quenched by the addition of 
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saturated aqueous NaHCO3 solution (2 mL). The reaction mixture was then allowed to 
warm to rt and the phases were separated. The aqueous phase was extracted with Et2O (3 
× 20 mL). The organic phases were combined, dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished by flash 
chromatography on a 3 × 12 cm column, eluting with 20% EtOAc/hexanes (1000 mL), 
collecting 18 × 150 mm test tube fractions. The product containing fractions (19-22) were 
combined and concentrated under reduced pressure to give the product 3.13 (93.6 mg, 
64%) as a colorless oil: Rf = 0.24  (20% EtOAc/hexanes); [ ] =20Dα -17.3 (c = 2.21, CHCl3); 
500 MHz 1H NMR (CDCl3) 1H NMR (CDCl3) δ 7.73-7.66 (m, 4H), 7.46-7.35 (m, 6H), 
4.75 (s, 1H), 4.55 (s, 1H), 4.24-4.17 (m, 1H), 4.00-3.92 (m, 1H), 3.04-2.97 (m, 1H), 2.88 
(dd, J = 15.1, 3.4 Hz, 1H), 2.71 (d, J = 14.2, Hz, 1H), 2.65 (dd, J = 15.6, 8.3 Hz, 1H), 
2.58 (dd, J = 12.2, 4.8 Hz, 1H), 1.93 (d, J = 11.7 Hz, 1H), 1.89-1.84 (m, 1H), 1.60-1.50 
(m, 3H), 1.47 (s, 9H), 1.47-1.42 (m, 2H), 1.32-1.24 (m, 6H), 1.10 (s, 9H);  125 MHz 13C 
NMR (CDCl3) 198.4, 142.5, 136., 126.1, 135.0, 124.0, 129.8, 129.6, 127.7, 127.6, 112.3, 
74.7, 70.2, 67.6, 53.2, 48.7, 47.9, 44.7, 44.2, 37.8, 35.8, 32.0, 30.1, 27.2, 19.6, 19.4; 125 
MHz DEPT (CDCl3) CH3 δ 30.1, 27.2; CH2 δ 112.3, 53.2, 48.7, 44.7, 44.2, 37.8, 35.8, 
32.0, 19.4; CH δ 136.2, 136.1, 129.8, 129.6, 127.7, 127.6, 70.2, 67.6, 67.3; CH0 δ 198.4, 
142.5, 135.0, 134.0, 74.7, 47.9, 19.6; IR (neat) 2954, 2853, 1741, 1681, 1611, 1513, 1430, 
1364, 1331, 1250, 1168, 1108, 1038, 841, 744, 704, 610, 536 cm-1; HRMS (ESI/TOF) 





Preparation of (3R,9S,11R)-methyl 11-(tert-butyldiphenylsilyloxy)-13-(tert-
butylthio)-9-(4-methoxybenzyloxy)-13-oxo-3,5-bis(trimethylsilyloxy)tridecanoate 
(3.15). To a stirring solution of ketone 3.14 (220.2 mg, 0.2504 mmol, 1.0 equiv) in 
MeOH (12.5 mL, 0.02 M) at rt was added CeCl3·7H2O (46.6 mg, 0.1252 mmol, 0.5 equiv) 
in one portion. The mixture was stirred at rt until all crystals had dissolved. Then the 
solution was cooled to 0 °C, NaBH4 (18.9 mg, 0.5008 mmol, 2.0 equiv) was added in one 
portion, and the mixture was stirred at 0 °C for 15 min and then quenched by the addition 
of saturated aqueous NH4Cl solution (2 mL). The mixture was extracted with 50% 
EtOAc/hexanes (3 × 25mL), and the combined organic phases were dried over Na2SO4, 
filtered, and concentrated under reduced pressure. The resulting crude product was 
carried into the next step without purification. 
To a stirring solution of the aforementioned intermediate alcohol (0.2504 mmol, 
1.0 equiv) in MeOH (12.5 mL, 0.02 M) at 0 °C was added CSA (116.3 mg, 0.5008 mmol, 
2.0 equiv) in one portion. The solution was stirred at 0 °C for 5 h, and then quenched by 
the addition of saturated aqueous NaHCO3 solution (10 mL). The mixture was then 
extracted with 50% EtOAc/hexanes (3 × 50 mL). The combined organic phases were 
dried over Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude 
product was carried into the next step without purification. 
To a stirring solution of the aforementioned intermediate alcohol (0.2504 mmol, 
1.0 equiv) in CH2Cl2 (12.5 mL, 0.02 M) at rt in a 50 mL rb flask was added NEt3 (506.7 
mg, 5.008 mmol, 20 equiv) and TMSCl (272.0 mg, 2.504 mmol, 10 equiv) via syringe. 
The mixture was stirred at rt overnight, and then quenched by the addition of saturated 
aqueous NaHCO3 solution (20 mL). The aqueous phase was separated and extracted with 
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CH2Cl2 (3 × 50 mL). The combined organic phases were dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  Purification was accomplished using a 3 × 16 cm 
flash chromatography, eluting with 10% EtOAc/hexanes (500 mL), collecting 18 × 150 
mm test tube fractions.  The product containing fractions (6-12) were combined and 
concentrated under reduced pressure to give the product 3.15 (191.5 mg, 84% over 3 
steps) as a clear colorless oil: Rf = 0.28 (10% EtOAc/hexanes); [ ] =20Dα    -17.3 (c = 2.21, 
CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.73-7.68 (m, 4H), 7.44-7.35 (m, 6H), 7.12 (d, J = 
8.8 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 4.37 (dddd, J = 6.3, 6.3, 5.9, 5.9 Hz, 1H), 4.25-4.20 
(m, 2H), 4.07 (d, J = 11.2 Hz, 1H), 3.80 (s, 3H), 3.69 (s, 3H), 3.28 (dddd, J = 9.8, 5.4, 5.4, 
5.4 Hz, 1H), 2.71 (dd, J = 14.6, 5.9 Hz, 1H), 2.62 (dd, J = 14.2, 5.9 Hz, 1H), 2.51 (dd, J = 
15.1, 4.4 Hz, 1H), 2.43 (dd, J = 15.1, 8.3 Hz, 1H), 1.79 (ddd, J = 20.5, 7.8, 6.3 Hz, 1H), 
1.65 (ddd, J = 13.7, 6.4, 6.4 Hz, 1H), 1.62-1.54 (m, 2H), 1.42 (s, 9H), 1.38-1.22 (m, 6H), 
1.05 (s, 9H), 0.12 (s, 9H), 0.11 (s, 9H); 125 MHz 13C NMR (CDCl3) δ197.8, 172.2, 159.1, 
136.1, 136.1, 134.1, 134.0, 131.1, 129.8, 129.8, 129.3, 127.8, 113.8, 76.1, 70.2, 69.6, 69.1, 
67.2, 55.4, 53.0, 51.7, 48.1, 45.8, 43.0, 42.6, 37.8, 34.6, 30.0, 27.2, 21.4, 19.6, 0.7, 0.5; 
125 MHz DEPT (CDCl3) CH3 δ 55.4, 51.7, 30.0, 27.2, 0.7, 0.5; CH2 δ 70.2, 53.0, 45.8, 
43.0, 42.6, 37.8, 34.6, 21.4; CH δ 136.1, 136.1, 129.8, 129.8, 129.3, 127.8, 113.8, 76.1, 
69.6, 69.1, 67.2; CH0 δ 197.8, 172.2, 159.1, 134.1, 134.0, 131.1, 48.1, 19.6; IR (neat) 
2954, 2859, 1741, 1682, 1613, 1513, 1430, 1364, 1301, 1250, 1168, 1108, 1038, 841, 744, 







Preparation of (3R,5S,11S)-S-tert-butyl 3-((tert-butyldiphenylsilyl)oxy)-9,11-
dihydroxy-5-((4-methoxybenzyl)oxy)-13-((trimethylsilyl)methyl)tetradec-13-
enethioate (3.16). Powdered CeCl3 ·7H2O (1.451 g, 3.895 mmol, 10.0 equiv) was placed 
in a 25 mL rb flask and heated to 170 ºC under 1 mm Hg vacuum. After 16 h at 170 ºC, 
the dried CeCl3 was cooled to rt, and the flask was purged with N2. THF (5.0 mL) was 
added, and the mixture was stirred at rt for 2 h.  
Meanwhile, a 25 mL three-necked rb flask equipped with condenser and magnetic 
stir bar was charged with magnesium turnings (124.0 mg, 5 mmol, 1.0 equiv), and a 
crystal of iodine. The flask was heated with a heat gun for 5 min while stirring. THF (5.0 
mL) was added via syringe, and the reaction mixture was heated with the heat gun to 
reflux. TMSCH2Cl (0.613 g, 5.0 mmol, 1.0 equiv) was then added dropwise via syringe. 
The mixture was stirred at rt for 1.5 h to give an assumed 1.0 M solution of 
TMSCH2MgCl.  
The CeCl3/THF mixture was cooled to -78 ºC, and then a solution of 
TMSCH2MgCl (3.895 mL of 1.0 M, 3.895 mmol, 10.0 equiv) was added to the mixture 
dropwise via syringe. After 1 h at -78 ºC, a solution of ester 3.15 (355.0 mg, 0.3895 
mmol, 1.0 equiv) in THF (1.6 mL) was added to the reaction mixture via cannula. 
Additional THF (2 × 0.6 mL) rinse was used to transfer the remaining ester residue into 
the reaction mixture. The mixture was allowed to warm to rt and stirred overnight, and 
then cooled to -78 ºC, and quenched by the addition of saturated aqueous NaHCO3 
solution (5 mL). The mixture was then allowed to warm to rt and the phases were 
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separated. The aqueous phase was extracted with Et2O (3 × 30 mL). The organic phases 
were combined, dried over Na2SO4, filtered, and concentrated under reduced pressure. 
The residue was dissolved in THF (10 mL), and the resulting solution was cooled to 0 ºC. 
Two drops of 1N HCl solution was added into the flask via pipette. After 5 min at 0 ºC, 
the reaction mixture was quenched by the addition of saturated aqueous NaHCO3 solution 
(2 mL). The reaction mixture was then allowed to warm to rt and the phases were 
separated. The aqueous phase was extracted with Et2O (3 × 20 mL). The organic phases 
were combined, dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash chromatography on a 3 × 14 cm column, eluting 
with 20% EtOAc/hexanes (1000 mL), collecting 18 × 150 mm test tube fractions. The 
product containing fractions (13-25) were combined and concentrated under reduced 
pressure to give the product 3.16  (159.1 mg, 51%) as a colorless oil: Rf = 0.59 (50% 
EtOAc/hexanes); [ ] =20Dα  -10.9 (c = 0.745, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.74-
7.67 (m, 4H), 7.44-7.34 (m, 6H), 7.12 (d, J = 8.8 Hz, 2H), 6.83 (d, J = 8.3 Hz, 2H), 4.71 
(s, 2H), 4.35 (dd, J = 6.4, 5.9 Hz, 1H),4.22 (d, J = 10.7 Hz, 1H), 4.08 ( d, J =11.2, Hz, 
1H), 3.98-3.92 (m, 1H), 3.80 (s, 3H), 3.79-3.74 (m, 1H), 3.30-3.22 (m, 2H), 2.78 (bs, 1H), 
2.70 (dd, J = 14.7, 6.3 Hz, 1H), 2.63 (dd, J = 14.6, 5.9 Hz, 1H), 2.12 (d, J = 5.9 Hz, 2H), 
1.79 (ddd, J = 14.2, 6.8, 6.8 Hz, 1H), 1.63-1.52 (m, 5H), 1.43 (s, 9H), 1.32-1.20 (m, 6H), 
1.04 (s, 9H), 0.05 (s, 9H);  125 MHz 13C NMR (CDCl3) 198.1, 159.2, 144.2, 136.2, 136.1, 
134.2, 134.0, 131.2, 129.9, 129.8, 129.4, 127.8, 127.8, 113.8, 110.8, 76.0, 72.6, 70.3, 70.1, 
69.2, 55.5, 52.9, 48.1, 47.3, 42.5, 38.1, 34.1, 30.0, 27.2, 27.0, 20.9, 19.6, -1.2; 125 MHz 
DEPT (CDCl3) CH3 δ 55.5, 30.0, 27.2, -1.2; CH2 δ 110.8, 70.1, 52.9, 47.3, 43.0, 42.5, 
38.1, 34.1, 27.0, 20.9; CH δ 136.2, 136.1, 129.9, 129.8, 129.4, 127.8, 127.8, 113.8, 76.0, 
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72.6, 70.3,  69.2; CH0 δ 198.1, 159.2, 144.2, 134.2, 134.0, 131.2, 48.1, 19.6; IR (neat) 
3459 (broad), 3070, 2932, 2858, 1717, 1683, 1641, 1613, 1513, 1460, 1428, 1363, 1301, 
1248, 1172, 1108, 1040, 850, 823, 739, 704, 610 cm-1;  HRMS (ESI/TOF) calcd for 






dienoate (3.18). This material was prepared from ketone 3.17 in the same manner as 
2.105. Purification was accomplished by flash chromatography on a 3 × 13 cm column, 
eluting with 10% EtOAc/hexanes (500 mL) and 15% EtOAc/hexanes (500 mL), 
collecting 18 × 150 mm test tube fractions. The product containing fractions (15-22) were 
combined and concentrated under reduced pressure to give the product 3.18 (86.7 mg, 87% 
over 2 steps) as a colorless oil: Rf = 0.54 (30% EtOAc/hexanes);  [ ] =20Dα  -9.4 (c = 0.34, 
CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.39-7.34 (m, 4H), 7.33-7.27 (m, 1H), 7.22 (d, J = 
8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 6.19-6.15 (m, 2H), 5.97 (d, J = 16.1 Hz, 1H), 5.91 
(s, 1H), 5.75 (d, J = 15.1 Hz, 1H), 5.48 (s, 1H), 5.37 (ddd, J = 15.6, 5.4, 5.4 Hz, 1H), 4.87 
(d, J = 2.4 Hz, 1H), 4.67 (d, J = 2.4 Hz, 1H), 4.62 (d, J = 10.7 Hz, 1H), 4.44 (d, J = 10.7 
Hz, 1H), 4.12 (dd, J = 6.3, 4.9 Hz, 1H), 4.10-4.03 (m, 3H), 3.90 (ddd, J = 10.3, 4.4, 2.0 
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Hz, 1H), 3.78 (s, 3H), 3.68 (s, 3H), 3.52 (dd, J = 15.1, 2.0 Hz, 1H), 3.25 (s, 3H), 2.37-
2.27 (m, 1H), 2.22-2.04 (m, 2H), 1.92 (ddd, J = 13.7, 9.5, 1.5 Hz, 1H), 1.74 (ddd, J = 
14.2, 10.3, 2.4 Hz, 1H), 1.52-1.42 (m, 3H), 1.23 (d, J = 6.4 Hz, 3H), 1.13 (s, 3H), 1.12 (s, 
3H), 0.93 (t, J = 7.3 Hz, 3H), 0.90 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H) ; 125 MHz 13C NMR 
(CDCl3); 166.7, 165.6, 159.3, 152.7, 146.5, 145.7, 138.1,138.1, 130.7, 129.5, 128.7, 
128.6, 128.0, 127.9, 125.0, 118.7, 117.5, 114.0, 102.9, 93.5, 77.0, 72.6, 72.1, 71.9, 69.6, 
68.4, 64.8, 55.4, 51.7, 51.3, 45.9, 36.5, 35.3, 32.7, 26.2, 24.5, 23.7, 22.0, 18.6, 15.0, 13.9, 
-4.8; 125 MHz DEPT (CDCl3) CH3 δ 55.4, 51.7, 51.3, 26.2, 24.5, 23.7, 15.0, 13.9, -4.8; 
CH2 δ 93.5, 72.1, 69.6, 64.8, 36.5, 35.3, 32.7, 22.0; CH δ 146.5, 145.7, 138.1, 138.1, 
129.5, 128.7, 128.6, 128.0, 127.9, 125.0, 118.7, 117.5, 114.0, 77.0, 72.6, 71.9, 68.4; CH0 
δ 166.7, 165.6, 159.3, 152.7, 130.7, 102,9, 45.9, 18.6; IR (neat) 2956, 2932, 1720, 1642, 
1614, 1514, 1462, 1382, 1302, 1250, 1132, 1106, 1043, 836, 777, 737, 698, 590, 536 cm-





methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl) octa-2,4-dienoate (3.19). To a 
stirring solution of the TBS ether 3.18 (36.8 mg, 0.0425 mmol, 1.0 equiv) in methanol 
(2.1 mL, 0.02 M) at 0 °C in a 25 mL rb flask was added CSA (2.0 mg, 0.0085 mmol, 0.2 
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equiv). The solution was stirred at 0 °C for 3 h, and then quenched by pipetting it into a 
mixture of saturated aqueous NaHCO3 solution (1 mL) and 50% EtOAc/hexanes (40 mL) 
in a separatory funnel. The aqueous phase was separated and extracted with 50% 
EtOAc/hexanes (3 × 25 mL). The combined organic phases were dried over Na2SO4, 
filtered, concentrated under reduced pressure.  Purification was accomplished by flash 
chromatography on a 2 × 14 cm column, eluting with 30% EtOAc/hexanes (500 mL), 
collecting 13 × 100 mm test tube fractions. The product containing fractions (14-30) were 
combined and concentrated under reduced pressure to give the product 3.19 (31.2 mg, 
98%) as a colorless oil: Rf = 0.18 (30% EtOAc/hexanes);  [ ] =20Dα  -20 (c = 0.20, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 7.40-7.34 (m, 4H), 7.33-7.28 (m, 1H), 7.22 (d, J = 8.3 Hz, 
2H), 6.85 (d, J = 7.8 Hz, 2H), 6.19 (s, 1H), 6.18 (d, J = 6.8 Hz, 1H), 5.99 (d, J = 16.1 Hz, 
1H), 5.91 (s, 1H), 5.76 (d, J = 15.1 Hz, 1H), 5.51 (s, 1H), 5.47 (ddd, J = 15.1, 5.4, 5.4 Hz, 
1H), 4.86 (d, J = 2.0 Hz, 2H), 4.68 (s, 2H), 4.62 (d, J = 11.2 Hz, 1H), 4.43 (d, J = 10.7 Hz, 
1H), 4.15 (dd, J = 6.5, 4.4 Hz, 1H), 4.10-4.04 (m, 1H), 4.01 (s, 2H), 3.92 (ddd, J = 9.8, 
4.4, 2.0 Hz, 1H), 3.79 (s, 3H), 3.68 (s, 3H), 3.49 (dd, J = 15.6, 2.4 Hz, 1H), 3.25 (s, 3H), 
2.36 (t, J = 13.7 Hz, 1H), 2.23-2.14 (m, 2H), 1.95 (ddd, J = 14.2, 9.8, 2.0 Hz, 1H), 1.75 
(ddd, J = 13.7, 10.3, 2.5 Hz, 1H), 1.52-1.41 (m, 3H), 1.23 (d, J = 6.4 Hz, 3H), 1.14 (s, 
3H), 1.11 (s, 3H), 0.94 (t, J = 7.3 Hz, 3H) ; 125 MHz 13C NMR (CDCl3); 166.8, 165.8, 
159.4, 152.6, 146.9, 146.2, 140.0, 138.1, 130.7, 129.5, 128.7, 128.5, 128.0, 128.0, 125.1, 
118.6, 117.5, 114.0, 102.9, 93.5, 76.9, 72.5, 72.0, 72.0, 69.7, 68.6, 64.5, 55.5, 51.6, 51.3, 
46.3, 36.4, 35.3, 32.9, 24.3, 22.1, 14.8, 13.9; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 51.6, 
51.3, 24.3, 14.8, 13.9; CH2 δ 93.5, 72.0, 69.7, 64.5, 36.4, 35.3, 32.9, 22.1; CH δ 146.9, 
146.2, 140.0, 129.5, 128.7, 128.5, 128.0, 128.0, 125.1, 118.6, 117.5, 114.0, 76.9, 72.5, 
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71.9, 68.6; CH0 δ 166.8, 165.8, 159.4, 152.6, 138.1, 130.7, 102,9, 72.0; IR (neat); 3484 
(b), 2932, 1717, 1642, 1614, 1513, 1459, 1382, 1302, 1249, 1134, 1106, 1041, 820, 739, 






-5-oxopent-3-en-2-yl)tetrahydro-2H-pyran-3-yl) octa-2,4-dienoate (3.5). This material 
was prepared from alcohol 3.19 in the same manner as 2.107. Purification was 
accomplished by flash chromatography on a 2 × 12 cm column, eluting with 20% 
EtOAc/hexanes (500 mL), collecting 13 × 100 mm test tube fractions. The product 
containing fractions (12-24) were combined and concentrated under reduced pressure to 
give the product 3.5 (26.4 mg, 85%) as a colorless oil: Rf = 0.59 (30% EtOAc/hexanes);  
[ ] =20Dα  -9 (c = 0.16, CHCl3); 500 MHz 1H NMR (CDCl3) δ 9.44 (d, J = 7.8 Hz, 1H), 
7.37-7.23 (m, 5H), 7.21 (d, J = 8.3 Hz, 2H), 7.22-7.16 (m, 1H), 6.85 (d, J = 8.3 Hz, 2H), 
6.12-6.08 (m, 2H), 5.91 (dd, J = 16.1, 7.8 Hz, 1H), 5.90 (s, 1H), 5.60 (s, 1H), 5.58 (d, J = 
15.6 Hz, 1H), 4.87 (t, J = 7.3 Hz, 1H), 4.85 (q, J = 7.8 Hz, 1H), 4.67 (s, 2H), 4.63 (d, J = 
11.2 Hz, 1H), 4.42 (d, J = 10.7 Hz, 1H), 4.17 (dd, J = 6.4, 4.4 Hz, 1H), 4.16-.411 (m, 1H), 
3.90 (ddd, J = 9.8, 3.9, 2.0 Hz, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 3.51 (dd, J = 16.1, 1.8 Hz, 
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1H), 3.27 (s, 3H), 2.44 (dd, J = 14.7, 13.2 Hz, 1H), 2.16 (q, J = 6.8 Hz, 2H), 1.97 (ddd, J 
= 14.2, 9.8, 2.0 Hz, 1H), 1.78 (ddd, J = 13.7, 10.3, 2.5 Hz, 1H), 1.47 (q, J = 7.3 Hz, 2H), 
1.27-1.20 (m, 1H), 1.24 (d, J = 6.4 Hz, 2H), 1.17 (s, 3H), 1.14 (s, 3H), 0.93 (t, J = 7.3 Hz, 
3H) ; 125 MHz 13C NMR (CDCl3); 194.7, 166.8, 166.4, 165.2, 159.4, 152.1, 147.4, 146.6, 
137.9, 130.5, 129.4, 128.6, 128.3, 127.9, 127.9, 127.2, 117.8, 117.4, 114.0, 102.8, 93.6, 
76.7, 72.2, 71.8, 70.7, 69.7, 69.0, 55.5, 51.4, 47.6, 36.3, 35.3, 33.4, 23.7, 22.3, 22.0, 14.7, 
13.9; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 51.4, 23.7, 22.3, 14.7, 13.9; CH2 δ 93.6, 71.8, 
69.7, 36.3, 35.3, 33.4, 22.0; CH δ 194.7, 166.8, 147.4, 146.6, 129.4, 128.6, 128.3, 127.9, 
127.9, 127.2, 117.8, 117.4, 114.0, 76.7, 72.2, 70.7, 69.0,; CH0 δ 166.4, 165.2, 159.4, 
152.1, 137.9, 130.5, 102.8, 47.6; IR (neat); 3484 (b), 2956, 1718, 1687, 1641, 1513. 1459, 
1381, 1302, 1248, 1133, 1042, 819, 739, 699, 589, 535 cm-1; HRMS (ESI/TOF) calcd for 




















xoethylidene) tetrahydro-2H-pyran-3-yl octa-2,4-dienoate (3.20). To a stirring 
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solution of hydroxyallylsilane 3.16 (8.1 mg, 0.0010 mmol, 1.1 equiv) and aldehyde 3.5 
(7.1 mg, 0.0095 mmol, 1.0 equiv) in Et2O (1.0 mL, 0.01M) in a 10 mL rb flask at -78 ºC 
was added a solution of TMSOTf in Et2O (34.2 μL of 1.0 M, 0.0342 mmol, 3.6 equiv) via 
syringe. After 1 h at -78 ºC, the reaction mixture was quenched by the addition of 
saturated aqueous NaHCO3 solution (2 mL). The mixture was warmed to rt, and then the 
aqueous phase was separated and extracted with Et2O (3 × 10 mL). The organic phases 
were combined, dried over Na2SO4, filtered, and concentrated under reduced pressure.  
Purification was accomplished by flash chromatography on a 2 × 15 cm column, eluting 
with 20% EtOAc/hexanes (500 mL), collecting 13 × 100 mm test tube fractions. The 
product containing fractions (28-37) were combined and concentrated under reduced 
pressure to give the product 3.20 (7.1 mg, 51% yield) as colorless oil: Rf = 0.45 ( 30% 
EtOAc/hexanes); [ ] =20Dα  -15 (c = 0.13, CHCl3);  500 MHz 1H NMR (CDCl3) δ 7.72-7.66 
(m, 4H), 7.42-7.30 (m, 13H), 7.21 (d, J = 8.3 Hz, 2H), 7.10 (d, J = 8.3 Hz, 2H), 6.85-6.79 
(m, 4H), 6.20-6.16 (m, 2H), 6.04 (d, J = 16.1 Hz, 1H), 5.90 (s, 1H), 5.77 (d, J = 15.6 Hz, 
1H), 5.52 (s, 1H), 5.35 (dd, J = 16.1, 6.4 Hz, 1H), 4.86 (s, 2H), 4.73 (d, J = 14.2 Hz, 2H), 
4.67 (d, J = 4.9 Hz, 2H), 4.62 (d, J = 10.7 Hz, 1H), 4.44 (d, J = 10.7 Hz, 1H), 4.34 (t, J = 
5.7 Hz, 1H), 4.21 (d, J =10.7 Hz, 1H), 4.14-4.08 (m, 2H), 4.05 (d, J = 10.7 Hz, 1H), 3.92-
3.86 (m, 1H), 3.80-3.70 (m, 4H), 3.79 (s, 3H), 3.78 (s, 3H), 3.67 (s, 3H), 3.54-3.46 (m, 
2H), 3.24 (s, 3H), 2.67 (dd, J = 15.6, 6.3 Hz, 1H), 2.61 (dd, J = 14.2, 5.9 Hz, 1H), 2.22-
2.12 (m, 4H), 2.04-1.88 (m, 4H), 1.79-1.70 (m, 2H), 1.65-1.45 (m, 9H), 1.41 (s, 9H), 1.23 
(d, J = 6.3 Hz, 3H), 1.11 (s, 3H), 1.10 (s, 3H), 1.02 (s, 9H), 0.92 (t, J = 7.3 Hz, 3H) ; 125 
MHz 13C NMR (CDCl3); 198.0, 166.7, 165.6, 159.3, 159.1, 152.8, 146.7, 146.0, 143.7, 
139.7, 138.1, 136.1, 134.2, 130.7, 129.9, 129.8, 129.5, 129.4, 128.7, 128.6, 128.0, 127.9, 
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127.8, 125.8, 118.6, 117.4, 114.0, 113.8, 109.4, 93.6, 79.9, 79.4, 77.1, 76.0, 72.8, 72.2, 
71.9, 70.1, 69.7, 69.1, 68.4, 55.5 (×2), 52.9, 51.7, 51.3, 48.1, 46.1, 42.6, 42.5, 41.1, 40.6, 
37.8, 36.6, 35.3, 34.3, 32.9, 30.0, 27.2, 24.5, 23.8, 22.1, 21.0, 19.6, 15.1, 14.0; 125 MHz 
DEPT (CDCl3) CH3 δ 55.5 ( ×2 ), 51.7, 51.4, 30.0, 27.2, 24.5, 23.9, 15.1, 14.0; CH2 δ 
109.4, 93.6, 72.2, 70.1, 69.7, 52.9, 42.6, 42.5, 41.1, 40.6, 37.8, 36.6, 35.3, 34.3, 32.9, 22.1, 
21.0; CH δ 146.7, 146.0, 139.7, 136.1, 129.9, 129.8, 129.5, 129.4, 128.7, 128.6, 
128.0,127.9, 127.8, 125.8, 118.6, 117.4, 114.0, 113.8, 79.9, 79.4, 77.1, 76.0, 72.8, 69.1, 
68.4; CH0 δ 198.0, 166.7, 165.6, 159.3, 159.1, 152.8, 143.7, 138.1,136.2, 134.2, 
134.0,131.2,130.7, 48.1, 46.1, 19.6; IR (neat); 3512, 2953, 1718, 1686, 1642, 1613, 1513, 
1460, 1362, 1302, 1248, 1107, 1042, 888, 831, 740 cm-1; HRMS (ESI/TOF) calcd for 





l) oxy)-10-(tert-butylthio)-6-((4-methoxybenzyl)oxy)-2,10-dioxodecyl)-4-methylene te 
trahydro-2H-pyran-2-yl)-2-methylbut-3-en-2-yl)-2-methoxy-4-(2-methoxy-2-oxoethy 
lidene)tetrahydro-2H-pyran-3-yl octa-2,4-dienoate (3.21) To a stirring solution of 
alcohol 3.20 in MeCN (0.778 mL, 0.005 M) was added TEMPO (18.2 mg, 0.117 mmol, 
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30 equiv) and diacetate iodobenene (37.7 mg, 0.117 mmol, 30 equiv). The reaction 
mixture was stirred at rt for 2 h, and then quenched by the addition of saturated aqueous 
NaHCO3 solution (1 mL). The aqueous phase was separated and extracted with Et2O (3 × 
10 mL). The organic phases were combined, dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  Purification was accomplished by flash 
chromatography on a 2 × 13 cm column, eluting with 20% EtOAc/hexanes (500 mL), 
collecting 13 × 100 mm test tube fractions. The product containing fractions (10-25) were 
combined and concentrated under reduced pressure to give the product 3.21 (4.7 mg, 83%) 
as colorless oil: Rf = 0.45 (30% EtOAc/hexanes); [ ] =20Dα -18 (c = 0.08, CHCl3);  500 
MHz 1H NMR (CDCl3) δ 7.72-7.66 (m, 4H), 7.42-7.30 (m, 13H), 7.21 (d, J = 8.3 Hz, 
2H), 7.10 (d, J = 8.3 Hz, 2H), 6.85-6.79 (m, 4H), 6.20-6.16 (m, 2H), 6.01 (d, J = 16.1 Hz, 
1H), 5.90 (s, 1H), 5.77 (d, J = 15.6 Hz, 1H), 5.52 (s, 1H), 5.35 (dd, J = 16.1, 6.0 Hz, 1H), 
4.86 (ABq, J = 7.3, Δν = 5.7 Hz, 2H),  4.73 (d, J = 14.2 Hz, 2H), 4.67 (d, J = 4.9 Hz, 2H), 
4.62 (d, J = 10.7 Hz, 1H), 4.43 (d, J = 10.7 Hz, 1H), 4.34 (t, J = 5.7 Hz, 1H), 4.21 (d, J 
=10.7 Hz, 1H), 4.14-4.08 (m, 2H), 4.04 (d, J = 10.7 Hz, 1H), 3.92-3.86 (m, 1H), 3.79 (s, 
3H), 3.78 (s, 3H), 3.74-3.68 (m, 3H), 3.66 (s, 3H), 3.3.47 (d, J = 4.7 Hz, 1H), 3.23 (s, 3H), 
2.68 (dt, J = 15.1, 5.9 Hz, 2H), 2.61 (dd, J = 14.2, 5.9 Hz, 1H), 2.40 (dd, J = 16.1, 6.4 Hz, 
2H), 2.25 (dd, J = 7.8, 4.4 Hz, 2H), 2.20-2.12 (m, 3H), 2.00-1.84 (m, 3H), 1.84-1.70 (m, 
3H), 1.59-1.44 (m, 5H), 1.42 (s, 9H), 1.23 (d, J = 6.3 Hz, 3H), 1.12 (s, 3H), 1.10 (s, 3H), 
1.02 (s, 9H), 0.94 (t, J = 7.3 Hz, 3H); 125 MHz 13C NMR (CDCl3); 208.6, 198.0, 166.7, 
165.7, 159.4, 159.1, 153.0, 146.8, 146.0, 143.8, 138.9, 138.1, 136.2, 126.1, 134.1, 134.0, 
131.1, 130.7, 129.9, 129.9, 129.5, 129.4, 128.7, 128.6, 128.0, 127.9, 127.8, 126.4, 118.6, 
117.0, 114.0, 113.8, 109.5, 102.8, 93.6, 79.3, 75.7, 74.5, 72.6, 72.1, 71.6, 70.1, 69.7, 69.1, 
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68.3, 55.5, 52.9, 51.5, 51.3, 49.2, 48.2, 46.2, 44.0, 42.4, 40.6, 40.5, 36.4, 35.2, 33.4, 29.9, 
27.1, 24.2, 24.0, 22.0, 19.1, 14.9, 13.9; 125 MHz DEPT (CDCl3) CH3 δ 55.5 51.4, 51.3, 
30.0, 27.1, 24.3, 24.0, 14.9, 13.9; CH2 δ 109.5, 93.6, 72.1, 70.1, 69.7, 52.9, 49.2, 43.9, 
42.4, 40.6, 40.5, 36.4, 35.3, 33.5, 33.2,  22.1, 19.1; CH δ 146.8, 146.1, 138.9, 136.1, 
129.9, 129.9, 129.5, 129.4, 128.7, 128.6, 128.0, 127.9, 127.8, 126.3, 118.6, 117.0, 114.0, 
113.8, 79.3, 75.7, 74.5, 72.6, 71.6, 69.0, 68.3; CH0 δ 208.6, 198.0, 166.7, 165.7, 159.4, 
159.1, 153.0, 143.8, 138.1, 134.1, 134.0, 131.1, 130.7, 48.2, 46.2, 19.1; IR (neat); 2929, 





-3-en-2-yl)tetrahydro-2H-pyran-3-yl octa-2,4-dienoate (3.28) To a stirring solution of 
PMB ether 3.5 (13.4 mg, 0.0179 mmol, 1.0 equiv) in CH2Cl2 (1.2 mL, 0.015 M) in a 10 
mL rb flask at 0 ºC was added tert-butyl alcohol (0.6 mL) and aqueous pH 7 buffer (0.6 
mL) and DDQ (40.6 mg, 0.179 mmol, 10.0 equiv). The reaction mixture was stirred at 0 
ºC for 5 h, and then quenched by the addition of saturated aqueous NaHCO3 solution (2 
mL). After being stirred vigorously for 10 min at rt, the aqueous phase was separated and 
extracted with CH2Cl2 (3 × 25 mL). The combined organic phases were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
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accomplished by flash chromatography on a 2 × 13 cm column, eluting with 30% 
EtOAc/hexanes (500 mL), collecting 13 × 100 mm test tube fractions. The product 
containing fractions (19-35) were combined and concentrated under reduced pressure to 
give the product 3.28 (8.0 mg, 83%) as colorless oil: Rf = 0.29 (30% EtOAc/hexanes); 
[ ] =20Dα -20 (c = 0.18, CHCl3);  500 MHz 1H NMR (CDCl3) δ 9.48 (d, J = 7.8 Hz,1H), 
7.38 -7.30 (m, 5H), 7.19 (dd, J = 15.1, 9.8 Hz, 1H), 6.16-6.11 (m, 2H), 5.92 (dd, J = 16.1, 
7.8 Hz, 1H), 5.90 (s, 1H), 5.64 (s, 1H), 5.58 (d, J = 15.6 Hz, 1H), 4.86 (d, J = 6.8 Hz, 1H), 
4.68 (ABq, J = 11.7 Hz, Δν = 17.5 Hz, 2H), 4.35-4.28 (m, 1H), 3.90-3.83 (m 1H), 3.70 (s, 
3H), 3.70-3.67 (m, 1H), 3.65 (t, J = 6.4 Hz, 1H), 3.50-3.45 (m, 1H), 3.46 (s, 3H), 2.71 (d, 
J = 4.4 Hz, 1H), 2.46 (dd, J = 14.2, 13.7 Hz, 1H), 2.16 (dd, J = 13.2, 6.8 Hz, 2H), 1.77-
1.72 (m, 2H), 1.47 (ddddd, J = 7.3, 7.3, 7.3, 7.3, 7.3 Hz, 2H), 1.28 (d, J = 6.4 Hz, 3H), 
1.20 (s, 3H), 1.16 (s, 3H), 0.93 (t, J = 7.3 Hz, 3H); 125 MHz 13C NMR (CDCl3) 195.0, 
167.1, 166.6, 165.3, 152.4, 147.6, 146.7, 137.6, 128.8, 128.4, 128.1, 128.1, 127.1, 117.8, 
117.2, 102.8, 94.0, 78.3; 125 MHz DEPT (CDCl3) CH3 δ 51.4, 51.4, 23.7, 22.4, 17.1, 
13.9; CH2 δ 94.0, 70.2, 39.9, 35.3, 33.4, 22.0; CH δ 195.0, 167.1, 147.6, 146.7, 128.8, 
128.4, 128.1, 128.1, 127.1, 117.8, 117.2, 78.3, 71.2, 70.8, 68.5; CH0 δ 166.6, 165.3, 152.4, 
137.6, 102.8, 47.6; IR (neat); 3507, 2952, 2929, 2875, 2724, 1716, 1685, 1496, 1455, 
1433, 1241, 1214, 1176, 1103, 1040, 1004, 857, 783, 742 cm-1; HRMS (ESI/TOF) calcd 






(4-methoxybenzyloxy)-13-((trimethylsilyl)methyl)tetradec-13-enoic acid (3.29). To a 
stirring solution of thiolester 3.16 (36.7 mg, 0.0455 mmol, 1.0 equiv) in a mixture of 4:1 
THF/H2O (4.6 mL, 0.01 M) in a 25 mL rb flask at 0 ºC was added LiOH•H2O (19.1 mg, 
0.455 mmol, 10 equiv) and H2O2 (103 μL, 0.910 mmol, 20 equiv). The mixture was stirred 
at 0 °C for 1 h, and then warmed to rt and stirred overnight. The mixture was diluted with 
50% EtOAc/hexanes (20 mL), quenched by the addition of pH 4 buffer solution (5 mL). 
The aqueous phase was separated and extracted with EtOAc (3 × 10 mL). The combined 
organic phases were dried over Na2SO4, filtered, and concentrated under reduced 
pressure to give the crude product. Purification was accomplished by flash 
chromatography on a 2 × 16 cm column, eluting with 5% MeOH/15% EtOAc/hexanes 
(500 mL), collecting 13 × 100 mm test tube fractions. The product containing fractions 
(10-12) were combined and concentrated under reduced pressure to give the product 3.29 
(28.5 mg, 85%) as a colorless oil: Rf = 0.31 (5% MeOH/30% EtOAc/hexanes), [ ] =20Dα  
+1 (c = 0.14, CHCl3);  500 MHz 1H NMR (CDCl3) δ 7.72-7.65 (m, 4H), 7.45-7.30 (m, 
6H), 7.10 (d, J = 8.3 Hz, 2H), 6.82 (d, J = 8.3 Hz, 2H), 4.70 (s, 2H), 4.30-4.20 (m, 2H), 
4.05 (d, J = 10.7 Hz, 1H), 3.92-3.82 (m, 1H), 3.81-3.77 (m, 2H), 3.78 (s, 3H), 3.29-3.24 
(m, 1H), 2.57 (dd, J = 15.1, 5.9 Hz, 1H), 2.53 (dd, J = 15.1, 5.4 Hz, 1H), 2.16-2.06 (m, 
2H), 1.88-1.78 (m, 1H), 1.68 (dt, J = 14.2, 5.4 Hz, 1H), 1.60-1.48 (m, 5H), 1.48-1.28 (m, 
7H), 1.04 (s, 9H), 0.04 (s, 9H); 125 MHz 13C NMR (CDCl3) 175.1, 159.2, 144.1, 136.1, 
136.1, 135.2, 133.8, 133.6, 130.7, 130.0, 129.5, 127.9, 114.0, 110.8, 75.9, 72.5, 70.2, 68.9, 
66.4, 55.4, 47.3, 42.9, 42.7, 37.9, 33.8, 27.1, 26.9, 20.7, 19.5, -1.2; 125 MHz DEPT 
(CDCl3) CH3 δ 55.4, 27.1, -1.2; CH2 δ 110.8, 70.2, 47.3, 42.9, 42.7, 42.2, 37.9, 33.8, 26.9, 
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20.7; CH δ 136.1, 136.1, 130.0, 129.6, 129.5, 127.9, 113.9, 75.9, 72.5, 70.2, 68.9; CH0 δ 
175.1, 159.2, 144.1, 135.2, 133.8, 19.5; IR (neat); 3379, 3071, 2932, 2857, 1712, 1612, 
1561, 1248, 1172, 1110, 847, 822, 704 cm-1. 
 
 
Preparation of (3R,5S,11S)-3-((tert-butyldiphenylsilyl)oxy)-5-((4-methoxyben 
zyl)oxy)-9,11-bis((triethylsilyl)oxy)-13-((trimethylsilyl)methyl)tetradec-13-enoic acid 
(3.30). To a stirring solution of alcohol 3.29 (8.8 mg, 0.012 mmol, 1.0 equiv) in CH2Cl2 
(0.6 mL, 0.02 M) at 0 °C was added imidazole (8.2 mg, 0.12 mmol, 10 equiv) and TESCl 
(9.0 mg, 0.060 mmol, 5 equiv) via syringe. The mixture was stirred at 0 °C for 1 h, and 
then diluted with CH2Cl2 (5 mL), and quenched by the addition of saturated aqueous 
NH4Cl solution (5 mL). The aqueous phase was separated and extracted with CH2Cl2 (3 × 
15 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated 
under reduced pressure to give the crude product. Purification was accomplished by flash 
chromatography on a 2 × 15 cm column, eluting with 20% EtOAc/hexanes (500 mL), 
collecting 13 × 100 mm test tube fractions. The product containing fractions (9-20) were 
combined and concentrated under reduced pressure to give the product 3.30 (8.6 mg, 75%) 
as a colorless oil: Rf = 0.23 (20% EtOAc/hexanes), [ ] =20Dα  +7.6 (c = 0.18, CHCl3); 500 
MHz 1H NMR (CDCl3) δ 7.72-7.65 (m, 4H), 7.45-7.30 (m, 6H), 7.10 (d, J = 8.3 Hz, 2H), 
6.82 (d, J = 8.3 Hz, 2H), 4.65-4.58 (m, 2H), 4.30-4.25 (m, 2H), 4.01 (d, J = 10.7 Hz, 1H), 
3.91-3.86 (m, 1H), 3.81-3.77 (m, 1H), 3.79 (s, 3H), 3.28-3.20 (m, 1H), 2.58 (dd, J = 9.8, 
5.4 Hz, 1H), 2.50 (dd, J = 15.1, 5.4 Hz, 1H), 2.20 (ddd, J =32.7, 13.7, 5.3 Hz, 1H), 2.07 
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(ddd, J = 15.615.6, 7.8 Hz, 1H), 1.86-1.78 (m, 1H), 1.72-1.62 (m, 2H), 1.60-1.48 (m, 3H), 
1.46-1.15 (m, 6H), 1.05 (s, 9H), 0.98 (t, J = 8.3 Hz, 9H), 0.97 (t, J = 8.3 Hz, 9H), 0.61 (q, 
J = 7.8 Hz, 6H), 0.60 (q, J = 7.8 Hz, 6H), 0.04 (s, 9H); 125 MHz 13C NMR (CDCl3) 
176.4, 159.2, 144.3, 136.2, 136.1, 133.8, 133.8, 130.9, 130.0, 129.4, 127.9, 127.8, 113.9, 
110.2, 110.2, 76.3, 70.2, 69.7, 69.3, 69.0, 68.9, 55.4, 47.4, 47.0, 45.5, 45.2, 42.9, 42.6, 
38.6, 37.5, 34.7, 34.5, 29.9, 27.5, 27.3, 27.1, 27.1, 20.9, 19.5, 7.3, 7.2, 5.6, 5.4,  -1.2; 125 
MHz DEPT (CDCl3) CH3 δ 55.4, 27.1, 7.2, 7.2, -1.2; CH2 δ 110.1, 70.2, 47.3, 42.9, 42.7, 
42.2, 37.9, 33.8, 26.9, 21.0, 5.6, 5.3; CH δ 136.1, 136.1, 130.0, 129.6, 129.5, 127.9, 113.9, 
75.9, 72.5, 70.2, 68.9; CH0 δ 175.1, 159.2, 144.1, 135.2, 133.8, 19.5; IR (neat) 2932, 
2867, 1712, 1611,1563, 1248, 1172, 1110, 847, 822, 704 cm-1; HRMS (ESI/TOF) calcd 





((2E,4E)-octa-2,4-dienoyloxy) tetrahydro-2H-pyran-2-yl)butan-2-yl 3-((tert-butyldi 
phenylsilyl)oxy)-5-((4-methoxybenzyl) oxy)-9,11-bis((triethylsilyl)oxy)-13-((trimethyl 
silyl) methyl) tetradec-13-enoate (3.31). To a stirring solution of carboxylic acid 3.30 
235 
 
(9.1 mg, 0.0094 mmol, 1.1 equiv) in toluene (0.86 mL) at rt was added triethylamine (4.4 
mg, 0.043 mmol, 5.0 equiv) and 2,4,6-trichlorobenzoyl chloride (2.5 mg, 0.010 mmol, 
1.2 equiv). The mixture was stirred at rt for 3 h. A solution of alcohol 3.28 (5.4 mg, 
0.0086 mmol, 1.0 equiv) in toluene (0.4 mL) was added via syringe. The residue of 
alcohol was rinsed with toluene (2 × 0.2 mL ) and the solutions were transferred to the 
reaction flask via syringe. DMAP (2.8 mg, 0.023 mmol, 2.7 equiv) was added in one 
portion. The mixture was stirred at rt for 0.5 h. Purification was accomplished by flash 
chromatography on a 2 × 12 cm column, eluting with 15% EtOAc/hexanes (500 mL), 
collecting 13 × 100 mm test tube fractions. The product containing fractions (8-13) were 
combined and concentrated under reduced pressure to give the product 3.31 (11.3 mg, 
84%) as a colorless oil: Rf = 0.61 (30% EtOAc/hexanes);  [ ] =20Dα  -6 (c = 0.16, CHCl3); 
500 MHz 1H NMR (CDCl3) δ 9.44 (d, J = 7.3 Hz, 1H), 7.70-7.66 (m, 2H), 7.45-7.32 (m, 
8H), 7.30-7.20 (m, 5H), 7.17 (dd, J = 15.6, 9.8 Hz, 1H), 7.06 (d, J = 8.8 Hz, 2H), 6.82 (d, 
J = 8.8 Hz, 2H), 6.18-6.10 (m, 2H), 5.93 (s, 1H), 5.85 (dd, J = 16.1, 7.8 Hz, 1H), 5.54 (d, 
J = 15.1 Hz, 1H), 5.44 (s, 1H), 5.31-5.26 (m, 1H), 4.75 (s, 2H), 4.68-4.57 (m, 2H), 4.61 
(s, 2H), 4.41-4.35 (m, 1H), 4.31 (d, J = 10.8 Hz, 1H), 4.01 (dd, J = 10.7, 5.9 Hz, 1H), 
3.19-3.82 (m, 2H), 3.79 (s, 3H), 3.82-3.68 (m, 4H), 3.70 (s, 3H), 3.54 (d, J = 15.6 Hz, 
1H), 3.51-3.44 (m, 1H), 3.11 (s, 3H), 2.47 (dd, J = 15.1, 5.4 Hz, 1H), 2.40 (dd, J = 15.1, 
7.8 Hz, 1H), 2.31 (dd, J = 13.7, 13.2 Hz, 1H), 2.16 (ABq, J = 6.8 Hz, Δν = 12.2 Hz, 2H), 
2.10-2.04 (m,1H), 1.93 (td, J = 12.2, 2.4 Hz, 1H), 1.80-1.74 (m, 1H), 1.72-1.64 (m, 2H), 
1.60-1.52 (m, 3H), 1.50-1.40 (m, 5H), 1.38-1.22 (m, 5H), 1.12 (s, 3H), 1.09 (s, 3H), 1.04 
(d, J = 6.4 Hz, 3H), 1.02 (s, 9H), 1.00-0.94 (m, 18H), 0.60 (q, J = 7.8 Hz, 12 H), 0.03 (s, 
9H); 125 MHz 13C NMR (CDCl3) 195.0, 170.5, 166.8, 166.6, 165.2, 159.1, 151.5, 147.5, 
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146.7, 144.3, 137.9, 136.1, 134.0, 133.8, 131.3, 130.0, 129.2, 128.7, 128.3, 128.0, 127.9, 
127.8, 126.9, 118.1, 117.8, 113.7,110.2, 93.7, 76.1, 73.0, 71.1, 70.3, 70.1, 69.8, 69.3, 69.0, 
68.4, 68.1, 55.5, 51.4, 51.3, 47.3, 47.0, 45.5, 45.3, 43.6, 43.0, 38.7, 37.6, 35.3, 34.8, 32.5, 
31.8, 27.1, 23.8, 22.1, 21.2, 19.5, 15.4, 13.9, 7.3, 7.2, 5.7, 5.4, -1.2; 125 MHz DEPT 
(CDCl3) CH3 δ 55.4, 51.4, 51.3, 27.0, 23.8, 22.0, 15.3, 13.9, 7.3, 7.2, -1.2; CH2 δ 110.1, 
93.6, 70.1, 69.7, 47.3, 47.0, 45.2, 43.5, 43.0, 38.6, 37.6, 35.5, 35.3, 32.4, 22.0, 21.2, 5.7, 
5.4; CH δ 195.0, 166.7, 147.5, 146.7, 136.1, 129.9, 129.2, 128.6, 128.3, 128.0, 127.9, 
127.8, 126.9, 118.1, 117.8, 113.7, 76.0, 73.0, 71.1, 70.3, 69.3, 68.9, 68.4, 68.1; CH0 δ 
170.5, 166.8, 165.2, 159.1, 151.5, 144.3, 137.9, 134.0, 133.9, 131.3,  45.5, 19.5; IR (neat) 
2952, 2911, 2876, 1720, 1688, 1246, 1106, 1042, 1005, 854, 740, 481 cm-1; HRMS 
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2.43 13C NMR (125 MHz, CDCI3) 
~ >, ...... , , , 
. "". ... '" i I . , '" ' 
' I [11 I I I" r r 1'1 I I I r 1 T I I ' I 1' 1 1'1 r I ' I I I I r 1 I r I' I I r I I 1 I I I' I I I I' I 1 '1' 1' 1 I T I I I II I I I [' I I I II I I I I ' I I I (' r 1 I 1 '1 I r]' r I I I" r r]' I I I I 
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O OTBDPS CDCI ) 





a l l protonatad carbons 
'I [11 I I I" r r 1'1 I I I r 1 T I I' I 1'1 1'1 r I' I I I I r 1 I r I' I I r I I 1 I I I' I I I I' I 1'1'1' 1 IT I I I II I I I [' I I I II I I I I' I I I (' r 1 I 1'1 I r]' r I I I" r r]' I I I I 































2.2 13C NMR (125 MHz, CDCI3) 
I 
." . II 
.' . ' 
" 
'I [11 I I I" r r 1'1 I I I r 1 T I I' I 1'1 1'1 r I' I I I I r 1 I r I' I I r I I 1 I I I' I I I I' I 1'1'1' 1 IT I I I II I I I [' I I I II I I I I' I I I (' r 1 I 1'1 I r]' r I I I" r r]' I I I I 









all protonatad carbons 
I r I I II I I I I r I 1 I I' I I' [' I I I ]1 I I I I r 1 I 1 1'1 I r 111 I I II I I I I' I rIll I I I I' I rIll I I I [' 11 I I T 1'1 II I I I (I r 1 I I' r I I I' r r I I' I I I I' I I I I' 1 I I I' T 














2.44 13C NMR (125 MHz, CDCI3) 
--. ---------~--- ---~--
'I [11 I I I" r r 1'1 I I I r 1 T I I' I 1'1 1'1 r I' I I I I r 1 I r I' I I r I 111 I I' I I I I' I 1'1'1' 1 IT I I I II I I I [' I I I II I I I I' I I I (' r 1 I 1'1 I r I' r I I I" r r]' I I I I 
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all protonatad carbons 
I I 
I I' I I I I I I I 1 II I I I I r I I I II I I I l' I I I I' r I I I' T I I I' I I r I' I I I 1'1 r 1 I' I I I IT I rIll I I I [' I I I [' I I I I' I I I I' I 1 I I' I 1 I I' I I I 11'11 I' I I 1 1'1 I I I r 




































2.45 13C NMR (125 MHz, CDCI3) 
J .L 
[ ' r r I II I r 'I r I 11 I' r 'I I' I I I I I I I I I'll I I' Til ]' I I I I' I TIl' I I 1 I I I I I (I 111 I' I I I ]' I I I (' I 1 1 I' I I I I' I I I (' I 1 I 1'1 I I I' r I I I' I I 1 I' I I I I 








a l l protonatad carbons 
2.45 DEPT NMR (125 MHz, CDCI3) 
1 ill ] 
,r 111 I I I" I I I' I I I I r III II I I I I ' 1'1 I' 1 r I I' I I I 11 II I 1'1 1'1'1'1 I' r 1'1'" I I r I I I I' I 1 r III I 'II 1 I II" I I I' 1 I I I' I 1 I I' I I I I' I II 11'1'11 I II I' I 















































































o OTBDPS ~ 246 DEPT NMR (125 MHz, CDCI3) H OPMB • 
ca3 carbona 
ca2 carbona 
l I l j , 
eM oar»oa.a 
J l 
all protonatad carbons 
I I l Il I 
I I' r I I I' I r I I' I I I (' I 1 I I' I I I)' I I I I r I I I I' I I I 1'1 I I I' r I I I' T r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1'1 I I I T 1'1 I' I I I I' 1 I I I' I 






































2.14 13C NMR (125 MHz, CDCI3) 
,[ I I 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I II I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I I I I I I r r 1 I I I 1 r 1 I r I I I I I I 'I 1'1 I I I' I I I [I 1 I I I 









all protonatad carbons 
2.14 DEPT NMR (125 MHz, CDCI3) 
.I I I I ,I 
I I' r I I I' I r I I' I I I (' I 1 I I' I I I)' I I I I r I I I I' I I I 1'1 I I I' r I I I' T r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1'1 I I I T 1'1 I' I I I I' 1 I I I' I 
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2.48 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona 
. ' . ~; . t i ' " 4 , If l If .:06 t *. ' , '4 i" '. if d h, .:wI t • " 4' I W4 
ca2 carbona 
eM oar»oa.a 
all protonatad carbons 
I I' r I I I' I r I I' I I I (' ill I' I I I)' I I I I r I I I I' I I I 1'1 I I I' r I I I' T r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1'1 I I I T 1'1 I' I I i I' 1 I I I' I 
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0 0 OBn 
EtO~ 
2.41 13C NMR (125 MHz, CDCI3) 
, , .. . . . . J J l.l J ' .U. ,H. 
, . .. 
[ ' r r I II I r 'I r I 11 I' r 'I I' I I I I I I I I I'll I I' Til ]' I I I I' I TIl' I I 1 I I I I I (I 111 I' I I I ]' I I I (' I 1 1 I' I I I I' I I I (' I 1 I 1'1 I I I' r I I I' I I 1 I' I I I I 
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o 0 OBn 
EtO~ 
2.41 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona 
J 




all protonatad carbons 
I 
,r 111 I I I" I I I' I I I I r III II I I I I ' 1'1 I' 1 r I I' I I I 11 II I 1'1 1'1'1'1 I' r 1'1'" I I r I I I I' I 1 r III I 'II 1 I II" I I I' 1 I I I' I 1 I I' I I I I' I II 11'1'11 I II I' I 
































0 OH OBn 
Eto~ 
2.49 13C NMR (125 MHz, CDCI3) 
J_ _l. _1 
[ ' r r I II I r 'I r I 11 I ' r 'I I ' I I I I I I I I I 'll I I' Ti l ]' I I I I ' I T I I ' I I 1 I I I I I ( I I r 1 I ' I I I ]' I I I ( ' I 11 I' I I I I ' I I I ( ' I 1 I 1 ' 1 I I I' r I I I' I I 1 I' I I I I 
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?i 9H 9Bn 
EtO~






all protonatad carbons 
11 [' I I I I' I I r I' I II II I I r I' I I I I' I I I, r I I T I' I I r I' I I I I' r r 1, I II I I r 11 I II 11 I]' I I I IT I I I I' II I, III I II I r I r I 1 I I I' I I I I' II I I r I 1 1I1I 1'111 I II' T 

































































































o -II ~ ~Bn 
EtO~ 
ca3 carbona 
2.50 DEPT NMR (125 MHz, CDCI3) 
ca2 carbona 
a~_~ II --------~] " 1 
on .~'o .. h' o~ ] LlJ LLJ j L 
I I' r I I I' I r I I' I I I (' I 1 I I' I I I)' I I I I r I I I I' I I I 1'1 I I I' r I I I' T r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1'1 I I I T 1'1 I' I I I I' 1 I I I' I 
































2.40 13C NMR (125 MHz, CDCI3) 
> , , 
~'" '.- - , 
[ ' r 1 I II I I I 1 r 1 I I I' I I I 1 I I I I I' I I I I' 1 I I I I I I I I' I I I I'll r I' I I T 111 I I)' r I 1 I' I I I I I I 11 I I I r I [' r I I II Til 11 I I I I' I 11 I' I r I I' r I I I' I 1 I 11 I I I I 








all protonated carbona 
I rill I] I" I I I' I I I I r III II I I I IT I I I I' 1 r I I' I I I 11 II I 1'1 1'1'1 I I I' r 1'1'1 I I I r I I I I' I 1 r III I 'II 1 I II' I I I I' 1 I I I' I 1 I I' I I I I' I II II I I I 11 I II I' I 












































2.39 13C NMR (125 MHz, CDCI3) 
1 • '" l ~ .1 1 
.. .~ 
[ ' r I I II I I I 1 r 1 I I I' I I I 1 I I I I I' I I I I' 1 I I I' I I I I r I I I I'll r I' I I T 1' 1 I I)' I I 1 I' I I I I I I I I I I I r I [' r I I I' Til I' I I I I' I 1 1 I' I I I I' 1 I I II I 1 I I' I I I I 




OTBDPS 2.39 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona OPMB 
ca2 carbona 
I ~ I I I I . "I I 
eM oarl:>oa.a 
j I I I. • 
all protonatad carbons 
I r I' 1 I I I" I I I' I I I I [ 1 1 I II I I I I I I II I' 1 r I I' I I I 11 II I 1 ' 1 I I I ' I I I I' r I I I" I I I r II I I 'll r I I I I 'I I r I II ' II ' I ' I I I I ' 11 I I' I I I I ' I 1 1 I ' I I I II ' I I I' I 






































2.51 13C NMR (125 MHz, CDCI3) 




OH 2.51 DEPT NMR (125 MHz, CDCI3) 
OPMB 
ca3 aarbona 
_____ _________ _ ._ _.. . .. _ .. _IL __ ... _ ~ ___ l . .___ 
ca2 aarbona 
L ~_ .. __ _ .... ___ _ .... L__ L .. l ___ .. [J _______ .... _~ ... i 
,.-.~---.--.--.-----.---.-. ----.-- .---' 
eM oar»oa.. 
U •• ~'o .. hOo~ , . . I II , 1,1111, ~ 1,1 
I rill I] I" I I I' I I I I r III II I I I IT I I I I' 1 r I I' I I I 11 II I 1'1 1'1'1 I I I' r 1'1'1 I I I r I I I I' I 1 r III I 'II 1 I II' I I I I' 1 I I I' I 1 I I' I I I I' I II II I I I 11 I II I' I 









































o OH 0 
OTBOPS 
OPMB 
2.52 13C NMR (125 MHz, CDCI3) 
[ ' r 1 I II I I I 1 r 1 I I I' I I I 1 I I I I I' I I I I' 1 I I I I I I I I r I I I I'll r I' I I T 1' 1 I I)' I I 1 I' I I I I I I 11 I I I r I [' r I I I' Til I' I I I I' I 1 1 I' I r I I' I I I II I 1 I I' I I I I 




OTBOPS 2.52 DEPT NMR (125 MHz, CDCI3) 




&11 protonatad carbons 
I I' r I I I' I r I I' I 1 I II I 1 r I' I I I)' I I I I r I I I I' I I I I' I I I I' r I I I' I r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1'1 I I I T 1'1)' I I r I' 1 I I I' I 












































2.53 13C NMR (125 MHz, CDCI 3) 
.. .tc " . , . . r> . 




[ ' r 1 I II I I I 1 r 1 I I I' I I I 1 I I I I I' I I I I' 1 I I I I I I I I' I I I I'll r I' I I T 111 I I)' r I 1 I' I I I I I I 11 I I I r I [' r I I II Til 11 I I I I' I 11 I' I r I I' r I I I' I 1 I 11 I I I I 









l . l lKL t . 
eM oarl:>oa.a 
&11 protonatad carbons 
I I' r I I I' I I I I' I I J II I 1 r I' I I I)' I I I I r I I I I' I I I II I I I I' r I I I' T r 1 I' I I I 1'1 I I I' I I I I' I I I (I I r 1 [I I I I I' I I I)' I 1'1'1 I I I T 1'1 I J I I I I' 1 I I I' I 
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[ ' r 1 I II I I I 1 r 1 I I I' I I I 1 I I I I I' I I I I' 1 I I I I I I I I r I I I I'll r I' I I T 1'1 I I)' I I 1 I' I I I I I I 11 I I I r I [' r I I I' Til I' I I I I' I 11 I' I r I I' I I I II I 1 I I' I I I I 









I II I I all protonatad carbons l l J.ULlI-lI..........J.....JlLI[[ L...............L~_~ 
I l I I Jl I 
I I' r I I I' I r I I' I 1 I II I 1 r I' I I I)' I I I I r I I I I' I I I I' I I I I' r I I I' I r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1'1 I I I T 1'1)' I I r I' 1 I I I' I 








































EtO. /'... /'... /'... .... D 
° I ° OTMS 
""OTBDPS 
OPMB 
2.54 13C NMR (125 MHz, CDCI3) 
j 
.I 
[ ' r I I II I I I 1 r 1 I I I' I I I 1 I I I I I' I I I I' 1 I I I' I I I I r I I I I'll I I' I I T 1'1 I I I' r I 1 I' I I I I I I I I I' I r I [' r I I I' Til I' I I I I' I 11 I' I I I I' I I I II I 11 I' I I I I 




OTBDPS 2.54 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona OPMB 
ca2 carbona 
eM oar»oa.a 
all protonatad carbons 
ttl I I I III I 
I I' r I I I' I I I I' I I I (' I 1 I I' I I I)' I I I I r I I I (' I I I 1'1 I I I' r I I I' T r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1'1 I I I T 1'1 I' I I I I' 1 I I I' I 












































2.55 13C NMR (125 MHz, CDCI3) 
J 
'w [ ' r I I II I I I 1 r 1 I I I' I I I 1 I r I I I' I I I I' 1 I I I' I I I I r I I I I'll I I' I I T 111 I I I' r I 1 I' I I I I I I 11 1'1 r I [I r I I I' Til I' I I I I' I 11 I' I r I I' 1 I I I' I 11 I' I I I I 




OTBDPS 2.55 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona OPMB 
ca2 carbona 
, , I ~I 
e i 
a._._. I II I 
, I " I' ..,,' ~ , . . II II I 
a l l protonatad carbons 
I I' r I I I' I i I I' I i I (' ill I' i I I)' I I I I r i I I (' I I I 1'1 I I I' r I I I' T r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1 ill I I T 1'1 I' I I i I' 1 I I I' I 










































2.58 13C NMR (125 MHz, CDCI3) 
<IL, , 





, , ., 
'P' .'" 
, , ..... ,. 
"fl" ".. '1" " .. ~ " ., 
-.' "'''1"''1' 
[ I r I I II I I r I I 1 r 1 I' I I I I I 11 I II I I I I I I I 1 1'1 I I I' I I I I' I I I 1'1 I I 11 I I 1 I' I I I I' 1 I I I I I I I II I r I I I I 1 I II I I 1 11 I I I II I 11 I I I I I II I I I [I I I 1 11 I I I I 





2.58 DEPT NMR (125 MHz, CDCI3) 




all protonatad carbons 
I I I I I I I I I " I I I I I I I I I " I I I 1 1 I I I I I 1 I " I I 1 I I I I " TIll I I I I r I r I I T I I I I r r r I I " " I I I " I " " I 1 r , I II I I I I 1 1 r I II I I I I I I I I I I " I I I I 1 I )1 TTl , I 1 I I I I I 1 1 I I I I I I r I 
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2.56 13C NMR (125 MHz, CDCI3) 
J ''' .I. 
[ ' r I'll I I I 1 r 1 I I I' I I I 1 I r I I I' I I I I' 1 I I I' I I I I r I I I I'll I I' I I T 111 I I I' r I 1 I' I I I I I I 11 1'1 r I [I r I I I' Til I' I I I I' I 1 1 I' I r I I' 1 I I I' I 11 I' I I I I 




OTBDPS 2.56 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona OPMB 
ca2 carbona 
~,; . "", ....... ".t •• ~ ~ .. .., ,."" .' . , ..... ~ ,! ' ",.-."..,' 10 .',~,,,,, ,. __ " ..... ' .• , . ......... h .... . .... ""10 .... " 1'" .. I' I ,.;~ "L;."" ,,; ", .lI.~ , .J . .I\~~~""'" .• "' . ... , ~ j ~h."' •• d ... r 
eM oar»oa.a 
..... ~ " .'., " .. il .,'''  [,,'" 'IIIP(h .• ~: Ai. 1 tAl" 04 , t Ln" u ' J:1 t IJl ItU ! t"'~\ WI' ., i l l· ' f [ ~I'" 41 ' .• .J!...Jj,., "'""' •. ~. ,, ~ i ' ..... I, , I' ; ' . \". ij~'" iI " '" ~. ' ," "" .,,,,,G 
all protonatad carbons 
!lu I .1 J I~ -~ 
I I' r I I I' I r I I' I 1 I (' I 1 I I' I I I)' I I I I r I I I (' I I I 1'1 I I I' r I I I' T r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1'1 I I I T 1'1 I' I I I I' 1 I I I' I 









































2.57 13C NMR (125 MHz, CDCI3) 
1 .1 
[ ' r I I II I I I 1 r 1 I I I' I I I 1 I I I I I' I I I I' 1 I I I' I I I I r I I I I'll I I' I I T 1'1 I I 1'1 I 1 I' I I I I I I I I I' I r I [' r I I I' Til I' I I I I' I 11 I' I I I I' I I I II I 11 I' I I I I 




OH 0 y 
OH 
~ ~OTBDPS 2.57 DEPT NMR (125 MHz CDCI ) 
"" ....... 6PMB '3 I I 
; I I t, , .. , I , ' p ' T 151 , t f I I ' I I +., I • J "J I , ' I. .... , • d ' "" '" I • , I ' , ; • • JFi;(l ij' 4 " t ... t k d ' h t ! q ,. I . d 4 r ,.,.. 
CII2 carbons 
.. 1 1 [ttl . l 
eM oar»oa.a 
all protonatad carboDs 
I I' r I I I' I r I I' I 1 I (' I 1 I I' I I I)' I I I I r I I I (' I I I 1'1 I I I' r I I I' T r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1'1 I I I T 1'1" I I I I' 1 I I I' I 






























2.66 13C NMR (125 MHz, CDCI3) 
220 140 120 ppm 
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", ,. """ ii, lliU L ,. ., 
eM oar»oa.a 
all protonatad carbons 
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2.65 13C NMR (125 MHz, CDCI3) 
[ ' r I I II I I I 1 r 1 I I I' I I I 1 I r I I I' I I I I' 1 I I I' I I I I r I I I I'll I I' I I T 111 I I I' r I 1 I' I I I I I I 11 1'1 r I [I r I I I' Til I' I I I I' I 1 1 I' I r I I' 1 I I I' I 11 I' I I I I 
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ca3 carbona OTBDPS 
2.65 DEPT NMR (125 MHz, CDCI3) 
ca2 carbona 
eM oar»oa.a 
all protonatad carbons 
I rill I r I" I I I' I I I I r III II I I I IT I I I I' 1 r I I' I I I 11 II I 1'1 1'1'1 I I I' r 1'1'1 I I I r II I I' I 1 r III I 'II 1 I II' I I 1 I' 1 I I I' I 1 I I' I I I I' I II I' I I'll I II I' I 




2.67 1H NMR (500 MHz, CDCI3) 






OMe H OPMB 
Me'" M~ 
o 
O. I /".. ~OTBS 
I Me' "OBOM 
. C02Me 
2.67 13C NMR (125 MHz, CDCI3) 
J ,~Ll1L"m 
[ ' r I I II I I I 1 r 1 I I I' I I I 1 I I I I I' I I I I' 1 I I I' I I I I r I I I I'll I I' I I T 1'1 I I I' r I 1 I' I I I I I I I I I' I r I [' r I I I' Til I' I I I I' I 1 1 I' I I I I' I I I II I 11 I' I I I I 
220 200 180 160 140 120 100 80 60 40 20 ppm 
 
31  17 
OTBDPS 2.67 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona 
" 1 I II Il l! I It 
ca2 carbona 
I I H~J, . . ",. 
eM oar»oa.a 
~ •• ~'o .. hOo~ / ]1/ I J I 
I I I I Ii III I I ~ ~ HL " ~Jj L 
I I' r I I I' I r I I' I 1 I (' I 1 I I' I I I)' I I I I r I I I (' I I I 1'1 I I I' r I I I' T r 1 I' I I I 1'1 I I I' I I I I' I I I (' I r 1 r I I I I I' 1 I I)' I 1'1'1 I I I T 1'1 I' I I I I' 1 I I I' I 








































2.63 13C NMR (125 MHz, CDCI3) 
[ ' r I I II I I I 1 r 1 I I I' I I I 1 I r I I I' I I I I' 1 I I I' I I I I r I I I I'll I I' I I T 111 I I I' r I 1 I' I I I I I I 11 1'1 r I [I r I I I' Til I' I I I I' I 11 I' I r I I' 1 I I I' I 11 I' I I I I 









all protonatad carbons 
OTBDPS 2.63 DEPT NMR (125 MHz, CDCI3) 
'IOBOM 
,r 111 I r I" I I]' I I I I r III II I I I I ' I r I l' 1 r I I' I I I 11 II I 1'1 1'1'1'1 I' r 1'1" I I I r I I I I' I 1 r III I 'II 1 I II" I I I' 1 I I I' I 1 I I' I I I I' I II II I I'll I II I' I 








2.68 1H NMR (500 MHz, CDCI3) 




Me C. e O\" ~ Me/" 'OBOM ~O C02Me 
2.68 13C NMR (125 MHz, CDCI 3) 
220 200 180 160 140 120 100 80 60 4.0 20 o ppm 
 
32  23 
OH 2.68 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona 
ca2 carbona 
I i - : q I I to; ; !!!I II 1 b I L I J , . II 
a ._._. III I 
I ! . I" 11111 
all protonatad carbons 
.1 1 J J.jllilL. .. 11L . "g~, I .JJIj l, l 1 I 
,r 111 I r I" I 1]1 I I I I r III II I I I I ' I r I l' 1 r I I' I I I 11 II I 1'1 1'1'1'1 I' r 1'1'" I I r I I I I'll r III I 111 1 I II" I I I' 1 I I I' I 1 I II I I I I' I II 11'1'11 I II I' I 
220 200 180 160 140 120 100 80 60 40 20 0 ppm 
 
3224 
OTBS Me'" M~ 
~'XMe/" IOBOM 
o C02Me 
2.69 1H NMR (500 MHz, CDCI3) 
__ L ~u 




Me\ ~ ' 
Me 
OTBS 
r Me <;>"'X Me/ "" OBOM 
~O CO~e 
2.69 13C NMR (125 MHz, CDCI3) 









OTBS ,~,~,9 • ~~T NM~ :125, ~HZ' C~I~)" M-U, ,,, ,J "l . '" "A.. , • 
"'OBOM 
C02Me 
a .... _. ]1 I 
. "1;; ' tth: bt BY 11 I " ; ' t %/ h', *1 1' ! ' iI; .,,! t.UkJ) liP L Pt .,': JI 
all protonatad carbons 
11 [' I I I (' I I r I' I II II I I r I' I I I I' I I I, r I I T I' I I r I' I I I I' r r 1, I II I I r 11 I II 11 I]' I I I IT I I I I' II I, III I II I r I r I 1 I I I' 1'1 I' II I I r I 1 1I1I 1'111 I II' T 




























r Me <t'X Me/"" OBOM 
~O COzMe 
2.70 13C NMR (125 MHz, CDCI3) 
[ ' r I I II I I I 1 r 1 I I I' I I I 1 I r I I I' I I I I' 1 I I I' I I I I r I I I I'll I I' I I T 111 I I I' r I 1 I' I I I I I I 11 1'1 r I [I r I I I' Til I' I I I I' I 11 I' I r I I' 1 I I I' I 11 I' I I I I 













2.70 DEPT NMR (125 MHz, CDCI3) 
J lh Hl 
r~~~~~ ~~-'~~~~~~~~~'" 
u •• ~'o .. ,"Oo~ j U 1 ~ ~ ~ i wl U 11 
..... "'l.III __ .j. __ ;" •.•. IIil.~ ••••.• _.'~ .. 1.lir ..... __ 4l"~i.~'''1'''ifJ 
,r 111 I r I" I I]' I I I I r III II I I I I ' I r I l' 1 r I I' I I I 11 II I 1'1 1'1'1'1 I' r 1'1'" I I r I I I I'll r III I 'II 1 I II" I I I' 1 I I I' I 1 I I' I I I I' I II 11'1'11 I II I' I 
220 200 180 1 60 140 120 100 80 60 40 20 0 ppm 
 
3330 
OH Me\~ ' 
Me 
r Me ,?" 'Y / " ~_ Ll~ Me 'OBOM 
o C02Me 
2.73 1H NMR (500 MHz, CDCI3) 










c:;("X Me/"" OBOM 
° COzMe 
2.73 13C NMR (125 MHz, CDCI3) 


















2.73 DEPT NMR (125 MHz, CDCI3) 
J,.",."" ....• t "'.A. . .J J. , _,~ , .U . J ,,~ ,Il, J IJl~, 11 ... 
































Me' " Mel 
~'XMe/" 'OBOM 
o C02Me 




2.74 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona o 
Me' " M~ 
c:J:~ C0 2Me 
ca2 carbona 
eM oar»oa.a 
all protonatad carbons 








2.74 NOESY1D (500 MHz, CDCI3) 
H20 







2.74 NOESY1D (500 MHz, CDCI3) 





H H • ~ Irad. 




2.75 1H NMR (500 MHz, CDCI3) 
10 9 8 7 6 5 4 3 2 1 - 0 ppm 
 
3440 
























° C0 2Me 
Merle 27 1H NMR (500 MHz, CDCI3) 







rMe (t '~Me""""" " OH 
~O CO~e 
Merle 27 13C NMR (125 MHz, CDCI3) 












Merle 27 DEPT NMR(125 MHz, CDCI3) 
140 120 100 80 60 40 20 o ppm 
 
3445 







o C0 2Me 
2.71 1H NMR (500 MHz, CDCI3) 











2.71 13C NMR (125 MHz, CDCI3) 












c:;t'y Me/ " 'OBOM 
o C02Me 
'<'Pl - 1 
a l l protonatad carbons 
220 200 180 160 140 
2.71 DEPT NMR (125 MHz, CDCI3) 
1  • • 1110 










2.72 1H NMR (500 MHz, CDCI3) 







2.72 13C NMR (125 MHz, CDCI3) 













e ~ a::: I- ~ 0 Z III 
0 
I'"i 
~ ~ ~ a... 0 
0 0 '" III 

























































































OBCM OM. 2.100 DEPT NMR (125 MHz, CDCI,) II 
Ca3 carbona I I 
ca2 carbona 
J Ll I~, , I 
a ._._. ~ I j Wl'----,----~-
all protonatad carbons ~LL " , ... ,' --------L-...--_ . 
r I r I I I II 1'1 I r 1 11)" I I II I I 1 I T I I I I r I 1 r I' r 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' 1 I I (' I r 1 I' I I I I' r 1 I)' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' T 





































Mel.- J OPMB "'OBOM V1e 
2.101 13C NMR (125 MHz, CDCI3) 
1.1 .J . I II 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I I' I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I 11 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1'1 I I I I I I I [I 1 I I I 
200 180 160 140 120 100 80 60 40 20 ppm 
 
35  55 
0 ... _OMe 




u~ '~,'O"h':~ " .' , '~'~,. I LJllLJ 
r I r I 1 I II 1'1 I r 1 11)" I I II I I 1 I T I I I I r I 1 r I' r 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' 1 I I (' I r 1 I' I I I I' r 1 I)' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' T 










































2.102 13C NMR (125 MHz, CDCI3) 
[ ' r r I II I r 'I r I 11 I' r 'I I' I I I I I I I I I'll I I' Til ]' I I I I' I T I I' I I 1 I I I I I (I I r 1 I' I I I ]' I I I (' I 11 I' I I I I' I I I (' I 1 I 1'1 I I I' r I I I' I I 1 I' I I I I 




Me ,~. 0 H OPMB 
Me I 2.102 DEPT NMR (125 MHz, CDCI3 ) 
Ca3 carbona "'OBOM 
Me J 
ca2 carbona 
" ,'" , , , , , ' , ,.IL,J .. ,[ .,'_, , 
eM oar»oa.a 
1 1 1 1 
all protonatad carbons 
r I' I I I II 1'1 I' 1 11)" I 1 II I I 1 I T I I , I r I 1 r I' I r I I' I I I" 1 I I I' I r 1 1'1 I I 1'1 I I)' I I I I' I I I (' I rIll I I I I' r 1 I I' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' I 






































2.103 13C NMR (125 MHz, C DCI3) 
I 





II all II. IlIi .. J1LL, j u 
... 
I ' r I I I I r r I I ' I I r I 1 r I I I ' I I I 1'1 I I I' I I I I' I I I I ' I I I I I r I I I' 1 r r II I I r I ' I I I 1' 1 I I II I I I I 1 1 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1' 1 I I I I I I I [I 1 I I I 










.u .~'o .. h' o~ l~ llL l 
I I l J I . I I " l. J ~---.-~---- . ---- - ---'--- --~.---
r I' I I I II 1'1 I r 1 11)" I 1 II I I 1 I T I I I I r I 1 r I' I 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' I I I (' I rIll I I I I' r 1 I I ' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' I 




































2.93 13C NMR (125 MHz, CDCI3) 
I I I L .L . .~ 1III ,1 l~lJJ!,IiJijI~I""' ,." . , .. , .~ 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I I' I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I 11 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1'1 I I I I I I I [I 1 I I I 





OPMB 2.93 DEPT NMR (125 MHz, CDCI3) 
ca2 carbona 
II I l j I 
eM oar»oa.a 
all protonatad carbons 
______________________________________________________ 4-__ ~.~I~ ________ ~ __ ~------~ ~ " I I , 4 ~ 
r I' I 1 I II 1'1 I r 1 11)" I 1 II I I 1 I T I I I I r I 1 r I' I 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' I I I (' I rIll I I I I' r 1 I I' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' I 












































2.104 13C NMR (125 MHz, CDCI3) 
._ " ' "".l.. " .. ,,~._ ..• Jl I 1.1 ..• ,t .1 .- lI.. .l .1 J I 
I ' r I I I I r r I I ' I I r I 1 r I I I ' I I I 1'1 I I I' I I I I' I I I I ' I I I I I r I I I' 1 r r I I I I r I' I I I 1' 1 I I II I I I I 11 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1' 1 I I I I I I I [I 1 I I I 




ca3 carbona OPMB 2.104 DEPT NMR (125 MHz,CDCI,) L ltJ __ .....J" 
~,=-. II I I 
_____ ---J-...-...-l -----JLLJ 'j . I , 
eM oar»oa.a 
J lJ 
a l l protonatad carbons ~. l j J .. U I 
r I ' I 1 I II 1 '1 I r 1 11 )" I 1 II I I 1 I T I I I I r I 1 r I ' I 1 I I' I I I " 1 I I I' I r 1 1'1 I I 1 ' 1 I I) ' I I I I ' I I I ( ' I rI ll I I I I' r 1 I I ' I I 1 I r I I I I ' I 1 11 1 I I I I ' I 1 I I' I 














































2.105 13C NMR (125 MHz, CDCI3) 
~., ... ~,., J~ •. j~_ l 
--
....,.j ~\U"Ilo"_",,,,-
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I I' I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I 11 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1'1 I I I I I I I [I 1 I I I 





OPMB 2.105 DEPT NMR (125 MHz, CDCI3) 
( Me 9'" 
' ..... " •• ~O i" "" r " " 'OBOM 
ca2 carbona 
,'0,'" ",I :,~" . ," 
eM oar»oa.a 
--~--~----~------~~------------~~----~--~.~~ ~ ~~' ~' ~----'~T--------~~~~------------~~---
all p r otona tad c arbons I j ~ , . J"l " '~.~~" ',,,,,, .,,' ''''~'q • • , ...... 
........ __ ""' .............. _..,. ..... _ ........ ....., ..... ~ .......... ___ ........... __ ..... ::~:~~:::~:;:~~~~'~~'~:'. :'~.~'~t"""::.~~ 1fN'1c ~ tl1t'N!wI'-~ ti" "'f.~ i . r~* frt . '~'J ' · fI.1" J.,t, .. , l ~, . ""'''1' . ", A, 1",,4" · . ll\: ~ ! d ~ ! F .-1 , ",< ' . {!~; i t ' .. ,\\ ·f >W\IiII .4r,~. ·4 i4 ,,:t.,'r .!t' .. ~!·WJ ·~ · " \I ~~ . l t .. ~ ";41 , ... ",,, . , , 
r I' I 1 I II 1'1 I r 1 11)" I 1 II I I 1 I T I I I I r I 1 r I' I 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' I I I (' I rill I I I I' r 1 I I' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' I 




































2.106 13C NMR (125 MHz, CDCI3) 





= -.-. .1 lu " llil1JI " ~ 
ell carbons 
1 j I l 
~ r 
." -~.-, m~.. J lu 1[,.1 ~ .. iliLJ._, 1~J. ." "'~~._ ~ .. ~,.~. 
"';;4I4fi4t ,lII't .. , ....... "" • ,"', , ,I II'''. l ... yt" 1IPt;*"""teC · \.,,,.v '"(tWtN+'Iii"'~" tit, <,"14 ~. . '. 
rTT' I II I ' I i , I iii 'I i I I iii i' i I" I [II I I j iii i t I" i I I' i 11 Iii i it i' t I I' I i 'I i I II Ii I I ii' ii' 1 i I 1' 1' 1 i I I' 1 '1 I' i I II i i II I' I i j I i I I iii iii I' I i I lit I I I ' I I I I' I 
220 200 180 160 140 120 100 80 60 40 20 o -20 ppm 
 
3774 
0 ., JH 
OPMB 
~'XMe/ " 'OBOM 
o C02Me 
2.107 1H NMR (500 MHz, CDCI 3) 
~ 
10 9 8 7 6 5 4 3 2 1 - 0 ppm 
 
3775 
0,,- ~ H 
OPMB 
~'~Me/"'OBOM 
o C0 2Me 
2.107 13C NMR (125 MHz, CDCI3) 
200 180 160 1 40 
~~ 





~, =_. . _ . l il . .. . lliLLu~. ' _ 
eM oar»oa.a t. Lt . ill 1 ... L 
... > .. , ••• , •• 0 ~ 
, , " " ' ' 1..1. ,' ~ I. 11., ,.l ,-", iJ .~-...... "  .. _ , i¥Y r~",J'O- 1 F , r 
r I' I I I II 1'1 I r 1 11)" I 1 II I I 1 I T I I I I r I 1 r I' I 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' I I I (' I rIll I I I I' r 1 I I' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' I 








































0., ~ H 
OTBS 
~'y'Me/ " ' OBOM 
o C02Me 
2.92 13C NMR (125 MHz, CDCI3) 
200 180 160 140 120 100 80 60 40 20 ppm 
 
37  79 
0 , ..... /H 
ca3 carbona 
OTBS 2.92 DEPT NMR (125 MHz, CDCI3) 
C:J:" Me 0 ~ I I ',.. I 
.. '-.1 .... ,.." , 0 
" 'OBOM 
ca2 carbona 
' . , ~ .~ ." ._. .' .... , ." ...  I,, ',', ". I " .'" 4'1. ' ''',j"I. 0 ' • • , . ' ,"~ L ~'" ",, ' . ,,, . 
all protonatad carbons 
r I ' I I I II 1 '1 I r 1 11 )" I 1 II I I 1 I T I I I I r I 1 r I ' I 1 I I' I I I I r 1 I I I' I r 1 I ' I I I 1 ' 1 I I) ' I I I I ' I I I ( ' I rI ll I I I I' r 1 I I ' I I 1 I r I I I I ' I 1 11 1 I I I I ' I 1 I I' I 








2.108 1H NMR (500 MHz, CDCI3) 











2.108 13C NMR (125 MHz, CDCI3) 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I I' I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I 11 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1'1 I I I I I I I [I 1 I I I 










2.108 DEPT NMR (125 MHz, CDC',) t , 
________________________ ~~----~ ~~I -------
eM oar»oa.a 
all protonatad carbons 
I r I I I II 1'1 I r 1 11)" I I II I I 1 I T I I I I r I 1 r I' r 1 I I' I I I I r 1 I I I' I r 1 I' I I I I'll I)' I I I I' 1 I I (' I r 1 I' I I I I' r 1 I)' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' T 
200 180 160 140 120 100 80 60 40 20 0 ppm 
 
3883 
Me' ~ ' 
Me 
OTBDPS 
r Me 9 " 'XMe/" 'OBOM 
~O C0 2Me 
2.91 1H NMR (500 MHz, CDCI3) 
10 9 8 7 6 5 4 3 2 1 - 0 ppm 
 
38  84 






2.9113C NMR (125 MHz, CDCI3) 
[ ' r r I II I r 'I r I 11 I' r 'I I' I I I I I I I I I'll I I' Til ]' I I I I' I TIl' I I 1 I I I I I (I 111 I' I I I ]' I I I (' I 1 1 I' I I I I' I I I (' I 1 I 1'1 I I I' r I I I' I I 1 I' I I I I 





ca3 carbona 'bPMB 
OTBS Me" -M~ 
"""'", '1 ., -"" "'~ -XMe/"'OBOM 
o C02Me 
ca2 carbona 
' j' . ,r" f r • hat . cI ' , 1;,. ....to' it . Til ' t i:IoIi & 'til !I' 1 ! 
eM oar»oa.a 
a l l protonatad carbons 
r I' I 1 I II 1'1 I r 1 11)" I 1 II I I 1 I T I I I I r I 1 r I' I 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' I I I (' I rIll I I I I' r 1 I I' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' I 
200 180 160 140 120 100 80 60 40 20 0 ppm 
 
3886 
Me\ ~ ' 
Me 
OH 
r Me 9"'XMe/ " 'OBOM 
~o CO~e 
2.109 1H NMR (500 MHz, CDCI 3) 







2.10g 13C NMR (125 MHz, CDCI3) 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I I' I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I 11 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1'1 I I I I I I I [I 1 I I I 







"'OPMS 2.109 DEPT NMR(l25 MHz, CDCI,) it 
OTBS I 
" 'OBOM . " .. .1 .1 '" L 1 . JJ •• 
CO~e 
CH2 carbons 
! ! :1 .;\111 I !, , , I iI ulillJJlJ ,j I ____ ~~~J~,-, ~~
=-- ~ I . 
-_-.--.---__ -'---1 WI, L LJ~'U_!"""--i -----r------.-----
111'ii i iiiiijilj'I'llt:il.I;"'tl!IIIliii,!iti':' ' :-rT"'""""T i . • ' iliijllllilllil j l"I'I~,I ' l lli ili l Iliii" li! 'l l iji iIJ I , llli !il ' II~'1"'" 









OTBS Me' " M~ 
~'~Me/" 'OBOM 
o C02Me 
2.110 1H NMR (500 MHz, CDCI 3) 
__ L~ 









('Me <?" '~Me/" /OBOM 
~O CO~e 
2.110 13C NMR (125 MHz, CDCI3) 
.l I ~ ~LJ_ .. ~ 
. '""'" 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I I' I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I 11 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1'1 I I I I I I I [I 1 I I I 




'OPMB ca3 carbona 2.110 DEPT NMR (125 MHz, CDCI3) 
Me" -M~ 
OTBS 
c:;(o " 'OBOM CO~e 
ca2 carbona 
______________ ~~~u ,. ruill~J ----
,,1.J uAu " 
-----'-"-----
eM oar»oa.a 
all protonatad carbons 
I r I 1 I II 1'1 I r 1 11)" I I II I I 1 I T I I I I r I 1 r I' r 1 I I' I I I I r 1 I I I' I r 1 I' I I I I'll I)' I I I I' 1 I I (' I r 1 I' I I I I' r 1 I)' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' T 







o C0 2Me 
2.111 1H NMR (500 MHz, CDCI3) 








2.11113C NMR(125 MHz, CDCI3) 











all protonatad carbons 





2.113 1H NMR (500 MHz, CDCI3) 
10 9 8 7 6 5 4 3 2 1 - 0 ppm 
 
3996 
Me0 2C' ~ OAc 
r;I'IY 





2.1 13 13C NMR (125 MHz, CDCI3) 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I II I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I I I I I I r r 1 I I I 1 r 1 I r I I I I I I 'I 1'1 I I I' I I I [I 1 I I I 




o 2.113 DEPTNMR(125 MHz, CDCI3> 
ca3 carbona 







Me0 2C' ~ .OAe 
Me'" MEt 
~O 























































Me0 2C' ~ 
o Merle 33 1H NMR (500 MHz, CDCI3) 
Me' ~ ' 
Me 
C:;:~ 
__ _____'""', J< \ ~~, 








Merle 33 13C NMR (125 MHz, CDCI3) 
~i!~."o 
200 180 160 1 40 120 100 80 60 40 20 ppm 
 
4002  






.0 Merle 33 DEPT NMR (125 MHz, CDCI3) 
C.o2Me 
=-- JW '_~~i~)_~~~":Ww't_~r~j.~~~~ 
l .iio , .11.1 
j ~LJ.II1u..W.lll" LIJu .. , . If.~ "~ 
elf carbona 
" ..... .... ", 
""'" 
all pxotonate4 carbon. 
























































3.10 13C NMR (125 MHz, CDCI3) 
'" ill'''' , ' - l .. II • ,d L """ ~~" ~ "~, ''f "'f' , """"'" --L 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I II I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I I I I I I r r 1 I I I 1 r 1 I r I I I I I I 'I 1'1 I I I' I I I [I 1 I I I 




o j OH 
OTBS 
3.10 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona 
ca2 carbona 
L l II 
ell 0&I:))OD8 
__________ ~ ________ U~[, --____ _ 
all protonated carbona 
______ ~ __ ~~ __ ~~ ____ . ____ ~ ____ _L __________ ~ ________________ ~.k~-l _ U~' _' __ ~-N~ __ ~ ______ 4-___ 
I r I I I II 1'1 I r 1 11)" I I II I I 1 I T I I I I r I 1 r I' r 1 I I' I I I I r 1 I I I' I r 1 I' I I I I'll I)' I I I I' 1 I I (' I r 1 I' I I I I' r 1 I)' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' T 




































3.8 13C NMR (125 MHz, CDCI3) 
j I t_ I 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I I' I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I 11 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1'1 I I I I I I I [I 1 I I I 










all protonated carbona 
________ --'-------'-----_____ ,LI I I 
I r I I I II 1 '1 I r 1 11 )" I I II I I 1 I T I I I I r I 1 r I ' r 1 I I' I I I I r 1 I I I' I r 1 I' I I I I ' l l I)' I I I I ' 1 I I ( ' I r 1 I ' I I I I' r 1 I )' I I 1 I r I I I I ' I 1 11 1 I I I I ' I 1 I I' T 





































I l l 
" '-J , l .I U • , 
[ ' I I I I I I r I I r I r I I I r I I I' I I I I 1 I I 1 1'1 I I I I I I I ]1 I I I I I I 11 I' I I I I 1 I I I 11 I I 1 I I I I I I I I I I I 1 I I 1 I' I I I I I I I I I' I I I I I I I I I'll I I I I I 1 I' I I I I 






3.7 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona 
ca2 carbona 
I I I I . 
a ._._. I di I I II 
U •• ~'o .. hOo~ I II 
I j l III ! I I I I I ! I " ! 
I r I I I II 1'1 I r 1 11)" I I II I I 1 I T I I I I r I 1 r I' r 1 I I' I I I, r 1 I I I' I r I I' I I I I'll I I' I I I j' 1 I I (' I r 1 I' I I I I' r 1 I)' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' T 










































3.1113C NMR (125 MHz, CDCI3) 
I I 
[ ' I I I I I I r I I r I r I I I r I I I' I I I I 1 I I 1 1'1 I I I I I I I ]1 I I I I I I 11 I' I I I I 1 I I I 11 I I 1 I I I I I I I I I I I 1 I I 1 I' I I I I I I I I I' I I I I I I I I I'll I I I I I 1 I' I I I I 










l l II It I L I 
a._._. I ~I III 
a l l protonatad carbODS 
I r I I I II 1'1 I r 1 11)" I I II I I 1 I T I I I I r I 1 r I' r 1 I I' I I I, r 1 I I I' I r I I' I I I I'll I I' I I I j' 1 I I (' I r 1 I' I I I I' r 1 I)' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' T 






::::s g'" !E 
chen U 
00. ~ ()o III 
:E I-
























3.1213C NMR(125 MHz, CDCI3) 
, L 1.lI I~Jl , I 
[ ' r r I II I r 'I r I 11 I' r 'I I' I I I I I I I I I'll I I' Til ]' I I I I' I T I I' I I 1 I I I I I (I I r 1 I' I I I ]' I I I (' I 11 I' I I I I' I I I (' I 1 I 1'1 I I I' r I I I' I I 1 I' I I I I 





3.12 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona . COS-tBu 
OTBDPS 
ca2 carbona 
LJ_J _,JLL. J 
eM oar»oa.a 
all protonatad carbons 
r I' I I I II 1'1 I' 1 11)" I 1 II I I 1 I T I I , I r I 1 r I' I r I I' I I I" 1 I I I' I r 1 1'1 I I 1'1 I I)' I I I I' I I I (' I rIll I I I I' r 1 I I' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' I 









CD U CO 
.... , ~-rJ) 0rJ) 
uQ... ~ 0 
CD 0 
I- 0 














HO ~ a . cos.,"" 
OTBDPS 
3.13 13C NMR (125 MHz, CDCI3) 
t.IL. .15" """ " .. ,JJ" ,'- , . 11 A ,,, I , ~.~ ,'~" , ,I. ' , ... , ' .r'!. :I, , .  lL ,j, 1,,~1 _4.1 I. 
'''- ' W '..,.< I 'i!' IT 
" '"'' """.,."" ·,r "" 
[ ' r r I II I r 'I r I 11 I' r 'I I' I I I I I I I I I'll I I' Til ]' I I I I' I T I I' I I 1 I I I I I (I I r 1 I' I I I ]' I I I (' I 11 I' I I I I' I I I (' I 1 I 1'1 I I I' r I I I' I I 1 I' I I I I 









.' " I . iL l 11 . 1.1 I, !" III . 
a ._._. I I 
I II , , p . . • 
all protonatad carbons 
1 J. J1 JJJ~~lLl 1. 
[ ' r r I II I r 'I r I 11 I' r 'I I' I I I I I I I I I'll I I' Til ]' I I I I' I T I I' I I 1 I I I I I (I I r 1 I' I I I ]' I I I (' I 11 I' I I I I' I I I (' I 1 I 1'1 I I I' r I I I' I I 1 I' I I I I 





















3.13 NOESY1D (500 MHz, CDCI3) 










. COS-tBu 5 
OTBDPS 











































r 'I o 
TBDPSO S-tBu 
3.1S13C NMR{12S MHz, CDCI3) 
'''1 • __ .. .1 f f l I . LWl l 
.... , ', f iv"" . f .... ';,_ - ..... JlJJ ~ i .. ,. • '" " "" , / ...... ,.... . ,f .~",,"r ' ." UI , " .. 'J I;)' . .L _L L 
--I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I II I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I 1'1 I I I I I I I I r r 1 I I I 1 r 1 I r I I I I I I 'I 1'1 I I I' I I I [I 1 I I I 




o , OTMS 
OTMS 




l II ,[ 1, .l 
a ._._. I j I I ,u 
all protonatad carbons 
r I ' I I I II 1 '1 I r 1 11 )" I 1 II I I 1 I T I I I I r I 1 r I ' I 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1 ' 1 I I)' I I I I ' I I I ( ' I rI ll I I I I' r 1 I I ' I I 1 I r I I I I ' I 1 11 1 I I I I ' I 1 I I' I 
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(/) 
























































































1 ,l I..l1 I I , LJ~ ____________ 
eM oar»oa.a 
L 
all protonatad carbons 
I r I I I II 1'1 I r 1 11)" I I II I I 1 I T I I I I r I 1 r I' r 1 I I' I I I, r 1 I I I' I r I I' I I I I'll I I' I I I I' 1 I I (' I r 1 I' I I I I' r 1 I)' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' T 
















































~ OMeH Me", 0 OPMB 
Me 
Me 0 " Me "'OBOM 
~O I C02Me 
3.18 13C NMR (125 MHz, CDCI3) 
_"'_ .... _illJ . , .I .' . ~ !~ J, 
............. ..". 
.,. . 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I II I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I I I I I I r r 1 I I I 1 r 1 I r I I I I I I 'I 1'1 I I I' I I I [I 1 I I I 





3.18 DEPT NMR (125 MHz, CDCI3) 





all protonatad carbons 
r I r I I I II 1'1 I r 1 11)" I I II I I 1 I T I I I I r I 1 r I' r 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' 1 I I (' I r 1 I' I I I I' r 1 I)' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' T 





Me O" 'XMe/"'OBOM ~O IC02Me 
3.19 1H NMR (500 MHz, CDCI3) 





Me O\"~ Me/ " 'OBOM ~O I C02Me 
3.19 13C NMR (125 MHz, CDCI3) 





ca3 carbona 3.19 DEPT NMR (125 MHz, CDCI3) 
Me 0'" " 'OBOM 
_I~o 
ca2 carbona 
ill n~ " ILill~ _.11 . " .... ,! tJ • . ""' .tI!L' ,.I. t L~ ...... ",l.l.LJ ld .M . .. .. " , 
'T~' 
eM oar»oa.a 
all protonatad carbons 






Me o"'y'Me)." OBOM ~O IC02Me 
3.5 1H NMR (500 MHz, CDCI3) 





Me O\" ~Me/ " 'OBOM ~O I C02Me 
3.5 13C NMR (125 MHz, CDCI3) 





.. ::: ~:,~:'~:.:::::~Z~:::~" .. ,.L_ -.L .. "~,_ Me 0'" 
.. ,., .... "'''''''''_PI' ..... ; . ..,,! . .... ' ...... I'''~IiI\o· O
ca2 carbona 
,' *.. .. • ,' ..... , ,. , .. ,."., ..... ~, ..• •• , "1 ".' • • , .; I, 'I " .. .. L .. '.'''.I....,;o.J,. of' • • • ,", . " •• ~ •• ,"II' ~"'" <Ii'Ii'_ 
eM oar»oa.a 
all protonatad carbons 




Me o"·y M~·" OBOM ~O I C02Me 
3.20 1H NMR (500 MHz, CDCI3) 




Me O\'·y M~· " OBOM ~O I C0 2Me 
3.20 13C NMR (125 MHz, CDCI3) 
200 180 160 1 40 120 100 80 60 40 20 ppm 
 
44  42 
ca3 carbona 3.20 DEPT NMR (125 MHz, CDCI3) 
Me 0 '" 
--.... ·"-·~O "'OBOM 
ca2 carbona 
a m._. ~ illJJJl 
all protonatad carbons 
• • / .· • • .',01'\01 To' ,., M.,~~~I ... '~'+-l-I' "', ~," .. . ~~~,.'"' ;~~".  .... . l ,.".~ .... ,~~ •• i.., .. .J~ .. . ",,., .... , ,,.,,,  .. ~, .. IiI'l ' 'I"" 
r I r I I I II 1'1 I r 1 11)" I I II I I 1 I T I I I I r I 1 r I' r 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' 1 I I (' I r 1 I' I I I I' r 1 I)' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' T 
200 180 160 140 120 100 80 60 40 20 0 ppm 
 
44  43 
Me O" '~ Me" "OBOM ~O I C02Me 
3.21 1H NMR (500 MHz, CDCI3) 
10 9 8 7 6 5 4 3 2 1 - 0 ppm 
 
4444 
Me 0'" ~ Me' " 'OBOM 
~O C02Me 
3.21 13C NMR (125 MHz, CDCI3) 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I I' I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I 11 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1'1 I I I I I I I [I 1 I I I 




3.21 DEPT NMR (125 MHz, CDCI3) 
~";~Me 0 '" " 'OBOM _~lill\~~M"""Iii!II'!fI~!u',~-,~~~~w.'~ 
O 
ca2 carbona 
!.it i . ... -;.i~"""!.~,~ .......... fO!~~ ... 1 ;"'I!J""IIIjOOW!'lIoi""~~)o,""~",~" joIjOlotlIr'\o'l . ~, .... :.~J,)~ ' ;I'IIt '~I~MfM\~ 
eM o ar»oa.a 
oII,o~"'IIHII"''''I'loic~'I'"",~· "",.,""',~j~~~'iIJ " ,;"" 'u;./fw~!lI~"''',rJ'~'''IiI/'''".t.Ir''M;l 
a ll p r otonat ad c arbons 






































~ OMe H 
Me,. , 0 OH 
Me 
Me 0 '" Me " ' OBOM ~O I C0 2Me 
3.28 13C NMR (125 MHz, CDCI3) 
200 180 160 1 40 120 100 80 60 40 20 ppm 
 
44  48 
O~ , H 
Me" , OH 
ca3 carbona 
3.28 DEPT NMR (125 MHz, CDCI3) 




! .. L:f.:. J" , . 11,1 0'" l.~...J.t.:. .L:.ll1 fTlq " 
-:Olf'"'''' T"ll"l f "..- "" II""," I ~ • ~ II' ' "l" · ,,,, I· q;->" "l"'r1 "-' r" l1T l! ~ 
all protonatad 










































3.29 13C NMR (125 MHz, CDCI3) 
I ' r I I I I r r I I' I I r I 1 r I I I' I I I 1'1 I I I' I I I I' I I I I' I I I I I r I I I' 1 r r II I I r I' I I I 1'1 I I II I I I I 11 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1'1 I I I I I I I [I 1 I I I 









], . 1 lLLLL_J"--___ -
eM oar»oa.a 
L 
,"::~'O"::,'~~ " ..... .. .. ~~,. ..C J.I ... ~, '. L 









































· l __ . ___  l. ____ _ l ... 
........ ~~ - ~ -.. . ..... L_. _ __ .~ •• . _. _ . ' L_. _ • . C ~_. __ . _ • • _ _. _ •• • _, ..I. . 
 . ,L 
I ' r I I I I r r I I ' I I r I 1 r I I I ' I I I 1'1 I I I' I I I I' I I I I ' I I I I I r I I I' 1 r r I I I I r I' I I I 1' 1 I I II I I I I 1 1 I I I r r 1 I I I 1 r 1 I ' I I I I I I 'I 1' 1 I I I I I I I [I 1 I I I 





3.30 DEPT NMR (125 MHz, CDCI3) 
ca3 carbona 
ca2 carbona 
____________________________ ~ ________ ~ __ ~~IILu~,l~I--~----
a ._._. Lll I U_--.----.'---~_ 
a ll protonat ad carbons ~ l 
r I' I I I II 1'1 I r 1 11)" I 1 II I I 1 I T I I I I r I 1 r I' I 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' I I I (' I rIll I I I I' r 1 I I' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' I 
200 180 160 140 120 100 80 60 40 20 0 ppm 
 
4555 
TMS ." OPMB 
o 
0 ..... _H TBDPSO 
o 
Me O"'~ / "'OBOM ~O I C02Me 
3.31 1H NMR (500 MHz, CDCI3) 
10 9 8 7 6 5 4 3 2 1 -0 ppm 
 
45  56 
TM S ",OPMB 
o 
0. .... _H TBDPSO 
o 
Me O" '~ / " 'OBOM ~O I C02Me 
3.3113C NMR (125 MHz, CDCI3) 
200 180 160 140 120 100 80 60 40 20 ppm 
 
45  57 
TMS ." OPMB 
o 
o H TBDPSO 
ca3 carbona 
3.31 DEPT NMR (125 MHz, CDCI3) 
'I\'J6r~,!" ~'"!"'''i~L~dM4 
o ~'.I'~"il~~..v.'-~· "M'H~I.,... .... "",,~.L-J~~~ 
Me 0 '" " 'OBOM 
~O 
ca2 carbona 
''\O~''J_'; ........, • • ,, '''' ..... , i .. j\;"'~.' ....... ,.,.,.,.", ... " .... ''','_ .... ..,·' ... '' ''r .. ' ' I ..... . "'\>oo.-~ ,\,,- , "/ '. ". ~. . I ~ j I ' . . " "F;g, .... , •• • !It , 1/f ... ,.,.4Ir t4,.. i wIfT;iI~ ,'tiA, ~,.~ \ l"""t~~Iw"..~, . "'i l'~L ,. oJ 
eM oar»oa.a 
-- " .. .... "'" ''''1--'''''''~''''''' I~ .. J, 
a l l protonatad carbons 
r I' I I I II 1'1 I r 1 11)" I 1 II I I 1 I T I I I I r I 1 I I' I 1 I I' I I I I r 1 I I I' I r 1 I' I I I 1'1 I I)' I I I I' I I I (' I rIll I I I I' r 1 I I' I I 1 I r I I I I' I 1 111 I I I I' I 1 I I' I 
200 180 160 140 120 100 80 60 40 20 0 ppm 
